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Abstract 
In animals, the interaction of numerous proteins with glycosaminoglycans (GAGs) regulates 
many aspects of their functions, and so organism development and homeostasis, as well many 
related pathologies. The interactions between the GAG heparan sulfate (HS) and the fibroblast 
growth factors (FGFs) have become a major paradigm for how such interactions regulate 
biological outcomes. Thus, binding HS controls FGF stability, its diffusion between cells and 
the generation of intracellular signals via the cognate FGF receptors (FGFRs). The basic 
arginine and lysine amino acids on the surface of FGFs have an important role in binding the 
polysaccharide via its numerous sulfate and carboxyl groups. Indeed electrostatic bonds 
between FGF and GAG dominate the interaction, at least kinetically. However, the contribution 
of arginine residues on the protein surface to GAG binding has generally not been established. 
This has been addressed directly in this thesis. A means to selectively label and so identify 
arginine side chains involved in binding heparin as an approximation for cellular GAGs was 
developed and evaluated, using the two most studied FGFs, FGF1 and FGF2. Two chemicals 
which selectively and specifically react with the guanidino group of arginine, phenylglyoxal 
(PGO) and hydroxyphenylglyoxal (HPG) were chosen for the purpose of this work. By 
combining mass spectrometry and an automatic programming language, the multiple products 
of PGO’s reaction with arginine were readily deconvoluted. 
The method was then applied to the other thirteen paracrine FGFs, which were produced as 
recombinant proteins. In addition, lysine selective labelling data were acquired for those FGFs 
where this was lacking. Thus, a complete description of the surface electrostatic map on fifteen 
paracrine FGFs guiding heparin engagement was obtained. The addition of arginine residues 
into the map of binding makes adjustments to the definition of heparin binding sites (HBSs) in 
some FGFs, for instance, FGF4. The refinement of the assignment of residues to secondary 
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HBSs is consistent with data obtained by others on the ability of particular FGFs (FGF4, FGF6, 
FGF17, FGF18 and FGF10) to cross-link HS chains. IN addition, the data raise some 
interesting properties of GAG binding, for example, the dual specificity of the secondary 
heparin binding site, HBS-3, in some FGFs, which is also involved in binding the FGFR. While 
the results generally support the idea that the conservation of structures for GAG binding in 
FGFs is related to their evolutionary divergence, it also suggests that changes in the structures 
in GAG binding may in some instances have diverged more rapidly since an amino acid 
substitution between members of a subfamily enables a significant alteration in heparin 
engagement. This suggests that in some instances, changes to the heparin binding properties of 
an FGF may contribute to a diversification of function within a subfamily.  
A further method was developed, whereby the entire selective labelling was done in solution, 
without the need for a heparin affinity column. The method was applied to the interactions of 
members of the FGF7 subfamily (FGF3, FGF7, and FGF10) with heparin, followed by 
chondroitin sulfate (CS), dermatan sulfate (DS). This allowed the analysis of lysine residues 
involved in binding physiologically relevant GAGs rather than heparin. Finally, the wider 
applicability of the method was acquired by determining the lysine and arginine residues that 
bind heparin in a ‘phage display antibody’, HS4C3. Due to the selectivity of HS4C3 for 
anticoagulant structures in heparin through its CDR3 loop, it was possible to use the data to 
propose a means to model protein-GAG binding. This was demonstrated using the knowledge 
of the binding specificity of HS4C3 for 3-O-sulfate and the positions of residues identified by 
the selective labelling. Taken together, the work in this thesis provides new insight into the 
involvement of arginine and lysine residues in the engagement of proteins to GAGs. This may 
enable future ‘omics’ approaches to identify GAG binding sites in proteins in cells and tissues, 
and to predict from principles where such sites are on a protein surface.  
v 
 
Contents 
CHAPTER 1 GENERAL INTRODUCTION  
1.1 OVERVIEW                                                                                                                      1 
1.2 FIBROBLAST GROWTH FACTORS                                                                             1 
1.2.1 FGF sub-families                                                                                                  2 
1.2.2 Genes encoding FGFs                                                                                                 4 
1.2.3 Evolution of FGFs                                                                                                     4 
1.2.4 Roles of paracrine FGFs in development                                                                 6 
1.2.5 Structural features                                                                                                     7 
1.3 PROTEOGLYCANS                                                                                                        9 
1.3.1 Structural properties of GAGs                                                                           10 
1.3.2 Hierarchical biosynthesis of GAGs                                                                    11 
1.3.2.1 Chain initiation in HS and CS/DS synthesis                                                       12 
1.3.2.2.1 Chain elongation (chain polymerization)                                                    13 
1.3.2.2.2 Chain modification                                                                                      13 
1.3.2.2.3 Major and minor pathways for HS                                                              14 
1.3.2.2.4 Degradation of surface-bound and extracellular HS                                   15 
1.3.2.3 Next stages in the bioynthesis of CS/DS                                                            17 
1.3.2.3.1 CS- Chain elongation (chain polymerization)                                             17 
1.3.2.3.2 CS- Chain modification                                                                               17 
1.3.2.3.3 Epimerization of DS                                                                                    19 
1.3.2.3.4 The interplay between HS and CS Biosynthesis                                         20 
1.3.3 Structural comparison between HS, heparin, and CS and DS                           20 
1.3.3.1 Consequence of biosynthetic pathways differences between heparin and HS . 21 
1.3.3.1.1 Biosynthetic pathways differences between heparin and HS                      21 
1.3.3.1.2 Domain structure of HS and evidence for variation in S & NA & NS domains
 ................................................................................................................................... 22 
1.3.3.1.3 Critique of using heparin as a proxy for an S-domain.                                22 
1.3.3.2 Difference in spatial position of sulfate and carboxylate in CS/DS                  24 
1.3.3.3 Chain flexibility                                                                                                 25 
1.4 HEPARIN/HEPARAN SULFATE AND PROTEIN INTERACTIONS                       27 
1.4.1 General overview of heparin binding proteins                                                   27 
1.4.2 How do heparin/HS recognize a protein                                                               27 
vi 
 
1.4.3 How do protein engage to GAGs                                                                           29 
1.4.4 Electrostatic interactions (arginine and lysine)                                                   30 
1.4.5 The canonical HBSs and the secondary HBSs                                                   30 
1.4.6 Cellular functions of heparin/heparan sulfate and protein interactions               32 
1.4.6.1 Localisation and diffusion                                                                                  32 
1.4.6.2 HS as a co-receptor in signalling complexes                                                     33 
1.4.7 The binding interfaces of the ternary complex, FGF-HS-FGFR                           33 
1.5 APPROACHES FOR IDENTIFICATIONS OF GAG BINDING SITES IN PROTEIN34 
1.5.1 Low throughput methods                                                                                       35 
1.5.2 High throughput methods                                                                                       36 
1.5.3. Bioinformatics tools                                                                                       37 
1.5.4 The lysine selective labelling approach                                                               37 
1.6 RATIONALE AND AIMS OF THE THESIS                                                            38 
CHAPTER 2 MATERIALS AND METHODS                                                               40 
2.1 ELECTROPHORESIS                                                                                                    40 
2.1.1 Agarose electrophoresis                                                                                       40 
2.1.2 SDS PAGE                                                                                                               40 
2.1.3 SILVER STAIN                                                                                                   40 
2.2 BACTERIAL CULTURE STRAINS                                                                             43 
2.2.1 Vectors and cDNAs                                                                                                  43 
2.2.2 Medium for bacterial culture                                                                           43 
2.2.3 Competent cell list and culture                                                                           43 
2.2.4 Competent cell preparation                                                                                   43 
2.2.5 Transformation                                                                                                   44 
2.2.6 Miniprep                                                                                                               44 
2.3 PROTEIN EXPRESSION                                                                                                 44 
2.3.1 IPTG induction                                                                                                   44 
2.3.2 Cell harvesting                                                                                                   44 
2.4 CHROMATOGRAPHY                                                                                                  45 
2.4.1 Chromatography columns                                                                                       45 
2.4.2 Heparin affinity chromatography                                                                           45 
2.4.3 Ion exchange chromatography                                                                           46 
2.4.4 Ni2+ chelation chromatography for His-tag purification                                       46 
 
vii 
 
2.5 SELECTIVE LABELLING ON LYSINE RESIDUES ............................................. 47 
2.5.1 Protection of lysine residues                                                                           47 
2.5.2 HBS Lysine Biotinylation                                                                                       47 
2.5.3 Protein Digestion                                                                                                   48 
2.5.4 Biotinylated Peptide Purification                                                                           48 
   2.6 SELECTIVE LABELLING ON ARGININE RESIDUES .................................... 49 
2.6.1 Protection of arginine side chains                                                                           49 
2.6.2 Labelling of Arginine side chain                                                                           49 
2.6.3 Sample preparation for Mass spectrometry                                                              50 
 
2.7 PROTECT AND LABEL WITH POLYSACCHARIDE IN SOLUTION .............. 51 
2.7.1 Buffer exchange proteins                                                                                       51 
2.7.2 Protection of lysine/arginine exposed to solvent                                                   51 
2.7.3 Selective labelling of lysine/arginine of binding sites                                       52 
2.7.4 Sample preparation for MALDI-TOF                                                               53 
 
2.8 MALDI-TOF FOR IDENTIFICATIONS OF LABELLED PEPTIDES ................ 53 
2.9 PYTHON SCRIPTS FOR THE IDENTIFICATIONS OF LABELLED RESIDUES
 .............................................................................................................................................. 54 
 
CHAPTER 3 PURIFICATION OF PARACINE FGFs                                                   57 
3.1 INTRODUCTION ........................................................................................................ 57 
3.2 PURIFICATIONS OF PROTEINS ............................................................................ 58 
3.2.1. Purification of FGF-2                                                                                       58 
3.2.2. Purification of FGF-1                                                                                       61 
3.2.3. Purification of FGF-4                                                                                       64 
3.2.4. Purification of Halo-FGF6, FGF9 and FGF17                                                   64 
3.2.4.1 Purification of FGF6 ......................................................................................... 65 
3.2.4.1 Purification of FGF9 ......................................................................................... 67 
3.2.4.1 Purification of FGF17 ....................................................................................... 68 
3.2.5. Purification of FGF-3, FGF16 and FGF18                                                   69 
3.2.5.1 Purification of FGF3 ......................................................................................... 69 
3.2.5.1 Purification of FGF16 ....................................................................................... 70 
3.2.5.1 Purification of FGF18 ....................................................................................... 71 
viii 
 
3.2.6. Purification of Halo-FGF5                                                                                       72 
3.2.7. Purification of Halo-FGF8                                                                               73 
3.2.8. Purification of Halo-FGF22                                                                           76 
 
CHAPTER 4 SELECTIVE LABELLING OF ARGININE RESIDUES ENGAGED IN 
BINDING SULFATEDGLYCOSAMINOGLYCAN                                                   79 
4.1 INTRODUCTION ........................................................................................................ 79 
4.2 THE CHEMICAL MODIFICATION OF ARGININE ............................................ 80 
4.2.1 Arginine modification, reagents, and conditions                                                   81 
4.2.1.1 Phenylglyoxal                                                                                                    82 
4.2.1.2 2,3 butanedione                                                                                                  83 
4.2.1.3 1,2 cyclohexanedione                                                                                         84 
4.2.1.4 p-hydroxyphenylglyoxal (HPG)                                                                        84 
4.2.2 Choice of reagents and the challenges                                                               84 
 
4.3 MANUSCRIPT: SELECTIVE LABELLING OF ARGININE RESIDUES 
ENGAGED IN BINDING SULFATEDGLYCOSAMINOGLYCAN…………………   85 
 
CHAPTER 5 THE IDENTIFICATION OF LYSINE AND ARGININE RESIDUES 
INVOLVED IN HEPARIN BINDING IN THE FIFTEEN PARACRINE FIBROBLAST 
GROWTH FACTORS  
5.1. INTRODUCTION ..................................................................................................... 145 
5.2 RESULTS .................................................................................................................... 148 
5.2.1 FGF4 subfamily (FGF4/5/6)                                                                         150 
5.2.1.1 FGF4 ............................................................................................................... 150 
5.2.1.2 FGF6 ............................................................................................................... 158 
5.2.1.3 FGF5 ............................................................................................................... 162 
5.2.2 FGF9 subfamily (FGF9/16/20)                                                                         168 
5.2.2.1 FGF9 ............................................................................................................... 168 
5.2.2.2 FGF20 ............................................................................................................. 172 
5.2.2.3 FGF16 ............................................................................................................. 176 
5.2.3 FGF8 subfamily (FGF8/17/18)                                                                         179 
5.2.3.1 FGF8 ............................................................................................................... 179 
5.2.3.2 FGF17 ............................................................................................................. 183 
5.2.3.3 FGF18 ............................................................................................................. 186 
5.2.4 FGF7 subfamily (FGF3/7/10/22)                                                                         189 
ix 
 
5.2.4.1 FGF7 ............................................................................................................... 189 
5.2.4.2 FGF10 ............................................................................................................. 193 
5.2.4.3 FGF3 ............................................................................................................... 196 
5.2.4.4 FGF22 ............................................................................................................. 199 
5.3 DISCUSSION .............................................................................................................. 203 
 
CHAPTER 6 ELECTROSTATIC INTERACTIONS BETWEEN FIBROBLAST 
GROWTH FACTORS OF FGF7 SUBFAMILY AND CHONROITIN SULFATE, 
DEMANTAN SULFATE IN SOLUTION                                                                         243 
6.1 INTRODUCTION ...................................................................................................... 243 
6.2 RESULTS .................................................................................................................... 244 
6.2.1 FGF7                                                                                                             244 
6.2.1.1. The interaction of FGF7 with heparin performed in PB buffer containing 50 mM 
NaCl ............................................................................................................................ 244 
6.2.1.2. The interaction of FGF7 with CS performed in PB buffer, 10 mM NaCl ..... 246 
6.2.1.3. The interaction of FGF7 with DS performed in PB buffer, 10 mM NaCl ..... 247 
6.2.1.4. Location of labelled lysine residues on the surface ....................................... 248 
6.2.2 FGF3                                                                                                             251 
6.2.2.1 The interaction of FGF3 with heparin ............................................................ 251 
6.2.2.2 The interaction of FGF3 with DS performed in PB buffer 10 mM NaCl ....... 252 
6.2.2.3 Location of labelled lysine residues in FGF3 on the surface .......................... 253 
6.2.3 FGF10                                                                                                             255 
6.2.3.1 Lysine residues involving in the engagement of FGF10 to heparin ............... 255 
6.2.3.2 Lysine residues involving in the engagement of FGF10 to CS ...................... 256 
6.2.3.3 Lysine residues involving in the engagement of FGF10 to DS ...................... 256 
6.2.3.4 Location of labelled lysine residues on the surface ........................................ 257 
6.3 DISCUSSION .............................................................................................................. 260 
 
CHAPTER 7 SELETIVE LABELLING OF LYSINE AND ARGININE RESIDUES FOR 
NON- FIBROBLAST GROWTH FACTORS PROTEIN- HS4C3 ANTIBODY 270 
7.1 INTRODUCTION ...................................................................................................... 270 
7.2 RESULTS .................................................................................................................... 271 
7.2.1 Optimization of the conditions for protect and label on heparin mini-column 271 
7.2.2 Protect and Label strategy for the identification of arginine/lysine in proteins that 
engage heparin (Section Method 2.7, 2.8 and 2.9)                                                 273 
x 
 
7.2.3 Locations of modified arginine residues in the sequence and structure.             274 
7.3 DISCUSSION .............................................................................................................. 278 
 
CHAPTER 8 MODELLING OF HEPARIN BINDING PATTERN ON HBS4C3 279 
8.1 INTRODUCTION ........................................................................................................ 279 
8.2 RESULTS ..................................................................................................................... 279 
8.3 DISCUSSION………………………………………………………………………….290 
 
CHAPTER 9 GENERAL DISCUSSION AND PERSPECTIVE 292 
9.1 DISCUSSION ............................................................................................................... 292 
Further work ....................................................................................................................... 300 
REFERENCES                                                                                                             304 
 
 
  
xi 
 
List of Figures: 
Figure 1.1: Phylogenetic tree of the paracrine FGFs. 3 
Figure 1.2: The structure of FGF2 illustrating the core beta trefoil. 9 
Figure 1.3: Disaccharide repeating unit of GAG members 11 
Figure 1.4: Chain initiation of HS/CS/DS in synthesis. 12 
Figure 1.5: Synthesis of HS. Major and Minor pathways of HS biosynthesis 16 
Figure 1.6: Structures of 6 defined CS disaccharide units 18 
Figure 1.7: The two distinct degrees of disaccharide [(-4GlcAβ1-3GalNAcβ1-)] of CS. 25 
Figure 1.8: Conformation of glucuronic acid. 26 
Figure 1.9: Interactions of arginine and lysine side chains with sulfate groups. 31 
Figure 3.1: Expression and purification of FGF2. (FGF2 molecular weight: 16.7 kDa) 60 
Figure 3.2: Expression and purification of FGF1. (FGF1 molecular weight: 19.1 kDa) 62 
Figure 3.3: Expression and purification of FGF4. (FGF4 molecular weight: 19.2 kDa). 63 
Figure 3.4: Expression and purification of Halo-FGF6. (Molecular weight: 51.1 kDa).  64 
Figure 3.5: Expression and purification of FGF9. (FGF9 molecular weight: 23.4 kDa) 65 
Figure 3.6: Expression and purification of FGF17. (FGF17 molecular weight: 23.3 kDa)  66 
Figure 3.7: Expression and purification of FGF3. (FGF3 molecular weight: 26.89 kDa)  68 
Figure 3.8: Expression and purification of FGF16. (FGF16 molecular weight: 21.4 kDa) 69 
Figure 3.9: Expression and purification of FGF18. (Molecular weight: 24.03 kDa)  70 
Figure 3.10: Purification of Halo-FGF5 (Molecular weight 58.95 kDa) 72 
Figure 3.11: Purification of Halo-FGF8 (Molecular weight 57.5 kDa) 74 
Figure 3.12: Purification of Halo-FGF22 (Molecular weight 52.3 kDa) 76 
Figure 5.1: Selective labelling of arginine residues in the heparin binding sites of FGF4.  153 
Figure 5.2: Heparin binding arginine and lysine residues in FGF4. 155 
Figure 5.3: Heparin binding arginine and lysine residues in FGF6. 159 
Figure 5.4: Heparin binding arginine and lysine residues in FGF5. 165 
Figure 5.5: Heparin binding arginine and lysine residues in FGF9. 169 
Figure 5.6: Heparin binding arginine and lysine residues in FGF20. 173 
Figure 5.7: Heparin binding arginine and lysine residues in FGF16. 176 
Figure 5.8: Heparin binding arginine and lysine residues in FGF8. 180 
xii 
 
Figure 5.9: Heparin binding arginine and lysine residues in FGF17. 183 
Figure 5.10: Heparin binding arginine and lysine residues in FGF18. 186 
Figure 5.11: Heparin binding arginine and lysine residues in FGF7. 189 
Figure 5.12: Heparin binding arginine and lysine residues in FGF10. 192 
Figure 5.13: Heparin binding arginine and lysine residues in FGF3. 195 
Figure 5.14: Heparin binding arginine and lysine residues in FGF22. 199 
Figure 5.15: Positions of labelled arginine and lysine residues in the picture of the 
subfamily sequence alignment 
204 
Figure 6.1: Labelled lysine residues in GAG-binding sites of FGF7 249 
Figure 6.2: Labelled lysine residues in GAG-binding sites of FGF3. 253 
Figure 6.3: Labelled lysine residues in GAG-binding sites of FGF10. 258 
Figure 7.1: Testing conditions for the selective labelling of lysine residues on HS4C3 272 
Figure 7.2: The locations of labelled lysine and arginine residues on the sequence of the 
antibody HS4C3 
277 
Figure 7.3: The locations of lysine, arginine residues engaging heparin. 277 
Figure 7.4: Electrostatic density of Antibody surface. 278 
Figure 8.1: The binding of CDR3 to the core of heparin dodesaccharide. 283 
Figure 8.2: Territory of the antibody binding reducing end sugars -1 to -5. 284 
Figure 8.3: Territory of the antibody binding non-reducing end sugars +3 and +6. 286 
Figure 8.4: Model for binding of labelled lysine and arginine residues on antibody to 
sugar based on distance 
288 
Figure 9.1: The chemical structure of Biotin-S-S-linker-PGO. 291 
  
  
xiii 
 
List of Tables: 
Table 1.1: Different CS disaccharide units. 19 
Table 2.1: SDS-PAGE Gel preparation 43 
Table 3.1: Recombinant human FGF proteins and their N-terminal tag. 58 
Table 5.2A: FGF4 MS analysis based on prediction by Prospector. 210 
Table 5.2B: FGF4 MS analysis based on prediction by PeptideMass.  211 
Table 5.3A: FGF6 MS analysis based on prediction by Prospector. 212 
Table 5.3B: FGF6 MS analysis based on prediction by PeptideMass. 213 
Table 5.4A: FGF5 MS analysis based on prediction by Prospector. 214 
Table 5.4B: FGF5 MS analysis based on prediction by PeptideMass. 215 
Table 5.4C: Selective labelling of lysine residues. FGF5 peptide analysis based on 
prediction by PeptideMass. 
216 
Table 5.5A: FGF9 peptide analysis based on prediction by Prospector. 217 
Table 5.5B: FGF9 peptide analysis based on prediction by PeptideMass. 218 
Table 5.6A: FGF20 peptide analysis based on prediction by Prospector. 219 
Table 5.6B: FGF20 peptide analysis based on prediction by PeptideMass. 220 
Table 5.7A: FGF16 peptide analysis based on prediction by Prospector. 222 
Table 5.7B: FGF16 peptide analysis based on prediction by PeptideMass. 223 
Table 5.7C: Selective labelling of lysine residues. FGF16 peptide analysis based 
on prediction by PeptideMass. 
224 
Table 5.8A: FGF8 peptide analysis based on prediction by Prospector. 225 
Table 5.8B: FGF8 peptide analysis based on prediction by PeptideMass. 226 
Table 5.8C: Selective labelling of lysine residues. FGF8 peptide analysis based on 
prediction by PeptideMass. 
227 
Table 5.9A: FGF17 MS analysis based on prediction by Prospector. 228 
Table 5.9B: FGF17 MS analysis based on prediction by PeptideMass. 229 
Table 5.10A: FGF18 MS analysis based on prediction by Prospector. 230 
Table 5.10B: FGF18 MS analysis based on prediction by PeptideMass. 231 
Table 5.11A: FGF7 peptide analysis based on prediction by Prospector. 232 
Table 5.11B: FGF7 peptide analysis based on prediction by PeptideMass. 233 
Table 5.12A: FGF10 peptide analysis based on prediction by Prospector. 234 
xiv 
 
Table 5.12B: FGF10 peptide analysis based on prediction by PeptideMass. 235 
Table 5.13A: FGF3 peptide analysis based on prediction by Prospector. 236 
Table 5.13B: FGF3 peptide analysis based on prediction by PeptideMass. 237 
Table 5.14A: FGF22 peptide analysis based on prediction by Prospector. 239 
Table 5.14B: FGF22 peptide analysis based on prediction by PeptideMass 240 
Table 5.14C: Selective labelling of lysine residues. FGF22 peptide analysis based 
on prediction by PeptideMass. 
241 
Table 6.1A: FGF7 interaction with heparin, MS analysis. 262 
Table 6.1B: FGF7 interaction with CS, MS analysis. 263 
Table 6.1C: FGF7 interaction with DS, MS analysis. 264 
Table 6.2A: FGF3 interaction with heparin, MS analysis. 265 
Table 6.2B: FGF3 interaction with DS, MS analysis. 266 
Table 6.3A: FGF10 interaction with heparin, MS analysis. 267 
Table 6.3B: FGF10 interaction with CS, MS analysis. 268 
Table 6.3C: FGF10 interaction with DS, MS analysis. 269 
Table 7.1: MS analysis based on prediction by Prospector for the modifications on 
lysine residues of the antibody. 
279 
Table 7.2: MS analysis based on prediction by Prospector for the modifications on 
arginine residues of the antibody. 
280 
Table 9.1: FGF subfamilies with differences in HBS configuration  
 
295 
  
xv 
 
List of Abbreviations 
ACN: Acetonitrile  
Arg: Arginine  
BSA: Bovine serum, albumin  
CS: Chondroitin sulfate  
DMSO: Dimethyl sulphoxide  
DMEM: Dulbecco’s modified Eagle medium  
dp: Degree of polymerization 
DS: Dermatan sulfate  
DSF: Differential scanning fluorimetry  
DTT: Dithiothreitol  
ECM: Extracellular matrix  
EDTA: Ethylenediamine tetra-acetic acid  
FA: Fibronectin adhesion-promoting peptide  
FGF: Fibroblast growth factor 
FGFR: Fibroblast growth factor receptor  
HA: Hyaluronic acid  
HBS: Heparin binding site 
HPG: P-hydroxyl phenylglyoxal 
HS: Heparan sulfate  
HSPGs: Heparan sulfate proteoglycans  
GAG: Glycosaminoglycans  
GlcNAc: N-acetylglucosamine  
GlcNS: N-sulfoglucosamine 
xvi 
 
IdoA: L-iduronic acid  
IPTG: Isopropyl β-D-1-thiogalactopyranoside  
LB: Lysogeny broth  
Lys: Lysine  
MW: Molecular weight  
NHS: N-hydroxysuccinimide  
PAGE: Polyacrylamide gel electrophoresis  
PBS: Phosphate-buffered saline 
PCR: Polymerase chain reaction  
PDB: Protein data bank  
PGO: Phenylglyoxal 
PI: Phosphatidylinositol  
RE: Reducing end  
SDS: Sodium dodecyl sulphate  
TB: Terrific Broth  
TCA: Trichloroacetic acid  
TEMED: N,N,N’,N’,Tetramethylethylenediamine  
TFA: Trifluoroacetic acid  
TM: Melting temperature  
Tris: Tris (hydroxymethyl) methylamine 
Tween 20: Polyoxyethylenesorbitan monolaurate 
 
1 
 
CHAPTER 1 GENERAL INTRODUCTION 
1.1 OVERVIEW 
Communication through the assembly of ligand and receptor complex present at an 
extracellular interface is common in multicellular organism. The specificity in binding between 
FGF, its unique subset of FGFRs and the cofactor HS tightly controls the response to FGF 
simulation [1]. The engagement of FGF with HS also regulates the transport of different FGFs 
in extracellular matrix (ECM) [2]. HS is ubiquitous in the ECM and are important actors to 
guide complex biological phenomena, such as embryonic development and organism 
homeostasis. Besides HS, other two proteoglycans CS and DS also interact with FGFs, 
however, the structural properties of these interactions have been obscured. What are the 
structures of FGFs, HS, CS and DS?? What do we know about these interactions in terms of 
structures and functions? How have we studied them? Those three points will be briefly 
introduced later. 
1.2 FIBROBLAST GROWTH FACTORS 
Fibroblast growth factors (FGFs) are a family of 22 members in mammals (FGF1 to FGF23, 
with humans possessing FGF19, but not FGF15 and mice FGF15, but not FGF19). These 
proteins have 13 % to 71 % sequence identity and a highly conserved central β trefoil structure. 
First identified were basic FGF (FGF2) and acidic FGF (FGF1) which were isolated from 
pituitary and brain [3][4][5]. Thereafter, twenty-two fgf genes have been added to the list of 
FGF family, fgf1-23. Among them, fifteen of the FGFs are paracrine effectors, which bind the 
glycosaminoglycan HS and these are the focus of this study. 
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1.2.1 FGF sub-families 
The original classification of FGFs was made according to their amino acid sequence 
conservation [6]. Following the Human Genome Project, which defined the human fgf genes, 
the same approach was used to establish phylogeny of the entire family. Accordingly, the 22 
FGFs in mammals are classified into 7 sub-families, FGF1/2; FGF4/5/6; FGF7/3/10/22; 
FGF8/17/18; FGF9/16/20; FGF11/12/13/14 and FGF19/21/23 [1]. However, the classification 
of FGF3 and FGF5 is debated and more recently, other classifications have been proposed. 
First, the work based on synteny in invertebrates [7] and vertebrates [8] suggested that FGF3 
would be in the same subfamily as FGF4 and FGF6, and further grouped with the FGF19/21/23 
subfamily to form a single subfamily FGF3/4/6/19/21/13. The same analysis indicates that 
FGF5 would belong to the FGF1/2 subfamily. A deeper approach was taken by Oulion and 
colleagues [9], who used many characteristics of FGFs including gene content, phylogenetic 
distribution, and conservation of synteny to classify FGF3 into a new single family. This study 
also used a deeper synteny analysis of human FGF5 locus to claim that this FGF belongs to 
FGF4 family rather than FGF2 family.  
Based on their location, their binding partners and so their functions, FGFs are classified as 
intracellular, endocrine and paracrine. Paracrine FGFs are the largest group comprising the 
FGF1, FGF4, FGF7, FGF8, and FGF9 subfamilies. These all bind HS and possess a dual 
receptor system of HS co-receptor and FGF receptor (FGFR) tyrosine kinase. The FGF19 
subfamily (in humans FGF19, FGF21 and FGF23) do not bind HS and signal through a dual 
receptor system consisting of  members of Klotho family, α-Klotho or β-Klotho and an FGFR 
[10]. The absence of binding to HS enables their systemic release. Bearing high sequence and 
structural identity to FGFs are the FGF homologous factors (FHFs) or so called intracellular 
FGFs, also sometimes called (incorrectly) intracrine FGFs. These are the FGF11 subfamily 
with FHF1 = FGF12, FHF2 = FGF13, FHF3 = FGF11, FHF4 = FGF14 [11][12]. Unlike other 
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FGFs that function through FGFR-dependent manner, FHFs bind to intracellular proteins and 
modulate their function. For example, FHF1, FHF2 and FHF4 bind to the cytosolic carboxyl 
terminal tail of voltage-gated sodium channels (VGSCs) [13] and FHF2 to a neuronal MAP 
kinase scaffold protein, islet-brain-2 (IB2) [14]. 
 
Figure 1.1: Phylogenetic tree of the paracrine FGFs. They can be arranged into five 
subfamily: FGF1, FGF4, FGF7, FGF8, FGF9. Branch lengths are proportinal to the 
evolutionary distance between each genes. 
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1.2.2 Genes encoding FGFs 
In general, fgf genes comprise three to five coding exons, named as number 1, 2 to 5 but the 
introns between them are extremely varied from 4.9 kb (in fgf3 and fgf4) to over 100 kb (in 
fgf12) [15]. Some fgf genes have unique properties. fgf2 and fgf3 have additional 5’ transcribed 
region. In fgf8, exon 1 is subdivided into two, three or four alternatively spliced sub-exons, 
denoted as 1A, B, C, D [16]. When the coding region starts with exon 1, it initiates with 
methionine (coded as AUG), however, when it has 5’ transcribed region, the start is upstream 
CUG codons [17]. For members of the fgf8 family, AUG is always the initiation codon [16] . 
This gene organisation is conserved in mammals. 
1.2.3 Evolution of FGFs 
 
The fact that most of the fgfs in humans locate in paralogons (sets of paralogous chromosal 
regions) indicates that they follow the general scheme of evolution of the human genome, 
which included two large-scale duplications [1]. The consequence of the first series of 
duplication from a single or few acheo-FGFs or alternatively FGF ancestor genes generated 
eight proto-FGFs, but losses occurred later bringing the number of proto-FGFs to two in 
protostomians. This was followed by the second major expansion in early vertebrates. The 
number of fgf genes increased dramatically before gene losses happened again and resulted in 
the 22 present day fgfs. 
The arguments for synteny are somewhat convoluted. Thus, it is argued that gene linkage will 
exist between members of each sub-family, whereas any such linkage between members of 
different FGF subfamilies arises by chance [1] [8]. For example, fgf3, fgf4, and fgf19 are close 
in the q13.3 region of chromosome 11, and fgf6 and fgf23 are linked on chromosome 6. On the 
other hand, fgf1 locates in chromosome 5, but fgf2 is on chromosome 4. fgf4, fgf5 and fgf6 of 
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the FGF4 family are located in three different chromosomes, chromosome 11, 4 and 12, 
respectively. 
Given the short length of the FGF domain and the divergence of the sequences between the 
different lineages, the phylogenetic distribution of FGF genes into eight subfamilies was 
employed to solve the orthology relationship between the different members of this family [9]. 
As a result, there are two major evolutionary scenarios. The first one suggests that the ancestral 
eumetazoan contained an fgf gene set of at least two genes, which are orthologs of fgf1/2 and 
fgf8/17/18/24. Indeed, the present diversity of the fgf genes into eight subfamilies was 
generated from the important chordate-specific duplications [9]. The second hypothesis starts 
from the maximum (eight genes in the eumetazoan ancestor). It implies the presence of two fgf 
genes, orthologs of the fgf9/16/20 and fgf8/17/18/24 families in the ancestor of nematodes. 
Moreover, it highlighted a higher degree of gene loss during metazoan evolution including six 
gene losses in cnidarians, five in protostomes and five in ambulacrarians. However, one 
important aspect missing from these analyses is ‘b’ and ‘c’ FGFR isoform selectivity. In an 
extant nematode, C. elegans, there are just two fgfs and one fgfr; alternative splicing of the fgfr 
leads to selectivity for the two fgfs [9]. This is a recurrent theme in metazoan development: ‘b’ 
isoform fgfr is generally produced by epithelial tissues, and ‘b’ isoform selective fgf ligand by 
the neighbouring mesenchyme, whereas the opposite is true for ‘c’ isoform fgfr and ‘c’ isoform 
selective FGF ligand. This is an essential feature of mesenchyme-epithelial communication 
during development (Section 1.2.1). So what can be concluded from the above is the occurrence 
of events of gene duplication and gene loss at different times and in different evolutionary 
lineages during evolutionary history of FGF gene family. 
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1.2.4 Roles of paracrine FGFs in development 
A number of functions of paracrine FGFs in development have been established by many 
studies on Fgf knockout mice. Most essential during embryonic developments are Fgf4 and 
Fgf8 genes when the mouse with these two genes knocked out all died [18] [19]. The germline 
mutation of Fgf2 gene is related to a reduced number of cortical neurons in the adult. Indeed, 
during the middle to late stage of neurogenesis, the downregulation of Fgf2 and Fgfr1 has been 
observed [20]. Fgf5 gene knockout results in abnormal long hair in mice [21] whereas Fgf7 
gene is involved in kidney development [22]. Related to the development of mesenchyme are 
Fgf9, Fgf10 and Fgf18, with gene knock out leading to the death of mice shortly after birth. 
Fgf-10-deficient mice fail to initiate limb buds [23]. These mice also showed perinatal lethality 
due to complete lack of lungs. The disruption of Fgf9 resulted in a  reduced lung mesenchyme 
and decreased branching of airways in mice lungs, suggesting that Fgf9 has impact on lung 
size through stimulating mesenchymal proliferation [24]. Fgf18-deficient mice exhibited 
several abnormal phenomena, including the delay of the progress of cranial suture closure, the 
decrease of the proliferation of calvarial osteogenic mesenchymal cells, and the postponement 
of terminal differentiation of these cells to calvarial osteoblasts. These observations suggested 
functions of FGF18 in the regulation of cell proliferation and differentiation in osteogenesis 
and in chondrogenesis [25]. The functions of Fgf3 in the development of the ear and tail in 
mice have been addressed by gene targeting experiments [26]. In these, mice carrying a 
targeted insertion of a neor gene in the int-2 (Fgf-3) did not often survive to adulthood. Mice 
with knockout of Fgf16 were viable, but had a decrease in heart weight and cardiomyocyte cell 
numbers at 6 months of age [27]. Moreover, Fgf1 knock out no phenotype in development, but 
did have in the adult if it had been stress with a high-fat diet, suggesting its potential role in 
nutrient homeostasis [28]. 
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1.2.5 Structural features 
 
Structural studies of FGFs identified from the outset are that they possess a β trefoil structure 
of 12 antiparallel β strands (120-130 amino acids) arranged as four-stranded β sheets arranged 
in a triangular array in the conserved core region (Figure 2) [29]. This folding pattern  is similar 
to that of the interleukins IL-1β and IL-1α [30]. Some structure have β strand XI as an α-helix 
but others have very poor definition here, for example FGF 10 [31]. 
Even though 3-D structures of FGFs represented a high level of similarity across families, there 
are some undeniable differences. For example, FGF7 and FGF10 in the FGF7 subfamily [32] 
[31] have a longer β strand I (11 amino acids) than that of FGF1 and FGF2 (3 amino acids) 
[29] [33]. In addition, the length of loop between β strands I-II and β strands IX-X of FGF1 
and FGF2 is much shorter than that of FGF9 [34], FGF7 and FGF10 [31]. 
The HS canonical binding sites, so called HBS-1, locates in the region between β10 and 
β12,which is rich in arginine and lysine [35][36] [37] [38].  
Variations in loops and N-, C-termini 
The function of the N-terminus, including N-terminal spliced regions of FGF8 and N-terminal 
alternatively translated extensions of FGF2 and FGF3 are poorly understood. There is very 
little structural information, as the N-terminus is often disordered. In FGF2, an NMR study 
suggests that the N-terminus of the protein translated form the AUG adopts two structures that 
are in equilibrium [39]. Higher-molecular-weight forms (22.5, 23.1, and 24.2 kDa) of FGF2 
contain the colinear N-terminal extensions of up to 53 amino acids which then direct, post-
translationally, the extended forms of FGF2 to the nucleus [40] [41]. Members of FGF1 
subfamily, FGF1 and FGF2 do not have the signal sequence but because they are present in the 
cell surface and within ECM, hence they are secreted by a typical mechanism called alternative 
exocytotic that bypasses the endoplasmic reticulumn Golgi pathway [17]. In the FGF9 family, 
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the N-terminus is found to adopt an α helical structure in crystals and is thought to contribute 
to the dimerization of these FGFs and in this way regulates binding to the FGFR [42] [34]. The 
N-terminal spliced variants of FGF8 have been found to contribute to the interaction with the 
FGFR. 
The structure and function of the C-terminus in the paracrine FGFs is also not understood. It 
has been demonstrated that in FGF1, the deletion of C-terminus caused a decrease in protein 
synthesis simulated by FGF1 on the cells [43]. Among the paracrine FGFs, FGF3 and FGF5 
possess the longest C-tails with a high density of positive charge residues. In particular, 
dominant in FGF5’s C-tail is lysine and for FGF3, is arginine. This indicates the potential for 
binding to a negatively charged partner such as HS. Members of the FGF8 sub-family (FGF8, 
FGF17 and FGF18) also have extended C-termini, which are relatively conserved and include 
4 to 6 basic amino acids. 
For the FGFs secreted conventionally via the endoplasmic reticulum/Golgi, the signal peptide 
is located at the N-terminus [6]. In most of these FGFs the secretory signal peptide is believed 
to be cleaved, as seen in FGFs 3-8 [6], FGF10, FGF17-19, 21 and 23 [44]. By contrast, some 
FGFs do not contain a cleavable N-terminal signal peptide. Thus, the signal peptide remains 
associated with the native protein, but the protein is secreted and is not membrane-associated. 
This is the case for the FGF9 subfamily (Fig. 1). For FGF22, its putative N-terminal signal 
peptide is cleaved, but then apparently remains attached to the cell surface [44]. 
Another difference between the structures of these FGFs is the conformation of the in N- and 
C-termini. The two termini in the FGF-1 sub-family are disordered in crystal structures to the 
extent that these proteins are expressed as truncated variants in order to obtain crystals. In 
contrast, in FGF-9, the N-terminal contains an α helix and the C-terminal of FGF-9 (17 amino 
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acids), which is much longer than that of FGF-1 (4 amino acids) and FGF-2 (3 amino acids) 
also contains a short helical structure 
 
Figure 1.2: The structure of FGF2 illustrating the core beta trefoil. The typical beta trefoil 
(FGF2, PDB 1BFG [29]) has 12 antiparallel β strands (120-130 amino acids) arranged as four-
stranded β sheets arranged in a triangular array. 
1.3 PROTEOGLYCANS 
Proteoglycans (PGs) are O-glycosylated proteins which are secreted into the ECM, inserted 
into the plasma membrane, or stored in secretory granules. Perlecan, glypicans, decorin, and 
syndecans are classic PGs. Proteoglycans comprises two elements, first, a core protein, second, 
a glycosaminoglycan (GAG) chain linked to the side chain of a serine side chain and in some 
instances to that of an asparagine. Glycosaminoglycans are linear polysaccharides mainly 
consisting of disaccharide building blocks of an amino sugar (N-acetyl-α-D-glucosamine or N-
acetyl-β-D-galactosamine) and a uronic acid (β-D-glucuronic acid or α-L-iduronic acid) or 
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an amino sugar and galactose (Figure 1.3). The family of GAGs includes 4 members based on 
their disaccharide repeat units and biosynthetic pathway: chondroitin sulfate (CS) and dermatan 
sulfate (DS), hyaluronic acid (HA), keratan sulfate (KS), heparan sulfate (HS) and heparin [45].  
1.3.1 Structural properties of GAGs 
Hyaluronic acid (HA) consists of β-D-glucuronic acid linked to 2-acetamido-2-deoxy-β-D-
glucopyranose (N-acetyl glucosamine) though alternating 1→3 and 1→4 linkages. It is the only 
GAG that is synthesized on the plasma membrane, not built on a core protein in the Golgi, and 
that does not contain sulfate groups (Figure 1.3). In the case of KS, the chains are linked to 
either Asn or Ser/Thr residues in core proteins. The main component of the chain is sulfated 
poly-N-acetyl-galactosamine (Figure 1.3).  
The GAG chains of CS/DS and HS/heparin are attached to the serine residues in core proteins. 
The building block of CS/DS is a disaccharide of sulfate-substituted N-acetyl galactosamine 
(GalNAc)-GlcA polymerized into long chains. Owing to the common disaccharide unit, DS 
was known as chondroitin sulfate B, however, it is distinguished from chondroitin sulfates-A 
(4-O-sulfated) and -C (6-O-sulfated) by the presence of iduronic acid (IdoA), which is formed 
post-polymerisation by epimerisation of the GlcA (Figure 1.3).  
HS is composed of disaccharide repeating units comprising 1,4 linked β-D-glucuronate, (GlcA) 
and N-acetyl-α-D-glucosamine (GlcNAc) [46] with diverse modifications including sulfation 
at 2-O-, 3-O-, 6-O- and N positions and epimerisation of GlcA to L-iduronic acid (IdoA) 
(Figure 1.3) [47]. 
Heparin shares with HS the disaccharide building block 1,4 linked β-D-glucuronate, (GlcA) 
and α-D-N-acetyl glucosamine (GlcN)NAc, however, it has much more extensive levels of 
modifications. 
11 
 
 
Figure 1.3: Disaccharide repeating unit of GAG members. For HS and heparin, the 
repeating disaccharide unit contains: a D-glucuronic acid or L-iduronic acid and a D-
glucosamine. For CS and DS, the repeating disaccharide unit contains: a D-glucuronic acid or 
L-iduronic acid and D-galactosamine. HA is composed of the repeating units of a D-glucuronic 
acid and 2-aceteamido-deoxyl- β-D-glucopyranose. For KS, the repeating disaccharide unit 
contains: a galactose and a D-glucosamine. 
1.3.2 Hierarchical biosynthesis of GAGs 
The biosynthesis of two classes of GAGs (CS/DS and HS/heparin) have a common chain 
initiation biosynthesis pathway. The discrimination between them occurs at the last step of 
chain initiation, which then leads to two distinct pathways of chain elongation and 
modification. 
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1.3.2.1 Chain initiation in HS and CS/DS synthesis 
 CS/DS/HS/heparin are synthesized as covalent complexes, in which, the first step is the 
assembly of a linker tetrasaccharide attached to core protein of proteoglycans (PGs) at a 
specific Ser-Gly motif flanked by at least two acidic amino acid residues. The linker 
tetrasaccharide β Xyl-β GlcA-1,3-β Gal-1,3-β Gal (Figure 1.4) is formed by the attachment of 
a xylose (Xyl) by Xylosyltransferase to the serine side chain, followed by the addition of  
two galactose (Gal) residues by galactosyltransferases I and II (GalTI and GalTII), and then 
finally by the addition of glucuronic acid (GlcA) by glucuronosyltransferase I (GlcATI) 
linkage [45][48]. The subcellular localization of each step in chain initiation is not identical. 
While the attachment of xylose to the core protein is believed to occur in the endoplasmic 
reticulum (ER), the further assembly of the linkage region and the other parts of the chain has 
been shown to be in the Golgi apparatus. 
 
Figure 1.4: Chain initiation of HS/CS/DS in synthesis. The synthesis of HS, CS and DS 
shares the initiation step of synthesis the GAG-core protein linkage region. They start to branch 
out from the step of chain elongation. 
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1.3.2.2 Next stages in the biosynthesis of HS 
1.3.2.2.1 Chain elongation (chain polymerization)  
The elongation step is where the biosynthesis of heparan sulfate/heparin and chondroitin 
sulfate/dermatan sulfate diverge (Figure 1.4), which occurs by the attachment of a N-
acetylglucosamine (GlcNAc) residue by O-linked N-acetylglucosamine (O-
GlcNAc) transferase to direct the synthesis of a chain of heparan sulfate/heparin or a N-
acetylgalactosamine (GalNAc) residue by N-acetylgalactosaminyl transferase (chondroitin 
sulfate/dermatan sulfate), which results in the synthesis of a chain of CS/DS (Figure 1.4). There 
follows the stepwise addition of GlcA and GlcNAc residues in the case of heparan 
sulfate/heparin and for CS/DS the addition of GlcA and GalNAc residues.  
1.3.2.2.2 Chain modification 
The diversity in arrangement of post-polymerization modifications along the HS and hepairn 
chain leads to substantial structural variability (Figure 1.5) and is mediated by four classes of 
sulfotransferases and an epimerase. 
The next stage, is catalysed by the GlcA C5 epimerase (heparosan-N-sulfate-glucuronate 5-
epimerase), which epimerises β-D-GlcA to α-L-IdoA. For substrate recognition, the GlcNS 
residue has to be linked to the non-reducing side of a potential GlcA [49]. This epimerase 
(Glce) required in HS and heparin synthesis is different from the one involved in epimerisation 
of dermatan sulfate, which is Dse1-2. Some IdoA units are then sulfated at C2 by HS2ST1. 
The occasional addition of 2-O-sulfate groups to GlcA blocks the epimerization reaction. 
O-sulfation can occur at positions 3 and 6 of the glucosamine [50]. There are three 
glucosaminyl 6-O-transferases (6OSTs) that act on GlcNAc and GlcNS. The 6-O sulfation of 
GlcNS blocks 2-O sulfation of a neighbouring IdoA. A number of 3-O-sulfated disaccharides 
are produced by the seven glucosaminyl 3-O-sulfotransferases (3OSTs) [51]–[53], though the 
14 
 
products of these enzymes have not been dissected in depth: GlcA-GlcNS(3S±6S) is produced 
by 3OST1 and 3OST5, IdoA(2S)-GlcNH2(3S±6S) is produced by 3OST3a, 3OST3b, 3OST5 
and 3OST6, and 3OST2 and 3OST4 produce GlcA/IdoA(2S)-GlcNS(3S).  Despite being the 
largest family of HS modification enzymes, 3-O-sulfation is observed less often in HS. 
The N-deacetylation/N-sulfation of GlcNAc residues to form GlcNS is commonly the first 
reaction, as there is a strong dependence of subsequent modifications on GlcNS. It is catalyzed 
by members of a family of four GlcNAc N-deacetylase/N-sulfotransferase enzymes (NDSTs). 
A study on mice where the NDST2 gene was knocked out showed that the mast cells are 
abnormal and lack heparin, although HS from other tissues appeared unaffected, indicating that 
this isoform is responsible for the synthesis of heparin [54]. On the other hand, the N-sulfation 
of HS is mainly performed by NDST-1 [55]. These observations lead to the conclusion that the 
regulation of enzyme activities at the level of transcription, translational and activity through 
posttranslational modification is likely to contribute to the formation of different patterns of N-
acetylation. 
1.3.2.2.3 Major and minor pathways for HS 
The pathway of HS or heparin biosynthesis discussed above is widely accepted, but the 
sequence of reactions, starting with an NDST is unable to explain all the disaccharides found 
in HS/heparin, for example IdoAGlcNAc,6S [56]. Therefore, it has been proposed [56] that 
there are two branches of HS biosynthesis. One, described above has been called the major branch, 
since it accounts for the majority of disaccharides found in the polysaccharide. The other, called the 
minor branch is responsible for the reminder of the modification patterns observed. This bifurcation 
of the synthesis has been ascribed to the preference of the HS epimerase in converting GlcA-GlcNS 
to IdoA-GlcNS efficiently, but also GlcA-GlcNAc to IdoA-GlcNAc inefficiently (Figure 1.5).  
An important feature of HS biosynthesis is that the hierarchical dependence of modifications of the 
major pathway on N-sulfation and directionality imposed by, for example, 6-O sulfation of GlcNS 
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preventing subsequent 2-O sulfation of IdoA, coupled to the partial processivity (apparent if not 
mechanistic) of NDSTs leads to a domain structure.  Thus, the NDSTs tend to modify shorter or 
longer (as in the case of NDST1) tracts of disaccharide units. Before and after these segments they 
‘slip’, modifying only around one GlcNAc in two and in between they appear to ‘pause’ not 
modifying any substrate. The result is that HS chains have NA domains, where every disaccharide 
has a GlcNAc residue, transition domains, where around one in two disaccharides contain GlcNS 
and sulfated domains where every disaccharide contains GlcNS in minor pathway [57] (Figure 1.5) 
[56]. 
1.3.2.2.4 Degradation of surface-bound and extracellular HS 
The 6-O-sulfate groups in HS in the extracellular space can be removed by the extracellular 
sulfatases family (Sulfs), SULF1 and SULF2 which are HS-specific 6-O-endosulfatases [58]. 
Across the family, there are evolutionarily conserved amino acid regions of hydrophilic 
domains (HD) which could anchor Sulf to the cell surface, bind to HS substrates, and mediate 
HS 6-O-endosulfatase enzymatic activity. Degradation of 6-O-sulfation of cell surface HS 
chains promotes Wnt signaling and inhibits growth factor signaling in embryonic tissue 
patterning [59], so this is an important aspect of functional regulation. 
In mammals, extracellular HS may be processed by the secreted enzyme heparanase, an endo-
glucuronidase, which cleave the HS chains into smaller and potentially bioactive HS 
oligosaccharides [60]. This includes the formation of heparin (10–20 kDa) from the newly 
synthesized heparin chains (60–100 kDa) on the serglycin core protein [60].  
HS chains may also be released from the cell surface by shedding. This occurs through the 
action of matrix metalloproteinases cleaving, for example, the core protein of Syndecans [61] 
or  by the action of the notum protein and phospholipases in the case of the lipid-anchored 
glypicans [62] [63]. 
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Figure 1.5: Synthesis of HS. Major and minor pathways of HS biosynthesis (after [56]). 
The upper panel presented the common synthesis of HS. Whereas, the lower panel showed the 
conceptual modifications happening during the synthesis using major pathway (right) or minor 
pathway (left). 
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1.3.2.3 Next stages in the bioynthesis of CS/DS 
1.3.2.3.1 CS- Chain elongation (chain polymerization) 
The polymerization of CS and DS is catalyzed by one or more bifunctional enzymes 
(chondroitin synthases- ChSy) that have β3- glucuronyltransferase-II (GlcATII) and β4-N-
acetylgalactosaminyltransferase-II (GalNAcTII) activities to add individual sugars stepwise to 
the nonreducing end of the growing chain. This results in a chain of up to 70 kDa. Chondroitin 
polymerization also requires the concomitant expression of chondroitin polymerizing factor 
(ChPF), a protein that lacks catalytic activity, but acts as a specific activating factor for ChSy 
to promote the formation of polymers over oligomers [64].  
1.3.2.3.2 CS- Chain modification 
Sulfation of CS/DS in vertebrates is variable and along with epimerisation of GlcA, defines the 
name given to the polymer; the sulfation may occur on GalNAc at position 4- or 6-, or both, in 
the same glycosaminoglycan chains of CS with some GlcA 2- or 3-O-sulfated. DS often has 
GalNAc 4-O-sulfate and IdoA 2-O-sulfate along with some nonsulfated GalNAc and some rare 
GalNAc 6-O-sulfate [48]. Unlike HS, CS/DS chain shows no domain structure, but long tracts 
of fully modified disaccharides. 
The modification patterns of a disaccharide unit composing CS has been characterised as letter, 
A, B (DS), C, D, E, H and K (Figure 1.6 and detail was provided in Table 1). The ordinary 
mature CS, designed CS-A, CS-C and hybrid CS chains are composed of monosulfated 
disaccharide units A and C (Table 1) in various proportions. The peculiar disulfated 
disaccharide units named D, E, H and K units depicted in Table 1 are components of  
oversulfated CS chains [65]. The H unit has also been named as iE, in which the abbreviation 
‘i’ in ‘iE’ stands for IdoUA [66]. Interestingly, the K unit possesses 3-O-sulfation on GlcA 
(Table 1).  
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While many IdoA residues of DS possess 2-O-sulfation, this sulfation is relatively rare in GlcA 
of CS. The activity of 2-sulfotransferase on IdoA is likely dependent on the sulfation of the 
adjacent GalNAc. Thus, IdoA adjacent to nonsulfated GalNAc is generally not sulfated, the 
sulfation is slightly increased with 6-O-sulfated GalNAc, and it is strongest when IdoA is 
adjacent to 4-O-sulated GalNAc [67] [48] . 
In mammals, there is no report of 3-O-sulfation in CS or DS, however, this has been found in 
king crab cartilage [68]. It is also clear that no N-sulfate was observed in these two GAGs. 
 
Figure 1.6: Structures of 6 defined CS disaccharide units (After [65]). 
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Table 1.1: Different CS disaccharide units. The sulfation of disaccharide units and 
epimerisation of GlcA is used to classify CS. CS-B is an old name for DS. The occurrence of 
a single more complex disaccharide, in the context of a simpler disaccharide, is sufficient to 
define the chain. Thus a single IdoA in a chain results in it being called DS. 
Chain type Site of sulfation 
CSA Carbon 4 of the N-acetylgalactosamine (GalNAc) sugar 
CSB (DS) Carbon 2 of the iduronic acid and carbon 4 of the GalNAc 
CSC Carbon 6 of GalNAc 
CSD Carbon 2 of the glucuronic acid and 6 of the GalNAc 
CSE Carbon 4 and 6 of the GalNAc 
CS K Carbon 3 of the glucuronic acid and 6 of the GalNAc 
CS H The iduronic acid and Carbon 4 and 6 of the GalNAc 
 
1.3.2.3.3 Epimerization of DS 
DS is derived from CS by the epimerization of GlcA to IdoA. This event can only occur at a 
low level following polymerisation, since the non-sulfated GAG is a poor substrate for the 2-
O sulfotransferase, however, following 4-O-sulfation, the epimerization is significantly 
accelerated [69]. For example, a study on human skin fibroblasts showed that CS/DS had all 
IdoA adjacent to GalNAc-4S and only GlcA adjacent to nonsulfated GalNAc residues [70]. 
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Chain termination 
It seems that there is no specific saccharide terminating the synthesis of CS/DS. Some studies 
proposed that GalNAc 4-O-sulfate at the nonreducing end may be a signal for termination [71], 
however, this hypothesis is challenged by the study on cartilage microsomal system, which 
found poor 4-sulfation and no 6-sulfation of terminal GalNAc [72].  
In the case of HS, the nonreducing end is often, but not always, occupied by NS domains. There 
is an observation that when a short segment of N-sulfated disaccharides dominates the 
nonreducing end, the further synthesis of the chain can be blocked [73], though as for CS there 
is no clear rule for chain termination. 
1.3.2.3.4 The Interplay between HS and CS Biosynthesis 
A relationship between HS and CS biosynthesis has been indicated by a number of studies. For 
example, non-functional uxs1 (UDP-glucuronic acid decarboxylase 1) 
and b3gat3 (Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3) mutants 
which were uxs1hi954 and b3gat3hi307, respectively in zebrafish impaired biosynthesis of both 
HS and CS, but on different levels. The larvae with these mutants failed to synthesize CS, but 
still produced 50% of the wild-type level of HS [74]. In sprouting angiogenesis using mouse 
embryonic stem cells lacking EXT1, the embryoid bodies showed a complete loss of HS 
production and an increase in CS biosynthesis [75]. In these and other studies there is, however, 
no clear answer as to how and why the synthesis of CS and HS are related.  
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1.3.3 Structural comparison between HS, heparin, and CS and DS 
1.3.3.1 Consequence of biosynthetic pathways differences between heparin and HS 
Heparin and HS share structural similarities in terms of the composition of an amino hexose 
and uronic acid, either GlcA or IdoA, joined by (1→ 4) glycosidic linkages. 
1.3.3.1.1 Biosynthetic pathways differences between heparin and HS 
During synthesis, due to the extensive tracts of GlcNAc acted on by NDST1, the uronic acid 
epimerization and sulfation on heparin are more extensive than that on HS. Moreover, heparin 
is excised from the full heparin chain by heparanase, a β-D glucuronidase (Section 1.3.2.2). 
Since GlcA is more common adjacent to GlcNAc, this will increase the sulfation of the ~17 
kDa heparin product. Hence, in terms of composition, heparin contains mainly α-L-iduronate 
(over 70%), whereas in HS, β-D-glucuronate is predominant. While most of the D-glucosamine 
residues in HS are N-acetylated, the majority are N-sulfated in heparin. After epimerization, 
most of the newly formed iduronate residues and N-sulfated glucosamine residues in heparin 
are sulfated at C-2 and C-6. However, the level of sulfation in HS in regions where GlcNS is 
present is lower, and since NDST2-4 sulfates shorter tracts that NDST1, there are frequent 
segments of contiguous GlcNAc containing disaccharides  [76]. These differences result in the 
degree of sulfation of 2.3–2.8 sulfates/disaccharide in heparin, but only 0.6–1.5 sulfates per 
disaccharide in HS [77]. These fundamental differences in composition lead to distinct 
conformations such as glycosidic linkage geometry (torsion angles, ϕ and ψ) and pyranose ring 
conformational equilibria between these closely related GAGs. In general, HS chains, as well 
as being longer, are more flexible than heparin. 
1.3.3.1.2 Domain structure of HS and evidence for variation in S & NA & NS domains 
Owing to NDSTs acting on tracts of GlcNAc containing disaccharides and the dependence on 
GlcNS of subsequent modifications in the major pathway of HS biosynthesis (Fig. 1.5, Section 
1.3.2.2), HS exhibits a domain structure. Thus, there are stretches of low/non sulfated 
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disaccharide repeats, rich in GlcA-GlcNAc (termed NA-domains);  shorter, highly sulfated 
regions where every glucosamine is N-sulfated glucosamine and L-iduronate is common 
(termed S-domains); and  intervening mixed regions with alternating GlcNAc and GlcNS 
disaccharides (termed NA/NS domains) (Figure 1.5) [78]. The definition of these domains has 
been obtained experimentally through the actions of heparinases I, II, III and K5 lyase and the 
latter enzyme requires an octasaccharide of GlcA-GlcNAc [78]. NA/NS domains can contain 
up to three GlcA-GlcNAc disaccharides between GlcA-GlcNS disaccharides. In contrast, 
heparin is characterized as a more or less continuous NS-domain due to the lack of alternating 
NA- and NS-domains, though it does contain short stretches of NA/NS domains. 
1.3.3.1.3 Critique of using heparin as a proxy for an S-domain. 
Owing to the commercial availability of heparin and heparin affinity chromatography matrices, 
heparin is widely used as a proxy for HS S-domains, however, there are drawbacks to this 
approach, because HS and heparin are different in their level of sulfation and chain domain 
structure (Section 1.3.3.1.2). First, the use of heparin to determine the sugar binding 
preferences for interacting proteins may bias the data towards ionic interactions, because of the 
high sulfation of heparin. Indeed, there are examples of where relatively low sulfated HS-
derived oligosaccharides have similar interacting properties as heparin [79].  Besides ionic 
bonds, there are a variety of different interactions. Thus, hydrogen bonds can also make 
significant contributions to the engagement of HS by proteins. For instance, ionic bonds only 
contribute 6 % to the binding free energy between brain natriuretic peptide (BNP) and heparin, 
whereas 94 % of the free energy comes from the hydrogen bonding between polar amino acids 
of BNP and heparin [80]. There are also data indicating contributions from other bonds 
including van der Waal’s bonding, e.g., between FGF2 and heparin [81], but it is not clear 
whether these are from protein-sugar interactions or from protein conformational change. 
There is, as yet, no example of a protein binding to NA domains, though this may be due to the 
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use of heparin affinity columns. However, GlcNAc-containing disaccharides and small NA 
domains have one function, which is to act as flexible spacer, which allow flanking NA/S or S 
domains to interact with bipartite binding sites on proteins that are at 90° to 180° to each other 
on the protein surface. This is the case for interferon γ [82] and vascular endothelial growth 
factor [83]. 
Another issue is that the variation of sulfation is likely the key factor for the specificity of HS, 
which cannot be reflected by heparin [84] [37] [85]. For example, the studies on the 
modifications required for FGF2 binding with chemically modified heparin or native HS 
preparations demonstrated that N-sulfate on GlcNAS and 2-O-sulfate of IdoA 2 are essential 
for binding, but not the 6-O-sulfate of GlcNS [86].  
Compared to heparin, HS is more ubiquitous, whereas heparin is produced by connective-tissue 
type mast cells [87] and almost all cells expresses HS. It is obvious that HS rather than heparin 
is the physiological binding partner for proteins. However, there are polysaccharides isolated 
from non-mammalian organisms that seem to be hybrids of HS/heparin [88]. For example, a 
heparin/HS-like polysaccharide was isolated from the heads of Litopenaeus vannamei shrimp. 
It has the high degree of N- and 6-O-sulfation and low levels of N-acetylation of glucosamine, 
like heparin but is similar to HS in its glucuronic acid content [89]. Often detected in this 
context is IdoA-2S.   
There are further structural differences between HS and heparin. Heparin chains (~17.5 kDa) 
are much shorter than HS, chains (25 kDa- 100 kDa), because they are excised from the heparin 
chains on serglycin [90]. Moreover, the presence of GlcNAc and NA domains in HS, as noted 
above, makes HS chains more flexible around the glycosidic linkages (torsion angles ϕ and ψ, 
Fig 1.6) than heparin, but heparin is more conformationally plastic, due to its proportionally 
higher IdoA content and this residue is uniquely in equilibrium between two conformers,  1C4 
and 2S0 (Fig 1.6) [91]. ϕ is the dihedral angle defined by H1–C1–O–C4 and ψ is the dihedral 
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angle defined by C1–O–C4–H4. To study the permissible ϕ and ψ angles of various 
disaccharides, molecular-modelling has been used to examine the glycosidic bonds of GlcNS-
IdoA, GlcNAc- IdoA, IdoA-GlcNS and IdoA-GlcNAc where the GlcN(S) is in the 4C1 
conformation, whereas the IdoA is in both the 1C4 and the 
2S0 conformations [92]. The results 
show that IdoA-(1,4)-GlcN glycosidic bonds have more freedom that GlcN-(1,4)-IdoA 
glycosidic bonds, while the other disaccharides have ϕ and ψ angles that are quite limited due 
to steric interactions. Indeed, the 1C4 and the 
2S0 conformations adopt different ϕ and ψ angles. 
Moreover, protein binding can have a major affect on the sugar conformation. For example as 
measured by 1H-NMR spectroscopy when bound to FGF2, the ϕ and ψ angles of ∆UA(2S)-
GlcNS(6S) and GlcNS(6S)-IdoA(2S) –are significantly different compared to the free form of 
the polysaccharide, whereas the ϕ and ψ angles of GlcNS(6S)-IdoA(2S)-GlcNS(6S) did not 
change compared to the free sugar [93]. A key point made by such work is that polysaccharide 
conformation can play an important role in protein interactions and that the sugar’s pendant 
sulfate groups, while important, are insufficient on their own to explain binding. 
1.3.3.2 Difference in spatial position of sulfate and carboxylate in CS/DS 
Owing to the dimer repeat, the CS glycosidic backbone has two distinct (ϕ1, ψ1) for 1-3  
glycosidic linkage and (ϕ2, ψ3) for 1-4 glycosidic linkage (Figure 1.7). The charged group 
combination is a key factor for the conformational preferences. A study comparing the 
disaccharides β-D-Gal-(1 → 4)-β-GlcNAc, 6S and β-D-Gal-(1 → 4)-β-GlcNAc, 4S, 6S showed 
a slight repulsive effect between the 6-O-sulfate groups and the carboxylate group and a small 
change of the preferred population of the glycosidic linkage. In contrast, the sulfate group at 
C-4 of β-D-GlcA-(1→3)-β-D-Gal disaccharides and the carboxylate group had an attractive 
interaction that led to a change of the conformation of the glycosidic linkage by about 30°. 
When both 4-O and 6-O were sulfated, the rotamer population of the C-6 groups can be 
observed [94]. 
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Figure 1.7: The two distinct degrees of disaccharide [(-4GlcAβ1-3GalNAcβ1-)] of CS 
backbone conformational freedom (ϕ1, ψ1) and (ϕ2, ψ2) [95]. For O1 which is the 1  3 
linkage, ϕ1 = O-ring-1-O-glycosidic-3 and ψ1 = 1- O-glycosidic-3-4 (“(ϕ1, ψ1)”), and for O2 
which is the 1  4 linkage, ϕ2 = O-ring-1-O-glycosidic-4 and ψ2 = 1- O-glycosidic-4-5 (“(ϕ2, 
ψ2)”). 
In disaccharides with the β-(1→4)-linkage and the 4-O and 6-O sulfations, the sulfate group(s) 
and the carboxylate group were on opposite sides, so that the molecules could adopt a 
conformation similar to those described for uncharged β-(1→4)-linked disaccharides [94]. In 
contrast, the sulfate groups and the carboxylate groups were on the same side the β-(1→3)-
linked disaccharides [94]. 
1.3.3.3 Chain flexibility 
It has been argued that heparin has unusual mobility (in the iduronate ring) and considerable 
rigidity  (in the glycosidic conformations), in part because the iduronate pyranose rings can 
adopt at least two conformations depending on pattern of sulfations without altering the overall 
shape of the heparin chain [96]. However, co-crystal structures of protein-oligosaccharide 
complexes suggest that the 2S0 of IdoA does alter chain direction, but up to 90° over a 
trisaccharide, e.g. 1AXM [97]. NMR analysis of a single sugar within heparin observed 
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unsubsituted IdoA as either 1C4 or 
4C1 chair form. For IdoA-2-sulfate (IdoA-2S), 
1C4 and 
2S0 
co-existed (Figure 1.8). In a combination of IdoA-2S and preceding a 3-O-sulfated 
glucosamine, 2S0 skew boats dominated, whereas when the IdoA 2S was at the non-reducing 
direction at the end of the chain, this equilibrium changed towards 1C4 form. In the 
4C1 form, 
there are 1,3 diaxial non-bonded interactions, where four of the substituents are axially oriented 
and only the carboxylate group is equatorial. Hence, this conformer is unfavourable for the 
stability of the chains [98] [93]. One chain may show multiple conformation of the iduronate 
pyranose rings, for example, a mixture of 1C4 and 
2S0 form of the central iduronate residues 
were defined when polydisperse heparin interacts with foot and mouth virus (PDB code 1QQP) 
[99] [98], while in a co-crystal structure of FGF2 and a heparin-derived hexasaccharide, there 
is an IdoA residue in the 2S0 confromation, alongside two in 
1C4 [100]. 
 
Figure 1.8: Conformation of β-D glucuronate acid and α-L idoronate acid. Pyranose ring 
of each glucuronic acid could adopt three different conformation, which are 1C4, 
4C1 and 
2S0. 
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In C4S and C6S the glucuronic acid and galactosamine both adopt the 4C1 chair conformation. 
The conformation of IdoA in DS has been unresolved for a long time due to two conflicting 
pieces of evidence provided from the studies of IdoA pyranose ring conformations in the solid 
state and in solution. While the 4C1 and 
1C4 conformations were incompatible with the rise per 
residues and the number of residues per turn, the 2S0 conformation gave a left-handed helix 
similar to those of the other GAG solid-state structures. More recent NMR data has indicated 
a distorted 1C4 chair, evidenced by the preference of oxidized DS toward vicinal equatorial 
hydroxyls, as found in a 4C1 chair. In equilibrium, the mixture of 
1C4 and 
2S0 with small 
proportions of 4C1 was proposed by the examination of NMR proton-proton coupling constants 
[101]. 
1.4 HEPARIN/HEPARAN SULFATE AND PROTEIN INTERACTIONS 
1.4.1 General overview of heparin binding proteins 
A large number of proteins, including cytokines and chemokines, enzymes and enzyme 
inhibitors, extracellular matrix proteins, and membrane receptors are classified as heparin- 
binding proteins (HBPs), since they have been shown experimentally to bind this 
polysaccharide. The interactions between HS and HBPs regulate many of the key functions 
associated with multicellularity, such as cell migration, cell differentiation, morphogenesis, 
organogenesis, and contribute to many disease states such as inflammatory conditions. 
1.4.2 How do heparin/HS recognize a protein? 
NS or NA/NS domain are the protein binding structures of HS chains for the reason that the 
interaction between HS and HBP depends on the sulfate groups and on the conformational 
versatility of the iduronate residues. For instance, the HS binding FGF-2 requires IdoA2S and 
GlcNS [102]. The IdoA2S residues in a co-crystal of FGF2 (PDB code 1BFC [100]) with a 
heparin-derived hexasaccharide are in two conformations, while the third iduronate ring adopts 
a 1C4 chair conformation, the fifth ring adopts a 
2S0  skew boat conformation [100]. In a 
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different arrangement, the crystal structure of a heparin tetrasaccharide with annexin V, shows 
that the IdoA2S which interacts with the protein is in a 2S0 conformation, whereas IdoA2S in 
the 1C4 conformation does not interact with annexin V [103]. Thus, the ability of IdoA to 
exchange between two conformations enables the polysaccharide to fit different protein 
surfaces. This conformation flexibility in the modified area may explain the reason many 
proteins, e.g., FGF3, bind to DS, but not to CS, despite the similar charge density of these 
polysaccharides [37]. 
The conformation and dynamics of a heparin pentasaccharide, representing a binding site of 
heparin for antithrombin III, have been investigated both in the crystal [104] and solution states 
[105]. Both show that the iduronate residues adopt the 2S0 skew-boat conformation in the 
protein-bound status. In contrast, NMR studies of the complex of a heparin tetrasaccharide with 
AT claimed that the binding to protein causes a distinct change in conformation of the 
glycosidic linkage and the iduronate residue then adopt the 1C4 chair conformation  [106]. 
A considerable body of evidence shows that different HBPs recognise distinct HS through often 
overlapping patterns of sulfation in HS. For example, while FGF-1 and FGF-2 both bind to 
sequences containing IdoA2S-GlcNS, FGF-1 also binds well to oligosaccharides containing 
IdoA-GlcNS, 6S [107] [108]. In addition, platelet factor 4 (PF-4) and interleukin 8 (IL-8) form 
1:1 complexes with long sugar sequences of 12-20 saccharides, whereas vascular endothelial 
growth factor (VEGF), interferon-gamma and chemokines require short NS domains separated 
by spacer region containing N-acetylated residues (NA/NS domains) [83] [45]. The underlying 
reason is the ability of the N-acetyl–rich 'spacer' or NA-domain (six to seven saccharides) in 
HS to allow much more conformational freedom for the simultaneous. 
The level of structural specificity required for HS-protein interactions remains an open 
question. There are several factors that have hindered progress.  One on the protein side is the 
absence of a systematic analysis of the heparin binding sites of a large number of unrelated 
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proteins, due to a lack of such data. On the GAG side, the complexity of polysaccharide chain 
structure in solution has confounded analysis, which often simply considers the sequence of 
saccharides. 
1.4.3 How do proteins engage GAGs? 
 
The binding of heparin and HS to proteins is driven by electrostatic bonds [47] between the 
sulfate and carboxyl groups on the polysaccharide and the basic amino acids arginine and lysine 
present in the HBS of most proteins [109]. While these interactions may not dominate 
energetically (Section 1.4.2), they do dominate kinetically. In an attempt to determining a 
consensus sequence of basic amino acids in heparin-binding sites, Cardin and Weintraub 
compared the HBS of 21 proteins [110] and proposed two consensus sequences of amino acids: 
XBBXBX and XBBBXXBX, where B is a basic residue and X is a hydropathic residue. 
Molecular modelling studies assumed the sequence XBBXBX as a β-strand conformation with 
the basic amino acids on one face of the β-strand. Similarly, the sequence XBBBXXBX folds 
into an α-helix with the basic amino acids displayed on one side and hydrophobic amino acids 
pointing back into protein core. Another consensus proposed was: XBBBXXBBBXXBBX, 
where 'B' represents a cationic residue coming from a molecular modelling of von the 
Willebrand factor HBS [111]. However, such sequences of amino acids derived from the linear 
sequence of HBSs may not be representative, since these patterns of residues are not found in 
many HBPs. Margalit et al suggested that a distance of around 20 Å between basic residues is 
required for the interaction [112]. Moreover, many HBSs are formed by amino acids distant in 
sequence, but adjacent in structure, so the sequence of a protein does not necessarily predict 
the interaction with the polysaccharide [109].  
One challenge in studying GAG binding sites is the high variation of the interactions, as the 
structural similarity and evolutionary relatedness of proteins is not always reflected by common 
GAG binding sites. Taking platelet factor 4 (PF4) and IL-8 as an example, these two proteins 
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are members of the α-chemokine family sharing common monomeric three dimensional 
structures, with anti-parallel β-strands and an α-helix in the C-terminus. However, while PF4 
engages heparin through the sequence 'KKIIKK', the equivalent heparin ⁄ HS binding domain 
of IL-8 is 'KENWVQRVVEKFLKR' [113] [98]. 
One important consequence of the above is that, there is at present no bioinformatic tool that 
is able to predict heparin binding sites in proteins. 
1.4.4 Electrostatic interactions (arginine and lysine) 
Both the guanidino group of arginine and prime amine of lysine have pKa over 10, therefore, 
they are positively charged at physiological pH.  These properties enables lysines and arginines 
to be involved in hydrogen-bonding, ion pair, as short range interactions, or electrostatic 
interactions as long range ones [114] [115] [116]. In terms of their basicity, the lysine side 
chain primary amino group is symmetric and the charge focussed in a small volume. This 
results in lysine being able to form a single bond (Figure 1.9). In contrast the guanidinino group 
of arginine is planar and asymmetric (Nε, Nη1, Nη2), with the conjugation occurring between 
the double bond and the nitrogen pairs. This allows the delocalization of the positive charge 
and, therefore, multiple ion pair and H-bonding interactions with sulfate/carboxylate groups 
(Figure 1.8). The electrostatic interactions formed by the guanidino group with sulfate are 
relatively stronger than the ones formed by the primary amine, based on Pearson’s concept of 
soft acid soft base interactions (Figure 1.9) [117] [114]. In addition, there are up to 5-6 H-bonds 
that can be formed by the guanidino group whereas H-bonds formed by lysine are not only 
fewer but also much more dynamic [118]. In terms of energy, contact ion pairs formed by 
arginine can be more energetically favourable compared to those of lysine [119]. The 
interaction between carboxylates and arginine can formed from the side-on and end-on 
interactions (bidentate configuration) or the backside interaction (monodentate configuration) 
involving the Nη1 hydrogen closest to Nε [114]. 
31 
 
 
Figure 1.9: Interactions of arginine and lysine side chains with sulfate groups. (A) Charge 
delocalization in the guanidino group of arginine. (B) Lys and Arg ion pair interactions with 
sulfates. The chemical structure was drawn by ChemDraw. 
1.4.5 The canonical HBSs and the secondary HBSs 
The theory of the secondary HBS, including HBS-2, HBS-3 and HBS-4 emerged from the 
study on FGF1 subfamily [120] [36], in which HBS-2 locates at the area of β-strand IX and X, 
HBS-3 tends to position at the N-terminus and C-terminus of the protein, finally, the work on 
FGF7 [36] introduced HBS-4 which form a large T-shape patch relatively to HBS-1, hence 
stopping a single polysaccharide chain from crossing over. Compared to the canonical HBS-1, 
the affinity of those binding sites to heparin is modest but they contribute significantly to the 
functions. One example is the deletion of HBS-3 resulted in the dramatic reduction in the 
mitogenic activity of FGF-2 [121].  
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1.4.6 Cellular functions of heparin/heparan sulfate and protein interactions 
The interaction of effector proteins and HS can be considered to have two types of function. 
One relates to the regulation of the localization and diffusion of the HBPs. The other relates to 
the assembly of functional complexes of HBPs and polysaccharide.  
1.4.6.1 Localisation and diffusion 
As a regulator for the movement of effectors between cells, HS was shown to control the 
transport of FGF2 across Descemet’s membrane (DM), the basement membrane of the corneal 
endothelium with fast, reversible binding [122]. Morphogen-HS interactions were  also 
demonstrated to contribute to gradient formation and so regulating the development of the 
embryo in contexts ranging from vertebrates to Drosophila [2][123][124]. As an example, the 
lower binding affinity of FGF7 compared to FGF10 for HS results in the formation of two 
distinguishable gradients that lead to distinct activities during branching morphogenesis [2]. 
The mechanism of the regulation remains unclear, however, some recent work has provided 
some insights. The study of nanoparticle-labelled FGF2 demonstrated that the spatial 
distribution of HS binding sites on proteoglycans of the pericellular matrix is not homogeneous, 
but heterogeneous and clustered over length scales ranging from 22 nm and above [125]. 
Moreover, in this environment, FGF2 undergoes five distinct types of movement, including 
immobile/highly confined, confined diffusion, simple diffusive, slow directed diffusion and 
long and fast directed diffusion. Recently, biophysical experiments have shown that some 
effectors, such as FGF2 and CXCL12γ which possess more than one binding sites for HS can 
cross-link the polyanion chains [126]. Moreover, the level of binding, the spatial distribution 
of binding sites and the diffusion in the pericellular matrix of fibroblasts are remarkably 
different for five paracrine FGFs [127]. The interpretation of these data has given rise to the 
idea that HS chains in extracellular matrix possess long-range (supramolecular) structure due 
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to the chains forming a dynamic network of interlinked molecules resulted from the high 
multiplicity of interactions among endogenous HBPs.  
1.4.6.2 HS as a co-receptor in signalling complexes 
For many effectors, HS functions as a co-receptor. The classic system in this respect is the FGF 
signalling system [128] [129], where binding to HS can determine the strength and duration of 
the signalling [85] [130] [131]. There are two models derived from co-crystal structures of FGF 
ligand, model heparin oligosaccharides and FGFR extracellular domain,  the symmetric 2:2:2 
and asymmetric 1:1:1 stoichiometry complexes [132][130] [133], though only the former is 
currently considered to reflect what may occur at the cell surface. What is agreed is that FGF 
ligands can bind FGFR in the absence of HS and generate intracellular signals [134] [135], but 
that a full mitogenic response requires the engagement of the HS co-receptor. Experimentally, 
heparin is found to bind both the FGF ligand and the FGFR, suggesting that engagement of all 
three species in a complex is likely to increase its stability with respect to dissociation [136].  
1.4.7 The binding interfaces of the ternary complex, FGF-HS-FGFR 
The knowledge of the binding interface of the ternary complex comes mainly crystal structure 
studies, hence, quite limited. In general, there are four areas of binding reported. For example, 
the asymmetric FGF-1-FGFR2-heparin DP10 crystal structure (PDB: 1E0O) presented the 
engagement at the areas of first, β1 and loop βI-βII (Y30, Y35 and Y37), second, the loop βIII-
IV (R50 and R52) and loop IV-V (V66), third, βVIII to loop βVIII-IX (E102, 104-LEE-106 
and 108-HYN-109), last, on β XII (L148 and L150).  
In the crystal of FGF2-FGFR1-heparin [130], the pivotal function of 6-O-sulfation of heparin 
was highlighted when this sulfation formed the hydrogen bonds with both FGF and FGFR. 
Three areas on FGF2 involved in binding, the β I-II loop (Asn-27), the β IX-X loop (Arg-120, 
Thr-121), the β XI-XII (Lys-125, Lys-129, Gln-134, Lys-135, Ala-136). In addition to 
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interacting with the FGF-FGFR preformed complex, heparin was shown to form 5 hydrogen 
bonds with the adjoining receptor across the 2-fold dimer. 
Besides a small number of studies which investitage the terrary complex as whole, there are 
several attempts of investigating the interaction between FGFs and their cognate receptors. The 
crystal structures of FGF10 and FGFR2b (PDB: 1nun [31]) and FGF8b and FGFR2C (PDB: 
2fdb [137]) individually reported four areas of engagement on protein surface which are 
aligned in terms of sequence to those in FGF1 and FGF2. Those areas on FGF10 are: first,  the 
N-terminus and β strand I (71-HLLQGDVR-78, R80, F83 and F85), second, loop of β strands 
III-IV to β-strand VI (K102, E104, 113-ITSVEIG-119, V121 and Y131), third, the loop of β 
strands VII-VIII to β strand IX (F146, 154-ERI-156 and 159-NGY-161), last, β strand XII 
(L202 and M204). Four areas on FGF8b are: first, the N-terminus and β strand I (containing 
11 residues: F50, H53, V54, Q57, D62, L64, R66, L68, R70, Y75 and R77), second, the loop 
of β strands IV-V (V106, T108, F111 and S113), third, the loop of β strands VIII-IX (E159, 
V161, L162 and 165-NYT-167), last, β strand XII (193-MKR-195). The consistence in binding 
pattern of FGF to FGFR demonstrated the conservation evolution impact on this family. 
1.5 APPROACHES FOR IDENTIFICATIONS OF GAG BINDING SITES IN 
PROTEIN 
Proteins have in the past been identified as binding HS serendipitously. The result was a 
gradual growth of the number of HBPs, which in 2008 were catalogued as numbering 214 [45]. 
An affinity proteomics approach increased this number to 435 [138] and subsequently to 831 
[139]. An understanding of the functional significance of the protein-polysaccharide 
interaction lags behind. For example, the interaction between FGF-1 and FGF-2 with heparin 
was critical in their original purification and the cloning of their cDNAs [15] [140]. However, 
it was only in 1991 that the requirement for HS in the assembly of the FGF2-FGF receptor 
signalling complex was discovered. Regarding to the specificity and selectivity of protein and 
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HS interactions, improvements have only made through the development of new experimental 
approaches. These are discussed below. 
1.5.1 Low throughput methods 
The identification of the binding site of the polysaccharide on the protein has in the past 
depended on structural and molecular biology approaches  that are low throughput e.g. NMR 
spectroscopy, site-directed mutagenesis [141] [142] and X-ray crystallography [100], [143], 
[144]. Of these, X-ray crystallography has been the largest contributor, as seen by the number 
of models of protein-heparin oligosaccharide co-crystals uploaded onto the PDB 
(https://www.rcsb.org/). In addition to being low throughput and requiring the formation of 
crystals, a further weakness of this approach is that X-ray crystallography will select for a rigid 
protein conformation, should several conformations exist in equilibrium. This is highlighted 
by the identical structures of FGF2 and FGF2 in complex with a heparin hexasaccharide [145] 
[100], despite the long-established fact that FGF2 bound to heparin is more rigid, possessing 
more secondary structure than the unbound protein  [146][147], which has been used more 
recently to measure in high throughput interactions with different model GAG structures [102]. 
With NMR and the actual conformation of the protein in the bound state could be obtained 
with the information of the rearrangements of protein and sugar structure [148]. However, 
NMR spectroscopy is limited by the size of protein that can be analysed, as well as being low 
throughput. 
1.5.2 High throughput methods 
Screening by surface noncovalent affinity mass spectrometry (SNA-MS) 
The development of mass spectrometric (MS) approaches has abled this to go further than the 
analysis of proteins to forward the characterization of many biological components, including 
heparin/heparan sulfate-like glycosaminoglycan (HLGAG), resulting the emerge of the 
36 
 
approach named surface noncovalent affinity mass spectrometry (SNA-MS) [149]. The overall 
strategy for SNA-MS requires the immobilization of protein on a thin hydrophobic film, 
followed by the absorbance of target proteins onto MS targets. Then, oligosaccharides were 
eluted and their structures were identified by MALDI-TOF using chelation with (RG)19R [149]. 
This method allowed the rapid parallel screening of an oligosaccharide library against multiple 
proteins, however, it is limited only to proteins actively immobilized on the target. 
Identification of protein–GAG interactions by surface plasmon resonance 
SPR binding assays use the change in refractive index at a surface to measure the interaction 
between a partner bound to the surface and one in solution [150]. These assays have been used 
to identify new protein–GAG interactions and in competition format can identify preferences 
for GAG structures [151]. The identification of binding sites in proteins requires either the use 
of competing synthetic peptides [121] or the use of mutant proteins [82]. 
Pull-down and 2D gel electrophoresis 
Recent studies of the interactions between proteins and polyanions such as heparin, actin, 
tubulin and DNA used simple pull-down experiments performed on COS-7 cell extracts in 
combination with the two-dimensional electrophoretic methods and antibody arrays [152]. The 
number of heparin binding protein identified here was 944 out of a total of 1,751 which was 
double the number of actin and tubulin interactors [152]. However, because using the 
chromatographic method, this work could not distinguish the proteins which directly engages 
to heparin and the proteins which binds to heparin binding proteins. 
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1.5.3. Bioinformatics tools 
Molecular docking 
Computational docking has been used to study protein interactions such as those with GAGs. 
The process basically involves two steps: 1) molecular docking (for example, AUTODOCK 
software) and 2) molecular dynamic simulation (for instance, MD simulation refinement) 
[150]. Step 1 is able to identify the position of a rigid fragment on the protein surface, then step 
2 is used to refine the docked model. There are many successful examples of using this process 
on addressing the binding sites of heparin on proteins such as endostatin [153] and the 
engagement of HS to FGFs [154]. A study docking different oligosaccharides to the potential 
surface of chemokines which are positively charged demonstrated that the different selected 
oligomers contact different clusters of basic amino acids, giving some important cues for the 
specificity of GAG-chemokine interactions [155].  
A heparin docking server is available [156]. This method overcomes the general restriction of 
other docking strategies that search for a binding pocket, which limits the search around the 
defined heparin binding sites. In the future with more availability of the structural data, it will 
be possible to generate more precise models of interaction between GAG and proteins, more 
potentially for a group of related proteins, that fit with available data. If successful, this work 
will be extremely useful for the design of new therapeutics. However, validation of docking 
has still relied on low throughput methods. 
1.5.4 The lysine selective labelling approach 
A high throughput method has been developed for identifying lysine residues in heparin 
binding sites (HBSs) of HBPs was called  “protect and label” and using mass spectrometry 
identification of labelled lysine residues [120]. In the protection step, the protein is bound to 
heparin in a chromatography column and exposed lysine residues are reacted with NHS-
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acetate. Thus, the lysine side chains not involved in binding heparin are protected from further 
reaction. The protein is then eluted from the heparin affinity column and any lysine side chains 
protected by the interaction with heparin are then labelled by reaction with NHS-biotin. 
Biotinylated peptides may be purified quantitatively and are then identified by mass 
spectrometry. An interesting feature of this method is that it identifies canonical, high affinity 
heparin binding sites in proteins and lower affinity secondary binding sites [120][36]. Since, 
there are far more identified HBPs than HBPs with identified polysaccharide binding sites and 
in the absence of a bioinformatics approach to HBSs other than by alignment with a well 
characterised member of the same protein family, the lysine protect and label method fills a 
major gap. 
However, the lysine protect and label method has its limitations. The “protect and label” 
approach only detects lysine side chains involved in binding of the polysaccharide, but arginine 
residues are equally important (Section 1.4.4). In addition, the heparin binding sites in some 
proteins may contain arginine residues, e.g., the canonical heparin binding site of FGF-22 
predicted by sequence alignment with other FGFs [36]. As the method depends on the use of a 
heparin affinity chromatography matrix, it is also unable to probe protein interactions with 
more physiologically relevant HS or other GAGs. 
1.6 RATIONALE AND AIMS OF THE THESIS 
Ionic interactions play an important role in the interactions of proteins and GAGs evidenced 
by the work on the lysine selective labelling on many FGFs. However, some proteins, for 
example FGF22, do not contain any lysine but arginine amino acids in their binding sites. 
Indeed, the contribution of arginine to the electrostatic interactions is essential to 
comprehensively understand the engagement of protein to sugar.  
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Hence, the first aim of this thesis is to develop an approach which can quickly and efficiently 
identify the arginine residues on protein responsible for the electrostatic engagement to the 
sulfated GAGs. The second aim is to produce a complete panel of all fifteen paracrine FGFs 
and determine the structure in these proteins involved in heparin binding using the method of 
selective labelling arginine and lysine. This piece of information was then used to justify 
whether FGFs in the same subfamily may share some common features in this kind of 
interaction. Moreover, the positions of labelled arginine and lysine residues on protein draw a 
map of electrostatic distribution on the protein surface which, together with the information of 
the selectivity/specificity of that protein toward the modifications on the sugar, is valuable to 
predict the potential binding pattern of sugar on a specific protein. 
For long, heparin has been used as the proxy to the S-domain of HS. Indeed, interest in 
interactions of the protein with heparin and HS overwhelmed other GAGs, such as CS, DS due 
to some technical limitations. Here, the third purpose is to overcome the heavy dependence of 
the selective labelling approach on heparin beads by sensible alteration of the original version 
to the selective labelling “in-solution” using commercially available heparin, CS and DS. This 
method is first tested on the FGF7 sub-family. 
 As the fourth aim, one of the known HS-binding proteins is selected to apply both selective 
labelling of arginine and lysine. This shows that selective labelling is a handy approach which 
could be used to study the electrostatic interactions of many proteins with GAGs. 
Longstanding questions are how specific and selective protein-glycosaminoglycan interactions 
are, to what extent can HBSs be predicted, and, if the residues in an HBS are known, what 
might be the sugar specificity of that protein. A model of the engagement between protein and 
heparin is desired to develop using the knowledge gained here of the basic residues on the 
protein surface and the selectivity toward sulfations of polysaccharide chain. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 ELECTROPHORESIS 
2.1.1 Agarose electrophoresis 
Agarose gels (1.2 %, w/v) were made by melting agarose (0.4 g) (Bioline, London, UK) in 48 
mL TAE buffer (40 mM Tris-Cl, 20 mM acetic acid, and 1 mM EDTA, pH 8). When the 
agarose had cooled slightly, 4 μL 10,000x SYBR (New England Biolab, UK) was added. The 
molten agarose was poured into the gel making tray and allowed to cool. The samples and 
DNA ladder (1 kb New England Biolab, Herts, UK) were loaded on the gel after the gel tray 
was placed in the gel tank and covered with TAE buffer. Electrophoresis was carried out at 100 
V, 30 min for each gel. 
2.1.2 SDS PAGE 
To prepare samples for SDS-PAGE, sample (30 μL) was mixed with 10 μL 4x SDS-PAGE 
loading buffer (50 % (v/v) glycerol, 10 % (w/v) SDS, 25 % (v/v) 2-mercaptoethanol in 0.3 mM 
Tris-Cl, pH 6.8 and coloured with bromophenol blue), and then heated at 95°C for 10 min. Ten 
μL of the samples along with 10 μL SDS-PAGE markers (SDS7-1VL, Sigma) were loaded 
onto a 12 % (w/v) SDS-polyacrylamide gel (Table 2.1) and the gels were run at 30 mA (per 
gel), 200 V for 50 min with running buffer (50 mM Tris-Cl, 192 mM glycine and 0.1 % (w/v) 
SDS). 
2.1.3 SILVER STAIN 
 
After electrophoresis, the gels were soaked in fixative (40 % (v/v) ethanol, 10 % (v/v) acetic 
acid) for 1 hour following by soaking twice in 10 % (v/v) ethanol (5 min/each) and washing in 
RO water three times, each for 5 min. 
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Following incubation in 0.2 % (v/v) silver nitrate for 30 min, the gels were washed with water 
for 15 s and then dipped in freshly made developer solution (2.5 % (w/v) Na2CO3, 0.03 % (v/v) 
formaldehyde) until the solution went brown. New developer was then used to further stain the 
gel until bands were stained to the required intensity. Stop solution (1 % v/v acetic acid) was 
used to stop the reaction between silver and formaldehyde. The gels were then washed with 
water six times for 5 min each. Freshly made reducer (0.6 % w/v sodium thiosulphate, 0.3 % 
w/v potassium ferricyanide, 0.1 % w/v sodium carbonate) was used to remove the excess silver 
and clear the background. The gels were then quickly washed with a large volume of water and 
followed by five washes with water (5 min/each). When required, gels were re-stained to 
increase the sensitivity of detection, starting by the addition of 0.2 % (v/v) silver nitrate for 30 
min. 
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Table 2.1: SDS-PAGE Gel preparation 
SDS-PAGE Resolving Gel (ingredients for 12 % gel – 2 gels)                      Total 10 mL 
Acrylamide/ bis-acrylamide stock (30 %, w/v) 4.0 mL 
Tris-HCl (3 M), pH 8.85 2.5 mL 
DD- Water 3.5 mL 
10 % Sodium dodecyl sulfate (SDS) w/v 100 μL 
TEMED(N, N, N’, N’, Tetramethylethylene diamine) 10 μL 
Ammonium persulphate 50 mg/mL (freshly made) 100 μL 
 
SDS-PAGE Stacking Gel (ingredients for 12 % gel – 2 gels)                        Total 5 mL 
Acrylamide/ bis-acrylamide stock (30 %, w/v) 650 μL 
Tris-Cl (1.25 M), pH 6.8 500 μL 
DD- Water 3.5 mL 
10 % Sodium dodecyl sulfate (SDS) w/v 50 μL 
TEMED (N, N, N’, N’, Tetramethylethylene diamine) 10 μL 
Ammonium persulphate 50 mg/mL (freshly made) 50 μL 
 
The gels were incubated in Coomassie stain (50 % (v/v) methanol v/v, 10 % (v/v) acetic acid, 
0.25 % (w/v) CBB R-250) for 60 min, then soaked in destaining buffer (40 % (v/v) methanol, 
10 % (v/v) acidic acid) until the bands became clear. 
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2.2 BACTERIAL CULTURE STRAINS 
2.2.1 Vectors and cDNAs  
Existing expression vectors were used: pET-14b containing cDNAs encoding FGF1 and FGF2 
[36] and pET-M11 vector containing FGF7 cDNA encoding FGF3, FGF10, FGF16, FGF17, 
FGF20, FGF6, FGF5, FGF8 and FGF22 as well as HaloTag [102]. All of the protein sequences 
corresponding to the above cDNAs are listed in Table 3.1. Bacterial cells: DH5α, BL21 (DE3) 
pLysS and SoluBL21 were a gift from Olga Mayans, University of Liverpool.  
2.2.2 Medium for bacterial culture 
Lysogeny Broth (LB) and LB Agar culture medium was made following the instructions of the 
manufacturer (Merk, East Yorkshire, UK).  
2.2.3 Competent cell list and culture 
DH5α cells, CL41 cells and BL21 (DE3) were stored in -80 °C. Competent cells were thawed 
on ice. Ten μL was plated out onto LB agar plates. Plates were incubated overnight at 37 °C. 
2.2.4 Competent cell preparation 
A single colony (Section 2.2.3) was picked from the plate and cultured in 8 mL LB overnight 
at 37°C. The next day, 1 ml of bacterial culture was transferred into 100 ml LB and this culture 
was incubated at 37 °C, until the absorbance at 600 nm reached 0.3-0.5. The culture was 
immersed in ice for 5 minutes and divided into 4 pre-chilled sterile centrifuge tubes and then 
centrifuged at 6000 rpm for 5 minutes, 4 °C, to collect the cells. The pellets were re-suspended 
in 20 mL Transformation buffer I (Tbf I- 30 mM potassium acetate (KOAc), 100 mM RbCl, 
10 mM CaCl2, 50 mM MnCl2, 15% (v/v) glycerol, pH 5.8) and then were put on ice for 5 min, 
followed by centrifugation at 4°C, 6000 rpm, for 5 min to collect the cells. Finally, cells were 
re-suspended in 2 mL Transformation buffer II (Tbf II- 10 mM MOPS, 70 mM  CaCl2, 10 mM 
RbCl, 15% (v/v) glycerol, pH 6.5). The competent cells were put on ice for 15 min before they 
were placed in aliquots in pre-chilled tubes and stored at -80 °C. 
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2.2.5 Transformation 
A stock of competent cells and plasmids were thawed on ice. A mixture of 70 µL competent 
cells and 70 ng (~1 µL) plasmid was placed on ice for 30 minutes, followed by heating at 42 
°C for 45 seconds and then immediately placed again on ice for 2 minutes. In a new tube, 1 ml 
Lysogeny Broth (LB) medium (Merck, Watford, UK) was added to the mixture and incubated 
for 60 minutes at 37 °C on a 250 rpm shaker. The tube was centrifuged to collect the pellet, 
which was suspended in 100 µL LB. On a LB Agar-antibiotic plate (antibiotic dependent on 
the plasmid, either ampicillin or kanamycin from Sigma-Aldrich Ltd. Dorset, UK, 100 mg/mL 
stock), 20 µL of this mixture was spread and the dish was incubated at 37 °C for 16 hours. 
After that, the plate could be stored in the cold room.  
2.2.6 Miniprep 
A single colony was taken (Section 2.2.5) and cultured in 8 mL of LB broth overnight at 37°C 
(shaken at 240 rpm). Plasmids were purified the next day using the Qiagen Miniprep Kit 250 
(Qiagen, Manchester, UK) following the manufacturer’s instructions and then stored at -20 °C. 
2.3 PROTEIN EXPRESSION 
2.3.1 IPTG induction 
A single colony (Section 2.2.5) was cultured in a tube of 8 mL of LB Broth and 8 µL of the 
appropriate antibiotic from a 1000x stock at 37 °C overnight (shaken at 240 rpm). Generally, 
six colonies were expanded in this way. In the next step, the culture tubes were pooled into a 2 
L flask containing 800 mL of LB broth with 800 µL of the appropriate antibiotic and then 
cultured at 37°C with shaking (240 rpm) until the absorbance at 600 nm reached 0.4-0.5. For 
all FGFs except for FGF2, the temperature was then reduced to 16 °C. When the absorbance at 
600 nm was 0.6, 800 µL IPTG (1 mM final concentration) was added to each flask and the 
bacteria were grown at the same temperature for 3 h (37 °C) or overnight (16 °C) with shaking 
(240 rpm). 
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2.3.2 Cell harvesting 
The bacteria were harvested by centrifugation at 6000 rpm for 15 min (4°C) in Sorvall RC6 
centrifuge (Thermo Scientific, UK) using  a Fiberlite™ F10-6 x 500y Fixed-Angle Rotor. 
The cell pellets were re-suspended in 30 mL lysis buffer (0.1 to 0.3 M NaCl, 50 mM Tris-Cl 
(pH 7.2)) for each centrifuge tube. 
2.4 CHROMATOGRAPHY 
2.4.1 Chromatography columns 
The bacterial pellet suspended in lysis buffer (Section 2.3.2) was kept on ice prior to sonication 
with a Soniprep 150 Plus (MSE, UK). Cells were disrupted by six cycles of 30 s sonication at 
12 amplitude and 60 s break between each cycle). To remove cell debris, the disrupted cells 
were centrifuged at 15000 x g for 40 min in a Sorvall RC-5B refrigerated super-speed 
centrifuge. The supernatant was then filtered through a 0.45 μM pore filter prior to 
chromatography. 
2.4.2 Heparin affinity chromatography 
An affinity column was made with 3 mL heparin agarose (Affi-Gel Heparin, BioRad, UK). It 
was first equilibrated with washing buffer (50 mM Tris-Cl, 0.3 M NaCl, pH 7.2) at a flow rate 
of 1.0 mL/min. The supernatant after filtration (Section 2.4.1) was applied to the column and 
the flow-through fraction was collected. After that, the column was washed with 5 volume of 
each of two or three washing buffers (0.4M NaCl, 0.5M NaCl, and 0.6M NaCl, all in 50 mM 
Tris-Cl, pH 7.2), depending on the FGF purified. Higher ionic strength elution buffers 1.0 M 
NaCl, 1.5 M NaCl or 2.0 M NaCl (depending on the FGF) in 50 mM Tris-Cl, pH 7.2 were 
applied to the column to elute the bound proteins. During purification, the column effluent was 
monitored at 280 nM with an Econo UV monitor (Bio-rad, Hertfordshire, UK). 
Owing to the requirement of subsequent experiments, phosphate-buffered saline PBS (137 mM 
NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2.0 mM KH2PO4, pH 7.4) was used in place of 50 mM 
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Tris-Cl buffer in some instances, but the heparin affinity chromatography procedure was 
otherwise unchanged. 
2.4.3 Ion exchange chromatography 
A cation-exchange column (1 mL HiTrap SP-HP, GE Healthcare Life Sciences, UK) or DEAE 
Sepharose (1 mL) (GE Healthcare Life Sciences, UK) column for anion-exchange 
chromatography was equilibrated with 0.2 M NaCl, 50 mM Tris-Cl, pH 7.2 for a minimum of 
5 min at a flow rate of 1.0 mL/min. The fractions from heparin affinity chromatography 
(Section 2.4.2) were diluted with 50 mM Tris-Cl, pH 7.2, so that the final concentration of 
NaCl in the loading solution was less than 0.1 M, and applied to the ion-exchange column. The 
column was then washed with steps of increasing NaCl (0.3 M, 0.4 M and 0.5 M) in 50 mM 
Tris-Cl, pH 7.2.  Depending on the FGF, proteins were eluted with 0.6 M, 0.8 M or 1.0 M NaCl 
in 50 mM Tris-Cl, pH 7.2. For the requirement of the subsequent experiments, in some 
preparations solutions were buffered with PB buffer (17.9 mM Na2HPO4, 2.1 mM NaH2PO4, 
pH 7.8) rather than Tris-Cl. 
2.4.4 Nickel (Ni2+) chelation chromatography for His-tag purification 
 
Ni2+ Sepharose (from GE Healthcare Life Sciences, UK) was used for the purification of some 
His-tag proteins. The column was equilibrated with 5 to 10 column volumes 20 mM sodium 
phosphate, 0.3 M NaCl, 50 mM imidazole, pH 7.4. The fractions from heparin affinity 
chromatography were diluted with 20 mM sodium phosphate, 50 mM imidazole, pH 7.4, so 
that the final concentration of NaCl in the loading solution was around than 0.1M, and applied 
to the Ni2+ column. The column was then washed with steps of increasing imidazole (0.1 M, 
0.2 M and 0.3 M) in 20 mM sodium phosphate, 0.3 M NaCl, pH 7.4.  Depending on the FGF, 
proteins were eluted with 0.4 M or 0.5 M imidazole in 20 mM sodium phosphate, 0.3 M NaCl, 
pH 7.4.   
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2.5 SELECTIVE LABELLING ON LYSINE RESIDUES 
2.5.1 Protection of lysine residues 
The method of Ori [120] was followed. To make a mini-column, a plastic air filter was placed 
at the end of a P10 tip (P50) and packed with 30 μL AF-heparin beads (Tosoh Biosciences 
GmbH, Stuttgart, Germany; binding capacity of 4 mg Antithrombin III/mL, generally, the 
loading capacity of FGFs to resin was estimated at 15 mg/mL). PB150 buffer (150 mM NaCl, 
17.9 mM Na2HPO4, 2.1 mM NaH2PO4, pH 7.8) (4 x 50 μL) was used to equilibrate the heparin 
column. A minimum of 10 μg FGF protein was loaded onto the column. The loading was 
repeated 3 times to ensure the binding between protein and heparin beads. After binding, 200 
μL (4 x 50 μL) PB150 buffer was used to wash the column and remove the unbound 
components. 
Lysine remaining exposed to solvent were acetylated by a quick rinse of the column with 20 
μL PB 150 containing 50 mM sulfo-NHS-acetate and followed by and incubation for 5 min 
with 20 μL of the above solution at room temperature. The minicolumn was then washed with 
200 μL PB150 buffer (4 x 50 μL). Bound proteins were collected in 2 x 20 μL elution buffer 
(2 M NaCl, 45 mM Na2HPO4, 5 mM NaH2PO4, pH 7.8). 
2.5.2 HBS Lysine Biotinylation 
Owing to the high concentration of NaCl in elution buffer, the acetylated protein was diluted 
with 200 μL PB buffer (17.9 mM Na2HPO4, 2.1 mM NaH2PO4, pH 7.8) and concentrated on a 
3.5 kDa-MWCO centrifugal filter (Sartorius Ltd., Epsom, UK), which was centrifuged for 25 
min at 13200 rpm until the volume was reduced to 37.2 μL. The biotinylation of lysine residues 
was accomplished by adding to the sample 2.8 μL 145 mM NHS-biotin in DMSO and 
incubating for 30 min at room temperature. The reaction was quenched with 4 μL 1 M Tris-Cl, 
pH 7.5. 
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The excess reagents were removed by 3 cycles of dilution on 3.5 kDa-MWCO centrifugal 
filters with 400 μL 10-times diluted PB150 buffer and 3 cycles of dilution with 400 μL HPLC 
water by centrifugation at 13200 rpm for 10 min. Products (40 μL) were then applied to a 
desalting centrifugal column (7K MWCO, Thermo Scientific, The UK) and covered by 70 μL 
HPLC grade water. The column was then centrifuged for 2 min at 1,200 x g. After freezing at 
-80 °C for 20 min, the sample was lyophilized for an hour. 
2.5.3 Protein Digestion 
Dried sample was dissolved in 8 M urea, 400 mM NH4HCO3, pH 7.8 (25 μL) and 45 mM DTT 
(2.5 μL) and incubated for 15 min at 56°C. Proteins were diluted with 70 μL HPLC grade water 
and digested overnight with 0.1μg of the appropriate enzyme, chymotrypsin or trypsin (both 
mass spectrometry grade, Promega, Southampton, UK). 
2.5.4 Biotinylated Peptide Purification 
A minicolumn of 40 μL Strep-Tactin Sepharose beads (IBA GmbH) was packed as above and 
equilibrated with 4 x 50 μL of 500 mM urea, 25 mM NH4HCO3. Digested protein was diluted 
to a final volume of 200 μL with HPLC grade water and applied to the column three times to 
ensure binding. The mini-column was washed with 3 x 50 μL 0.5 M urea, 25 mM NH4HCO3, 
followed by 3 x 50 μL HPLC grade water to remove unbound peptides. Biotinylated peptides 
were eluted with 2 x 20 μL 80% (v/v) acetonitrile 20% (v/v) triflouroacetic Acid (TFA), 5 mM 
biotin (Thermo Fisher Scientific). 
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2.6 SELECTIVE LABELLING ON ARGININE RESIDUES 
The detailed protocol is uploaded onto Protocol.IO an open access methods repository. 
https://www.protocols.io/view/selective-protection-and-labelling-of-arginine-lys-qqmdvu6 
2.6.1 Protection of arginine side chains 
Step 1: Binding  
Protein was loaded onto an AF-heparin mini affinity column as for lysine protect and label 
(Section 2.7.1).  
Step 2: Protection of arginine side chains 
PGO (Merck Ltd., UK, 97%) was used in the dark, as it is light sensitive. PGO was freshly 
prepared in 50% (v/v) DMSO, 50% (v/v) HPLC grade water at 1 M, which was then diluted to 
0.5 M and then 0.2 M with 0.2 M NaHCO3, pH 9.5. The pH was adjusted with 0.1 M NaOH to 
between 9.1 and 9.5, to ensure optimal reaction. The heparin mini column was rinsed with 30 
μL 0.2 M PGO solution to exchange buffers. A further 30 µL PGO solution was added to the 
column and the bound protein was allowed to react for 60 min at room temperature in the dark. 
The reaction was quenched with 5 μL 0.1% (v/v) Trifluoroacetic acid (TFA) in water, so that 
the final concentration of TFA was 0.01% (v/v). The mini-column was then washed with 200 
μL Na-1 buffer (4 x 50 μL). Bound proteins were eluted with 2 x 20 μL Na-2 buffer (2 M NaCl, 
0.2M NaHCO3,  pH 9.5) containing 0.1% (w/v) RapiGest SF Surfactant (Waters, UK). The 
addition of surfactant was important to ensure protein recovery in this and subsequent steps, 
due to the increased hydrophobicity of proteins following PGO conjugation to arginine side 
chains.  
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2.6.2 Labelling of Arginine side chain 
Step 3: Labelling of Arginine side chain by HPG 
The preparation of HPG was performed in the dark room, as it is even more light-sensitive than 
PGO, following a procedure identical to that used for PGO. The eluted protein was diluted with 
400 μL 0.2M NaHCO3, pH 9.5 and concentrated on a 3.5 kDa MWCO centrifugal filter (Merk 
Millipore, UK) to a final volume of 70~80 μL. The reaction with HPG was performed by 
incubating 80 μL diluted protein with 20 μL 0.5M HPG so that the final concentration of HPG 
in the reaction was 0.1 M. The pH was maintained at over 9.0. The reaction was performed for 
60 min at room temperature in the dark and then was quenched with 5 μL 0.1% (v/v) TFA in 
water. 
2.6.3 Sample preparation for mass spectrometry  
Step 4: Sample preparation for mass spectrometry 
Protein was buffer-exchanged by four cycles of dilution on 3.5 kDa MWCO centrifugal filters 
with 400 μL 10-fold diluted 0.2 M NaHCO3, pH 9.5 containing 0.1 % (w/v) RapiGest and 3 
cycles of dilution with 400 μL HPLC water containing 0.1% (w/v) RapiGest by centrifugation 
at 13200 g for 10 min. After freezing at -80 °C for 30 min, the sample was lyophilized for an 
hour. 
Step 5: Incubation with proteasses 
Chymotrypsin/trypsin: The freeze-dried protein was dissolved in a mixture of 80 μL 25 mM 
NH4HCO3 and 10 μL 1 % (w/v) RapiGest (~ 0.1 % w/v in final solution) and heated at 80 °C 
for 10 min. The mixture was quickly centrifuged at 3200 g for 30 seconds before 10 μL 50 mM 
DTT was added (5 mM final concentration) and incubated for 15 min at 56 °C. After cooling 
the sample to room temperature, proteins were carbamidomethylated with 5 μL 0.1 M 
iodoacetamide (freshly made) for 30 min in the dark. Proteins were then digested overnight 
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with mass spectrometry grade chymotrypsin or trypsin (Promega, Southampton, UK) at a ratio 
of 1:100 (w/w). 
Arg-C: The dried sample was dissolved in 400 mM NH4HCO3, pH 7.8 (25 μL) and 45 mM 
DTT (2.5 μL), and incubated for 15 min at 56 °C. After cooling to room temperature, 75 μL 
incubation buffer (50 mM Tris-Cl, 5 mM CaCl2, 2 mM EDTA, pH 7.8) was added to dilute the 
urea to 2.0 M. Arg-C protease (Promega, Southampton, UK) was freshly prepared in incubation 
buffer and then added to the protein solution at a ratio of 1:100 (w/w). Activation buffer 10X 
(50 mM Tris-Cl, 50 mM DTT, 2 mM EDTA, pH 7.8) was added to give a final concentration 
of 1X. The mixture was mixed gently and centrifuged briefly before allowing digestion to 
proceed overnight at 37 °C. 
2.7 PROTECT AND LABEL WITH POLYSACCHARIDE IN SOLUTION 
2.7.1 Buffer exchange proteins 
 
Step 1: Buffer exchange proteins 
The protein (~10 µg) was buffer-exchanged with 400 μL (1) 0.2M NaHCO3, pH 9.5 (Na-1 
buffer) for arginine and for lysine (2) PB150 buffer (See Section 2.7.1) when the protein had a 
slow dissociation form the GAG relative to labelling time or (3) PB buffer (no NaCl) if the 
protein apparently dissociated faster in a saline than the reaction time [157]. Thus, the 
concentration of NaCl could be adjusted depending on the dynamic of the individual protein 
and GAG interaction. The mixture was then concentrated on a 3.5 kDa MWCO centrifugal 
filter (Merk Millipore, UK) to a final volume of 70~80 μL. This step was repeated 4 to 5 times 
to ensure buffer exchange. 
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2.7.2 Protection of lysine/arginine exposed to solvent 
 
Step 2: Interaction between protein and GAG 
GAGs, including heparin, CS, DS were stored in water at 1mg/ml. GAG was added to protein 
at the ratio of 100:1 to 20:1 (GAG: protein Molar concentration), gently mixed and left at room 
temperature for 5 min. 
Step 3: Protection of lysine/arginine residues 
Sulfo-NHS-acetate (Section 2.7.1) or NHS-acetate (Thermo Scientific, UK) was prepared at 
250 mM in PBS.  This reagent was added to the mixture of GAG-protein for final concentration 
of 50 mM, followed by incubation for 5 min at room temperature. NHS-acetate was preferred 
to sulfo-NHS for protein GAG interactions that dissociated over the timescale of the labelling 
step, since it is less charged and does not compete for binding. 
PGO (Section 2.8.1) was at 0.5 M in 0.2 M NaHCO3, pH 9.5. The pH was adjusted with 0.1 M 
NaOH to between 9.1 and 9.5 to ensure optimal reaction. PGO was added to the mixture of 
GAG-protein at a final concentration of 0.2 M and was allowed to react for 60 min at room 
temperature in the dark. The reaction was quenched with 0.1% (v/v) trifluoroacetic acid (TFA) 
in water so that the final concentration of TFA was 0.01% (v/v). 
The excess NHS-acetate or PGO was removed by 3-4 cycles of dilution on 3.5 kDa-MWCO 
centrifugal filters with 400 μL PBS buffer (for lysine) and 0.2 M NaHCO3 (for arginine) using 
centrifugation at 13200 rpm for 10 min/each cycles. The final volume is recommended to 
around 70-100 μL. 
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2.7.3 Selective labelling of lysine/arginine of binding sites  
 
Step 4: Dissociation of the protein-GAG interaction 
The GAG:protein complexes were dissociated by the addition of one volume of 6 M NaCl, 45 
mM Na2HPO4, 5 mM NaH2PO4, pH 7.8 to a final concentration 3 M of NaCl and left for 5 min. 
Step 5: Labelling of lysine/arginine of binding sites 
For arginine, HPG was prepared at 0.5 M (Section 2.8.4) then added to the mixture, so that the 
final concentration of HPG in the reaction was 0.1 M, and then left for 60 min at room 
temperature in the dark. The reaction was quenched by adding 0.1% (v/v) TFA in water to a 
final concentration of 0.01%. 
For lysine, 150 mM NHS-biotin in DMSO was used. The final concentration of NHS-biotin 
was 10 mM and the reaction time was 30 min at room temperature. The reaction was quenched 
with 1 M Tris-Cl, pH 7.5 at 1:10 (v/v). 
2.7.4 Sample preparation for MALDI-TOF 
Step 6: Removal of excess reagent 
This step is similar to Section 2.7.2 (for lysine) and Section 2.8.3 (for arginine). After 
centrifugation, samples were kept at -80°C overnight followed by lyophilization for an hour. 
Then, the preparation of samples was identical to that described in Section 2.8.3. 
2.8 MALDI-TOF FOR IDENTIFICATIONS OF LABELLED PEPTIDES 
Peptides were concentrated by rotary evaporation to a final volume of 10 μL and desalted using 
C18 Zip-Tips (Millipore). C18 Zip Tips were first pre-wetted with 2 x 10 μL 100 % (v/v) 
acetonitrile and then pre-equilibrated with 2 x 10 μL 0.1% (w/v) TFA in water. The peptides 
were loaded on the Zip Tip, the loading was repeated 7 to 8 times to ensure binding. The Zip 
Tip was washed with 10 μL 0.1% (w/v) TFA. Finally, the peptides were eluted with 2 μL of 
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5mg/mL α-cyano-4-hydroxycinnamic acid (CHCA, > 99% purity, Sigma) in 50:50 
acetonitrile/water + 1% (w/v) TFA, straight onto a 96 spot MALDI (matrix-assisted laser 
desorption/ionisation) target plate.  
Analyses were performed on a Synapt G2-Si instrument (Waters, Manchester, UK) with 
MALDI source equipped with a frequency tripled Nd:YAG UV laser (λ = 355 nm), operating 
at 1 kHz. The spectrum acquisition time was 120 seconds, with 1 second scan rates, laser energy 
of 150 Au. The MS spectra were extracted by MASSLYNX v.4.1 (Waters, Manchester, UK) 
with the spectrum range from 500 Da to 4000 Da. The spectra were then processed using 
automatic peak detection including background subtraction. 
2.9 PYTHON SCRIPTS FOR THE IDENTIFICATIONS OF LABELLED RESIDUES 
The scripts for the identification of labelled residues have been uploaded onto GitHub. 
https://github.com/bpthao/PGO-HPG-mass-predictor_2 
and https://github.com/bpthao/Matchmaker_2 
Protein Prospector (v 5.19.1 developed at the USCF Mass spectrometry Facility) and Peptide 
Mass (ExPASy) were used to predict the possible peptides after incubation with an enzyme 
with the following parameters: enzyme, chymotrypsin or trypsin; maximum missed cleavages, 
5; mass range, 500 to 4000 Da; monoisotopic; instrument, MALDI-Q-TOF (Figure 1-B1). The 
list of peptides after enzyme cleavage was filtered to remove the peptides without arginine 
residues. 
Arginine: 
Because products from the reaction between PGO/HPG and arginine residues bring different 
additional masses to the peptides, the prediction of the peptide masses after the modification 
was achieved using a script, written in Python (version 3.5.3 released on January 17th, 2017, 
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available at http://www.python.org), named “PGO-HPG mass predictor” (available at Github: 
https://github.com/bpthao/PGO-HPG-mass-predictor_2).  Based on the number of arginine 
residues in each peptide, PGO-HPG mass predictor script” considers all possible reaction 
products of PGO and HPG with arginine, and generates a list of predicted mass of the modified 
peptides (Figure 1-B2). 
PGO-HPG mass predictor has two input files. First, the list of predicted peptides from the 
native proteins cleaved by enzyme from either Protein Prospector or Peptide Mass (ExPASy). 
The file has two columns, the native sequence of the peptide and the corresponding mass. 
Second, the file of modifications also has two columns, the mass shift of each modification and 
the description of products. Using the loop, PGO-HPG mass predictor automatically adds up 
all potential mass shifts to each peptide having one or more arginine residues in the sequence. 
All combinations of mass changes were covered. The output file has four columns, 1-the native 
sequence of the peptides, 2- the original mass, 3-the final mass after modifications, 4-
modifications, which make it easier for further processing. 
The observed list is the original mass of FGF peptides after modifications (Figure 1-B3), which 
provided the mass and intensity of each peak. The match between predicted and the observed 
list was carried out with a second Python script, “Matchmaker”, (available at Github in 
following link: https://github.com/bpthao/Matchmaker_2) with a mass difference tolerance set 
to 0.1~0.5 Da (Figure 1-B3), as recommend by Mascot. 
The output is a list of matching peptides with the native sequence, the predicted mass with 
modifications, the specific modifications associated with arginine residues and the actual 
observed mass. 
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Lysine: 
Each reaction between NHS-acetate with the amine side chain of lysine leads to a mass shift 
of 42.01 Da for the peptide. The mass change in case of biotinylation on lysine is 226.08. Both 
modifications on lysine containing peptides are considered by the script written in Python 
(available at Github in following link: https://github.com/bpthao/ Lysine mass predictor). 
This script automatically adds up all potential mass shifts to each peptides which have lysine 
residues in the sequence. The output file has four columns, 1-the native sequence of the 
peptides, 2- the original mass, 3-the final mass after modifications, 4-modifications. Because 
the lysine products have only a limited number of combinations, then the final mass after 
modifications was compared to what was observed in the spectra manually.  
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CHAPTER 3 PURIFICATION OF PARACINE FGFs 
3.1 INTRODUCTION 
The initial step in this work required the production of recombinant FGFs in E.coli. The 
protocol for purification of many paracrine FGFs has been described before [37] [36], including 
the use of Halo-tag as a solubilisation tag with some FGFs that were otherwise poorly 
expressed. Thirteen of the 15 paracrine FGFs had been successfully purified previously 
[120][36][37], but not FGF5 and FGF8. Moreover, only 11 paracrine FGFs have had their 
HBSs analysed by selective labelling of lysine residues, and data are lacking for FGF16 and 
FGF22 in addition to the two FGFs that had not been expressed in-house. 
In this thesis FGF5 and FGF8 were successfully purified as Halo-tag fusion proteins. All other 
FGFs were produced following existing protocols, except for FGF7, FGF10 and Halo-FGF20 
which were produced by Pawin Ngamlert, University of Liverpool. 
3.2 PURIFICATIONS OF PROTEINS 
 
The list of the recombinant FGFs used in this study is in Table 3.1 
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Table 3.1: Recombinant human FGF proteins and their N-terminal tag. FGF names, ID 
number and amino acid numbering are according to the Uniprot entry. The molecular weight 
of each FGF with the tag is provided. “Halo” is Halo-tag. FGFs with an N-terminal Halo-tag 
are called “Halo-FGF” here.  
Name UniProt 
accession 
number 
Molecular 
mass (kDa) 
N-terminal 
Tag 
Chromatography used 
FGF1 P05230 19.1 His Heparin & Cation-exchange 
FGF2 P09038-2 17.3 None Heparin & Cation-exchange 
FGF3 P11487-1 26.89 His Heparin & Ni2+ 
FGF4 P08620 19.2 His Heparin & Cation-exchange 
FGF5 P12034-1 58.95 Halo Heparin & DEAE 
FGF6 P10767 51.1  Halo Heparin & Cation-exchange 
FGF7 P21781 22.2  His  
FGF8b P55075-3 57.5  Halo Heparin & DEAE 
FGF9 P31371 23.4 His Heparin & Cation-exchange 
FGF10 O15520 22.7  His  
FGF16 O43320 21.4 His Heparin & Ni2+ 
FGF17 O60258-1 23.3 His Heparin & Cation-exchange 
FGF18 O76093 24.03 His Heparin & Ni2+ 
FGF20 Q9NP95 58.8  Halo  
FGF22 Q9HCT0 52.3  Halo Heparin  
 
3.2.1. Purification of FGF-2 
FGF-2 was produced from a culture of 800 µL x 4 flasks (Section 2.3.1). The protein eluting 
from the Affi-Heparin agarose column (Section 2.4.2) was then diluted before applying to a 
cation-exchange column (Section 2.4.3). The fractions collected from the columns along with 
samples corresponding to the starting material and unbound protein were analyzed by SDS-
PAGE. The results from heparin chromatography showed that a band, of ~17 kDa was present 
in fraction of 2.0 M NaCl (Fig 3.1A). This 2 mL was then diluted before applying on the cation-
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exchange column. This chromatography showed a single band of ~17 kDa in fractions of 0.6 
M NaCl, 1.0 M NaCl, 2.0 M NaCl but not 0.8 M NaCl (Fig 3.1A). The concentration of protein 
in the fraction of 2.0 M NaCl (Fig 3.1B) was 0.7 mg/mL, as measured by the absorbance at 280 
nm. The fractions with FGF2 were pooled and stored as 100 μL aliquots in elution buffer at -
80°C. 
For FGF2, the purification was repeated using phosphate buffer (Section 2.3.1) (Fig 3.1C). 
Upon heparin affinity chromatography, the bands at the molecular weight of FGF2 (~17 kDa) 
were detected in fractions eluting with 0.6 M NaCl and 1.0 M NaCl but not 2.0 M NaCl (Fig 
3.1C). The concentration of protein in fraction of 0.6 M NaCl (Fig 3.1C) was 0.5 mg/mL. 
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Figure 3.1: Expression and purification of FGF2. (FGF2 molecular weight: 16.7 kDa) 
A) Purification of FGF2 by heparin-affinity chromatography using Tris buffer (Section 2.4.2). 
Lane 1, bacteria before induction by IPTG. The following lanes all after induction by IPTG, all 
solutions buffered with 50 mM Tris-Cl, pH 7.2: lane 2, Pellet;  lane 3, sonicated whole cell 
lysate; lane 4, flow through (F/T); wash with 0.3 M NaCl (lane 5);  0.6 M NaCl (lane 6); lane 
7, elution with 1.0 M NaCl; lane 8, elution with 2.0 M NaCl; lane 9: makers. Black arrow, band 
corresponding to the molecular weight of FGF2. 
B) Further purification of FGF2 by cation-exchange chromatography (Section 2.4.3). After 
heparin-affinity chromatography, the sample was further purified on a 1 mL HiTrap SP-HP 
column with all solutions buffered with 50 mM Tris-Cl, pH 7.2. Lane 1, markers; lane 2, 0.3 
M NaCl; lane 3, 0.4 M NaCl; lane 4, elution ( with 0.6 M NaCl; lane 5, elution with 0.8 M 
NaCl; lane 6: elution with 1.0 M NaCl; lane 7: elution with 2.0 M NaCl. Black arrow, band 
corresponding to the molecular weight of FGF2. 
C) Similar protocol as panel A) however, instead phosphate buffer (Section 2.4.2) pH 6.8 was 
used in place of 50 mM Tris-Cl. 
3.2.2. Purification of His-tag FGF-1 
His-FGF-1 was produced using the plasmid described above (Section 2.2.1) from a culture of 
800 µL x 4 flasks (Section 2.3.1). The protein eluting from the Affi-Heparin agarose column 
(Section 2.4.2) in 2.0 M NaCl, 50 mM Tris-Cl, pH 6.8 was then diluted with the same buffer 
before applying it to a 1 mL HiTrap SP-HP cation-exchange column and eluting using 
phosphate buffered solutions (Section 2.4.3). The fractions collected from the second column 
were analyzed by SDS-PAGE. The results from cation-exchange chromatography showed that 
a band of ~19.1 kDa was present when the concentration of NaCl in the buffer was above 0.6 
M (Fig 3.2). A single band of ~19 kDa was in the 1.5 M NaCl elutate, whereas in other fractions 
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additional bands were present. The concentration of protein in fraction the 1.5 M NaCl eluate 
was 1.2 mg/mL as measured by the absorbance at 280 nm. These fractions were stored as 100 
μL aliquots in elution buffer at -80 °C. 
 
Figure 3.2: Expression and purification of His-FGF1. (His-FGF1 molecular weight: 19.1 
kDa). His-FGF1 was first subjected to heparin-affinity chromatography and the eluate was 
diluted with 50 mM Tris-Cl, pH 6.8 and applied to a 1 mL HiTrap SP-HP. The column was 
then washed and eluted with phosphate buffered solutions (Section 2.4.1). Lane 1: flow 
through; lane 2: (0.3 M NaCl; lane 3: 0.4 M NaCl; lane 4: 0.5 M NaCl; lane 5: elution (0.6 M 
NaCl); lane 6: elution (0.8 M NaCl); lane 7: elution (1.0 M NaCl); lane 8: elution (1.2 M NaCl); 
lane 9: elution (1.5 M NaCl); lane 10: elution (2.0 M NaCl). Black arrow, band corresponding 
to the molecular weight of His-FGF1. 
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3.2.3. Purification of His-tag FGF-4 
His-FGF-4 was produced using the plasmid described above (Section 2.2.1) from a culture of 
800 µL x 4 flasks (Section 2.3.1). The protein from cell lysis was loaded onto a Affi-Heparin 
agarose column (Section 2.4.2) in Tris-buffer, and the eluate from this subjected to  cation-
exchange chromatography on a 1 mL HiTrap SP-HP column, which was developed using 
phosphate buffer (Section 2.4.3). The fractions collected from both columns along with 
samples corresponding to the starting material and unbound protein were analyzed by SDS-
PAGE. FGF4 was eluted from heparin affinity column at the concentration NaCl of 1.5 M and 
2.0 M (Fig 3.3A). Those two fractions were diluted in phosphate buffer and then applied to the 
cation-exchange column (Section 2.4.3). The results from cation-exchange chromatography 
showed that a band of ~19 kDa was present when the concentration of NaCl in the buffer was 
above 0.6 M (Fig 3.3B). The fractions with presence of pure protein were pooled and stored as 
100 μL aliquots in elution buffer at -80 °C. 
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Figure 3.3: Expression and purification of His-FGF4. (His- FGF4 molecular weight: 19.2 
kDa). A) Purification of FGF4 by heparin-affinity chromatography using Tris-Cl buffer 
(Section 2.3.2). Lane 1, Pellet; lane 2, sonicated whole cell lysate; lane 3, flow through after 
loading cell lysate onto the column; lane 4, wash fraction (0.3 M NaCl); lane 5, wash fraction 
(0.6 M NaCl); Lane 6, elution (1.0 M NaCl); Lane 7, elution (1.2 M NaCl); Lane 8, elution (1.5 
M NaCl); Lane 9, elution (2.0 M NaCl). Lane 10, Ladder. B) Further purification of FGF4 by 
cation-exchange chromatography (Section 2.3.3). The eluate from heparin-affinity 
chromatography was diluted 20-fold in PB buffer, pH 6.8 and applied to a 1 mL HiTrap SP-
HP column. Lane 1, load; lane 2, flow through; lane 3, wash fraction (0.1 M NaCl); lane 4, 
molecular weight markers; lane 5, wash fraction (0.3 M NaCl); lane 6, wash fraction (0.4 M 
NaCl; lane 7, wash fraction (0.5 M NaCl); lane 8, elution (0.6 M NaCl); lane 9, elution (0.8 M 
NaCl) ); lane 10, elution (1.0 M NaCl) ); lane 11, elution (1.2 M NaCl). ); lane 12, elution (1.5 
M NaCl). Black arrow, His-FGF4. 
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3.2.4. Purification of Halo-FGF6, His-FGF9 and His-FGF17 
Halo-FGF6, His-FGF9 and His-FGF17 were all purified similarly to FGF4. Following heparin 
affinity chromatography, a major band was observed in the fractions eluting at the higher NaCl 
concentrations (Fig 3.4A, 3.5A and 3.6A). These fractions were diluted in 50 mM Tris-Cl, pH 
6.8 to 0.1 M NaCl and applied to a 1 mL HiTrap SP-HP column. Following washing, elution 
fractions were collected and analysed by SDS-PAGE. Each of these FGFs was successfully 
purified in this way (Figs 3.4B, 3.5C and 3.6C). 
3.2.4.1 Purification of FGF6 
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Figure 3.4: Expression and purification of Halo-FGF6. (Halo-FGF6 molecular weight: 
51.1 kDa). A) Purification of Halo-FGF6 by heparin-affinity chromatography using 50 mM 
Tris-Cl pH 6.8 buffer (Section 2.4.2). Lane 1, pellet; Lane 2, sonicated whole cell lysate; Lane 
3, flow through after loading cell lysate onto the column; Lane 4, wash fraction (0.3 M NaCl); 
Lane 5, wash fraction (0.6 M NaCl); Lane 6, elution (1.0 M NaCl); Lane 7, elution (1.2 M 
NaCl); Lane 8, elution (1.5 M NaCl); Lane 9: Ladder. B) Further purification of Halo-FGF6 
by cation-exchange chromatography using Tris-Cl buffer (Section 2.4.3). Lane 1, wash fraction 
(0.3 M NaCl); Lane 2, wash fraction (0.4 M NaCl); Lane 3, wash fraction (0.6 M NaCl); Lane 
4, elution fraction (0.8 M NaCl); Lane 5, elution fraction (1.0 M NaCl); Lane 6, elution fraction 
(1.2 M NaCl); Lane 7, elution fraction (1.2 M NaCl); Lane 8, elution fraction (1.5 M NaCl); 
Lane 9, elution fraction (2.0 M NaCl). Black arrow, Halo-FGF6. 
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3.2.4.1 Purification of His-FGF9 
 
 
Figure 3.5: Expression and purification of His-FGF9. (His-FGF9 molecular weight: 23.4 
kDa) A) Purification of His-FGF9 by heparin-affinity chromatography using 50 mM Tris-Cl 
pH 6.8 (Section 2.4.2). Lane 1, pellet; Lane 2, sonicated whole cell lysate; Lane 3, flow through 
after loading cell lysate onto the column; Lane 4, wash fraction (0.3 M NaCl); Lane 5, wash 
fraction (0.6 M NaCl); Lane 6, elution (1.0 M NaCl); Lane 7, elution (2.0 M NaCl). B) Further 
purification of His-FGF9 by cation-exchange chromatography (Section 2.4.3). After heparin-
affinity chromatography, the sample was further purified on HiTrap SP HP column. The 2.0 M 
NaCl fraction was diluted 20 times then applied to a 1 mL Hi Trap SP-HP column. Lane 1, 
molecular weight markers; Lane 2, wash fraction (0.1 M NaCl,); Lane 3, wash fraction (0.2 M 
NaCl); Lane 4, washing fraction (0.3 M NaCl); Lanes 5 and 6, elution (0.6 M NaCl); Lane 7, 
elution (1.0 M NaCl). Black arrow, His-FGF9. 
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3.2.4.1 Purification of His-FGF17 
 
 
Figure 3.6: Expression and purification of His-FGF17. (His-FGF17 molecular weight: 
23.3 kDa) A) Purification of His-FGF17 by heparin-affinity chromatography using 50 mM 
Tris-Cl, pH 6.8 buffer. Lane 1, cells before induction by IPTG; Lane 2, sonicated whole cell 
lysate; Lane 3, pellet; Lane 4, Flow through; Lane 5, wash fraction (0.3 M NaCl); Lane 6, wash 
fraction (0.6 M NaCl); Lane 7, elution (1.0 M NaCl); Lane 8, elution (2.0 M NaCl); Lane 9, 
molecular weight markers. B) Further purification of FGF17 by cation-exchange 
chromatography (Section 2.4.3). After heparin-affinity chromatography, the sample was 
further purified on a 1 mL HiTrap SP-HP column. FGF17 in the 1.0 M NaCl fraction following 
heparin affinity chromatography was diluted 10 times and then applied to the cation-exchange 
column. Lane 1, load after dilution; Lane 2, Flow through; Lane 3, wash fraction (0.2 M NaCl); 
Lane 4, wash fraction (0.3 M NaCl); Lane 5, elution (0.6 M NaCl); Lane 6, elution (0.8 M 
NaCl); Lane 7, elution (1.0 M NaCl); Lane 8, elution (2.0 M NaCl).  Black arrow, His-FGF17. 
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3.2.5. Purification of His-FGF3, His-FGF16 and His-FGF18  
His-FGF3, His-FGF16 and His-FGF18 were first purified from bacterial cell lysates by heparin 
affinity chromatography (Section 2.4.1). The fractions containing a major band (Fig 3.7A, 3.8A 
and 3.9A) were diluted in 50 mM Tris-Cl, pH 6.8 to 0,1 M NaCl and applied to a  1 mL Ni2+ 
affinity column (Section 2.4.3). Following washing, elution fractions were collected and 
analysed by SDS-PAGE, which demonstrates the successful purification of these FGFs (Figs 
3.7B, 3.8C and 3.9C). 
3.2.5.1 Purification of His-FGF3 
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Figure 3.7: Expression and purification of His-FGF3. (His-FGF3 molecular weight: 26.89 
kDa) A) Purification of His-FGF3 by heparin-affinity chromatography using 50 mM Tris-Cl 
buffer, pH 6.8. Lane 1: Pellet; lane 2: sonicated whole cell lysate; lane 3: flow through 
application of cell lysate onto the column; lane 4, wash fraction (0.3 M NaCl); lane 5, wash 
fraction (0.5 M NaCl); lane 6, wash fraction (0.6 M NaCl); lane 7, elution (1.0 M NaCl); lane 
8, elution (2.0 M NaCl). Lane 9, molecular weight markers. B) Further purification of His-
FGF3 by Ni2+ chromatography (Section 2.4.4). Lane 1: Load: Lane 2, Flow through; Lane 3, 
wash fraction (50 mM imidazole); Lane 4, wash fraction (0.1 M imidazole); lane 5, wash 
fraction (0.2 M imidazole); lane 6, elution (0.3 M imidazole); lane 7, elution (0.4 M imidazole); 
lane 8, elution (0.5 M imidazole); lane 9: molecular weight markers. Black arrow, His-FGF3. 
3.2.5.1 Purification of His-FGF16 
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Figure 3.8: Expression and purification of His-FGF16. (His-FGF16 molecular weight: 
21.4 kDa) A) Purification of FGF16 by heparin-affinity chromatography using 50 mM Tris-Cl 
pH 6.8 buffer. Lane 1, wash fraction (0.3 M NaCl); Lane 2, wash fraction (0.5 M NaCl); Lane 
3, wash fraction (0.6 M NaCl);  Lane 4, wash fraction (0.8 M NaCl); Lane 5, elution (1.0 M 
NaCl); Lane 6, elution (1.5 M NaCl);  Lane 7, elution (1.8 M NaCl); Lane 8 elution (2.0 M 
NaCl). B) Further purification of His-FGF16 by Ni2+ chromatography (Section 2.4.4). Protein 
from the 1.8 M and 2.0 M NaCl fractions were combined, diluted 20 times and then applied to 
the Ni2+ column. Lane 1, Load: Lane 2 Flow through; Lane 3, wash fraction (50 mM 
imidazole); Lane 4, elution (0.1 M imidazole); Lane 5, elution fraction (0.15 M imidazole); 
Lane 6, elution fraction (0.2 M imidazole); Lane 7, elution fraction (0.3 M imidazole); Lane 8, 
elution fraction (0.4 M imidazole); Lane 9, elution fraction (0.5 M imidazole). Black arrow, 
His-FGF16. 
3.2.5.1 Purification of His-FGF18 
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Figure 3.9: Expression and purification of His-FGF18. (His-FGF18 molecular weight: 
24.03 kDa) A) Purification of His-FGF18 by heparin-affinity chromatography using 50 mM 
Tris-Cl buffer, pH 6.8. Lane 1, Pellet; Lane 2, sonicated whole cell lysate; Lane 3, Flow 
through; Lane 4, wash fraction (0.3 M NaCl); Lane 5, wash fraction (0.6 M NaCl); Lane 6, 
wash fraction (0.8 M NaCl);  Lane 7, elution (1.0 M NaCl); Lane 8, elution (2.0 M NaCl); Lane 
9, molecular weight markers. B) Further purification of FGF18 by Ni2+ chromatography. After 
heparin-affinity chromatography, FGF18 from fractions eluting between 0.6 M NaCl and 2.0 
M NaCl was diluted 10 times before applying to the Ni2+ column. Lane 1, Flow through; Lane 
2, wash fraction (50 mM imidazole); Lane 3, elution fraction (0.1 M imidazole); Lane 4, elution 
fraction (0.2 M imidazole); Lane 5, elution fraction (0.3 M imidazole); Lane 6, elution fraction 
(0.4 M imidazole); Lane 7, elution fraction (0.5 M imidazole). Black arrow, His-FGF18. 
3.2.6. Purification of Halo-FGF5 
Halo-FGF5 was produced using the plasmid described in Section 2.2.1. To optimize the amount 
of protein, the expression was conducted at 16 oC for 4 hours. After sonication (Section 2.4.1), 
the insoluble material was removed by centrifugation. There was no band around the expected 
molecular weight of Halo-FGF5 (~59 kDa) in the pellet (Figure 3.10A, lane 1), but a band was 
apparent in the supernatant (Figure 3.10A, lane 2). Upon application to a heparin affinity 
column (Section 2.4.2), this protein remained bound, since no equivalent band was detectable 
in the flow through fraction (Figure 3.10A, lane 3). However, the band corresponding to FGF5 
was present in the elution fractions when the concentration of NaCl was increased to 1.0 M, 
although some contaminants were observed as well (Figure 3.10B, lanes 1 to 9). It could be 
seen that the elution range of the Halo-FGF5 was broad. There were two hypothesises for this 
phenomena. First, the amount of Halo-FGF5 was over the binding capability of the heparin 
column. Second, Halo-FGF5 molecules have different binding affinity to heparin due to their 
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folding in different conformations or to recognising with different affinities the different 
structures present in heparin, which is polydisperse (Section 1.3).  
To remove the contaminants, Halo-FGF5 in the fractions of 1.2 M and 1.5 M NaCl were diluted 
to 0.05 M NaCl with 50 mM Tris-Cl, pH 6.8 and then applied to a 1 mL DEAE-Sepharose 
column (Section 2.4.3) for further separation. DEAE chromatography takes advantage of the 
acidic isoelectric point of the Halo-tag moiety of the fusion protein. No protein was observed 
in the load and flow through fractions, likely due to the dilution of the sample (Fig 3.10C lane 
2, 3). A small amount of Halo-FGF5 could be seen in the 0.2 M NaCl fraction (Figure 3.10C, 
lanes 5 and 6). However, the majority of the Halo-FGF5 was eluted at 0.3 M NaCl (Figure 
3.10C, lane 7) as a single band. There were no detectable polypeptides in the higher ionic 
strength eluates (Figure 3.10C, lanes 8 and 9). The concentration of protein in lane 7 was 1.2 
mg/mL. 
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Figure 3.10: Purification of Halo-FGF5 (Molecular weight 58.95 kDa).  A, B. Heparin 
affinity chromatography. A) Lane 1, Pellet; Lane 2, sonicated whole cell lysate; Lane 3, Flow 
through; Lane 4, wash (0.3 M NaCl); Lane 5, molecular weight markers; Lane 6, wash fraction 
(0.5 M NaCl); Lanes 7 to 9: wash fraction (0.6 M NaCl). B) Eluates. Lane 1 to 4, serial 1 mL 
elutions (1.0 M NaCl); Lanes 5 and 6, elution (1.2 M NaCl); Lanes 7 and 8, elution (1.5 M 
NaCl); Lane 9, elution (2.0 M NaCl); Lane 10 molecular weight markers. C. DEAE 
chromatography. Lane 1: molecular weight markers; Lane 2, load following dilution; Lane 3, 
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Flow through; Lane 4, wash (0.1 M NaCl); Lanes 5 and 6, wash (0.2 M NaCl); Lane 7, elution 
(0.3 M NaCl); Lane 8, elution (0.4 M NaCl); Lane 9, elution (0.6 M NaCl). Arrow: Halo-FGF5. 
3.2.7. Purification of Halo-FGF8 
The 500 mL cultures of transformed with the plasmid encoding Halo-tag FGF8 were cultured 
for 16 hours at 16 oC (Sections 2.3.1). After sonication  and centrifugation (Section 2.4.1), there 
was no band around the expected molecular weight of Halo-FGF8 (~57.5 kDa) in the pellet 
(Figure 3.11A, lane 1). The applied sample and the flow through from the column contained a 
mixture of polypeptides, hence it was difficult to distinguish a band corresponding to Halo-
FGF8 (Figure 3.11A, lane 2, 3). The wash using Tris buffer containing 0.3 M and 0.4 M NaCl 
(Section 2.3.2) remove some contaminants (Figure 3.11A, lane 4, 5 and 6). Two large bands 
were apparent in the 0.5 M NaCl eluate (Figure 3.11A, lane 7). However, those bands were not 
detected in the eluate of 0.6 M NaCl (Figure 3.11A, lane 8). When the concentration of NaCl 
was increased to 1.0 M, a single major band equivalent to the expected size of Halo-FGF8 was 
detected (Figure B, lanes 2, 3 and 4). However, contaminants were also present, so elution at 
higher concentrations of NaCl was performed. The fractions eluted at 1.5 M NaCl (Figure 
3.11A, lane 7 and 8) and 2.0 M (Figure 3.11A, lane 9) had far less protein, but appeared to be 
sufficiently for use in experiments. 
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Figure 3.11: Purification of Halo-FGF8 (Molecular weight 57.5 kDa). A, B. Heparin 
affinity chromatography. A) Lane 1, Pellet; Lane 2, sonicated whole cell lysate; Lane 3, Flow 
through; Lane 4, wash fraction (0.3 M NaCl); Lane 5, washing fraction (0.3 M NaCl); Lane 6, 
wash fraction (0.4 M NaCl); Lane 7, wash fraction (0.5 M NaCl); Lane 8, wash fraction (0.6 
M NaCl); Lane 9, molecular weight markers B) Eluates Lane 1, 0.8 M NaCl; Lane 2 to 4, 1.0 
M NaCl; Lanes 5 and 6, 1.2 M NaCl; Lanes 7 and 8, 1.5 M NaCl; Lane 9, 2.0 M NaCl. C) 
DEAE chromatography (Section 2.4.4). Lane 1, load after dilution; Lane 2, Flow through; Lane 
3, wash (0.1 M NaCl); Lanes 4 and 5, wash (0.2 M NaCl); Lane 6, elution (0.3 M NaCl); Lane 
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7, elution (0.4 M NaCl); Lane 8, elution (0.6 M NaCl); Lane 9, elution (1.0 M NaCl); Lane 10, 
elution (2.0 M NaCl). Arrow, Halo-FGF8. 
There was a large amount of protein in the 1.0 M NaCl eluate from the heparin  affinity column, 
which also contained substantial levels of contaminants, so it was decided to further purify the 
Halo-FGF8 using DEAE Sepharose, taking advantage once again of the acidic isoelectric point 
of the Halotag protein. The 1.0 M NaCl eluates from the heparin column were combined and 
diluted to 0.1 M NaCl with 50 mM Tris, pH 7.4 and applied to a DEAE Sepharose column (1 
mL) (Section 2.4.4). After washing with 0.1 M NaCl (Fig 3.11C, lane 3), a step gradient, 
starting at 0.2 M NaCl (Fig 3.11C, lane 4 to 10) was used to elute proteins. A polypeptide 
corresponding to the expected size of Hal-FGF8 started to be eluted at 0.3 M NaCl (Fig 3.11C, 
lane 6) although other bands were detected in this fraction as well. The purest Halo-FGF8 was 
eluted with 0.4 M NaCl (Fig 3.11C, lane 7). There was a small amount of protein eluting at 
higher concentrations of NaCl when 0.6 M, 1.0 M and 2.0 M was loaded onto the column (lanes 
8, 9 and 10). ). The concentration of protein in lane 7 was 1.05 mg/mL. 
3.2.8. Purification of Halo-FGF22 
Halo-FGF22 was produced using the plasmid described in Section 2.2.1. Without the addition 
of IPTG, there was no band corresponding to the molecular size of Halo-FGF22 (~52.3 kDa) 
(Fig 3.12A, lane 1). When the culture condition was set at 37 oC for 1 h or 4 h, there was no 
protein corresponding to Halo-FGF22 detectable (Fig 3.12A lane 2 and 3). Hence, this protein 
was expressed at 16 oC for 4 hours as done for Halo-FGF5 (Section 3.2.11). After sonication 
and centrifugation (Section 2.4.1), the supernatant was applied to a heparin affinity column 
(Section 2.4.2). The pellet contained a mixture of proteins (Fig 3.12A, lane 4). The flow 
through fraction (Fig 3.12A, lane 5) and the two subsequent washes (0.3 M NaCl) (Fig 3.12A, 
lane 6), and 0.5 M NaCl (Fig 3.12A, lane 7) did not contain a detectable band corresponding 
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to Halo-FGF22. The 0.6 M NaCl and 0.8 M NaCl fractions contained a band corresponding to 
Halo-FGF22, as well as a number of other polypeptides (Fig 3.12A, lane 8 and 9).  
 
Figure 3.12: Purification of Halo-FGF22 (Molecular weight 52.3 kDa). A, B. Heparin 
affinity chromatography. A) Lane 1, Cells before the induction with IPTG; Lane 2, Cell lysate 
after 4 hours induction; Lane 3, Cell lysate after 1 hour induction; Lane 4, Pellet; Lane 5, Flow 
through; Lane 6, wash (0.3 M NaCl); Lane 7, wash (0.5 M NaCl); Lane 8, wash (0.6 M NaCl); 
Lane 9: wash (0.8 M NaCl) B) Elutions: Lanes 1 to 3, 1.0 M NaCl; Lanes 4 to 6, 1.2 M NaCl; 
Lane 7, 1.5 M NaCl. Arrow: Halo-FGF22. 
At 1.0 M NaCl (Fig 3.12B, lane 1, 2 and 3), the lower molecular weight contaminants observed 
in the 0.6 M fractions (Panel A, lane 8, 9) were greatly reduced. At 1.2 M NaCl there were two 
major bands detected, including the band of Halo-FGF22 and one band of lower molecular 
weight (Fig 3.12B, lane 4, 5 and 6). At 1.5 M NaCl, (Lane 7), a single band at the molecular 
weight of the Halo-FGF22 was observed and it was judged to be sufficiently pure for use in 
experiments. 
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CHAPTER 4 SELECTIVE LABELLING OF ARGININE RESIDUES 
ENGAGED IN BINDING SULFATED GLYCOSAMINOGLYCAN 
4.1 INTRODUCTION 
Arginine is an abundant residue in proteins, some of them participate in electrostatic 
interactions with the negative charged patterns, some contribute to π-cation interactions, other 
may engage in the intramolecular network of hydrogen bonds maintaining the local structure 
of proteins. Moreover, the heparin binding sites of some proteins have arginines, but no lysine 
residues, e.g., fibroblast growth factor FGF22 (Uniprot ID: Q9HCT0-1). To establish their 
functions clearly, a method for selective labelling of arginine has been developed, taking 
advantage of mass spectrometry. Selective labelling was first carried-out for lysine due to the 
specificity of on the reaction of N-hydroxysuccinimide (NHS) with the amino side chain of 
lysine residues. However, NHS cannot react with the guanidino side chains of arginine 
residues, leading us to other potential chemicals for the modification of arginine amino acid. 
Eventually, PGO and hydroxyl-phenylglyoxal (HPG) were chosen to develop a method for 
selective labelling of arginines with the assistance of modern mass spectrometry and automated 
analysis of spectra to overcome the weakness of multiple reaction products of PGO and 
guanidino groups of arginine.  
This approach is initially applied on two well-known FGFs, FGF1 and FGF2, to distinguish 
the arginine residues which form electrostatic interactions with sulfate groups of sugar chain 
from the one not involved in binding. The condition and analysis were optimized. The results 
were additionally verified using the previous works on interaction of FGF1 and FGF2 with 
heparin. 
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4.2 THE CHEMICAL MODIFICATION OF ARGININE 
4.2.1 Arginine modification, reagents, and conditions 
Reaction mechanisms: There are limited works on the chemical modification of arginine 
residues in proteins and the majority of them based on the reaction of vicinal dicarbonyl 
compounds including phenylglyoxal, p-hydroxyphenylglyoxal, 2,3-butanedione, 1,2-
cyclohexanedione, and methylglyoxal with guanidine group to form cyclic adducts [158].  
The arginine-specific reactions are commonly carried out in 25°C over a pH range of 7–10 with 
the wide range of buffer and reaction times ranging from 15 min to 24 hours. The rate of the 
reaction is relatively slow under alkaline conditions and the products are reversible in the 
presence of diones [159]. Universally, dicarbonyl compounds react with arginine in the dark to 
avoid possible photoactivation of these molecule, which could enhance nonspecific reactions 
with groups other than arginine [160] [161] [162]. Considered as a whole, the accessible 
reactions conditions are almost ideal to study proteins under native conditions.  
Choice of reagents: Several dicarbonyl compounds were considered for their suitability for the 
approach. As priority, the compounds must be specific for the guanidine side chain of arginine 
and avoid the side reactions with the side chain of lysine or histidine. Products have to be stable 
especially under mild acid condition (pH 2.0 of 0.1% TFA used in mass spectrometry) and 
enable unambiguous identification of peptides by mass spectrometry. Two reactants that are 
identical in terms of their reaction with arginine are required, which can be distinguished by 
mass spectrometry; ideally one will allow separation, e.g., using biotin-streptactin as with 
lysine directed protect and label. 
There are four promising candidates to arginine specific ‘protect and label’: Phenylglyoxal 
(PGO); 2,3 butanedione (BD); 1,2 cyclohexanedione (CHD) and p-hydroxyphenylglyoxal 
(HPG)  
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4.2.1.1 Phenylglyoxal 
 The ability of phenylglyoxal (PGO) to selectively modify guanidine group of arginine was 
first discovered by Takahashi [163] and has been utilized in numerous investigations, 
especially in enzymatic activity studies [164][165][166]. 
According to the model suggested by Takahashi, the ratio of PGO to arginine in the reaction 
determines the product. The reaction starts with the formation of an adduct of PGO with the 
guanidino group and is followed by the addition of a second PGO molecule (if sufficient 
reactant) to form the final product. Depending on the conformation and folding state of 
proteins, the degree of surface-accessibility of arginine changes and then affects the final 
products. A problem emerges in case of proteins containing a large number arginine residues 
such as creatine kinase and yeast hexokinase in which only one mol of [14C]-PGO for each 
subunit of the protein was observed. A reason may be that those residues are difficult to access 
by the reagent. 
A study on the effect of buffer and pH on the model reaction between PGO and L-arginine 
showed that the rate of the reaction increases with increasing pH from 7.5 to 11.5 and much 
faster in bicarbonate buffer than in borate, phosphate, or Tris buffer [167]. In addition, it has 
been confirmed that PGO does not react with α- NH2    group of L-Arg, indicating that this 
reagent selectively modifies the guanidine side chain only [168]. 
Borate changes the final products of the reaction. The borate buffer is an acid-base buffer used 
in biochemistry to maintain the pH within a relatively narrow range from 8 to 10 [169]. On the 
other hand, this buffer may affect the degree of hydration of PGO. The remove of borate from 
the modified protein solution by the Sephadex column could lead to the regeneration of some 
modified arginine residues [170]. It indicates that borate buffer system is not suitable for the 
analysis by MS where the buffer should be removed before enzyme digestion. 
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The product of labelling arginine with PGO has been identified by MS in case of rat creatine 
kinase (CK) [171], ribonuclease A [168] implying the stability of the product. On the model of 
peptides, it has been shown that PGO treatment did not change the ESI charge distribution of 
the peptides 
4.2.1.2 2,3 butanedione 
Among the reagents for modification of arginine, 2, 3-butanedione (BD) is becoming 
increasingly popular. The first study introduced BD as an arginine-modifying reagent 40 years 
ago [172]. BD has been utilized to modify arginine residues in a wide range of proteins 
including penicillin acylase P06875 (PAC_ECOLX), carboxylpeptidase A 
P15085 (CBPA1_HUMAN). The study of Riordan [173] showed that a 150-fold molar excess 
of BD with the presence of borate buffer were required to totally inactive the peptidase activity 
of carboxypeptidase A in 30 min [173]. The optimal concentration of borate was 0.05 M, and 
increasing or decreasing the concentration of borate resulted in incomplete reaction of arginine 
residues.  
However, the modification of arginine by BD has a number of serious disadvantages. 
Modification with monomeric BD is reversible. In addition, the constant presence of borate is 
required for stabilizing the reaction products which creates several final products causing 
additional inconveniences. It has been reported that in the absence of light, BD could modify 
certain Lysine [174]. The modification with the BD trimer may be accompanied by side 
reactions at free --SH and amino groups. 
4.2.1.3 1,2 cyclohexanedione 
The first work introducing 1,2 cyclohexanedione (CHD) as arginine modifying reagent was 
conducted in 1965 [162]. The final product was found to be stable in borate buffer (pH 8-9) 
but it slowly decomposed in neutral or alkaline solutions. At pH 9.0, the arginine residues are 
converted quantitatively into N7, N8- (l,2-dihydroxycyclohex-l,2-ylene) arginine. Stabilization 
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of the modification product in borate buffer and the high rate of the reaction were explained as 
the formation of a complex of borate ions with the vicinal cis-hydroxy groups of the product 
[175]. Completely modified lysozyme totally lost enzymatic activity in the presence of borate 
ions. The observation was interpreted as the consequence of the neutralization of a positive 
charge in the anion-binding site by borate ions. A similar phenomena was seen in case of BD. 
However, the product of 2 molecules of CHD and 1 molecule of L-arginine in borate buffer 
has been observed [168].  
4.2.1.4 p-hydroxyphenylglyoxal (HPG)  
Junkova et al suggested a method using PHG to increase the extension of modifying reaction 
between arginines and the reagent [176]. In this study, the technique was applied on matrix 
protein Mason-Pfizer monkey virus (M-PMV) (M-PMV) containing five arginine residues. 
The MS result demonstrated that all five arginines were 100% modified. In addition, the 
peptide spectra were used to confirm the result, and all of the individual modified arginines 
(R10, R22, R55, R57, and R58) were found.  
Another study used LC/MS with a LCQ-ESI ion trap instrument to estimate enzyme activity 
of amadoriase II toward fructosylglycine. It showed that chemical modification of amadoriase 
II with p-hydroxyphenylglyoxal,  resulted in an inhibition of enzyme activity [177]. 
In general, HPG modifies arginine in a similar manner to PGO. However, the rate of the 
reaction is higher than the reaction of PGO and it increases considerably with a rise in the pH. 
Moreover, at pH 9-10 p-hydroxyphenylglyoxal forms a single product with the guanidino 
group of arginine, which is stable at this pH. 
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4.2.2 Choice of reagents and the challenges 
Final choice of reagents: Phenylglyoxal and its close analog p-hydroxyphenylglyoxal were 
chosen for their high rate reactions with arginine under mild conditions as well as their high 
specificity and well-established stoichiometry making the identification of products by MS 
more convenient. Another advantage is the stability of the products in the absence of borate 
buffer and under mild acid condition. Noted that the MS is carried on at pH 2.0 to 3.0 with the 
presence of TFA. 
 
Reaction conditions:  
Arginine residues of proteins are reacted with PGO and HPG in 0.2M bicarbonate buffer (pH 
9.5). The reaction is carried on the dark, at room temperature for 60 min. The reagents are used 
at 100 fold excess of proteins. 
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4.3 PAPER: SELECTIVE LABELLING OF ARGININE RESIDUES ENGAGED IN 
BINDING SULFATEDGLYCOSAMINOGLYCAN 
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I- Abstract 
The activities of hundreds of proteins in the extracellular space are regulated by binding to the 
glycosaminoglycan heparan sulfate (HS). These interactions are driven by ionic bonds between 
sulfate and carboxylate groups on the polysaccharide and the side chains of basic residues in 
the protein. Here we develop a method to selectively label the guanidino side chains of arginine 
residues in proteins that engage the anionic groups in the sugar. The protein is bound to heparin 
(a common experimental proxy for HS) on an affinity column. Arginine side chains that are 
exposed to solvent, and thus involved in binding, are protected by reaction with the dicarbonyl 
phenylgyoxal (PGO). Elution of the bound proteins then exposes arginine side chains that had 
directly engaged with anionic groups on the polysaccharide. These are reacted with hydroxyl-
phenylglyoxal (HPG). PGO was found to generate three products: a 1:1 product, the 1:1 water 
condensed product and a 2:1 PGO:arginine product. These three reaction products and that of 
HPG had distinct masses. Scripts were written to analyse the mass spectra and so identify HPG 
labelled arginine residues.  Proof of principle was acquired on model peptides. The method 
was then applied to the identification of heparin binding arginine residues in fibroblast growth 
factors (FGF) 1 and 2. The data demonstrate that four out of eleven arginine residues on FGF2 
and five out of six arginine residues of FGF1 engage heparin. Our approach provides a rapid 
and reliable means to identify arginines involved in functional complexes such as those of 
proteins with heparin. 
  
88 
 
II- Introduction 
In the extracellular space, interactions between proteins and the glycosaminoglycan heparan 
sulfate (HS) regulate activities of hundreds of the proteins [77]. These proteins include growth 
factors, cytokines, chemokines, morphogens, enzymes, enzyme inhibitors, receptors, and 
extracellular matrix proteins, forming  the network of HS-binding proteins, termed the heparan 
sulfate interactome [178]. Binding to the polysaccharide may, for example, regulate ligand 
diffusion [125], [127], formation of signalling ligand-receptor complexes [130], [179] and 
enzyme activity [180]. 
The engagement of HS to protein often occurs on the surface or in shallow grooves of proteins 
with a major contribution from ionic interactions, due to the highly anionic nature of HS. These 
ionic interactions occur between the negatively charged sulfate and carboxyl groups on the 
polysaccharide chain with the positively charged residues, lysine, and arginine in proteins 
[114], [181]. Proteins may have more than one HS binding site, and the amino acids 
contributing to binding though adjacent on protein surface are usually not continuous in the 
amino acid sequences [36], [37], [126], [142], [184] [120]. 
The structural basis of the interaction of a protein with HS is often probed using the related 
polysaccharide, heparin, as an experimental proxy. Many approaches such as NMR 
spectroscopy [184], site-directed mutagenesis [185]–[187] and X-ray crystallography [100], 
[130], are low throughput. In the absence of a robust bioinformatics method to predict heparin 
binding sites in proteins, higher throughput experimental methods have been developed. These 
latter include a method to selectively label lysine residues involved in heparin binding, called 
“protect and label”, which was coupled with mass spectrometric identification of labelled 
peptides [120]. This was based on the reaction of N-hydroxysuccinimide (NHS) with the amino 
side chain of lysine residues and it has been applied successfully to a number of protein-heparin 
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interactions [36], [37], [188] and also to an electrostatically driven protein-protein interaction 
[189]. An interesting feature of this method is that it identifies canonical, high-affinity heparin 
binding sites in proteins, as well as lower affinity secondary binding sites [36], [37], [188]. 
NHS cannot react with the guanidino side chains of arginine residues, yet these are at least as 
important as lysine side chains in mediating the interactions of proteins with anionic partners 
such as sulphated GAGs [114]. Moreover, the heparin binding sites of some proteins have 
arginines, but no lysine residues, e.g., fibroblast growth factor FGF22 (Uniprot ID: Q9HCT0-
1). Since the heparin binding sites (HBS) on proteins consist of residues not necessarily 
adjacent in sequence, the identification of arginines, as well as lysines engaged with heparin 
would provide a comprehensive picture of the ionic interactions.  
The modification of arginine residues in proteins is a challenge, because the guanidino 
functional group of arginine has a pKa between 11.5 ~ 12.5, which makes it the most basic side 
chain in a protein and a poor nucleophile. There are limited studies on the chemical 
modification of arginine residues in proteins and the majority of them rely on the reaction of 
vicinal dicarbonyl compounds with the guanidino group to form cyclic adducts [158]. The 
ability of phenylglyoxal (PGO) to selectively modify the guanidino group of arginine was first 
discovered by Takahashi [190], and has been utilized since, especially in studies of enzyme 
activity [166], [191], [192]. In addition, it has been confirmed that PGO does not react with the 
α- NH2group of lysine, indicating that this reagent selectively modifies the guanidino side chain 
rather than primary amines [168]. The reaction of PGO with the guanidino side chain of 
arginine is a quantitativereaction but produces several products which may have contributed to 
the lack of popularity of this approach. However, modern mass spectrometry combined with 
automated analysis of spectra should allow the deconvolution of multiple reaction products. 
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Therefore, we have used PGO and hydroxyl-phenylglyoxal (HPG) to develop a method for 
selective labelling of arginines that are directly involved in binding heparin. PGO was reacted 
with the arginine residues that are not involved in binding to heparin and so protect them, then 
HPG was used to selectively label arginine residues in binding sites. The PGO-arginine 
reaction has three products, and these were readily distinguishable by mass spectrometry. The 
method was initially tested on the model of peptides and then on two FGFs that have extremely 
well characterised heparin binding sites (HBSs), FGF1 and FGF2. The data demonstrated the 
ability of PGO/HPG to quantitatively and selectively modify the guanidino group of arginine 
residues on proteins. The arginine residues in the primary HBS of FGF1 and FGF2 were all 
selectively labelled by HPG. The selectively labelling by HPG of arginines in the secondary 
binding sites of FGF1 and 2 provides a full structural definition of ionic bonding of these sites 
to the polysaccharide. Interestingly, the data demonstrated the potential for competition by 
arginine residues on the HBS3 of FGF1 for the binding to HS and the FGF receptor (FGFR) 
tyrosine kinase [179].  
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III- Materials and Methods 
Heparin-binding proteins 
Recombinant human FGF1 (UniProt accession P05230 – residues 1-155) and FGF2 (UniProt 
accession P09038 – residues 134-288) were expressed in C41 Escherichia coli cells using the 
pET-14b system (Novagen, Merck, Nottingham, UK) and purified, as described previously 
[145]. 
SDS-PAGE and Silver stain 
Samples were separated on 15% (w/v) polyacrylamide-SDS gels. Silver staining was done 
according to Heukeshoven and Dernick[193]. 
Selective protection and labelling of arginine side chains in HBSs of proteins using PGO 
and HPG (Fig 1A) 
A step by step guide is available at protocol.io at the following link:  
https://www.protocols.io/view/selective-protection-and-labelling-of-arginine-lys-qqmdvu6 
Step 1: Binding  
AF-heparin beads (Tosoh Biosciences GmbH, Stuttgart, Germany; binding capacity of 4 mg 
antithrombin III/mL) previously used in the lysine selective labelling protocol [120] were 
employed. A mini affinity column was made by placing a plastic air filter as a frit at the end of 
a P10 pipette tip (Star Lab Ltd., Milton Keynes, UK) and then packed with 20 μL AF-heparin 
beads. The mini-column was equilibrated with 4 × 50 μL 200 mMNaCl, 0.2 M NaHCO3, pH 
9.5  (Na-1 buffer). The buffer was dispensed slowly into the column using a 2 mL sterile 
syringe. A minimum of 10 μg FGF protein was loaded onto the column (generally, the loading 
capacity of FGFs to resin was estimated at 15 mg/mL). The loading was repeated 3 times to 
92 
 
ensure the binding between protein and heparin beads. After binding, the column was washed 
with 200 μL (4 x 50 μL) Na-1 buffer to remove any unbound protein. 
Step 2: Protection of arginine side chains 
PGO (Merck Ltd., UK, 97%) was used in the dark, as it is light sensitive. PGO was freshly 
prepared in 50 % (v/v) DMSO, 50 % (v/v) HPLC grade water at 1 M, which was then diluted 
to 0.5 M and then 0.2 M with 0.2 M NaHCO3, pH 9.5. The pH was adjusted with 0.1 M NaOH 
to between 9.1 and 9.5 to ensure optimal reaction. The FGF loaded heparin mini column was 
rinsed with 30 μL 0.2 M PGO solution to exchange buffers. A further 30 µL PGO solution was 
added to the column and the bound protein was allowed to react for 60 min at room temperature 
in the dark. The reaction was quenched with 5 μL 0.1 % (v/v) trifluoroacetic acid (TFA) in 
water. The mini-column was then washed with 200 μL Na-1 buffer (4 x 50 μL). Bound proteins 
were eluted with 2 x 20 μL Na-2 buffer (2 M NaCl, 0.2 M NaHCO3,  pH 9.5) containing 0.1 % 
(w/v) RapiGest SF Surfactant (Waters, UK). The addition of surfactant was important to ensure 
protein recovery in this and subsequent steps, due to the increased hydrophobicity of proteins 
following PGO conjugation to arginine side chains. 
Step 3: Labelling of Arginine side chain by HPG 
The preparation of HPG was performed in the dark room, as it is even more light-sensitive than 
PGO, following a procedure identical to that used for PGO. The eluted protein was diluted with 
400 μL 0.2 M NaHCO3, pH 9.5 and concentrated on a 3.5 kDa MWCO centrifugal filter (Merk 
Millipore, UK) to a final volume of 70~80 μL. The reaction with HPG was performed by 
incubating 80 μL diluted protein with 20 μL 0.5 M HPG so that the final concentration of HPG 
in the reaction was 0.1 M. The pH was maintained at over 9.0. The reaction was performed for 
60 min at room temperature in the dark and then was quenched with 5 μL 0.1 % (v/v) TFA in 
water. 
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Step 4: Sample preparation for Mass Spectrometry 
Protein was buffer-exchanged by four cycles of dilution on 3.5 kDa MWCO centrifugal filters 
with 400 μL 10-fold diluted 0.2 M NaHCO3, pH 9.5 containing 0.1 % (w/v) RapiGest and 3 
cycles of dilution with 400 μL HPLC water containing 0.1% (w/v) RapiGest by centrifugation 
at 13200 rpm for 10 min. After freezing at -80 °C for 30 min, the sample was lyophilized for 
an hour. 
Step 5: Incubation with proteases 
Chymotrypsin/trypsin: The freeze-dried protein was dissolved in a mixture of 80 μL 25 mM 
NH4HCO3 and 10 μL 1 % (w/v) RapiGest (~ 0.1 % w/v in final solution) and heated at 80 °C 
for 10 min. The mixture was quickly centrifuged at 3200 rpm for 30 seconds before 5 μL 50 
mM DTT was added (5 mM final concentration) and incubated for 15 min at 56 °C. After 
cooling the sample to room temperature, proteins were carbamidomethylated with 5 μL 0.1 M 
iodoacetamide (freshly made) for 30 min in the dark. Proteins were then digested overnight 
with chymotrypsin (Promega Ltd., UK) or trypsin (Sigma, UK) at a ratio of 1:100 (w/w). 
Incubation with Arg-C 
The dried sample was dissolved in 400 mM NH4HCO3, pH 7.8 (25 μL) and 45 mM DTT (2.5 
μL), and incubated for 15 min at 56 °C. After cooling to room temperature, 75 μL incubation 
buffer (50 mM Tris-Cl, 5 mM CaCl2, 2 mM EDTA, pH 7.8) was added to dilute the urea to 2.0 
M. Arg-C protease (Promega, Southampton, UK) was freshly prepared in incubation buffer 
and then added to the protein solution at a ratio of 1:100 (w/w). Activation buffer 10X (50 mM 
Tris-Cl, 50 mM DTT, 2 mM EDTA, pH 7.8) was added to give a final concentration of 1X. 
The mixture was mixed gently and centrifuged briefly before allowing digestion to proceed 
overnight at 37 °C. 
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Step 6: Mass spectrometry for the identification of peptides 
Peptides were concentrated by rotary evaporation to a final volume of 10 μL and desalted using 
C18 Zip-Tips (Millipore). C18 Zip Tips were first pre-wetted with 2 x 10 μL 100 % (v/v) 
acetonitrile and then pre-equilibrated with 2 x 10 μL 0.1% (w/v) TFA in water. The peptides 
were loaded on the Zip Tip, the loading was repeated 7 to 8 times to ensure binding. The Zip 
Tip was washed with 10 μL 0.1% (w/v) TFA. Finally, the peptides were eluted with 2 μL of 5 
mg/mL α-cyano-4-hydroxycinnamic acid (CHCA, > 99 % purity, Sigma) in 50:50 
acetonitrile/water with 1 % (v/v) TFA, directly on to a 96 spot MALDI (matrix-assisted laser 
desorption/ionisation) target plate.  
Analyses were performed on a Synapt G2-Si (Waters, Manchester, UK) with MALDI source 
equipped with a frequency tripled Nd:YAG UV laser (λ = 355 nm), operating at 1 kHz. The 
spectrum acquisition time was 120 seconds, with 1 second scan rates, laser energy of 150 Au. 
The MS spectra were extracted by MASSLYNX v.4.1 (Waters, Manchester, UK) with the 
spectrum range from 500 Da to 4000 Da. The spectra were then processed using automatic 
peak detection, including background subtraction. 
Identification of modifications of peptides 
Protein Prospector (v 5.19.1 developed at the USCF Mass spectrometry Facility) and Peptide 
Mass (ExPASy) were used to predict the possible peptides after incubation of protein with an 
enzyme with the following parameters: enzyme, chymotrypsin or trypsin; maximum missed 
cleavages, 5; mass range, 500 to 4000 Da; monoisotopic; instrument, MALDI-Q-TOF (Fig 1-
B1). The list of peptides after enzyme cleavage was filtered to remove the peptides without 
arginine residues. Because products from the reaction between PGO/HPG and arginine residue 
bring different additional masses to the peptides, the prediction of the peptide masses after the 
modification was achieved using a script, written in Python (version 3.5.3 released on January 
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17th, 2017, available at http://www.python.org), named “PGO-HPG mass predictor” 
(available at Github in following link: https://github.com/bpthao/PGO-HPG-mass-
predictor_2).  Based on the number of arginine residues in each peptide, “PGO-HPG mass 
predictor” script considers all possible reaction products of PGO and HPG with arginine, and 
generates a list of predicted masses of the modified peptides (Fig 1-B2). 
PGO-HPG mass predictor used two inputs. First, the list of predicted peptides from the native 
proteins cleaved by enzyme from either Protein Prospector or Peptide Mass (ExPASy). The 
first file is composed of two columns, the native sequence of the peptide and the corresponding 
mass. Second, the file of modifications also comprises of two columns, the mass shift of each 
product and its descriptions. Using a loop, PGO-HPG mass predictor automatically adds up 
all potential mass shifts to each peptide with has arginine residues. All combinations of mass 
changes were covered. The output file has four columns: 1-the native sequence of the peptides; 
2- the original mass; 3-the final mass after modifications; 4-the description of the reaction 
product(s), to facilitate. 
The observed list is the original mass of FGF peptides after modifications (Fig 1-B3), which 
provided the mass and intensity of each peak. The match between predicted and the observed 
list was carried out with a second Python script, “Matchmaker”, (available at Github in 
following link: https://github.com/bpthao/Matchmaker_2) with a mass difference tolerance set 
to 0.1 Da (Fig 1-B3), as recommend by Mascot. 
The output is a list of matching peptides with the native sequence, the predicted mass with 
modifications, the specific modifications associated with arginine residues and the actual 
observed mass. 
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IV- Results and discussion 
PGO reactions with arginine in model peptides 
The reaction of PGO with arginine, though highly selective, has been demonstrated to result in 
several products, influenced by the ratio of reactants and the adjacent amino acids [167], [171], 
[191], [194], [195]. Thus, according to Takahashi [190], the ratio of PGO to arginine in the 
reaction determines the product (Fig 2A). The reaction starts with the formation of an adduct 
of PGO with the guanidino group (Fig 2A, product {1}), which can then reversibly release a 
hydroxyl group from glyoxal, resulting in the alternative product (Fig 2A, product {2}). 
Following this is the reactionof a second PGO molecule (if sufficient reactant) onto either a 
nitrogen of the guanidino group of arginine (Fig 2A, products {3}) or the carbonyl group of 
the first PGO, which may reversibly release a hydroxyl group from glyoxal to form the further 
products (Fig 2A, products {4}). All of the reactions are highly dynamic, in the presence of 
even or excess of PGO, so a mixture of all products is formed, though in solution, product {2} 
predominates over product {1}[190]. 
In contrast, the reaction of HPG with arginine only has one product [176]. Since two reagents 
are required for selective labelling, one to protect arginines not involved in binding and a 
second to label arginines engaged in non covalent bonds with the polysaccharide, it was 
important to not just optimise these reactions, but also to establish which products are formed 
following reaction with PGO. To determine these parameters, model peptides were used in the 
first instance. These peptides were specifically chosen to represent arginine residues in 
particular contexts. Peptide FA (WQPPRARI) has two arginine residues, separated by a single 
alanine, which will provide insight into any differences in a reaction that may occur due to 
proximity of arginines on the surface of a protein (Table 1). Peptide NA provides the means to 
generate an N-terminal arginine (p-Glu-LYENKPRRPYIL) by pre- digestion with trypsin and 
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so identify any influence of the adjacent free amine of the N-terminus and the impact of lysine 
on PGO reaction with arginine (Table 1B). 
The reaction of PGO with arginine residues in peptide FA 
First, three concentrations of PGO were tested with peptide FA, which contains two arginines, 
to identify the conditions required for the reaction to go to completion (Table 1). Two reaction 
times (5 min and 30 min) were used, each with three different concentrations of PGO. Peptide 
FA was unmodified after reaction with 100 mM PGO for 5 min or 30 min(Table 1). However, 
with 200 mM PGO the peak of the original FA peptide was not detected demonstrating that 
arginines in the peptide were fully reacted with  PGO (Fig 2B). No peaks were identified when 
the peptide was reacted with 1 M PGO, which could be due to the aggregation of the peptide 
induced by the high concentration of PGO (Table 1). Thus, 200 mM was considered as the 
optimal concentration of PGO for the modification of arginine in this model peptide. 
Interestingly, six reaction products of peptide FA with PGO were detected (Table 1A). The 
mass of unreacted FA is 1023.58 Da, and after reaction three major peaks of 1139.60 Da, 
1255.61 Da and 1275.58 Da were detected, equivalent to a mass shift of 116.02 Da  of Product 
{2} (Fig. 2A) (Peak 1, Fig. 2B, Table 1A); a mass shift of 232.04 Da (Product {4}, Fig. 2A; 
Peak 2, Fig 2B, Table 1A); and 252.0 Da (Product {3}, Fig. 2A; Peak 3, Fig 2B, Table 1A), 
respectively. 
Peptide FA has two arginine residues and their reaction with PGO also produced three 
combinations of products. The combinations of product {2} and product {3} resulted in the 
mass of peak 4of 1388.62 Da (Fig 2B, Table 1A); of product {4} and product {3} resulted in 
peak 5 of 1410.60 (Fig 2B, Table 1A); finally, when both arginines formed product {3} with 
PGO, a mass shift corresponding to peak 6 of 1523.67 was observed (Fig 2B) (Table 1A).  
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The reaction of PGO with argininesin peptide NA 
It is clear from the above that the position of arginine resides can affect the reaction product. 
Since the side chain of an arginine at the terminus of a peptide has more steric freedom, it is 
more likely that the dicarbonyl group of PGO could form a reversible bond at a 2:1 ratio with 
the guanidino group of arginine, as described in Takahashi’s study [190]. To establish if this 
was the case, two peptides: peptide NA-I (RPYIL, molecular mass 661.38) and peptide NA-II 
(LYENKPR, molecular mass 1030.53) were produced by treating peptide NA with trypsin 
(Table 1B). This yielded one peptide with arginine at the N terminus (peptide NA-I) and 
another one with arginine at the C terminus (peptide NA-II). Both peptides were reacted with 
200 mM PGO in the dark for 30 min (Figs 2 C,D). 
For peptide NA-I, the product of this peptide with one PGO had amass shift of 116.02 Da 
(Product {2}, Fig. 1A; Peak 1, Table 1B) resulting in the product of 777.42 Da (Fig 2C), while, 
the peak at 795.40 Da (Fig 2C) indicated the presence of product {1} from the reaction between 
arginine and PGO. The addition of a second PGO resulted in the product of 896.41 Da, giving 
a mass shift of 232.03 Da (Product {4}, Fig 2A, Table 1B) and the product of 911.1 Da due to 
a mass shift of 250.04 Da (Product {3}, Fig 2A, Table 1B). 
In a similar manner, the products of peptide NA-II with PGO showed the mass shifts of all four 
products between arginine and PGO (Fig 2D, Table 1B). The peak of 1146.55 Da (Table 1B) 
corresponds to the mass shift of 116.02 Da (Product {2}, Fig 2A); the mass shift due to product 
{1} (Fig 2A) is detected as the peak at 1164.52 Da (Fig 2D, Table 1B); the product of two PGO 
reacting with one arginine are observed as the peak at 1262.58 Da (Fig 2D, Table 1B) of 
product {4} and the peak at 1280.56 (Fig 2D, Table 1B) was due to product {3}. In addition, 
for the mass shifts observed, only the arginine of peptide II was  modified by PGO and there 
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was no reactivity of its lysine or N-terminus towards PGO, in agreement with previous work 
[168]. 
The use of peptides with arginine residues in defined contexts demonstrated that 200 mM PGO 
was likely to fully protect all of the arginine residues in a protein regardless of the adjacent 
sequence. Moreover, the position of arginine in the peptides affected the formation of the 
Schiff’s base and types of products produced. However, these are resolvable by mass 
spectrometry. The next step was to determine whether HPG could similarly fully react with 
arginine residues. 
HPG reactions with arginine in model peptides 
For the labelling step, HPG, which has the same dicarbonyl moiety as PGO, was chosen. In 
general, HPG modifies arginine in a similar manner to PGO, but the rate of the reaction is faster 
than that of PGO and it increases with pH, where pH 9-10 is optimal [176]. HPG forms a single 
product with the guanidino group of arginine, which is stable at this pH (Fig 3A). The two 
peptides FA and NA were used again to validate the reactivity of HPG toward to guanidino 
group of arginine. HPG was dissolved in DMSO at 1 M and diluted stepwise to 500 mM and 
then 100 mM with 0.2M NaHCO3 pH 9.5 and then reacted with the peptides FA and NA for 10 
and 30 min. Peptide FA was not entirely modified after reaction with 100 mM HPG for 10 min 
(Fig 3B), as evidenced by the presence of two major peaks of unmodified and HPG-modified 
peptide FA, indicating that this time was too short for the reaction to go to completion. 
However, 100 mM HPG for 30 min modified all of the arginines in the FA peptide (Fig 3B), 
since the peak of the unmodified peptide FA was no longer detected. In a similar manner, HPG 
at 100 mM after 10 min reaction did not modify fully the arginines of peptide NA, evidenced 
by the observation of two major peaks of unmodified and HPG-modified peptide NA, whereas 
after 30 min, they were fully modified, as only one major peak was seen (Fig 3C). These 
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reactions with the model peptides demonstrated that HPG modifies arginine to form a single 
product. The difference in the reaction between HPG and arginine compared to that of PGO 
may be due to the presence of the hydroxyl group in HPG. 
Because the model peptides used here contained a small number of arginine residues in a 
reasonably simple environment, it was not known whether these reaction conditions would be 
applicable to a protein. Thus, the next issue to address was the ability of PGO to modify all 
arginine side chains in a protein. Arg-C was used to digest the protein after modification and 
so identify the unmodified arginine residues. These experiments used FGF2, which contains 
eleven arginine residues, as a model protein (Fig 4). 
The reaction of FGF2 with PGO 
The reaction between FGF2 and PGO was first conducted in the absence of heparin beads. 
After buffer exchange, half of the protein was reacted with 200 mM PGO in the dark, at 250C 
for 60 min (Material and Methods, step 2) and the other half was used as a control. Native 
FGF2 migrates as a band at round 18 kDa on SDS-PAGE (Fig 4A lane 1), but after digestion 
by chymotrypsin or by Arg-C no bands were apparent, demonstrating the expected cleavage of 
the protein by these enzymes (Fig 4A lanes 3 and 5). Reaction with PGO did not change 
appreciably the migration of the FGF2 (Fig 4A lane 2, PGO treated FGF2, no enzyme), and 
the modified protein was cleaved by chymotrypsin (Fig 4A lane 4). In contrast, PGO-modified 
FGF2 was not cleaved by Arg-C, since a band corresponding to FGF2 was clearly visible (Fig 
4A lane 6). This suggests that all arginine residues of FGF2 were modified. 
When FGF2 (Fig 4B- L) was loaded onto the heparin mini-column, no protein was observed 
in the flow through (Fig 4B- lane FT) and wash fractions, indicating that FGF2 bound as 
expected (Fig 4B- lanes FT and W). After the on-column reaction with 200 mM PGO, the 
excess PGO was removed (Fig 4B- lane PGO PROTECT FT) and the column was washed by 
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Na-1 buffer (Fig 4B- lane PGO PROTECT W) before elution with Na-2 buffer (Fig 4B- lane 
PGO PROTECT E) (Materials and Methods, step 2). No protein was detected in the PGO 
PROTECT FT and PGO PROTECT W fractions, indicating that the FGF2 remained bound to 
heparin during the reaction.  A band was observed in the elution fraction (Fig 4B-lane PGO 
PROTECT E), which was similar in size and amount as the loading control (Fig 4B lane L). 
This result indicated that protein was efficiently eluted from the column.  A quarter of the 
protein in the eluted fraction was incubated overnight with Arg-C or chymotrypsin and the 
products of digestion were analysed by SDS-PAGE. In both cases, no band was apparent, 
indicating that the enzymes had cleaved the PGO reacted FGF2 (Fig 4B PGO PROTECT lanes 
1 and 2). Thus, when FGF2 is reacted with PGO in solution, there is a complete modification 
of arginine residues, but when the reaction is performed on FGF2 bound to heparin, the 
modification is incomplete. This suggests that only arginine residues exposed to solvent in 
heparin bound FGF2 were able to react with PGO. 
The remaining half of the eluted protein (~20 µL) was diluted with Na-1 buffer until the final 
concentration of NaCl was less than 0.2 M and then reacted in solution with PGO at 100 mM 
final concentration. Half of this product was applied onto a mini heparin affinity column. The 
flow-through fraction contained a band of almost identical intensity to the reaction product (Fig 
4C, lane FT) and there was no protein detected in the wash (Fig 4C, lane W) and eluted fractions 
(Fig 4C, lane E) indicating that the FGF2 no longer bound to heparin. Thus, after the second 
reaction (equivalent to the labelling step in the original lysine selective protect and label [120]) 
the arginine residues in HBSs were blocked by PGO. The FGF2 reacted with PGO a second 
time and recovered from the flow through fraction was also probed with proteases. While 
chymotrypsin digested the FGF2 (Fig 4C lane 1), Arg-C was unable to do so, since there was 
a band (Fig 4C lane 2) at the same size as the initial reaction product (Fig 4D -L) and labelled 
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FGF2 (Fig 4C - FT). Hence, the arginine residues protected after the initial on-column reaction 
with PGO were successfully blocked in the second reaction of this FGF2 with PGO in solution.  
These data suggest that under the reaction conditions used PGO successfully modified the side 
chains of all 11 arginine residues of FGF2, and that following PGO modification of those 
arginine residues that remain exposed when FGF2 binds to heparin, the remaining arginine 
residues on the eluted protein  may also be successfully modified. 
The reaction of FGF1 with PGO 
The same series of experiments were repeated with FGF1. In the absence of heparin beads, 
after buffer exchange, half of the protein was reacted with 200 mM PGO in the dark, at room 
temperature for 60 min (Material and Methods, step 2) and the other half was used as a control. 
The expected cleavage of the native FGF1 (Fig 4D lane 1) by chymotrypsin or by Arg-C was 
observed, evidenced as no detectable bands (Fig 4D lanes 3 and 5). Whereas the PGO-modified 
FGF1 was cleaved by chymotrypsin (Fig 4D lane 4), it was not cleaved by Arg-C, since a band 
corresponding to FGF1 was clearly visible in this case (Fig 4D lane 6). This suggests that all 
arginine residues of FGF1 were modified. 
When FGF1 (Fig 4E- L) was loaded onto the heparin mini-column, no protein was detected in 
the flow through (Fig 4E lane - FT) and wash fractions,nor when PGO was applied  (Fig 4E - 
PGO PROTECT FT and PGO PROTECT W lanes), indicating that the FGF1 remained bound 
to heparin during the reaction.  A band was observed in the elution fraction (Fig 4E-lane PGO 
PROTECT E) lane, which was similar in size and amount as the loading control (Fig 4E L 
lane). This result indicated that protein was efficiently eluted from the column. When a quarter 
of the PGO reacted FGF1 was incubated overnight with Arg-C or chymotrypsin, no band was 
apparent (Fig 4E PGO PROTECT lanes 1 and 2), demonstrating that there remained unreacted 
arginine residues. After a second reaction of eluted protein with PGO at 200 mM final 
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concentration, chymotrypsin digested the FGF1 (Fig 4F lane 1), but Arg-C was unable to do 
so, since there was a band (Fig 4F lane 2) at the same size as the initial reaction product (Fig 
4F, lane L) and FGF1 reacted with PGO in solution (Fig 4F, FT lane). Moreover, this eluted 
FGF1 subjected to a second reaction in solution with PGO failed to bind to heparin column 
(Fig 4F, lane FT). Hence, the arginine residues engaged with heparin in the initial on-column 
reaction with PGO were successfully reacted in the second reaction of this FGF1 with PGO in 
solution. 
Protect and Label strategy for the identification of arginine residues in FGF1 and FGF2 
that bind heparin  
There is a large body of published structural, biophysical and biological data relating to the 
interactions of FGF1 and FGF2 with heparan sulfate and its experiment proximal heparin. 
FGF1 and FGF2 share a high level of similarity in structure and sequence, though they possess 
very different isoelectric points, 6.52 and 11.18, respectively. FGF1 and FGF2 were loaded on 
to AF-heparin mini columns and reacted in situ with 200 mM PGO (Fig 1) (Material and 
Methods, step 1). The eluted proteins were then reacted for 60 min with 100 mM HPG in the 
dark (Material and Methods, step 3) and processed for mass spectrometry (Material and 
Methods, step 4). In parallel, FGF1 and FGF2 were reacted with 200 mM PGO in the absence 
of heparin beads (Material and Methods, step 2). The native and modified proteins were then 
cleaved by chymotrypsin (Material and Methods, step 5).   
Peptides produced from digestions were predicted using two protein identification and analysis 
tools, Protein Prospector (v 5.19.1 developed by the USCF Mass spectrometry Facility) and 
Peptide Mass (ExPASy). In both cases, these provided parameters included the mass range 
from 500 Da to 4000 Da, maximum missed cleavages 5, monoisotopic only and the enzyme 
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used. For Protein Prospector, the oxidation of methionine was considered as the variable 
modification, whereas it was not included by Peptide Mass (ExPASy). 
To identify the reaction products of the arginine side chain and PGO, their structures and 
masses were evaluated (Table 2). Depending on the stoichiometry of the reactions and the loss 
of water, there were four possible products: 1:1 (1PGO: 1arginine), (Product 1- Fig 2A); 1:1 
water-condensed, (Product 2- Fig 2A) and 2:1 product water-condensed, (Product 3, 4- Fig 
2A). Product 3 and 4 had different structures, but they led to the same mass shift for the reacted 
arginine residue. The corresponding mass shifts resulting from these products are provided in 
Table 2. The 250 kDa product (Supplementary Fig 2C) was not considered, as neither of the 
two FGFs possesses a terminal arginine. To identify arginine residues protected by heparin 
binding, a second reagent was required, that would react similarly with arginine side chains, 
but yield a product with a different mass. HPG was chosen for this purpose, and this yields just 
a single, 1:1 product (Table 2, Fig 3). 
Peptides from the native and modified proteins produced by enzyme cleavage were analysed 
by MALDI-Q-TOF mass spectrometry. Following was the analysis of the mass spectra using 
scripts PGO-HPG mass predictor and Matchmaker. 
Identification of arginine residues in FGF2 involved in binding heparin  
FGF2 has eleven arginine residues in the sequence, R31, 42, 48, 53, 69, 81, 106, 116, 118 and 
129. The peptides generated from native FGF2 by cleavage with chymotrypsin were predicted 
by Peptide Mass and Prospector, then filtered with the script PGO-HPG mass predictor to 
remove peptides without arginine residues. Prospector predicted 158 peptides and there were 
126 peptides predicted by Peptide Mass with 100% sequence coverage, demonstrating that all 
arginine residues could be analysed. 
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Protection of arginine residues on FGF2 by PGO in solution  
To understand the accessibility of the reagent to arginine, FGF2 was reacted with 200 mM 
PGO for 60 min in 0.2 M NaHCO3, pH 9.5. Peptides of the modified FGF2 were generated by 
cleavage with chymotrypsin and analysed by mass spectrometry. The modification on each 
arginine residue was identified by PGO-HPG mass predictor and Matchmaker. The resulting 
peptides with information about modification, sequence, and final m/z are presented in 
Supplementary Tables 1 and 2 and the spectra are in Supplementary Fig 3. 
Among peptides predicted by Prospector, nine of them contained the reacted arginine residues 
(Supplementary Table 1, Supplementary Fig 3). PGO product 1 (Fig 2A) was observed in 
peptide 2 with R129, peptides 4, 5 and 8 with R116 and R118, peptide 7 with R69 and R81. R90 of 
peptide 3 reacted with PGO to generate product 2 (Fig 2A). Peptide 1 with R31, peptide 6 with 
R106 showed a mass shift corresponding to products 3, 4 (Fig 2A). A mixture of products was 
found in peptide 9 with R42, 48 and 53, as a combination of products 1 and 3. It was noticed 
that only two out of three arginines on peptide 9 reacted with PGO, indicating that one arginine 
was apparently not accessible to PGO in this context. Hence, the products of ten arginine 
residues with PGO were identified, though a lack of reactivity of one arginine to the reagents 
was also observed. 
Using the predicted peptides from ExPASy, the number of peptide with modified arginine 
residues was six, which completely overlapped with the list generated by Prospector 
(Supplementary table 2). 
Selective labelling of arginine residues on FGF2 by PGO and HPG on heparin mini column 
PGO-HPG mass predictor and Matchmaker scripts were used to identify the peptides 
containing the arginine residues that are labelled by HPG and therefore engaged with heparin. 
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The resulting peptides with information about modification, sequence, and final m/z are 
presented in Tables 3 and 4 and the spectra are in Supplementary Figs S4 and S5).  
After the protection step on the heparin affinity column with PGO and labelling with HPG ten 
peptides with modified ariginines were identified (Table 3) (Supplementary Fig 4). Of these, 
four peptides (peptides 4, 8, 9 and 10) contained PGO protected arginine residues only; 
peptides 1, 2, 3, 6 and 7 had a  mass shift corresponding to the product of HPG (132.02 Da) 
whereas, in peptide 5, a mixture of PGO and HPG products was observed (Table 3). 
The first arginine on the sequence is R31, situated in the disordered N-terminal region adjacent 
to beta strand I. Peptide 7 containing R31 had a mass shift corresponding to HPG (Table 3), 
indicating that this arginine engages heparin. From previously defined HBSs of FGF2, R31 is 
part of HBS-3 which locates to the N-terminus of the beta trefoil FGF (Fig 7).  
Following on in the sequence are R42, R48, and R53, which were detected on peptide 10. The 
mass shift of this peptide corresponded to two 1:1 condensed products between arginine and 
PGO. Hence, only two of the three arginines were modified by PGO, whereas one remained 
unreactive to PGO/HPG (Table 3). This peptide was also observed with just two modifications 
by PGO when the reaction was performed with FGF2 in solution in the absence of heparin 
(Supplementary table 1, peptide 9). The presence of an unlabelled arginine is surprising, since 
Arg-C could not cleave FGF2 after reaction with PGO and HPG (Fig 4A-C). The question of 
which arginine was not accessible to PGO, HPG or trypsin is addressed later. 
Next, Arg69 and Arg81 were protected by PGO, as observed in two sister peptides 8 and 9. They 
cover the sequence from the loop between β-strand IV-strand V to a loop between strand V-
strand VI, in which K75 has been defined as part of HBS-2. Peptide 9 is two amino acids longer 
than its sister, but their reaction products are distinct. While peptide 8 showed a single mass 
shift corresponding to the 2:1 condensed  product, the 1:1 product was observed in peptide 9, 
107 
 
but only one of it's two arginine reacted with PGO and the other failed to react with PGO or 
HPG. The MALDI-TOF data are not conclusive as to which arginine was modified in each 
case and to whether PGO reacted with one arginine in both cases or it reacted with different 
arginine residues. Interestingly, when FGF2 reacted with PGO in-solution, Arg69 and Arg81 
were both modified by PGO generating two 1:1 products (Supplementary table 1, peptide 7). 
These differences between reaction products may be due to the effect of either higher 
concentration of electrolytes in the reaction of the eluted protein with HPG or to a long-lasting 
effect on protein conformation of heparin binding. 
Two sister peptides, 2 and 3, containing R90 from strand VI/strand VII loop (Fig 7) were 
labelled by HPG (Table 3), indicating that this residue was involved in the binding of FGF2 to 
heparin. R90 has not been shown in previous publications to be part of any HBSs (Fig 7).  
Peptide 4 covers the sequence from F105 to Y115, containing Arg108 in strand VIII (Fig 7) which 
formed the 1:1 condensed product with PGO, resulting in the mass shift of 116 Da. 
Peptides 1 and 5 contain two arginine residues, R116 and R118 in strand IX, assigned previously 
though sequence alignment to HBS-2 (Fig 7) [36]. Peptide 1 showed a mass shift corresponding 
to one HPG, indicating that one of these two adjacent arginines engaged with heparin (Table 
3). In peptide 5 there were two modifications, one from reaction with HPG, one from reaction 
with PGO (Table 3). In solution, both R116 and R118 were modified by PGO generating two 1:1 
water condensed products (peptide 4 and peptide 5, Supplementary table 1). To answer the 
question of which of the arginine residues was bound to heparin, a protection reaction with 
PGO on a heparin mini-column was followed by sequential digestion for 5 hours with 
chymotrypsin then overnight with Arg-C. The peptides were analysed by MALDI_TOF MS. 
As result, R118 of peptide 5 (Table 3) was cut by Arg-C, resulting in peptide 113NTYRSR118 
with a mass before modification of 795.4 and a mass after modification of R116 by PGO of 
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1027.13 (Supplementary Fig 6). This observation demonstrated that R118 binds to heparin 
whereas R116 does not. The different behaviour of peptides 1 and 5 may be due to the N-
terminal location of the arginine residue causing the loss of a PGO in some instances. 
The last arginine on the sequence, R129 in strand X/strand XI loop (Fig 7) showed a mass shift 
of 132.02 corresponding to the modification by HPG (peptide 6, Table 3). This agrees with its 
prior assignment to HBS-1[120][36]. 
Using Peptide Mass (ExPASY) to predict peptides generated from native FGF2 by cleavage 
with chymotrypsin, Matchmaker found 12 modified peptides, summarized in Table 4 
(Supplementary Fig 4). Ten of them overlap with the list generated by Prospector prediction. 
The extra two peptides were sisters that showed a mass shift corresponding to HPG on R129 of 
the canonical HBS-1 (Table 4). 
Locations of modified arginine residues in the FGF2 structure 
The canonical HBS of FGF2, HBS-1, has been characterized by many different methods, 
including X-ray crystallography, NMR spectroscopy, and site-directed mutagenesis, while 
evidence for its two secondary binding sites, HBS-2 and HBS-3, has also been acquired by 
independent approaches [100], [143], [186], [187], [197], [120]. The primary binding site 
(HBS1) consists of Lys35 and Asn36 and the group of 17 amino acids from 128-144 (Fig 7) 
[185]. In addition, HBS-3 was identified towards the N-terminus, which consists of 5 amino 
acids in the region 25-30, and HBS-2 is formed by Lys75 and Gly76, 82LMAK86 and Lys119  
[197][120]. 
HBS-1, Arg129 and Arg90 
One arginine in HBS-1, R129, was labelled by HPG (peptide 6_Table 3; peptides 4, 5 and 
8_Table 4). HBS-1 is an extremely basic surface on FGF2 (Fig 5A) formed by Lys35, Asn36 
on strand I/strand II loop and residues in strand X/strand XI loop, strand XI and strand XI/strand 
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XII loop (Fig 7). The double mutation R129A/K143A dramatically reduced the binding of the 
protein to a heparin affinity column [185]. In addition, R129 is highly conserved inthe FGF 
family and it aligns to K128 of FGF1, which engages heparin,  as shown previously[36]. 
The location of R90 on the surface of FGF2 has suggested that this arginine is a part of HBS-1 
(Fig 5A). Peptides 2 and 3 (Table 3 and Table 4, respectively) demonstrated that R90 reacted 
with HPG and hence is bound to heparin. The involvement of R90 in heparin binding has been 
suggested by a docking model to be an indirect interaction through an intervening water 
molecule to the GlcNSO3- group of glucosamine 5 (GlcNS, -5) at the reducing end of the sugar 
ligand  [185][186]. 
HBS-2, Arg118 
HBS-2 comprises amino acids scattered in sequence, Lys75, K86 and 116RSRK119. Sequence 
alignment, following the selective labelling of lysine residues, suggested that R118 and R116 
were part of HBS2 [30]. However, the selective labelling of arginine residues demonstrates 
R118 but not R116 is bound to heparin. 118RK119 is separated from HBS1 by an acidic boundary 
(Fig 5B), and hence likely to constitute a distinct binding site. 
Re-assignment of K86 to HBS1 
The selective labelling of lysine has identified K86 as part of the secondary HBS2 [36]. 
However, on the surface, K86 is adjacent to R90 of HBS1 and situated on a positively charged 
region (Fig 5B). These observations prompted us to propose the re-assignment of K86 to HBS1 
rather than HBS2. 
HBS-3, Arg31 
HBS-3 is located N terminal to strand beta I (Fig 7). The lysine selective labelling of FGF2 
found K30 to be biotinylated and K27 to be acetylated, implying the involvement of K30 in 
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heparin engagement [36]. R31 reacted with HPG (Peptide 7 – Table 3, Peptide 9 – Table 4) so 
can be considered to be part of HBS3.  
Re-assignment of K75 to HBS3 
Interestingly, K75, which was considered as part of HBS2 by the selective labelling of lysine 
[36], is distant from 118RK119 of HBS2. On the other hand, it is close to K30 and R31 of HBS3 
(Fig 5C) in a continuous positively charged area of the protein’s surface. Hence, we propose 
that K75 of FGF2 is part of HBS3, not HBS2. 
HBS3 has two mutually exclusive partners: HS and FGFR  
The structure of a co-crystal of FGF2 and FGFR1c (1CVS) [133] indicated that N-terminal 
segment of FGF2 interacts with the third immunoglobin loop of FGFR1. In particular,  K31 of 
HBS3 forms a hydrogen bond with the side chain of Gln-284 and Asp-282 of FGFR1 [133]. In 
addition, sequence alignment data demonstrated that K30 and R31 were aligned to R84 and R85 
of FGF4, respectively, which have been shown to interact with FGFR1 [197]. These 
observations imply that HS and FGFR are mutually exclusive binding partners of HBS3, and 
these amino acids may switch partners during the formation of the receptor signalling complex.  
Arg42 of FGF2  is trapped in an intramolecular network of hydrogen bonds  
R42 of FGF2 (peptide 3 – Table 4) was not modified by PGO in the in solution context or on 
the heparin affinity mini column and was not a site for Arg-C cleavage. This implies that this 
residue may have intramolecular interactions, which are sufficient to prevent significant 
interactions with solvent (Supplementary Fig 7). The stick structure of FGF2 illustrates that the 
side chain of R42 is 0.29 nm and 0.38 nm from the side chain of D50; 0.29 nm and 0.38 nm to 
that of D57 and 0.34 nm and 0.38 nm to that of V52 (Supplementary Fig 7). These measurements 
suggested that the guanidino group of R42 is engaged in an intramolecular hydrogen bond 
network with the side chains of D50 and D57, the invariant residues in the FGF family, with the 
111 
 
side chain of V49 forming a hydrophobic environment for the aliphatic portion of the arginine 
side chain. These interactions hold the side chain of R42 and so prevent the access of Arg-C 
and PGO/HPG. This intramolecular network of R42, D50, V52, and D57 may serve to restrict the 
conformational freedom of the four antiparallel β strands I, II, III and IV. 
Identification of arginine residues on FGF1 engaging heparin by Protect and Label 
strategy 
FGF1, originally called acidic fibroblast growth factor due to its isoelectric point (pI) 6.52, has 
six arginine residues of which, only R134 and R137 located in HBS1 have been previously 
identified as interacting with heparin. The other arginine residues are R39, 50, 52 and 103. 
Solvent-exposed arginine residues in heparin-bound FGF1 were protected with PGO and 
following elution of the FGF1, any arginine side chains engaged with the polysaccharide were 
labelled with HPG. The resulting peptides with information about modification, sequence, and 
final m/z are presented in Tables 5 and 6 and the spectra are in Supplementary Figs 8 and 9).  
Prospector 
Prospector predicted 148 peptides after cleavage of FGF1 by chymotrypsin with 100% 
sequence coverage, indicating that all six arginine residues would be included in the analysis. 
However, analysis of the data with Prospector did not identify a peptide containing R39 (Table 
5) indicating that coverage was incomplete.  Subsequently, the filter and analysis identified ten 
peptides with HPG-labelled arginines (Table 5) (Supplementary Fig 8). 
R50 and R52 from beta strand III/beta strand IV loop (Fig 7) were found in peptide 8 (Table 5) 
and this showed a mass shift of two HPG products, indicating that both arginines were bound 
to heparin. R103 from beta strand VIII (Fig 7) reacted with HPG as observed in peptides 1, 2, 9 
(Table 5), indicating the binding of this arginine to heparin. 
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The engagement of R134 and R137 in the HBS1 of FGF1 to heparin was demonstrated by HPG 
modification and a mass shift of two HPG products were found in peptides 4, 5, 6 and 10 (Table 
5). However, peptide 3, which also contains R134 and R137, only showed the mass shift of one 
HPG (Table 5, Supplementary Fig 13), meaning that one arginine had not reacted. Peptide 3 is 
identical to peptide 4 and overlaps with peptides 6 and 10. The mass shift of peptide 7 (Table 
5, Supplementary Fig 8) is a combination of one HPG product and one 2:1 condensed product 
of reaction with PGO. Together these data suggest that while R134 and R137 are engaged to 
heparin, one of them may dissociate in the time of the protection step and so react with PGO, 
and moreover, may engage in intramolecular bonds rendering it resistant to reaction. 
Peptide Mass (ExPASY) 
In the case of FGF2, Prospector and ExPASY demonstrated a high level of overlap in terms of 
peptides containing modified arginine residues but, their predications are more diverse for 
FGF1. Nine peptides with modified arginines were identified when Peptide Mass (ExPASY) 
was used as the starting point for the analyses (Table 6, Supplementary Fig 9), but only two of 
them appeared in the list generated by Prospector, peptides 2 and 8.  
R39, R50,and R52 were in peptides 7 and 8 (Table 6). Three products are observed in peptide 7, 
in which, only two products of arginine and HPG were detected, the other is a 2:1 product of 
PGO and arginine. In the case of peptide 8, the mass shift was attributed to two products of 
arginine with HPG, implying a lack of long-lasting reaction between one arginine with PGO 
or HPG. With the additional evidence from peptide 8 (Table 3) generated by Prospector, it 
could be concluded that HPG reacted with R50 and R52. 
R103 from beta strand VIII was labelled with HPG, resulting in a mass shift of HPG in five 
peptides, 1, 2, 4, 5 and 9 (Table 6), demonstrating its involvement in heparin binding. 
R134 and R137 of HBS-1 were labelled by HPG as observed in peptides 3 and 6 (Table 6).  
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Locations of modified arginine residues in the FGF1 structure 
Previous work demonstrated that FGF1 has three regions on its surface that engage heparin: 
the canonical HBS-1 and the secondary binding sites, HBS-2 and HBS-3 [36], [198], [199]. 
The core of the canonical heparin binding site of FGF1 is almost aligned to that in FGF2 (Fig 
7), and extends from beta strand IX/beta strand X loop to beta strand XI/beta strand XII loop 
(Fig 7) as evidenced by X-ray crystallography and NMR spectroscopy[33], [36], [200], [201]. 
Lysine directed protect and label identify HBS-2 (K116, K117) in beta strand IX of FGF1, but do 
not include β strand VI as in FGF2 [36] and HBS-3, which locates towards the N-terminus, and 
consists of K24, K25 and K27.   
HBS-1, Arg134 and Arg137 
The canonical HBS-1 is highly conserved within the FGF sub-family in terms of both sequence 
alignment and structure. In terms of sequence, HBS-1 in FGF1 has a high density of basic 
residues. The selective labelling of lysines identified Lys-127, 128, 133 and 143 as interacting 
with heparin. The present data demonstrate that R134 and R137 (peptides 3, 4, 5, 6, 7 and 10, 
Table 5; peptides 3 and 6, Table 6; Fig 6A) also bound to heparin. The involvement of R134 in 
heparin binding of FGF1was indirectly evidenced in an NMR structure of FGF1 with inositol 
hexasulfate as a substitute for heparin [200]. Subsequently a direct involvement was shown 
using a synthetic heparin hexasaccharide which caused a chemical shift perturbation of R137 
[33], [201]. 
FGF1 may have a single continuous HBS1.  
Although FGF1 has an acid pI, its charged residues are segregated on its surface so that it 
possesses a largely basic face and a largely acidic face (Fig 6). With the additional data 
provided by arginine selective labelling we were able to re-examine the assignment of the basic 
residues to the different HBSs. 
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R103 in beta strand VIII (Fig 7) was labelled by HPG (Tables 5, 6).On the surface of FGF1, this 
arginine is adjacent to HBS1 and connected to HBS-2, 116KK117 (Fig 6 B – lower panel). This 
suggests that R103 is part of HBS1. Both R50 and R52 in FGF1 were labelled by HPG, indicating 
that they interact with heparin. R50 and R52 locate on the loop between beta strand III and beta 
strand IV (Fig 7). Although separated by an acidic Asp51 residue (Fig 7), inspection of the 
surface electrostatic potential shows that there is no acidic boundary between these arginines 
(Fig 6A, C), presumably because the Asp side chain is involved in a local hydrogen bonding 
network. Notably, R50 and R52 are on the same basic face of the protein, as is the previously 
defined HBS3 (Fig 6 C). These arginines connect HBS1 and 24KK25 and K27 in HBS3 of FGF1 
(Fig 6 C), implying that R50 and R52 as well as 24KK25 and K27 are part of HBS1. 
In conclusion, we propose here that FGF1 has a single long, continuous HBS1, which 
comprises 24KK25 and K27at the N-terminus of beta strand I, R50 and R52 between β strand III/β 
strand IV, going through K127, K128, R134, R137, and K143 in β strand X/β strand XI, R103 in beta 
strand VIII and 116KK117 in beta strand IX. Thus, although the position of most of these residues 
in the FGF1 structure is similar to that in the structure of FGF2, differences in the surface 
distribution of the acidic side chains in the two proteins lead to these sites likely coalescing in 
FGF1. 
These data demonstrate that although FGF1 and FGF2 are in the same sub-family and, possess 
a high level of sequence conservation, they may differ in their interactions with heparin/HS. 
FGF2 has the primary and the secondary binding sites separated by acidic boundaries implying 
that they may engage different polysaccharide chain. Indeed, this is supported by the 
demonstration that FGF2 can crosslink HS chains [202].  However, FGF1 possess a continuous 
HBS suggesting that it can bind a single HS. Analysis of the interactions of FGF1 with HS 
demonstrates that unlike FGF2, it does not crosslink HS chain [203]. This is consistent with 
FGF1 possessing a single, large HS binding site. 
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Conclusion 
Our strategy for selective labelling of arginine side chains involved in binding to heparin, in 
combination with our published data on lysines, allows a greater dissection of the electrostatic 
bonds that drive the interactions between proteins and GAGs. The results with the model 
peptides illustrated the highly selectivity and specificity of PGO/HPG modification of the 
guanidino group of arginine. One of the main limitations is the multiple products from reaction 
with PGO, but our strategy of integrating mass spectrometry and automated analysis 
successfully tackled this issue. The data on proteins show that: 1) heparin binding effectively 
protects the arginine residues engaged with the polysaccharide, allowing the protection of 
uninvolved arginines with PGO;2) the recovery of protein after the elution from heparin affinity 
mini-column is reasonably quantitative; 3) the automated analysis is sensitive enough to 
identify the modifications of each arginine residue. The method is rapid and so should be 
applicable for any protein-heparin interactions. Moreover, like lysine selective labelling, our 
arginine labelling method identifies the secondary, low affinity binding sites. The likely 
importance of these in contributing to the structure of extracellular matrix and the regulation 
of ligand diffusion is suggested by a recent biophysical analysis [202]. As well as protein-
sulfated GAG interactions, the method should be adaptable to any interactions involving 
arginine residues such as protein-nucleic acid and protein-phospholipid. 
The identification of arginines engaging heparin in FGF1 and FGF2 alongside the lysines 
involved in binding provides a number of new insights. For example, we are able to propose 
the reassignment of HBSs in both FGF2 and FGF1 and intriguingly, FGF1 would appear to 
have just a single, large HBS1, similar to FGF9 [36]. In addition, the data demonstrate that the 
arginine just N-terminal to β-strand I, which in at least some instances are involved in binding 
the cognate FGFR, can alternatively bind heparin. 
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Figure legends 
Figure 1: Workflow for selective labelling of arginine residues in proteins 
A. The arginine protect and label experimental workflow. There are four main steps in the 
workflow. In the first step, the engagement between protein and heparin affinity beads results 
in the exposure to solvent of only the non-binding-involved arginine residues. The second step 
is protection by PGO of these exposed arginine side chains. The protein is then disassociated 
from heparin with 2 M NaCl, so that the arginine residues in heparin binding sites are available 
for labelling with HPG in the third step. Finally, proteins are digested by enzymes and peptides 
are analysed by MALDI-Q-TOF mass spectrometry. B Analytical workflow for the 
identification of modified peptides: B1-1, 2. The corresponding mass and sequence of peptides 
after enzyme digestion were predicted by Prospector and Peptide Mass. B1-3. The peptides 
were then processed by the PGO-HPG mass predictor Python script, which added the possible 
mass shifts after modification by PGO or HPG on each peptide based on the number of arginine 
residues in the native sequence. B1-4. This step provides the theoretical list of modified 
peptides. B2. The second step starts with the list observed list of peptides from MALDI-TOF 
MS data, which contains the information of the m/z and intensity of each peak.  B3. 
Components in the predicted and observed lists are then matched by the Matchmaker Python 
script with a tolerance of difference of less than 0.1 Da. B4. The modified arginine residues 
were mapped onto the 3D structure of proteins back to identify their locations. 
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Figure 2: Optimization of the reaction between PGO and arginine residues on peptides. 
A. The description of the stoichiometry of PGO with arginine. Initially, PGO reacts with the 
guanidine group of arginine to form a first product (Product 1), which may then condens with 
the loss of a water molecule through a reversible process to yield product 2. The 2:1 water 
condensed product of PGO and arginine may appear in the presence of excess PGO (product 3 
or product 4), which have the same mass. B. Mass spectra of peptide FA reacted with PGO. 
The reaction between FA and 200 mM PGO was conducted in the dark, for 30 min at 25°C. 
There are six products observed. The products between FA and one PGO were demonstrated 
as three major peaks of 1139.60 Da, 1255.61 Da and 1275.58 Da. The reaction of FA with two 
PGO results in three peaks, numbered 4, 5 and 6 with the mass of 1388.62; 1410.60 and 
1523.67. C. Reactions of arginine residues located at N- or C-terminus of a peptide. Peptide 
NA was cleaved by trypsin to generate two peptides: i) NA-I: RPYIL, mass 661.38 Da with 
arginine at the N terminus and ii) NA-II: LYENKPR, mass 1030.53 Da with arginine at C 
terminus. Both peptides were reacted with 200mM PGO in the dark for 30 min. After the 
reaction, each peptide showed 4 products, indicated by the arrows and numbered 1, 2, 3 and 4. 
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Figure 3: Optimization of the reaction between HPG and arginine residues on peptides. 
A. The reaction of HPG and arginine. There is a single product generated after reaction between 
HPG and guanidino side chain of arginine residues. B. Mass spectra of FA reacted with HPG. 
The reaction between FA and 100 mM HPG was conducted in the dark, for 10 min (Upper 
panel) and 30 min (Lower panel), at 25°C. At 10 min, the original FA with the mass of 1023.5 
is observed along with and (FA+HPG) with a mass shift of 1156.6. At 30 min, only the product 
(FA+HPG) was observed. C. Mass spectra of NA reacted with HPG. The reaction between FA 
and 100 mM HPG was conducted in the dark, for 10 min (Upper panel) and 30 min (Lower 
panel), at 25°C. At 10 min, the original NA and along with the reaction product (NA+HPG) 
were detected. At 30 min, only the product (NA+HPG) was observed. 
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Figure 4: Selective labelling of arginine residues in the heparin binding sites of FGF2 and 
FGF1. The reaction between PGO and FGF2 or FGF1 was conducted in solution and or when 
bound to heparin beads in the dark, at 25°C for 60 min. The protein eluted from the column 
was further reacted with PGO in the same conditions. The products collected after reactions 
were incubated with chymotrypsin or Arg-C, at 37°C overnight. All samples were analysed by 
SDS-PAGE. A. Reactions of FGF2 with PGO. Lane 1: 1/10 of the native FGF2 used in the in 
solution experiment; lane 2: 1/10 of the protein after the reaction with 200 mM PGO; lane 3: 
products of the digestion of native FGF2 by chymotrypsin; lane 4: products of the digestion by 
chymotrypsin of PGO-modified FGF2; lane 5: products of the digestion by Arg-C of  native 
FGF2; lane 6: products of the digestion by Arg-C of PGO-modified FGF2. B. The reaction of 
FGF2 bound to heparin affinity column with PGO. L, 1/10 of the protein loaded onto the 
column; FT, 1/10 of the flow through fraction; W, 1/10 of the fraction washed with Na-1 buffer; 
PGO PROTECT FT, flow through fraction after the reaction between FGF2 and PGO; PGO 
PROTECT W, wash fraction after the reaction with PGO; PGO PROTECT E, Eluate from the 
column with Na-2 buffer; PGO PROTECT lane 1: the protein in the elution was digested with 
chymotrypsin; PGO PROTECT lane 2: the protein in elution was digested with Arg-C. C. 
Labelling of arginine residues in binding sites of FGF2. FGF2 from the eluate (panel B, fraction 
PGO PROTECT E) was reacted with PGO at a final concentration of 100 mM for 60 min. The 
product from this the second reaction was loaded onto a heparin affinity minicolumn. L, 1/10 
of the FGF2 labelled by PGO; FT, the flow through the minicolumn; W, 1/10 of the wash with 
Na-1 buffer; E, Elution with buffer Na-2; lane 1, the labelled FGF2 in FT fraction was digested 
by chymotrypsin; lane 2, the labelled FGF2 in FT fraction was digested by Arg-C. 
D. Reaction of FGF1 with PGO. Lane 1: 1/10 of the native FGF1 used in the in solution 
experiment; lane 2: 1/10 of the protein after the reaction with 200 mM PGO; lane 3: products 
of the digestion of native FGF1 by chymotrypsin; lane 4: products of the digestion by 
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chymotrypsin of PGO-modified FGF1; lane 5: products of the digestion by Arg-C of the native 
FGF1; lane 6: products of the digestion by Arg-C of PGO-modified FGF1. E. The reaction of 
FGF1 bound to heparin affinity column with PGO. L, 1/10 of the protein loaded onto the 
column; FT, 1/10 of the flow through fraction; W, 1/10 of the fraction washed with Na-1 buffer; 
PGO PROTECT FT, flow through fraction after the reaction between FGF1 and  PGO on the 
mini-column; PGO PROTECT W, wash fraction after the reaction with PGO; PGO PROTECT 
E, Eluate from the column with Na-2 buffer; PGO PROTECT lane 1: the protein in the elution 
was digested with chymotrypsin; PGO PROTECT lane 2: the protein in elution was digested 
with Arg-C. F. Labelling of arginine residues in binding sites of FGF1. FGF1 from the eluate 
(panel D, fraction PGO PROTECT E) was reacted with PGO at a final concentration of 200 
mM for 60 min, the product of this second reaction was loaded onto a heparin affinity mini-
column. L, 1/10 of the FGF1 labelled by PGO; FT, the flow through the mini-column; W, 1/10 
of the wash with buffer Na-1; E, Elution with buffer Na-2; lane 1, the labelled FGF1 in FT 
fraction was digested by chymotrypsin; lane 2, the labelled FGF1 in FT fraction was digested 
by Arg-C. 
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Figure 5: Labelled arginine and lysine residues in heparin-binding sites of FGF2. The 
FGF2 structure (PBD code 1bfg [44]) is shown as a surface. The electrostatic potential of FGF2 
and FGF1 was computed using Poisson-Boltzmann algorithm by Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
lysine residues [36] [120] are presented in yellow. Labelled arginine residues (Tables 3, 4) are 
coloured green. This colour scheme for electrostatic potential is used throughout the paper 
including Figs 5, 6. A. Basic residues in HBS1. R129 of the canonical HBS-1. Other basic 
residues in HBS1 include K128,  K134, K138, K144 [36] [120]. R90 and K86 which are now assigned 
to be part of HBS1 by this work are shown. B. Basic residues in HBS2. Location of R118 and 
K119 are shown on the surface in relative to the rest of HBS-2. All the basic residues in HBS1 
can also be seen from this viewpoint as well. C. Basic residues in HBS3. Location of K30, R31 
and K75. 
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Figure 6: Labelled arginine and lysine residues in the heparin binding sites of FGF1. The 
FGF1 structure (PBD code 2erm [33]) is shown as a surface. A. Location of labelled R50, R52, 
R134 and R137 on the surface as part of the canonical HBS-1. The other basic residues are K127, 
K128, K143, K116 and K117 [36]. K116 and K117, which previously were part of HBS-2, now are 
assigned to be in HBS1 by this work. B. (Upper) The location of is mapped to the surface, on 
the electronegative surface. (Lower) The connection of R103 to HBS1. C. Locations of K24, K25 
and K27 [36] situated at the N-terminal are shown along with locations of R50 and R52. K24, K25 
and K27 have been reassigned from HBS-3 [36] to HBS-1 in this study. 
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Figure 7: Sequence alignment of FGF2, FGF1 and location of labelled arginine and lysine 
residues in the heparin binding sites. Uniprot ID of FGF2 sequence is, P09038-2, Uniprot 
ID of FGF1 sequence is P05230. Labelled arginine residues are coloured in red, labelled lysine 
residues are coloured in blue, the HBSs are highlighted in red boxes. The β strands are 
presented as the arrows.  
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Tables 
Table 1: Reactions of arginine residues in peptide FA with PGO 
A. Screen for the conditions for PGO reaction on model peptide FA. Peptide FA at three 
different concentrations (100 mM, 200 mM, 1M) reacted with PGO at two different times (5 
min and 30 min). (X) corresponds to “does not react” and (V) indicates that the reaction 
between peptide and PGO was detected.        
 
Concentration 100 mM 200 mM 1M 
 Time  
FA 
WQPPRARI 
MW: 
1023.58 Da 
5 min 
 
X V X 
 
30 min 
 
X V X 
PGO 200 mM for 30 min 
Products Mass (Da) Shift 
1 1139.60 116.02 
2 1255.61 232.03 
3 1275.58 252.0 
4 1388.62 116.02+250.04 
5 1410.60 232.03+250.04 
6 1523.67 250.04+250.04 
 
B. Screen for the products for PGO reaction on model peptide NA. Peptide NA was pre-
treated by trypsin to generate two peptides: NA-I and NA-II. The resulting peptides reacted 
with PGO at concentration of 200 mM for 30 min. 
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Peptide NA 
(p-Glu-LYENKPRRPYIL) (PGO200 mM for 30 min) 
peptide NA-I: RPYIL 
MW: 661.38 Da 
peptide NA-II: YENKPR 
MW: 1030.53 Da 
Products Mass (Da) Shift Products Mass (Da) Shift 
1 777.42 116.02 1 1146.55 116.02 
2 795.40 134.03 2 1164.52 134.03 
3 896.41 232.03 3 1262.58 232.03 
4 911.46 250.04 4 1280.56 250.04 
 
Table 2: Products of PGO/HPG and arginine side chains with corresponding mass shift 
The summary of the products between PGO/HPG and arginine side chains.The first PGO reacts 
with the guanidino group to produce1:1 product (Fig 2A, product [1]), which could then 
reversibly release a hydroxyl group from glyoxal, resulting in the 1:1 product water-condensed 
product (Fig 2A, product [2]). Following is the reaction of a second PGO molecule (if sufficient 
reactant) onto either a nitrogen of the guanidino group of arginine (Fig 2A, products [3]) or the 
carbonyl group of the first PGO (Fig 2A, products [4]) to form the final 2:1 product water-
condensed product.  
# of product Product Mass shift 
Figure 2A 1 1:1 product  134.13 
Figure 2A 2 1:1 product water-condensed 116.12 
Figure 2A 3 2:1 product  252.23 
Figure 2A 4 2:1 product water-condensed 232.26 
Figure 3A HPG 132.12 
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Table 3: FGF-2 peptide analysis based on prediction by Prospector. The reference number of the peptide 
is followed by the predicted m/z and with the sequence of the peptide following cleavage of native FGF-2 by 
chymotrypsin.  The two columns under “Native FGF-2” present the predicted m/z and sequences of peptides 
after chymotrypsin digestion of FGF-2.The first two columns under “FGF-2 protect and label (P&L)” present 
the observed and predicted m/z for FGF-2 after modifications of arginine residues. The third column is the 
assignment of the peptide to one of the three HBSs of FGF2[36], [120]. The final columns indicates the 
modification occurring on the arginine residues of the peptides. 
  Native FGF-2 FGF-2 protect and label (P&L)
1
 
  m/z 
theoretical 
Sequence 
m/z 
observed 
m/z 
theoretical 
Published 
HBS
2. 
Modifications 
1 996.54 116RSRKYTSW123    1144.62 1144.56 
HBS2 (R116 and 
R118) 
1 R + 132 (HPG) and 
oxidation 
2 1032.55 83AMKEDGRLL92 1180.59 1180.59 HBS2 (R90)  
1 R + 132 (HPG) and 
oxidation 
3 1032.55 82LAMKEDGRL91 1180.59 1180.59 HBS2 (R90) 
1 R + 132 (HPG) and 
oxidation 
4 1318.61 105FFERLESNNY115 1434.63 1434.61  1 R +116(PGO) 
5 1374.69 113NTYRSRKYTW123 1738.82 1738.74 HBS2 (R118) 2 R + 132 (HPG)  + 232  
6 1439.84 124YVALKRTGQYKL135 1587.85 1587.86 HBS1 (R129) 
1 R + 132 (HPG) and 
oxidation 
7 1525.79 27KDPKRLYCKNGGF40 1673.79 1673.82 HBS3 (R31) 
1 R + 132 (HPG) and 
oxidation 
8 1979.01 
65QAEERGVVSIKGVCANR
Y82 
2211.15 2211.08 
HBS2 
1 R +232(PGO) 
9 2220.16 
63QLQAEERGVVSIKGVCA
NRY82 
2353.17 2353.15 
HBS2 (R69 and 
R81) 
R + 133 (PGO) 
1
0 
2537.41 
41LRIHPDGRVDGVREKSD
PHIKL62 
2769.45 2769.45  2 R + 116 x 2(PGO x2) 
 
 
 
 
 
                                                 
1 P&L: FGF-2 reacted in solution with PGO when bound to a heparin affinity column (protection step) and then, following 
elution, reaction of any protected arginine residues with HPG (labelling step).  
 
2 The bolded amino acids are a part of the known HBSs which were noted in column 3rd of FGF-2 on column. 
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Table 4: FGF-2 MS analysis based on prediction by Peptide Mass (ExPASy). The reference number of 
the peptide is followed by the predicted m/z and with the sequence of the peptide following cleavage of native 
FGF-2 by chymotrypsin. The two columns under “Native FGF-2” present the predicted m/z and sequences of 
peptides after chymotrypsin digestion of FGF-2.The first two columns under “FGF-2 protect and label (P&L)” 
present the observed and predicted m/z for FGF-2 after modifications of arginine residues. The third column 
is the assignment of the peptide to one of the three HBSs of FGF2 [36], [120]. The final columns indicates the 
modification occurring on the arginine residues of the peptides. 
 Native FGF2 FGF-2 (P&L)
3
 
  m/z 
theoretical 
Sequence 
m/z 
observed 
m/z 
theoretical 
Published 
HBS
4
 
Modifications 
1 996.54 116RSRKYTSW123    1144.63 1144. 56 
HBS2 (R116 and 
R118) 
1 R + 132 (HPG) and 
oxidation 
2 1032.55 82LAMKEDGRL91 1180.59 1180.58 HBS2 (R90) 
1 R + 132 (HPG) and 
oxidation 
3 1032.55 83AMKEDGRLL92 1180.59 1180.58 HBS2 (R90) 
1 R + 132 (HPG) and 
oxidation 
4 1198.66 124YVALKRTGQY134 1362.61 1362.67 HBS1 (R129) 
1 R + 132 (HPG)  and 
oxidation 
5 1276.77 125VALKRTGQYKL135 1408.71 1408.77 HBS1 (R129) 1 R + 132 (HPG) 
6 1318.61 105FFERLESNNY115 1434.63 1434.61  1 R + 116 (PGO) 
7 1374.69 113NTYRSRKYTW123  1738.82 1738.74 HBS2 2 R + 132 (HPG)  + 232  
8 1439.84 124YVALKRTGQYKL135 1587.85 1587.86 HBS1 (R129) 1 R + 132 (HPG) 
9 1525.79 27KDPKRLYCKNGGF40 1673.79 1673.82 HBS3 (R31) 1 R + 132 (HPG) 
10 1979.01 
65QAEERGVVSIKGVC
ANRY82 
2211.15 2211.08 
HBS2 
1 R + 232(PGO) 
11 2220.15 
63QLQAEERGVVSIKG
VCANRY82 
2369.17 2369.15 
HBS2 (R69 and 
R81) 
2 R + 133(PGO) 
12 2537.41 
41LRIHPDGRVDGVREK
SDPHIKL62 
2769.27 2769.26  2 R + 116 x 2(PGOx2) 
 
 
                                                 
3 P&L: FGF-2 reacted in solution with PGO when bound to a heparin affinity column (protection step) and then, following 
elution, reaction of any protected arginine residues with HPG (labelling step).  
 
4 The bolded amino acids are a part of the known HBSs which were noted in column 3rd of FGF-2 on column. 
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Table 5: FGF-1 MS analysis based on prediction by Prospector. The reference number of the peptide is 
followed by the predicted m/z and with the sequence of the peptide following cleavage of native FGF-1 by 
chymotrypsin. The two columns under “Native FGF-1” present the predicted m/z and sequences of peptides 
after chymotrypsin digestion of FGF-1.The first two columns under “FGF-1 protect and label (P&L)” present 
the observed and predicted m/z for FGF-1 after modifications of arginine residues. The third column is the 
location of arginine residues of HBS-1 of FGF-1. The final columns indicates the modification occurring on 
the arginine residues of the peptides. 
 Native FGF-1 FGF-1 (P&L)
5
 
  m/z 
theoretical 
Sequence 
m/z 
observed 
m/z 
theoretical 
Arginine of 
HBS1 
Modifications 
1 1349.65 100FLERLEENHY109 1481.67 1481.63 R103 1 R + 132 (HPG) 
2 1467.65 102ERLEENHYNTY109 1599.67 1599.69 R103 1 R + 132 (HPG) 
3 1901.03 124VGLKKNGSCKRGPRTHY140 2033.05 2033.07 R134 and R137 1 R + 132 (HPG) 
4 1901.03 124VGLKKNGSCKRGPRTHY140 2165.07 2165.07 R134 and R137 
2 R + 132 (HPG) 
x 2 
5 2048.10 123FVGLKKNGSCKRGPRTHY140 2312.14 2312.14 R134 and R137 
2 R + 132 (HPG) 
x 2 
6 2389.30 
127KKNGSCKRGPRTHYGQKAIL
F147 
2653.34 2653.30 R134 and R137 
2 R + 132 (HPG) 
x 2 
7 2389.30 
127KKNGSCKRGPRTHYGQKAIL
F147 
2753.39 2753.30 R134 and R137 
2R + 132 (HPG) 
+ 232 
8 2633.37 
40ILPDGTVDGTRDRSDQHIQLQ
L59 
2897.42 2897.39 R50 and R52 
2 R + 132 (HPG) 
x 2 
9 3105.55 
102ERLEENHYNTYISKKHAEKN
WFVGL126 
3253.57 3253.49 
R103 And 
HBS-2 
1 R + 132 (HPG) 
10 3197.74 
127KKNGSCKRGPRTHYGQKAIL
FLPLPVSSD155 
3461.88 3461.78 R134 and R137 
2 R + 132 (HPG) 
x 2 
 
                                                 
5 P&L: FGF-1 reacted in solution with PGO when bound to a heparin affinity column (protection step) and then, following 
elution, reaction of any protected arginine residues with HPG (labelling step).  
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Table 6: FGF-1 MS analysis based on prediction by Peptide Mass. The reference number of the peptide is 
followed by the predicted m/z and with the sequence of the peptide following cleavage of native FGF-1 by 
chymotrypsin. The two columns under “Native FGF-1” present the predicted m/z and sequences of peptides 
after chymotrypsin digestion of FGF-1.The first two columns under “FGF-1 protect and label (P&L)” present 
the observed and predicted m/z for FGF-1 after modifications of arginine residues. The third column is the 
location of arginine residues of HBS-1 of FGF-1. The final columns indicates the modification occurring on 
the arginine residues of the peptides. 
 Native FGF-1 FGF-1 (P&L)
6
 
  m/z 
theoretical 
Sequence m/z 
observed 
m/z 
theoretical 
Arginine of 
HBS1 
Modifications 
1 1089.50 102ERLEENHY109 1221.62 1221.65 R103 
 
1 R + 132 (HPG) 
2 1349.65 100FLERLEENHY109 1481.67 1481.64 R103 
 
1 R + 132 (HPG) 
3 1631.85 127KKNGSCKRGPRTH 
Y141 
1895.90 1895.82 R134 and R137 2 R + 132 (HPG) x 2 
4 1727.80 100FLERLEENHYNTY112 1859.82 1859.73 R103 
 
1 R + 132 (HPG) 
5 1898.90 89YGSQTPNEECLFLE 
RL104 
2030.92 2030.83 R103 
 
1 R + 132 (HPG) 
6 2242.23 127KKNGSCKRGPRTHYGQ
KAIL146 
2506.28 2506.32 R134 and R137 2 R + 132 (HPG) x 2 
7 2505.32 38LRILPDGTVDGTRDRSDQ
HIQL59 
3019.42 3019.39 R39, R50 and 
R52 
 
2 R + 132 (HPG) x 2 + 250 
(PGO) 
8 2633.37 39RILPDGTVDGTRDRSDQ
HIQLQL59 
2897.43 2897.40 R39, R50 and 
R52 
 
2 R + 132 (HPG) x 2 
9 3105.55 102ERLEENHYNTYISKKHA
EKNWFVGL126 
3267.58 3267.61 R103 
 
1 R + 132 (HPG) 
And 2 oxidation 
                                                 
6 P&L: FGF-1 reacted in solution with PGO when bound to a heparin affinity column (protection step) and then, following 
elution, reaction of any protected arginine residues with HPG (labelling step).  
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Supplementary data 
Supplementary figure 1: Mass spectra of the trypsin digestion products of peptide FA. A. 
FA was digested by trypsin. The larger part of the sequence was identified as “WQPPR”. B. 
Peptide FA after the reaction with PGO was digested with trypsin.  
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Supplementary figure 2: The stoichiometry of reaction of PGO with arginine residues in 
specific sequence contexts. A. B. PGO reacts to two adjacent arginine residues which are 
separated by a small sized amino acid, alanine.  (A) When PGO reactsindividually with each 
arginine; (B) When the dicarbonyl group of PGO reacts with NH2 groups on different arginine 
residues; (C) When PGO reacts to arginine at the N- or C-terminus forming 2:1 product of 
PGO:Arginine. 
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Supplementary figure 3: FGF2 MS spectra of peptides after in solution modification with 
PGO based on prediction by Prospector. The reference number of the peptide is followed 
by the observed m/z of the peptides produced by cleavage of FGF2 reacted in solution with 
PGO. 
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Supplementary figure 4:FGF2 MS spectra of peptides after modification based on 
prediction by Prospector. The reference number of the peptide is followed by the observed 
m/z of the peptides produced by the cleavage of FGF2which was before reacted with PGO 
when bound to a heparin affinity column (protection step) and then, following elution, reaction 
with HPG (labelling step). 
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Supplementary figure 5: FGF2 MS spectra of peptides after modification based on 
prediction by Peptide Mass (ExPASy). The reference number of the peptide is followed by 
the observed m/z of the peptides produced by the cleavage of FGF2 which was before it reacted 
with PGO when bound to a heparin affinity column (protection step) and then, following 
elution, reaction with HPG (labelling step). 
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Supplementary figure 6: In FGF2, R118 engages to heparin whereas R116 does not. 
Double digestion of FGF2 by chymotrypsin and Arg-C. After the protection of exposed 
arginine residues on the mini-column by 200 mM PGO, protein was eluted from the column 
and then cleaved for 5 hours by chymotrypsin and overnight by Arg-C. The red diamond 
presents for the modification by PGO on R116. R118 was cleaved by Arg-C resulting in peptide 
NTYRSR with the mass 1028.15, observed in the spectrum. 
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Supplementary figure 7: The intramolecular network of hydrogen bonds of R42 with D50, 
V52, and D57. The green presents R42; the orange shows the D50, V52, and D57. Their potential 
hydrogen bonds are presented as backlines with arrow. 
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Supplementary figure 8: FGF1 MS spectra of peptides after modification based on 
prediction by Prospector. The reference number of the peptide is followed by the observed 
m/z of the peptides produced by the cleavage of FGF1which was before reacted with PGO 
when bound to a heparin affinity column (protection step) and then, following elution, reaction 
with HPG (labelling step). 
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Supplementary figure 9: FGF1 MS spectra of peptides after modification based on 
prediction by Peptide Mass (ExPASy). The reference number of the peptide is followed by 
the observed m/z of the peptides produced by the cleavage of FGF1which was before reacted 
with PGO when bound to a heparin affinity column (protection step) and then, following 
elution, reaction with HPG (labelling step). 
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Supplementary table 1: FGF-2 MS analysis based on prediction by Prospector 
The reference number of the peptide is followed by the predicted m/z and with the sequence of 
the peptides following cleavage of native FGF-2 chymotrypsin.  The two columns under 
“Native FGF-2” present the predicted m/z and sequences of peptides after chymotrypsin 
digestion of FGF-2.The first two columns under “FGF-2 in-solution” present the observed and 
predicted m/z for FGF-2 after modification by PGO7. The final column indicates the 
modification occurring on the arginine residues of the peptides. 
 Native FGF2 FGF-2 in solution 
  m/z 
theoretical 
Sequence 
m/z 
observed 
m/z 
theoretical 
Modifications 
(PGO) 
1 919.54 27KDPKRLY33 1151.60 1151.69 R + 232 
2 1035.59 125VALKRTGQY134 1151.62 1151.69 R + 116 
3 1161.63 83LAMKEDGRLL95 1294.62 1294.62 
1 R + 133 and 
oxidation 
4 1083.70 116RSRKYTSW123 1315.62 1315.65 2 R + 116 x 2 
5 1624.79 113NTYRSRKYTW123 1856.84 1857.01 2 R + 116 x 2 
6 1907.90 92LASKCVTDECFFFERL107 2139.97 2139.80 R + 232 
7 1979.01 
65QAEERGVVSIKGVCANRY8
2 
2211.00 2211.00 2 R + 116 x 2 
8 2248.00 109ESNNYNTYRSRKYTSW123 2479.80 2479.90 2 R + 116 x 2 
9 2424.32 
41LRIHPDGRVDGVREKSDPHI
KL62 
2673.30 2673.17 2R + 116 + 133 
 
Supplementary table 2: FGF-2 MS analysis based on prediction by Peptide Mass 
(ExPASY). 
                                                 
7In solution: FGF-2 reacted in solution with PGO for 60 min in the dark.  
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The reference number of the peptide is followed by the predicted m/z and with the sequence of 
the peptides following cleavage of native FGF-2 chymotrypsin.  The two columns under 
“Native FGF-2” present the predicted m/z and sequences of peptides after chymotrypsin 
digestion of FGF-2.The first two columns under “FGF-2 in-solution” present the observed and 
predicted m/z for FGF-2 after modification by PGO8. The final column indicates the 
modification occurring on the arginine residues of the peptides. 
  Native FGF-2 FGF-2 in solution 
  m/z 
theoretical 
Sequence 
m/z 
observed 
m/z 
theoretical 
Modifications 
(PGO) 
1 1161.63 83LAMKEDGRLL95 1294.62 1294.62 
1 R + 133 and 
oxidation  
2 1624.79 113NTYRSRKYTW123 1856.84 1857.01 2 R + 116 x 2 
3 1907.90 92LASKCVTDECFFFERL107 2139.97 2139.79 R + 232 
4 1979.01 65QAEERGVVSIKGVCANRY82 2211.06 2211.00 2 R + 116 x 2 
5 2248.00 109ESNNYNTYRSRKYTSW123 2480.06 2479.80 2 R + 116 x 2 
6 2684.48 
40FLRIHPDGRVDGVREKSDPH
IKL62 
3264.64 3264.49 3 R + 116 + 232 x 2 
 
 
  
                                                 
8In solution: FGF-2 reacted in solution with PGO for 60 min in the dark.  
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CHAPTER 5 THE IDENTIFICATION OF LYSINE AND ARGININE 
RESIDUES INVOLVED IN HEPARIN BINDING IN THE FIFTEEN 
PARACRINE FIBROBLAST GROWTH FACTORS   
5.1. INTRODUCTION 
In humans there are 22 fibroblast growth factors (FGFs), which regulate many aspects of 
embryonic development and cellular homeostasis. The 15 paracrine FGFs elicit signals by 
forming a ternary complex with fibroblast growth factor receptors (FGFRs) and their heparan 
sulfate (HS) co-receptors. In addition to its role as a co-receptor, HS also regulates the transport 
of FGFs between source and target cells and so their bioavailability and gradients [204] [2][36]. 
Thus, HS is a key regulatory partner of the paracrine FGFs. HS is composed of disaccharide 
repeating units comprising 1,4 linked –β-D glucuronate (GlcA) and α-D-N-acetyl glucosamine 
(GlcNAc) with diverse modifications: de-acetylation/N sulfation and O sulfation at C3 and C6 
of glucosamine, epimerisation of GlcA to L-iduronic acid (IdoA) and 2-O sulfation of this 
uronic acid [47]. The clustering of these modifications results in HS chains possessing a domain 
structure: S-domains, where all glucosamine residues are N-sulfated, followed by transition 
domains with alternating GlcNS and GlcNAc containing disaccharides, and unmodified NA 
domains [57]. Heparin is widely used in vitro as a proxy for S-domains due to its high degree 
of sulfation. On each saccharide, the sulfate and carboxylate groups are completely ionized at 
physiological pH, and this high negative charge density results in electrostatic attraction driving 
the interaction between HS/heparin and protein [47]. 
The so-called heparin binding sites (HBSs) on proteins are enriched in arginine and lysine 
residues and consequently basic [114] [36][109]. However, it is well established that the 
interaction of proteins with sulfated GAGs is based on affinity and not simply ion-exchange 
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[148]. Some attempts have been made to determine a consensus sequence of basic amino acids 
representative of HBSs [110] [112]. However, such linear sequences of amino acids have not 
been generally useful. This is because HBSs are often formed by residues that are physically 
adjacent, but distant in the sequence [109]. For example, HBSs of FGFs locate to various β-
strands and loops [120] [36] [37]. It is also noteworthy that proteins often possess multiple 
HBSs. In at least some instance, this allows the protein to engage multiple HS chains, reducing 
the protein mobility [36]. Moreover, there are far more identified HBPs than HBPs with defined 
HBSs, so there is currently limited scope for developing a means to predict HBSs.  
The identification of the binding sites of the polysaccharide on proteins includes low 
throughput methods such as NMR spectroscopy [184], site-directed mutagenesis [185] 
[36][186] and X-ray crystallography [100] [143] [144]. A higher throughput method to identify 
lysine residues, called “protect and label” uses selective labelling and mass spectrometry 
[120][36][37], and has increased the number of characterised HBSs considerably. An 
interesting feature of this method is that it identifies both canonical, high affinity HBSs in a 
protein and lower affinity secondary binding sites [36] [37]. However, this approach is limited 
due to its selectivity for lysine and so can provide no information on arginine residues. 
Recently, an analogous selective labelling approach has been developed to identify arginine 
residues engaged with heparin (Section 4.2). The application of both lysine and arginine 
selective labelling thus enables the complete characterisation of the key basic residues in an 
HBS. In previous work [36][120] [37], we determined the lysine residues contributing to 
heparin binding in 12 of the 15 paracrine FGFs and arginine  residues in FGF1 and FGF2. This 
provided insight into the architecture of the HBSs and their evolutionary relationship. Here, we 
complete the analysis of the lysine and arginine residues involved in heparin binding in all 15 
paracrine FGFs. 
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The results underline the importance of the area between β-strands X and XII in engaging 
heparin and the critical contributions of other basic residues scattered across the sequence. The 
data demonstrate that while some FGFs have a single, continuous canonical HBS-1, many 
possess multiple HBSs, separated by an acidic border and changes in the positions of acidic 
residues can make important contributions to the diversification of HBSs in FGFs. In addition, 
HBS-3, which locates N-terminal to the core β-trefoil of FGFs is found in many of the FGFs 
and appears likely to overlap an FGFR binding site. 
5.2. RESULTS  
The selective labelling of lysine and arginine residues involved a protection step, in which the 
solvent exposed residues of protein bound to a heparin affinity columns are reacted. Following 
elution, any residues that were engaged with heparin were now exposed to solvent and could 
be labelled using the same reaction, but a different reagent. For lysine residues, the analyses 
are straight forward, since the reaction of N-hydroxy-succinimide functional groups with 
primary amines yields a single acidic stable product. Moreover, the use of NHS-biotin 
simplifies analysis, since biotinylated peptides are readily purified prior to mass spectrometry 
[120].  
In contrast, for arginine residues the analysis is more complex. Phenylglyoxal (PGO) is used 
to protect arginine side chains exposed to solvent in a heparin-bound protein. Hydroxyl-
phenylglyoxal (HPG) is then used to label exposed arginine side chains in the eluted protein. 
The complexity arises from the fact that the reaction of PGO with arginine side chains produces 
multiple products, which are acid labile [192]. The multiple products can be deconvoluted 
using newly developed software tools (Section 4.1), whereas the acid lability imposes a 
restriction on post-reaction processing of peptides. 
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We have used the lysine and arginine protect and label methods to complete the analysis of 
HBSs in the 15 paracine FGFs. The identified heparin-binding residues were then mapped onto 
existing modelled structures of the FGFs. This allowed a definitive assignment of the labelled 
residues between primary, canonical HBS and secondary HBSs based on the presence and 
absence of isolating acidic borders. The mass spectrometry data are in supplementary. 
5.2 RESULTS 
5.2.1 FGF4 subfamily (FGF4/5/6) 
5.2.1.1 FGF4 
Evaluation of the conditions used in the reaction between FGF4 and PGO 
The efficiency of the reaction between PGO and the arginines in FGF4 was examined first, 
using Arg-C, a protease which specifically cleaves at the arginine amino acids and the resulting 
products were analyased by SDS-PAGE and silver staining (Fig 5.1). The process is described 
for FGF4 only, but this evaluation step was applied to all analysed FGFs (Supplementary Figs 
5.1-5). 
The reaction between FGF4 and PGO was initially tested in solution at room temperature and 
for 60 mins. The reaction products were subsequently subjected to cleavage by chymotrypsin 
as a control, and by Arg-C to be able to confirm the completion of the reaction (Fig 5.1A). 
There was no band detectable when FGF4 was incubated with chymotrypsin or Arg-C, 
demonstrating that the enzymes were active. When FGF4 was reacted with PGO, chymotrypsin 
was still able to cleave the protein, but Arg-C failed to do so (Fig 5.1A). These results 
demonstrated that all arginine residues exposed on the surface of FGF4 had reacted with PGO. 
Subsequently, the reaction between FGF4 and PGO was performed on the mini heparin affinity 
column (Fig 5.1B, C). The FGF4 eluted from the heparin affinity column remained sensitive 
to digestion by Arg-C (Fig 5.1B), showing that the arginine residues not engaged were now 
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exposed to solvent. The eluted FGF4 was then the subjected to a second reaction with PGO. 
The product of this reaction was then applied to a heparin affinity column, and it failed to bind 
(Fig 5.1C). The flow through fraction was then treated with chymotrypsin and Arg-C. A band 
at equivalent molecular weight and concentration as the protein in the flow through fraction 
was observed in the land of Arg-C cleave product (Fig 5.1C), demonstrating that all arginine 
residues of FGF4 had reacted with PGO (Fig 5.1C). Thus, while binding to heparin protects 
some arginine residues, once the protein was eluted it did not affect their reaction with this 
dialdehyde. 
Selective labelling of arginine residues on FGF4 
Solvent-exposed arginine residues in heparin-bound FGF4 were protected with PGO and, 
following elution of the FGF4, arginine side chains engaged with the polysaccharide were 
labelled with HPG. After processing the protein, chymotryptic peptides were generated and 
analysed by MALDI-TOF mass spectrometry. The resulting peptides with information about 
modification, sequence, and final m/z are presented in Tables 5.2A and 5.2B and the spectra 
are in Supplementary Figs 5.1A and 5.1B. 
Prospector 
Using the list of peptides generated by Prospector, ten modified-arginine-containing peptides 
were identified (Table 5.2A). N-terminal to β-strand I, R45 and R46 were found to be labelled 
by HPG (peptide 1 and peptide 5, Table 5.2A) and so engaged to heparin, whereas R57 reacted 
with PGO (peptide 8, Table 5.2A), so was not involved in binding to heparin. R82, R84 and R85 
are close on the sequence, but the corresponding peptide possessed one HPG and two PGO 
products (peptide 2, Table 5.2A), indicating that only one of them was engaged to heparin. 
Neither R103 nor R112 were bound to heparin, since peptide 7 had two PGO products (peptide 
7, Table 5. 2A). There were three peptides containing R123 and R134 in their sequence, peptides 
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4, 6 and 9 (Table 5. 2A). They all showed one modification by PGO and one by HPG, indicating 
that one arginine was bound to heparin and one was solvent exposed. However, R134 is uniquely 
in peptide 3, which possessed just the product of the PGO reaction. Together, this indicated 
that R123 bound to heparin, but R134 did not. Located in the highly conserved area of the 
canonical HBS-1 is R192, which, as expected, reacted with HPG (peptide 10, Table 5. 2A), and 
thus was engaged to heparin. 
Peptide Mass (ExPASY) 
In contrast to Prospector, Peptide-Mass predicted eight peptides (Table 5.2B) (Supplementary 
figure 1B) and the binding status of arginine residues was consistent with that predicted by 
Prospector (Table 5.2A), although peptides containing R192 and R57 were missing. Thus, 
peptide 1 (Table 5.2B), which contained R45 and R46, was found to carry two HPG molecules, 
indicating that both arginine residues were engaged to heparin. One of three arginine residues, 
R82, R84 and R85 of the β-strand I reacted with HPG (peptides 2 and 6– Table 5.2B), whereas 
the other two reacted with PGO, due to the observed mass shifts of two PGO reaction products. 
R103 and R112 reacted with PGO, so were exposed to the solvent and not involved in binding to 
heparin (peptide 4, Table 5.2B). R123 in the loop between β-strands IV and V (peptides 3, 5, 7 
and 8, Table 5. 2B) reacted with HPG, hence were bound to heparin.  
Organisation of HBSs 
The original analyses of FGF1 and FGF2, using peptide mapping and mutagenesis indicated 
that the core of the canonical HBS-1 was located in the loop between β-strands X and XI, 
through β-strand XI until the loop of β-strands XI–XII [100], [143], [144]. Subsequent work, 
including X-ray crystallography and NMR confirmed this [29] [148]. Sequence alignment 
showed that this region was very basic in all the paracrine FGFs. The analysis of the lysine 
residues using the protect and label method led to the canonical heparin binding site, which 
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encompasses this region being called HBS1, with secondary binding sites in FGFs labelled 
HBS2-4 [36] [102]. In the case of FGF4, it was considered to have, in addition to the canonical 
HBS1, a secondary HBS, HBS3, situated towards the N-terminus of the beta-trefoil structure 
[102]. 
Thus, previous work demonstrated that HBS1 comprised  K183, K186, K188 and K189 in the core 
along with K142 and K144 on the loop of β-strands VI – VII and K173 [37] (Fig 5.2F). Even 
though distant in the sequence, the labelled R123 in the loop between β-strands IV – V loop is 
adjacent to K158 on the surface (Fig 5.2B, C), suggesting that this arginine also belongs to HBS-
1.  Thus, the present work adds R123and R192 to HBS1 (Figs 5.2A, F).   
FGF4’s secondary HBS, HBS3, was considered to comprise K81 in β-strand I (Fig 5.2B, C) and 
K158 in β-strand VIII (Fig 5.2B). One of three arginine residues, R82, R84 or R85 of β-strand I 
reacted with HPG (peptide 2– Table 5. 2A and peptide 2 and 6– Table 5. 2B). Of these, R82 is 
adjacent to both K81 and R123, which indicates that R82 is most likely the one to have reacted 
with HPG and it would then belong to the same HBS (Fig 5.2B, C). Inspection of the surface 
charge distribution shows some acidic areas between HBS1 and what was defined as HBS3 
(Fig 5.2 A, B, C), which is what led to the original assignment of K81 and K158 to HBS3 [37]. 
However, these acidic areas may not be able to truly separate these heparin binding regions on 
the surface of FGF4 (Fig 5.2E). Thus, although K158 of β-strand VIII (Fig 5.2B) is separated 
from to K173, assigned to HBS1 (Fig 5.2B, C) by an electronegative surface (Fig 5.2B, C), this 
is due to the peptide backbone and Y172 (Fig 5.2E), rather than a negatively charged amino acid 
side chain. It is unlikely to repel the negative charges on the sugar and may be able to interact 
through H-bonding with it. This implies that the sugar chain could bridge between K173 and 
K158 and so consequently it is likely that K158 and the adjacent K81 are both part of HBS-1. 
Moreover, many of the lysine and arginine side chains in FGF4 found to interact with heparin 
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protrude from the protein surface, which would reduce the effects of the backbone on sugar 
binding (Fig 5.2D). The alternative arrangement, whereby the polysaccharide chain binds on 
the other face of FGF4, bridging from the conserved area of HBS1 (K140, K188, K189 and R192) 
to K81 and R82 (Fig 5.2D) is not supported by the present data. Though there are three arginine 
residues R103, R112 and R134 in between these areas, they were all found to have reacted with 
PGO (R103, R112 (peptide 4, Table 5.2B) and R134 (peptide 3, Table 5.2A)), and so were not 
involved in binding heparin. 
Therefore, there is only one way the polysaccharide can bind FGF4, and the most parsimonious 
explanation is that the residues previously assigned to HBS3 are in fact an extension of HBS1. 
This would require the sugar chain to bend around the protein, which is seen in a crystal 
structure of a heparin decasaccharide with FGF1 [201] and in the interaction of HS with VEGF 
[205] [83] and IFN-gamma [206]. 
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Figure 5.1: Selective labelling of arginine residues in the heparin binding sites of FGF4.  
The reaction of PGO with FGF4 in the dark, at room temperature (~25 oC) for 60 min. The 
efficiency of the reaction was evaluated by cleavage of chymotrypsin and Arg-C (incubation 
at 37 °C overnight). Equal amount of protein were then analysed by SDS-PAGE. A) The 
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analysis of the products of reaction of FGF4 in solution with PGO by Arg-C digestion. 
FGF4 (~10 µg) was reacted in solution with 200 mM PGO (Right panel). Lane 1: The native 
FGF4, 1/10 equivalent of that used in the reaction; lane 2: 1/10 of the FGF4 after the reaction 
with 200 mM PGO; lane 3: products of the digestion of 1/10 equivalent of native FGF4 by 
chymotrypsin (Chy); lane 4: products of the digestion by chymotrypsin of 1/10 equivalent of 
PGO-reacted FGF4; lane 5: products of the digestion by Arg-C of 1/10 equivalent of native 
FGF4; lane 6: products of the digestion by Arg-C of 1/10 equivalent of PGO-reacted FGF4. B) 
Analysis of the products of reaction of FGF4 bound to a heparin affinity column with 
PGO. FGF4 (~10 µg) was applied to a heparin affinity mini column. The flow through (FT) 
was collected then PGO (200 mM) was applied. The eluate was then subjected to digestion 
with Arg-C and Chy (Right panel). Lane L, 1/10 equivalent of the protein loaded onto the 
column; lane FT, 1/10 equivalent of the flow through fraction; lane W, 1/10 equivalent of the 
fraction washed with Na-1 buffer; lane PGO PROTECT FT, flow through fraction after the 
reaction between FGF4 and PGO; lane PGO PROTECT E, Eluate from the column with Na-2 
buffer; lane PGO PROTECT 1: the protein in the elution after incubation with chymotrypsin; 
lane PGO PROTECT 2: the protein in elution after incubation with Arg-C. C) Analysis of 
PGO reacted with arginine residues in binding sites of FGF4. FGF4 bound to heparin (panel 
B, fraction PGO PROTECT E) was reacted with 200 mM PGO for 60 min, then the product 
from this second reaction was loaded onto a new heparin affinity mini-column. Lane FT, 1/10 
equivalent of the flow through from the mini-column; lane W, 1/10 equivalent of the wash with 
Na-1 buffer; lane E, 1/10 equivalent of elution with buffer Na-2; lane FT 1, 1/10 equivalent of 
the FGF4 from the FT fraction after incubation with chymotrypsin; lane FT 2, 1/10 equivalent 
of the FGF4 from the FT fraction after incubation with by Arg-C. 
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Figure 5.2: Heparin binding arginine and lysine residues in FGF4. 
The FGF4 structure (PBD code 1ijt [207]) is shown as a surface. The electrostatic potential of 
FGF4 was computed using the Poisson-Boltzmann algorithm in Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
lysine residues from [102] are presented as yellow. Labelled arginine residues (Tables 5.2A, B) 
are coloured green. This colour scheme for electrostatic potential is used throughout. A) The 
position of R192 (peptide 10, Table 5. 2A) relative to the core canonical HBS-1 K189, K188, K186, 
K183, K144 and K142 [102]. B) Location of R123 (peptide 4, 6 and 9, Table 5. 2A) (peptides 3, 5, 
7 and 8, Table 5. 2B) and R82 (peptide 8, Table 5. 2A) (peptides 2 and 6– Table 5. 2B) along 
with K158 and K81 previously assigned to HBS-3 are shown on the surface. C) The surface 
between K173 and the core HBS-1 is positively charged, whereas the surface between K173 and 
K158 is negatively charged. D) K81 and R82 are separated from K189, K188, K142 and R192 of HBS-
1 by a positively charged area, and these side chains protrude from protein surface. E) The 
electronegative path between K158 and K173 has no acidic residues but a tyrosine side chain, 
Y172. F) Sequence, secondary structure and location of labelled arginine and lysine 
residues. Uniprot ID of FGF4 sequence is P08620-1. Labelled arginine and lysine [102] 
residues are coloured in red and blue, respectively and the protected arginine residues are 
green. The HBSs assigned in reference [102] are highlighted in red boxes. The β strands are 
presented as arrows. This colour scheme for heparin engaging basic residues is used throughout 
the thesis. 
5.2.1.2 FGF6 
N-terminal to β-strand I are R60 and R62, which were both modified by HPG (peptides 1 and 6, 
Table 5. 3A and peptide 1, Table 5. 3B). Adjacent are R84, R86 and R87 in peptide 3 (Tables 
5.3A, B), which possessed two products from reaction with PGO and one product from reaction 
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with HPG, indicating that only one of these arginines was engaged to heparin. The same was 
observed in FGF4, as these four residues “KR(L/Q)RR” are conserved between these two 
FGFs. Hence, it is likely that as in FGF4, R84 of FGF6 engages with heparin. One of R125 or 
R134 was found to have reacted with HPG and the other with PGO (peptide 7, Table 5.3A and 
peptide 8, Table 5.3B). On the loop from β-strand X to β-strand XII, two arginine residues, 
R188 and R191, reacted with HPG (peptide 4 – Table 5.3A and peptides 4, 7- Table 5.3B), hence 
interacted with heparin. R205 of the disordered C-terminus (peptide 2, tables 3A and 3B) was 
also bound to heparin, since it was modified by HPG. 
Organisation of HBSs 
As for FGF4, previous lysine selective labelling and sequence alignment were interpreted to 
indicate that FGF6 had a canonical HBS1 and a secondary HBS3, N terminal to beta strand 1 
[37]. The current data add five arginine residues to the HBSs of FGF6, and the independence 
of the residues previously assigned to HBS3 from HBS1 seems less likely. The HBS1 of FGF6 
according to previous work (Figure 3A) comprises K185, K190, K194 of β-strand X – β-strand XI 
[37]. Located in this region and so part of this canonical binding site are two arginine residues 
R188 and R191 (Fig 5.3A, F). K144 of β-strand VII is next to R191 (Fig 5.3A, E) and was also 
previously assigned to HBS-1 [37]. 
Between K185 of HBS-1 and R205 is a positively charged surface (Fig 5.3C) and the distance 
between R205 and K185 is 2.4 nm, which is just over a tetrasaccharide. These observations 
suggest that R205 is likely part of HBS-1. There is also a basic path running from R188 of HBS-
1 to K83 (Fig 5.3C), but arginine residues (R134, R146 (peptide 5, Table 5.3A, B)), which lie 
along this path were protected rather than labelled. Thus, the polysaccharide is unlikely to 
engage FGF6 in this orientation. Neighbouring R205 on the surface are K83 and R84 (Fig 5.3D). 
K83 was previously assigned to HBS-3 [37], however, with the addition of R205 and R84 to 
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HBS1, this lysine should be reallocated to HBS-1. On the same basic surface with K83 and R84 
is R125 of β-strand V (Fig 5.3D), indicating that R125 belongs to HBS-1 as well. R125 and K158 
are close on the surface (Fig 5.3D), hence heparin can interact with both R125 and K158. K158 of 
β-strand VIII is separated from K144 and K194 of HBS-1 by an acidic border (Fig 3B), which 
was one reason for its assignment to HBS3 [37]. Here, there is a major difference between 
FGF4 and FGF6 in this area, since in FGF4 is the basic K173 of β-strand IX, but in FGF6 an 
acidic D174 is present. Thus, FGF6 has a true acidic border on this part of its surface. However, 
K158 could be connected to HBS-1 from the opposite direction through R125 as mentioned 
above, making this lysine part of HBS-1. Moreover, the side chains of R205, R84, R125 and K158 
protrude from protein surface (Fig 5.3B, C, D). Consequently, the simplest assignment of 
labelled residues to HBSs in FGF6 is that those residues previously assigned to HBS3 are in 
fact an extension of HBS1. A single long HBS1 is consistent with FGF6 and FGF4 requiring a 
DP12 for binding (length ~ 6 nm) [37]. Moreover, this conclusion supports the measurement 
of crosslinking of HS brushes [126] performed on FGF6, which was found not to cross-link 
HS chains, a property which is thought to require at least two independent HBSs [203]. 
Unassigned are R60 and R62 in the N-terminus of FGF6, which cannot be included in a structural 
model, as the corresponding template, FGF4 [207], does not include this part of the protein.  
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Figure 5.3: Heparin binding arginine and lysine residues in FGF6. The surface of FGF6 is 
generated on the FGF4 crystal structure (PDB code: 1ijt [207]). The electrostatic potential of 
FGF6 was computed using the Poisson-Boltzmann algorithm in Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
lysine residues from [102] are presented as yellow. Labelled arginine residues (Tables 3A, B) 
are coloured green. This colour scheme for electrostatic potential is used throughout. A) The 
position of R188 and R191 (peptide 4 – tables 3A and peptide 4, 7- Table 5.3B) relative to the 
core canonical HBS-1 K144, K185, K190 and K194 [102]. B) Location of R125 (peptide 7, Table 
5.3A and peptide 8, Table 5.3B) and R84 (peptide 3 (Table 5.3A, B)) along with K83 previously 
assigned to HBS-3 are shown on the surface. C) Location of R205 of the disorder C-terminus 
(peptide 2, tables 3A and 3B) is shown on the surface. The surface between R205 and the core 
of HBS-1 is positively charged. The distance between R205 and K185 of HBS-1 is presented. D) 
K158 and R125 are separated from K83, R84 and R205 of the extended area of HBS-1 by a positively 
charged area. E) Sequence, secondary structure and location of labelled arginine and 
lysine residues. Uniprot ID of FGF6 sequence is: P10767-1. Labelled arginine and lysine [102] 
residues are coloured in red and blue, respectively and the protected arginine residues are 
green. The HBSs assigned in reference [102] are highlighted in red boxes. The β strands are 
presented as arrows.  
5.2.1.3 FGF5 
FGF5 has not previously been analysed. Consequently, both lysine and arginine targeted 
protect and label were performed on the protein. 
Lysine 
Located N-terminal to β-strand I are K24 (peptide 3, Table 5.4C) and K29 (peptide 8, Table 
5.4C), which were biotinylated, indicating their engagement to heparin. Peptide 1 (Table 5.4C) 
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possessed three lysine residues, K146, K147 and K149 on the loop of beta-strands VI-VII and all 
were biotinylated, indicating that these bound to heparin. Similarly, K194, K197 and K199 in the 
area covering the loop of beta-strands X-XI through to β-strand XI and the loop of β-strands 
XI–XII all reacted with NHS biotin (peptide 9, Table 5.4C). K183 (peptide 6, Table 5.4C) was 
found to react with NHS-biotin, indicating its engagement to heparin. K220 located at the end 
of β-strand XII was also engaged to heparin as observed in peptide 4 (Table 5.4C). Finally, on 
the disordered C-terminus, K254 and K260 (peptide 5, Table 5.4C) were both biotinylated, 
indicating their binding to heparin. 
Arginine 
Adjacent to K24 described above is R25, which reacted with HPG, so was also engaged to 
heparin (peptide 4, Table 5.4B). On β-strand I, there were two labelled residues R86 and R87 
(peptides 2, 7 and 8, Table 5.4A) (peptide 5, Table 5.4B). Next in the sequence are R163 and 
R165 in β-strand VIII, which both bound to heparin (peptides 3 and 4, Table 5.4A) (peptide 2, 
Table 5.4B). On the loop of β-strands IX-X, R180 and R186 (peptide 5, Table 5.4A) (peptide 7, 
Table 5.4B) were found to react with HPG, indicating interaction with heparin. Two arginine 
residues R195 and R200, both reacted with HPG (peptides 9 and 10, Table 5.4A) (peptide 8, 
Table 5.4B), following by R218 (peptide 1, Table 5.4B). Lastly, on the disordered C-terminus, 
R253, R262 and R266 (peptide 1 and 6, Table 5.4A) all interacted with heparin, since peptides 1 
and 6 possessed the mass shift of 3 HPG modifications. 
Organisation of HBSs 
There is no prior study on the binding sites of FGF5 to sulfated GAGs, and the only information 
is the prediction on the basis of sequence alignment with FGF4 and FGF6  [37]. Hence, with 
the data on lysine and arginine residues that were bound to heparin presented here, the 
identification of heparin binding sites on FGF5 was addressed for the first time. There is also 
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no crystal structure of this FGF, consequently, a template had to be selected for the modelling 
of FGF5 surface. It is actually challenging, because unlike other FGFs (except FGF3), there is 
a controversy in the classification of FGF5 in the FGF4 or FGF2 subfamily [9]. Consequently, 
two model structures of FGF5 were built, using the crystal structure of FGF2 (4oee) (Fig 5.4A) 
and FGF4 (1ijt) (Fig 5.4B) as templates.  
The core of HBS1 is well conserved across the FGF family and locates in the loop of β-strand 
XI and β-strand XII. Hence, K194, R195, K197, K199 and R200 together delineate the core of FGF5’s 
HBS-1 (Fig 5.4A, B). Vicinal to this area on the surface are K146, K147 and K149 on the loop of 
beta-strands VI-VII. This indicates that these lysine residues are part of HBS-1 (Fig 5.4A, B).  
R180, K183 and R186 on the loop between β-strand IX and β-strand X together with R163 and R165 
of β-strand VIII form a cluster of basic amino acids (Fig 5.4A, B). However, in this area, the 
two model structures differ substantially in the loop between β-strands IX and X, which 
includes R180, R186 and K183 (Fig 5.4A, B). The orientations of those three residues differ, and 
of these, R180 is the most different (Fig 5.4A, B). This loop in FGF4 and FGF6 is relatively 
short (only 2 amino acids) (Fig 5.2F, Fig 3E) compared to that of FGF5 (10 residues) (Fig 
5.4D) and FGF2 (5 amino acids) or FGF1 (7 amino acids). In the model built on the FGF4 
template the side chains of R180, R186 and K183 are closer to each other than in the model built 
on the FGF2-template (Fig 5.4C). Indeed, HBS-2 of FGF2 covers areas of the loop of β-strand 
IX-X with R118 (Section 4) with K119 being labelled [120], which is consistent with the labelling 
of R180, R186 and K183 in FGF5. Thus, for this part of the FGF5 model the FGF2 template is 
likely to be a better approximation. Despite the differences mentioned above, this cluster of 
basic amino acids is likely part of HBS-1. In the model built from the FGF4 template, there is 
no acidic border between this cluster and the area of HBS-1 mentioned above (Fig 5.4B), so 
they form a single, contiguous binding site. Engaging these residues would require the sugar 
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chain to bend around the protein, which would be helped by the fact that, as in FGF4, the side 
chains of many labelled lysine and arginine residues protrude from protein surface (Fig 5.4B). 
In the model built from the FGF2 template, there is an acidic pocket in between the area of 
HBS-1 with K146, K147, and R180, R186 and K183 of FGF5. Since this pocket is formed by E182 
and E187, it likely blocks the path of the sugar chain. However, between R163, R165 and R195, 
R200 is an electropositive surface (Fig 5.4A), indicating no barrier for sugar chain. Indeed, in 
this model, R180 protrudes dramatically on the surface (Fig 5.4A), supporting the notion that a 
sugar chain could be able to reach the side chain of this arginine. Thus both models are 
consistent with these residues being an extension of HBS1. 
R218 neighbours to R86, R87 in β-strand I, and together, they form another cluster of basic 
residues (Fig 5.4A, B). Moreover, the surface between this cluster and the cluster of R163, R165, 
R180, K183 and R186 is positively charged, so presenting no barrier to a heparin chain. The two 
clusters are parallel to each other, separated by 2.25 nm (for FGF4-template model) and 2.8 
nm (for FGF2-template model) and one polysaccharide chain would be unlikely to engage both 
of them at the same time, due to the limitations of torsion angles around the glycosidic bond 
[208] [209]. The space between R218 and the edge of HBS-1(R195) is electropositive (Fig 5.4A, 
B), however, located there are two protected residues (R205 and K207), indicating that the 
polysaccharide does not engage to this area. Thus, it could be proposed that R218, R86, R87 are 
independent of HBS-1, and their position in sequence would mean they form an HBS-3 [120]. 
The neighbour of R218 on the surface, K220 would then also be part of HBS-3.  
K24, R25, and K29 are N-terminal to β-strand I and cannot be modelled on the template structure 
of FGF4 [207], which lacks the corresponding residues. Given the position of these residues in 
sequence, they may be part of HBS-3. In the β trefoil structure of FGFs, the C- and N-termini 
are vicinal. Consequently, R253, R262, K254, K260 and R266 in the C-terminus are assigned to 
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HBS-3. Whether the HBS3 of FGF5 is indeed large, as suggested by the above, or the folding 
of the N- and C-termini enable a single chain of the polysaccharide to bind to the residues 
assigned above to HBS1 and/or HBS2 remains to be determined. This could be done through 
measuring the interaction of FGF5 with an HS brush to determine if it is able to cross link HS 
chains [126] [203]. 
FGF5 has a long N-terminal that extends well beyond β-strand I of the β-trefoil structure and 
possesses the longest C-terminal tail of the FGF family. The function of C-terminus is not 
understood, but the present data suggest that it interacts with heparin and it is at least involved 
in binding HS. 
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Figure 5.4: Heparin binding arginine and lysine residues in FGF5. 
The surface of FGF5 is generated on the templates of FGF2 (PDB code: 4oee [210]) and FGF4 
crystal structure (PDB code: 1ijt [207]) The electrostatic potential of FGF5 was computed 
using the Poisson-Boltzmann algorithm in Swiss-PDBView with the positively charged areas 
coloured blue and the negatively charged areas coloured red. Labelled lysine residues (Table 
5.4C) are presented as yellow. Labelled arginine residues (Tables 4A, B) are coloured green. 
A) The locations of heparin binding arginine and lysine residues in FGF5 on the surface 
generated from FGF2 template. The positions of R195 and R200 (peptides 9 and 10, Table 5.4A) 
(peptide 8, Table 5.4B) of HBS-1 are presented on the surface. The lysine residues of HBS-1 
are K146, K147, K149 (peptide 1, Table 5.4C), K183 (peptide 6, Table 5.4C), K194, K197 and K199 
(peptide 9, Table 5.4C). On the surface, residues of HBS-2 R163 and R165 (peptides 3 and 4, 
Table 5.4A) (peptide 2, Table 5.4B) and R180, R183, R186 (peptide 5, Table 5.4A) (peptide 7, 
Table 5.4B) are shown. The labelled residues on the N-terminus R86, R87 (peptides 2, 7 and 8, 
Table 5.4A) (peptide 5, Table 5.4B) and on C-terminus R218 (peptide 1, Table 5.4B) and K220 
(peptide 4, Table 5.4C) are presented. B) The locations of heparin binding arginine and lysine 
residues in FGF5 on the surface generated from FGF4 template. The orientations of the surface 
were maintained the same as for FGF2 template. C) The superimposition of two FGF5 models 
generated from FGF2 and FGF4 templates. Residues of HBS-2 including R180, R183, R186 are 
highlighted for comparison. D) Sequence, secondary structure and location of labelled 
arginine and lysine residues. Uniprot ID of FGF5 sequence is P12034-1. 
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5.2.2 FGF9 subfamily (FGF9/16/20) 
The lysine residues contributing to heparin binding in FGF9 and FGF20 have previously been 
determined [37] and suggest that this family may possess a single extended HBS1, with FGF20 
potentially having a single, isolated lysine forming a secondary HBS. 
5.2.2.1 FGF9 
Reacting with HPG and thus bound to heparin in FGF9 were: R173, R177 and R180 (peptide 11, 
Table 5.5A) (peptide 7, Table 5.5B) on the loop of β-strands X to XII; R160 and R161 on the 
loop between β-strands X-XI (peptide 4 and 8, Table 5.5A) (peptide 5, Table 5.5B); R137 on β-
strand VIII (peptide 3, 7, Table 5.5A) (peptide 4, Table 5.5B); R108 on β-strand V (peptide 3, 
Table 5.5B); R91 on the loop of beta-strands III-IV and R86 on β-strand III (peptide 10, Table 
5.5A) (peptide 6, Table 5.5B); R62, R63 and R64 on β-strand I (peptide 2 and 5, Table 5.5A) 
(peptide 2, Table 5.5B). 
Organisation of HBS 
The area covering the loop between β-strands X and XI, β-strand XI and the loop from β-
strands XI to XII is the core of the canonical HBS-1. Together with the previous data on 
labelled lysine residues and sequence alignment of all FGFs, it could be concluded that R173, 
R177, and R180, along with K154, K168 and K179 belong to HBS1 [36]. On the surface, R160, R161, 
and R137 are adjacent to lysines previously assigned to HBS-1 (K154 and K179) [36] and R180 
mentioned above (Figure 5A), indicating that they are in the canonical HBS1 as well. These 
results are supported by the co-crystal structure of FGF9 with the mesenchymal “c” splice 
isoform of FGFR1 [211]. In this structure, R173 and R177 were bound to a sulfate group, and 
R180, R160, R161, R137, and K154 interact with other two sulfate groups (Fig 5.5D). On the other 
side of surface are K87 of HBS-1 which was biotinylated in the previous work [36] and its 
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neighbours R86 and R91 which were labelled by HPG, and all of them are also close to the 
canonical binding site. Thus, these residues are most likely an extension of HBS-1 (Fig 5.5B). 
On β-strand I are located three arginine residues, R62, R63 and R64, which all reacted with HPG 
(peptide 2 and 5, Table 5.5A) (peptide 2, Table 5.5B). These arginines occupy a position 
analogous to HBS3 in other FGFs, for example, FGF2 [120]. However, they are not separated 
from HBS-1 by an acidic border (Fig 5.5C), but an intervening electropositive surface. Indeed 
these residues, with those assigned to HBS-1, are part of a continuous basic surface on FGF9. 
On this basic surface, there is also the labelled R108, indicating that this arginine is part of HBS-
1. This surface requires the polysaccharide to bend considerably since it is not flat. Heparin, 
due to its many N-sulfated glucosamines and so S-domains of HS, has been considered to be 
relatively rigid [92]. However, a co-crystal of FGF1 and a heparin decasaccharide (1AXM) 
[97] indicated that this is not always the case. Moreover, a single N-acetylated glucosamine 
will enable the sugar chain to bend considerably. Thus, a single very extended HBS-1 on FGF9 
could indeed bind a single chain of HS. This is supported by the demonstration that in a HS 
brush, FGF9 cannot crosslink HS chains, unlike FGF2, which has three independent HBSs 
[202]. 
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Figure 5.5: Heparin binding arginine and lysine residues in FGF9. 
The FGF9 structure (PBD code 5w59 [212]) is shown as a surface. The electrostatic potential 
of FGF9 was computed using the Poisson-Boltzmann algorithm in Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
lysine residues from [36] are presented as yellow. Labelled arginine residues (Tables 5A, B) 
are coloured green. A) The positions of R137 (peptide 3, 7, Table 5.5A) (peptide 4, Table 5.5B), 
R160, R161 (peptide 4 and 8, Table 5.5A) (peptide 5, Table 5.5B), R173, R177 and R180 (peptide 
11, Table 5.5A) (peptide 7, Table 5.5B) on the surface relative to K154, K168 and K179 [36] B) 
The positions of R86 and R91 (peptide 10, Table 5.5A) (peptide 6, Table 5.5B) relative to K87 
[36] and K196 [36] C) The positions of R62, R63 and R64 (peptide 2 and 5, Table 5.5A) (peptide 
2, Table 5.5B) as well as R108 (peptide 3, Table 5.5B) on the surface. D) The interactions of 
R161, R177 and R180 with the sulfate groups in the crystal structure E) Sequence, secondary 
structure, location of labelled arginine and lysine residues in heparin-binding sites. 
Uniprot ID of FGF9 sequence is: P31371. 
5.2.2.2 FGF20 
In FGF20, HPG labelled arginine residues were found as follows: R176, R180 and R183 on the 
core of the canonical HBS-1 (peptide 8 and 9, Table 5.6A) (peptide 9 and 10, Table 5.6B); R163 
and R164 on β-strand X (peptide 4 and 7, Table 5.6A) (peptide 4, 7 and 8, Table 5.6B); R140 on 
β-strand VIII (peptide 3, Table 5.6A); R111 on β-strand V (peptide 6, Table 5.6A) (peptide 3, 
Table 5.6B); R89 in β-strand III (peptide 11, Table 5.6B); R72 on the loop between β-strands I-
II (peptide 2, Table 5.6A) (peptide 2 and 11, Table 5.6B); in the disordered C-terminus, R199 
(peptide 12, Table 5.6B); and 65RRR67 in β-strand I (peptide 1, Table 5.6A and B). 
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Organisation of HBS 
In the core of the canonical HBS-1, which covers the loop from β-strand X to XI, through β-
strand XI to the loop of β-strands XI–XII, all basic residues engage to heparin, K171, K182 [37] 
and R176, R180, and R183. R163 and R164 of β-strand X are adjacent to K182 and R183, hence they 
are part of HBS-1 (Fig5.6A). Next to R163 is R140 on β-strand VIII, followed by K157 of the β-
strand IX [37], so both will contribute to the canonical binding site (Fig 5.6A). In the other 
direction on the surface, close to K171 are R72 in the loop between of β-strands I-II and R89 in 
β-strand III, implying that they are also likely an extension of HBS-1 (Fig 5.6B). At the C-
terminus, because of R199 is close to R89, it too is in HBS-1 (Fig 5.6A). 
One feature of FGF20 highlighted previously is K124, which was previously identified as a 
possible independent heparin binding site [37], because it was surrounded by an acidic surface. 
However, this seems unlikely. K124 is adjacent to R180 (Fig 5.6F), which is identified here as 
heparin binding, and is bound to a sulfate ion in an FGF20 crystal structure (PBD code 3f1r 
[42]), supporting its interaction with the polysaccharide. K124 and R180 both protrude from the 
protein surface, whereas the intervening acidic patch is recessed (Fig 5.6D). Thus, it seems 
most likely that K124 is an extension of the canonical HBS1 of FGF20. 
The biotinylated K132 on the loop of β-strands VII–VIII is quite close to HPG labelled R111 on 
the β-strand V and also 65RRR67 in β-strand I (Figure 5.6C), hence they may form an HBS-3. 
Between these residues and the HBS-1 are three acidic amino acids E141, E144 and E145 forming 
an acidic border (Fig 5.6C). The sequence alignment showed that all but one labelled arginine 
of FGF20 are in the equivalent positions to those identified in FGF9 (Figure 5E and Figure 
6D), it could be expected that the assignment of these residues into HBSs is identical to that of 
FGF9. However, in FGF9 the heparin-binding R91 on the loop of beta-strands III-IV provides 
a means for the sugar chain to bridge the acidic residues, whereas in FGF20 this arginine is 
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replaced by a leucine. Consequently, this single change in the sequence may result in FGF20, 
unlike FGF9, possessing a truly independent HBS3. 
One issue relating to the involvement of R65, R66 and R67 and heparin binding is that in the 
crystal structure of FGF20 (PBD code 3f1r [42]), the proposed dimer interface includes R65, 
R66 and R67 (Fig 5.6E). It is known that FGF20 exits as a homodimer in solution [37], however, 
the side chains of these arginines cannot be buried in a dimer interface, since here they were 
found to bind react with HPG (peptide 1, Tables 5.6A and B). This observation suggests that 
FGF20 forms a monomer upon heparin binding or that the interface of the dimer in solution 
[37] differs from that in the crystal structure. The alternative, that the dimer dissociates at the 
high concentrations of electrolytes used to release the FGF20 from the heparin column seems 
unlikely, since these arginine residue in the crystal structure are involved in H-bonds with the 
backbone (Val 195) and π- stacking interactions with aromatic residues Trp147 and Tyr148.  
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Figure 5.6: Heparin binding arginine and lysine residues in FGF20. 
The FGF20 structure (PBD code 3f1r [42]) is shown as a surface. The electrostatic potential of 
FGF20 was computed using the Poisson-Boltzmann algorithm in Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
lysine residues from [102] are presented as yellow. Labelled arginine residues (Tables 6A, B) 
are coloured green. A) The positions of basic residues R163, R164 (peptide 4 and 7, Table 5.6A) 
(peptide 4, 7 and 8, Table 5.6B), R176, R180 and R183 (peptide 8 and 9, Table 5.6A) (peptide 9 
and 10, Table 5.6B) relative to K171, K182 defined in [102] on the surface. B) The positions of 
basic residues R89 (peptide 11, Table 5.6B), R72 (peptide 2, Table 5.6A) (peptide 2 and 11, 
Table 5.6B) and R199 (peptide 12, Table 5.6B) relative to K171 [102] on the surface. C) The 
positions of basic residues R140 (peptide 3, Table 5.6A) relative to K157 [102]. Moreover, the 
positions of R111 (peptide 6, Table 5.6A) (peptide 3, Table 5.6B), 65RRR67 (peptide 1, Table 
5.6A and B) and K132 [102] on the surface D) The position of K124 [102] and its neighbour 
residues R176, R180 as well as the surface between them. E) The dimer interface of FGF20 with 
the positions of 65RRR67. F) The distance between K124 [102] and R180. G) Sequence, 
secondary structure, location of labelled arginine and lysine residues in heparin-binding 
sites. Uniprot ID of FGF20 sequence is: Q9NP95.  
5.2.2.3 FGF16 
Selective labelling of lysine had not been previously established for FGF16. In this study, five 
lysine residues were found to be biotinylated, indicating their interaction with heparin, and all 
of them are assigned to the canonical HBS-1. They are K153 on β-strand IX (peptide 2, Table 
5.7C), K167 on the loop between β-strands X-XI (peptide 1, Table 5.7C), K178 and K182 on the 
loop between β-strands XI-XII (peptide 4, Table 5.7C) and K195 at the C-terminus (peptides 4, 
Table 5.7C).  
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Twelve arginine residues were labelled, comprising R107 in β-strand V (peptide 8, Table 5.7A) 
(peptides 11, 13, Table 5.7B); R136 in β-strand VIII (peptide 3, Table 5.7A) (peptide 4, Table 
5.7B); R159 of β-strand X (peptide 8, Table 5.7B); R172, R176 and R179 on the loop of β-strands 
XI-XII (peptides 2, 6 and 7, Table 5.7A) (peptides 3, 6, 9 and 14, Table 5.7B); 61RRR63 in β-
strand VII; R85 in β-strand III (peptide 1, Table 5.7B); R90 on the loop between β-strands III-
IV (peptide 2, Table 5.7B); R131 on the loop of β-strands VII-VIII (peptides 3 and 10, Table 
5.7A) (peptides 4 and 7, Table 5.7B), (Figure 7B). 
Organisation of HBS 
Located in the core of the canonical HBS-1 are three lysine residues K167, K178 and K182 , and 
three arginines R172, R176 and R179, which all were labelled (Fig 5.7A, B). Adjacent to R172 are 
R159 on β-strand X (Fig 5.7A) and R136, which is close to R176 of HBS-1, indicating that both 
are part of HBS-1 (Fig 5.7A). R131 neighbours to R136, hence this residue is part of HBS-1. The 
engagement of HBS-1 continues with R107, R62, R63, R90 and K195 (Fig 5.7C, D), as they are all 
adjacent to the preceding HBS-1 residues and close to each other. Lastly, R85 of β-strand III is 
separated from R90 by a positively charged surface, and on the other side it is near K167 (Fig 
5.7D), indicating that this arginine is an extension of HBS-1 also. Thus, it appears that similar 
to FGF9, FGF16 possesses a single, large HBS-1, which would bind a single sugar chain. 
Owing to the lack of a crystal structure, the model of FGF16 was built on the templates of both 
FGF9 and FGF20. Comparison of two models agree on the locations of R 61, R62, R63 at the 
dimer interface (Fig 5.7E), but the side chains of R61 point at different directions. Even though, 
R61 is not visible from the surface in the dimer structures, the present result demonstrates that 
this arginine side chain was labelled by HPG, so it cannot be buried. Hence, if FGF16 is a 
dimer similar to that of FGF20, FGF16 may form a monomer upon heparin binding or that the 
dimer interface in solution differs from that in the crystal structure. 
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Figure 5.7: Heparin binding arginine and lysine residues in FGF16. 
The FGF16 structure is modelled on the template of FGF9 crystal structure (PBD code 5w59 
[212]). The electrostatic potential of FGF16 was computed using the Poisson-Boltzmann 
algorithm in Swiss-PDBView with the positively charged areas coloured blue and the 
negatively charged areas coloured red. Labelled lysine residues (Tables 7C) are presented as 
yellow. Labelled arginine residues (Tables 7A, B) are coloured green. A) The positions of the 
basic residues in HBS1 R85 (peptide 1, Table 5.7B), R90 (peptide 1, Table 5.7B), R131 (peptides 
3 and 10, Table 5.7A) (peptides 4 and 7, Table 5.7B), R172 and R179 (peptides 2, 6 and 7, Table 
5.7A) (peptides 3, 6, 9 and 14, Table 5.7B) relative to K153 (peptide 1, Table 5.7C), K167, K178 
and K182 (peptide 2, Table 5.7C) on the surface B) The positions of the basic residues R136 
(peptide 3, Table 5.7A) (peptide 4, Table 5.7B), R176 and R179 (peptides 2, 6 and 7, Table 5.7A) 
(peptides 3, 6, 9 and 14, Table 5.7B) relative to K167, K178 on the surface. C) The positions of 
the basic residues 61RRR63 (peptide 1, Table 5.7B), R85 (peptide 1, Table 5.7B), R90 (peptide 2, 
Table 5.7B), R131 and R136 on the surface. D) The surface between  61RRR63, R85, R90, R131 and 
K128 to the core of HBS-1. E) The dimer interface of FGF16 with the positions of 61RRR63. F) 
Sequence, secondary structure, location of labelled arginine and lysine residues in 
heparin-binding sites. Uniprot ID of FGF16 sequence is: O43320. 
5.2.3 FGF8 subfamily (FGF8/17/18) 
5.2.3.1 FGF8 
FGF8 has not had its interactions with heparin analysed previously, and its HBSs were 
predicted based on alignment with the two members of this subfamily where heparin-binding 
lysines had been identified, FGF17 and FGF18 [36][37]. 
Reacting with NHS-biotin in FGF8 were: K71 on β-strand I; six lysine residues K112, K113, K115, 
K119, K123 and K125 (peptides 1 and 2, Table 5.8C) on the loop between β-strands VI-VII through 
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β-strand VII to the loop of β-strands VII–VIII;  K156, K161, K164 (peptide 6, Table 5.8C) and 
K176 (peptide 5, Table 5.8C) on the loop between β-strands X to β-strand XII. Hence, those 
residues contribute to the engagement of the protein to heparin. 
At the N-terminus R37 (peptide 2, Table 5.8A), (peptide 5, Table 5.8B), and R48, R49 and R52 
on the N-terminus and on β-strand I reacted with HPG (peptide 1 and peptide 8, Table 5.8A; 
peptide 5, Table 5.8B), hence interacted with heparin. On β-strand I, there are three HPG-
reacting arginine residues, R96, R98, and R100 (peptides 3 and 4, Table 5.8A) (peptide 1, 2 and 
7, Table 5.8B). R59 on the loop between β-strands I–II (peptide 6, Table 5.8B), R72 in β-strand 
III (peptides 5 and 11, Table 5.8A) (peptides 6 and 8, Table 5.8B) reacted to HPG. Finally, in 
the core of the HBS-1 are four heparin binding arginine residues R155, R158, R160 and R170 
(peptide 10, Table 5.8A). 
Organisation of HBS 
The sequence alignment of FGF8 with FGF17 and FGF18 predicted that the members of this 
subfamily possess the canonical HBS-1 and a secondary HBS-2. In FGF8, the core of the 
canonical HBS-1 comprises four arginine residues R155, R158, R160 and R170, and three lysine 
residues K156, K161 and K164 (Figure 8 A, B, E). K112, K113 and K115 on the loop between β-
strands VI and VII are adjacent to K161 and K164 (Figure 8A, B, E), indicating that they are part 
of HBS-1. This agrees with the sequence alignment with on FGF17 [36] and FGF18 [102]. 
Adjacent on the sequence, K119, K123 and K125 are distant from K112, K113 and K115 in the 
structure. However, there is no acidic barrier between these two groups of lysine residues, 
suggesting that they are an extension of the canonical HBS-1 (Figure 8A, B). Besides, scattered 
in the sequence, but likely part of HBS-1, are R59 on the loop between β-strands I–II, which is 
adjacent to R155 and R170 (Figure 8A), and R72 of β-strand III, which is close to K156 and R158 
(Figure 8A). Collectively these residues form a single HBS-1. Whereas the participation of R59 
180 
 
 
in heparin binding was expected from sequence alignment, that of R72 was not [36][37]. The 
participation of residues in β-strand VII and the loop between β-strands VII–VIII in binding 
heparin is only seen in this subfamily but not in others.  
The assignment based on the sequence alignment identified R49 in β-strand I, R100 on β-strand 
V, K176 in β-strand XII and R179 in C-terminus as forming a potential secondary HBS-2 in 
FGF8. However, R179 was not labelled, indicating that it is not involved in heparin binding. 
K176 is a neighbour of R170, located at the edge of HBS-1 (Fig 5.8C). The surface between these 
two residues is positively charged (Fig 5.8C), indicating the potential of this lysine as an 
extension of HBS-1. R48, R49 and R52 of β-strand I were all labelled and on the surface they are 
adjacent to K176 with no acidic border between them (Fig 5.8C). This observation implies they 
are part of HBS-1 rather than forming an independent HBS-2. On the other side of the surface, 
on β-strands IV and V are the HPG-reacting R96, R98 and R100. On the surface, R96 neighbours 
K123 and K125 of HBS-1 and R98 is adjacent to R48 and R49 (Fig 5.8D). R100 is isolated, but is 
located on the same electropositive surface as R96, R98, hence is likely part of HBS-1 (Fig 
5.8D). Thus, inspection of the surface charge shows no acidic barrier among all labelled 
residues of FGF8, which would appear to indicate that FGF8 has a single, large HBS1 rather 
than a secondary HBS-2.  
Taking the relative positions of all residues of HBS-1 under consideration indicated that the 
binding path of the polysaccharide on FGF8 results in an HBS-1 with a dogleg (Fig 5.8F). To 
clarify, a dogleg is composed of two paths, in which the longer part would consist of R155, R158, 
R160, R170, K156, K161 and K164 (Fig 5.8C, D, F) and the shorter part of R96, R48, R49, R52, R96, 
R98 and R100 (Fig 5.8C, D, F). Bear in mind that the dogleg is continuous and covers all residues 
above. The corner of the dogleg is formed by K125 and R98 (Fig 5.8F). The distance between 
these two residues is 0.5 nm. The polysaccharide may make a sharp bend by means of an 
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intervening GlcNAc residue or it may skirt around the bend, with a sulfate or carboxylic acid 
on the outer edge of the polysaccharide contacting by K125 and on the following saccharide an 
anionic group on the inside edge contacting R98. 
 
Figure 5.8: Heparin binding arginine and lysine residues in FGF8. 
The FGF8 structure (PBD code 2fdb [213]) is shown as a surface. The electrostatic potential 
of FGF8 was computed using the Poisson-Boltzmann algorithm in Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
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lysine residues (Tables 8C) are presented as yellow. Labelled arginine residues (Tables 8A, B) 
are coloured green. A) The positions of the basic residues R155, R158, R160 and R170 (peptide 10, 
Table 5.8A) along with the labelled K156, K161 and K164 (peptide 6, Table 5.8C) as well as K113, 
K115 (peptides 1 and 2, Table 5.8C) on the surface. B) The positions of K112, K113, K115, K119, 
K123 and K125 (peptides 1 and 2, Table 5.8C) together with R72 (peptides 5 and 11, Table 5.8A) 
(peptides 6 and 8, Table 5.8B) on the surface C) The positions of R37 (peptide 2, Table 5.8A), 
(peptide 5, Table 5.8B) along with R48, R49 and R52 (peptide 1 and peptide 8, Table 5.8A; 
peptide 5, Table 5.8B) on the surface. D) The locations of residues assigned to HBS-2 by the 
sequence alignment R100 (peptides 3 and 4, Table 5.8A) (peptide 1, 2 and 7, Table 5.8B), K176 
(peptide 5, Table 5.8C) in FGF8 surface. E. Sequence, secondary structure, location of 
labelled arginine and lysine residues in heparin-binding sites. Uniprot ID of FGF8 sequence 
is: P55075-3. F) The dogleg binding site formed by all the labelled basic residues of FGF8. 
5.2.3.2 FGF17 
Arginine residues of FGF17 that reacted with HPG were: R49 and R50 (peptide 5, Table 5.9A) 
(peptide 1, Table 5.9B) on the N-terminus and R60 (peptide 6, Table 5.9B) on the loop of β-
strands I-II; R96, R98 in β-strand V (peptide 5, Table 5.9B); R113 (peptide 1, Table 5.9A) in the 
loop between β-strands VI and VII; R145 in β-strand IX (peptide 4, Table 5.9A) (peptides 2 and 
4, Table 5.9B); R155, R158, R160, R164 and R166 in the core of the canonical HBS-1 (peptide 6, 
Table 5.9A) (peptide 8, Table 5.9B); R177 on β-strand XII (peptide 7, Table 5.9B). Therefore, 
these arginines all engage heparin. 
Organisation of HBS 
The prior study defined two HBSs for FGF17, the canonical HBS-1 and a secondary HBS-2 
[37]. First, with the canonical HBS-1, there are no lysine residues in the core of the canonical 
HBS-1, but only arginine residues, hence, the definition of this area was based on sequence 
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alignment data. This work confirmed that the core of the canonical HBS1 is in the area from 
the loop of β-strands X–XI to the loop of β-strands XI–XII,  and consists of five arginine 
residues, R155, R158, R160, R164 and R166 (peptide 6, Table 5.9A) (Figure 9B). The extended 
region of HBS-1 defined by previous work comprised five lysine residues, K112, K115, K119, 
K123, K125 [37] and the present work adds one arginine residue, R113 (Fig 5.9A, D) to this cluster. 
R145 of the β-strand IX is adjacent to K125 (Fig 5.9A) and R98 is next to K123 (Fig 5.9A), hence 
these two arginine residues are also part of HBS-1. Adjacent to the core of the canonical HBS-
1 is R60 (Fig 5.9B) which is a neighbour of R155. This arginine was not included in the binding 
site from the sequence alignment based assignment, but it is aligned to R59 in FGF8, where it 
was labelled as well.  
The HBS-2 of FGF17 was defined as comprising  K100 on β-strand V and K176 on β-strand XII 
[37]. However, the identification of the arginine residues involved in binding heparin suggests 
that FGF17 may not have an independent secondary HBS. R177, which reacted with HPG 
neighbours K176. Moreover, on the surface these two residues are adjacent to R155, R158, R60 of 
HBS-1 (Figure 9C). Thus, K176, R177 are likely an extension of HBS-1 rather than forming a 
distinct HBS. Towards the N-terminus, K176 and R177 are separated from R49 and R50 by a basic 
surface formed by Q51 and Y55, hence a single polysaccharide chain can bind both sets of 
residues (Fig 5.9C). Adjacent to R49 and R50 are R98, K100 of β-strand V (Fig 5.9A). K100 is 
distant from R98 and R50, however, there is no acidic border between them (Fig 5.9A), hence it 
too is likely to contribute to the same binding site, HBS-1.  
These observations showed that all labelled residues of FGF17 are on the same positively 
charged surface with no acidic barrier. Hence, it can be interpreted that FGF17 possesses a 
single, long, continuous HBS-1. However, similar to FGF8, the relative positions of the heparin 
engaging residues of FGF17 form a dogleg path for the polysaccharide (Fig 5.9E). The longer 
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part of the dogleg consists of R155, R158, R160, R164, R166, R113, K112, K115 and K119 (Fig 5.9E) 
and the shorter part is formed by K100, K123, R49, R50, R98 and R96 (Figs 5.9A, E) as for FGF8. 
However, FGF17 has been found to partially crosslink HS chains [203]. This suggests that the 
above interpretation is true part of the time, but there is a dynamic equilibrium with a binding 
mode of FGF17 involving two polysaccharide chains. In this later binding mode, it would seem 
likely that each polysaccharide chain engages independently each arm of the dogleg. 
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Figure 5.9: Heparin binding arginine and lysine residues in FGF17. 
The FGF17 structure is modelled on the template of FGF8 crystal structure (PBD code 2fdb 
[213]). The electrostatic potential of FGF17 was computed using the Poisson-Boltzmann 
algorithm in Swiss-PDBView with the positively charged areas coloured blue and the 
negatively charged areas coloured red. Labelled lysine residues [102] are presented as yellow. 
Labelled arginine residues (Tables 9A, B) are coloured green. A) The position of basic residues 
R49, R50 (peptide 5, Table 5.9A) (peptide 1, Table 5.9B), R96 (peptide 5, Table 5.9B), R113 
(peptide 1, Table 5.9A) and R145 (peptide 4, Table 5.9A) (peptides 2 and 4, Table 5.9B) relative 
to K112, K115, K119, K123, K125 [102] on the surface. B) The position of basic residues R155, R158, 
R160, R164, R166 (peptide 6, Table 5.9A) (peptide 8, Table 5.9B), R177 on β-strand XII (peptide 
7, Table 5.9B) and R60 (peptide 6, Table 5.9B) together with K176 [102] on the surface C) The 
surface between K176 and R177 and the core of the HBS-1. D) Sequence, secondary structure, 
location of labelled arginine and lysine residues in heparin-binding sites. Uniprot ID of 
FGF17 sequence is: O60258-1. E) The dogleg binding sites formed by all the labelled basic 
residues of FGF17. 
5.2.3.3 FGF18 
Arginine selective labelling identified seven residues bound to heparin. They are: R60 in β-
strand I (peptide 3, Table 5.10A); R98 in β-strand V (peptide 6, Table 5.10B); on the loop of β-
strands VI to VII, R112 (peptide 1 and 2, Table 5.10B); in the core of the canonical HBS-1, R158, 
R160 and R166 (peptide 7, Table 5.10A) (peptide 9, Table 5.10B); C-terminal to β-strand XII 
R177 (peptide 6, Table 5.10A), (peptide 3, Table 5.10B). Supporting some of these data is the 
observation in a crystal structure of FGF18 of R158 and R160 engaging sulfate anions [214]. 
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Organisation of HBS 
The core HBS1 has K155, K156, K161 and K164  identified as heparin-binding by previous work 
[36] and here R158, R160 and R166 (Figs 5.10A, B, D) were also found to bind heparin. 
Characteristic of the FGF8 sub-family is the involvement of basic residues in the loop of β-
strands VI-VII, through β-strand VII to the loop of β-strands VII–VIII in heparin binding. In 
the case of FGF18, one arginine, R112 (Fig 5.10A, B), is added to the four lysine residues K113, 
K115, K119 and K125 [36] in this region. They are adjacent to the core of HBS-1 and on the same 
electropositive surface (Fig 5.10A). Distant in the sequence, but adjacent on the surface to this 
enlarged HBS1, is R98 in β-strand V (Fig 5.10A, B), indicating that this arginine is part of HBS-
1 as well. In the other direction, R60 in β-strand I neighbours K155, K156, followed by R177 and 
K176, which are C-terminal to β-strand XII (Fig 5.10B). Hence, HBS-1 includes R60 and R177. 
The previous assignment of heparin binding sites in this subfamily classified K82 and K102  as 
an independent HBS, HBS-2 [36]. They are isolated from the basic residues of HBS-1 by acidic 
amino acids. In detail, between them and the closest residue of HBS1, R98, are E103 and E105 
(Fig 5.10E) and between them and K176 and R177 of HBS1 is E78 (Fig 5.10E). Hence, these two 
lysines are still likely separated from HBS-1 (Fig 5.10C, D). Consequently, FGF18 likely 
possesses a fully independent secondary HBS-2. It has been argued previously that the switch 
of Asp121 in FGF18 to Ser121 in FGF17  [36] altered the negative barrier on the protein surface, 
resulting in the subtle difference in binding sites between FGF17 and FGF18. Since in FGF8 
the corresponding residue is Asn139 in FGF8, it would appear that Asp121 is an important 
distinguishing feature in this FGF subfamily with respect to heparin binding. 
A further distinguishing feature of FGF18 is that the residues of HBS1 do not form a dogleg 
shaped path on the protein surface, unlike HBS1 residues in FGF8 and FGF17. Thus although 
FGF18, like FGF17 was found to partially cross-link HS [203], the immobilisation parameters 
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were shown to be different between FGF17 and FGF18 [203]. Briefly, FGF17 and FGF18 both 
bound slowly HS brushes, but after rinsing while FGF18 was not released from brush, FGF17 
exhibited a slow rate of dissociation into the bulk medium. This difference may relate to FGF17 
dynamically exchanging between binding modes involving a single HBS and two HBSs, 
whereas in FGF18 the HBSs are independent. 
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Figure 5.10: Heparin binding arginine and lysine residues in FGF18. 
The FGF18 structure (PBD code 4cjm [214]) is shown as a surface. The electrostatic potential 
of FGF18 was computed using the Poisson-Boltzmann algorithm in Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
lysine residues [36] are presented as yellow. Labelled arginine residues (Tables 10A, B) are 
coloured green. A) The position of basic residue R112 (peptide 1 and 2, Table 5.10B) and R166 
(peptide 7, Table 5.10A) (peptide 9, Table 5.10B) along with labelled K155, K156, K161 and K164 
[37] on the surface. B) The position of basic residues R60 (peptide 3, Table 5.10A), R158, R160 
(peptide 7, Table 5.10A) (peptide 9, Table 5.10B) and R177 (peptide 6, Table 5.10A), (peptide 
3, Table 5.10B) ) along with labelled K155, K156 and K176 [36] are shown on the surface. C) The 
surface between K82 and K102 [37] to the residues of HBS-1, including R112, K155, and K156. D) 
The position of basic residues R98 (peptide 6, Table 5.10B) and K82, K102 and K176 E) Between 
K82 and K102  which were classified as an independent HBS, HBS-2 and the residue R98 of HBS-
1 are E103 and E105. Lie between K82, K102 and the residues K176, R177 of HBS-1 is E78. F) 
Sequence, secondary structure, location of labelled arginine and lysine residues in 
heparin-binding sites. Uniprot ID of FGF18 sequence is: O76093. 
5.2.4 FGF7 subfamily (FGF3/7/10/22) 
5.2.4.1 FGF7 
In FGF7 six arginines were labelled with HPG: R65, R67 and R68 (peptides 5 and 7, Table 5.11A) 
(peptide 3, Table 5.11B), which are towards the N terminus; R72 on the loop of β-strand I-II 
(peptides 1, 2 and 3, Table 5.11A) (peptides 1 and 2, Table 5.11B); R78 and R82 on the loop of 
β-strand II-III (peptide 4, Table 5.11A); R101 on β-strand IV (peptide 6, Table 5.11A); and 
finally, R175 on the loop between β-strand XI-XII (peptide 8, Table 5.11A), (peptide 6, Table 
5.11B). 
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Organisation of HBS 
The selective labelling of lysines defined two HBSs in FGF7, the canonical HBS-1 and a 
secondary HBS-4, which occupies the loop of β-strand II-III and β-strand III. In addition, based 
on sequence alignment, a HBS3 was also proposed to exist. 
First, in the  core of HBS1, there are six lysine residues K170, K177, K178, K180, K181 and K184 
[36] and one arginine R175, which was labelled (peptide 8, Table 5.11A and peptide 6, Table 
5.11B, Fig 5.11A). Previous work [36] also assigned K155 on β-strand IX and K123 on the loop 
of β-strands VI-VII (Figure 11A, B) to HBS-1. K123 is adjacent to R175 of HBS-1 whereas K155 
is quite distant from the rest of HBS-1 (Figure 11A). Also some distance from the core of HBS-
1 is R101, which also reacted with HPG (Fig 5.11D). However, because there is no acidic barrier 
between this residue and the closest residues of HBS1, K155, K180 and K181 (Fig 5.11D), it is 
likely this in HBS-1. 
In previous work [36], it was argued that K81 and K84 were part of HBS-4. They formed a linear 
basic structure that was connected to residues in HBS-1, K123, K177 and K178. Visually, unlike 
the dogleg shape HBS-1 observed in FGF8 and FGF17, the HBS-1 and HBS-4 of FGF7 form 
a “T” shape (Fig 5.11 F), with HBS-4 consisting of K81, R82, K84 and R78 that meet HBS1 at 
K123, K175, K177 and K178 ([36] and Fig 5.11B, F). Consequently, R82 is assigned to HBS-4 and 
R78 is an extension of this secondary binding site (Fig 5.11F). The distance from the join of a 
“T” to K155 is 2.8 nm, making the binding pattern of FGF7 different from the dogleg shaped 
basic patch observed in FGF8 and FGF17 when one sugar chain could not engage K155 and 
turn back to engage to the other edge of the “T”. A ‘T’ shape of FGF7 requires two GAG chains 
to be able to bind all labelled lysine and arginine residues. There are two possible models for 
the overall engagement. In the first model (blue line, Fig 5.11F), one sugar chain will engage 
to residues of the central of HBS-1 and K155 and another chain engage to the linear charged 
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HBS-4 of K81, R82, K84 and R78. In the second model (purple line, Fig 5.11F), one sugar chain 
could bind to residues of HBS-4 and K155 and another chain engage remaining HBS-1 residues 
HBS-1. In at least the first model it seems likely that a requirement is an interaction with a 
sulfated unit at the non-reducing end of the polysaccharide chain. 
Previous work suggested that FGF7 might have an HBS3 towards the N-terminus [36][37], 
consisting of R65, R67 and R68. Here, they were indeed found to be labelled by HPG. On the 
surface, these residues are isolated from HBS-1 and HBS-4 by acidic residues. Thus, R65, R67 
and R68 form an HBS3, and so FGF7 likely has three HBSs. 
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Figure 5.11: Heparin binding arginine and lysine residues in FGF7. 
The FGF7 structure (PBD code 1qqk [31]) is shown as a surface. The electrostatic potential of 
FGF7 was computed using the Poisson-Boltzmann algorithm in Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
lysine residues [36] are presented as yellow. Labelled arginine residues (Tables 11A, B) are 
coloured green. A) The positions of the basic residues R82 (peptide 4, Table 5.11A) and R72 
(peptides 1, 2 and 3, Table 5.11A) (peptides 1 and 2, Table 5.11B) along with previously 
labelled  K81, K170, R175, K177, K178, K180, K181 and K184 [36] on the surface. B) The positions 
of the basic residues R175 (peptide 8, Table 5.11A), (peptide 6, Table 5.11B) and R78  (peptide 
4, Table 5.11A) together with K84 [36] on the surface. C) The positions of the basic residues 
R65, R67 and R68 (peptides 5 and 7, Table 5.11A) (peptide 3, Table 5.11B) along with R72 on 
the surface. D) The location of R101 (peptide 6, Table 5.11A) on the surface. The surface 
between R101 and R67, R68 is negatively charged. The surface between R101 and K155 (of HBS-
1) is positively charged. E) Sequence, secondary structure and location of labelled arginine 
and lysine residues in heparin-binding sites. Uniprot ID of FGF7 sequence is: P21781. F) 
Schematic showing the location of the residues forming the T shaped HBS1/HBS4 on 
FGF7. Possible paths of two polysaccharide chains shown in blue and purple. 
5.2.4.2 FGF10 
There are six arginine residues in FGF10 that reacted with HPG. They are R155 in β-strand VIII 
(peptide 7, Table 5.12B), R174 in β-strand IX (peptides 2, 3 and 6, Table 5.12A, and peptides 3 
and 5, Table 5.12B), R187, R188, R193 and R194 (peptide 7, Table 5.12A and peptide 6, Table 
5.12B) situated in the core of HBS-1. 
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Organisation of HBSs 
The selective labelling of lysine residues [37] and sequence alignment indicated that FGF10 
had three HBSs, HBS-1, HBS-3 which locates on β-strand I, and HBS-4, as found in FGF7. 
The core of the HBS-1 comprises three lysine residues identified previously K183, K191 and K195 
[37] and four arginine residues identified here: R187, R188, R193 and R194. Lying between K191 
and R194 is the labelled R174 in β-strand IX (Figure 12A), so this residue is part of HBS-1. Next 
to R194 and K195 is R155 of the β-strand VIII, indicating that this HPG-modified residue (peptide 
7, Table 5.12B) is an extension of HBS-1 (Figure 11A). K136, K137 and K139 in the loop between 
β-strands VI-VII (Figure 11A, B) and K87 on loop of β-strand I-II (Figure 11B) were assigned 
as HBS-1 residues [37]. 
Similar to FGF7, FGF10 possesses a HBS-4 which together with HBS-1 formed a “T” shape 
on the surface. The “T” shaped basic patch is composed of two groups of basic residues. HBS4 
is composed of K136, K137, K139, K183, K87, K94 and K97 [36] (Fig 5.12D) and HBS-1 (Fig 5.12B) 
R194, K195, R193, R174, K183, K191 and R78, with R187, R188 potentially belonging to either HBS. 
As for FGF7, the geometric relationship of these two groups of basic residues makes it difficult 
to envisage their engaging a single heparin chain. Thus, even though these residues that engage 
heparin in FGF10 are connected on the continuous basic surface, they are most likely to form 
two individual HBSs. This result supports the observation that FGF-10 can partially cross-link 
HS chains in an HS brush [203]. 
Whereas the expectation from sequence alignment was that FGF10, like FGF7, possessed a 
HBS-3, located on β-strand I, R78 and R80 were found to react with PGO (peptide 5, Table 
5.12A), hence were not involved in heparin binding. Thus, there is no HBS-3 in FGF10. 
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Figure 5.12: Heparin binding arginine and lysine residues in FGF10. 
The FGF10 structure (PBD code 1nun [31]) is shown as a surface. The electrostatic potential 
of FGF10 was computed using the Poisson-Boltzmann algorithm in Swiss-PDBView with the 
positively charged areas coloured blue and the negatively charged areas coloured red. Labelled 
lysine residues [102] are presented as yellow. Labelled arginine residues (Tables 5.12A, B) are 
coloured green. A) The positions of basic residues R155 (peptide 7, Table 5.12B), R174 
(peptides 2, 3 and 6, Table 5.12A, and peptides 3 and 5, Table 5.12B), R193, R194 (peptide 7, 
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Table 5.12A and peptide 6, Table 5.12B) along with K94 and K97, K136, K139, K191and K195 
defined previously [102] on the surface. B) The positions of basic residues R187, R188, R193, R194 
(peptide 7, Table 5.12A and peptide 6, Table 5.12B) together with K94 and K97 [102] on the 
surface. C) Sequence, secondary structure, location of labelled arginine and lysine 
residues in heparin-binding sites. Uniprot ID of FGF10 sequence is: O15520. D) Schematic 
showing the relative location of the lysine and arginine residues forming the “T” shaped 
HBS1/HBS4 of FGF10. 
5.2.4.3 FGF3 
In FGF3, engaged to heparin were: R44, R45 and R46 (peptide 1, Table 5.13A) (peptide 9, Table 
5.13B); R63 on the loop between β-strands II-III (peptides 4 and 5, Table 5.13A) (peptide 6, 
Table 5.13B), R89 in β-strand III (peptide 12, Table 5.13B), R102 and R104 on the loop of β-
strands VI-VII (peptides 2, 8 and 9, Table 5.13A) (peptide 1, Table 5.13B); R120 in β-strand 
VIII (peptide 10, Table 5.13B); R132 in β-strand IX (peptide 3, Table 5.13A) (peptide 2, Table 
5.13B); R162, R164, R165, R170 and R171 in the core area of HBS-1 (peptides 6 and 7, Table 5.13A) 
(peptides 3 and 11, Table 5.13B); R186 and R192, which are C-terminal to β-strand XIII also 
reacted with HPG (peptide 4, Table 5.13B). 
Organisation of HBS 
The results of previous lysine labelling and sequence alignment suggested that FGF3, like 
FGF7 and FGF10, possessed HBS-1 and HBS-3 which locates on β-strand I. However, the 
aligned area of HBS-4, between β-strands II-III, in FGF3 contained arginine residues, hence it 
was not clear whether FGF3 also possessed a HBS4. 
The core HBS-1 of FGF3 consists of five arginine residues R162, R164, R165, R170 and R171 
(Figure 13A, B), as well as K160 and K168 [37]. The addition of those arginine residues to the 
previous defined HBS-1 with only two lysine residues expands this binding site (Figure 13A, 
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B). Adjacent to R170 and R171 on the surface is R132 in β-strand IX (Figure 13A), suggesting this 
residue is part of HBS-1. R120 in β-strand VIII neighbours R171, hence this residue is an 
extension HBS-1. Similar to the aligned residues on FGF7 and FGF10, R102 and R104 on the 
loop between β-strand VI-VII in FGF3 (Figure 13B) were labelled, hence, together with K101 
defined before [37] are an extension of HBS-1. On the surface, those amino acids are next to 
R164 and R165 (Figure 13A, B). 
Besides the core of HBS-1, R63, R102 and R104 were also labelled. From sequence alignment it 
was expected that R63 on the loop between β-strands II-III would be part of HBS-4 [37]. The 
position of R63, R102 and R104 on the surface relative to that of the core of HBS-1 indicated that 
FGF3 was similar other two members, FGF7 and FGF10 in possessing a HBS-4 which joins 
HBS1 to form a “T” shape (Fig 5.13E). In this “T” arrangement, the basic patch is composed 
of two binding sites. HBS-1 would comprise  R120, R132, R164, R165, K168, R170 and R171 (Fig 
5.12B), and  HBS4 would be formed by K101, R102, R104, R63 and K160. The residues at the 
junction, R164 and R165 (Fig 5.13E) could be assigned to either HBS-1 and HBS-4. 
As for FGF7, the geometric relationship of these two groups of basic residues makes it difficult 
to envisage their engaging a single heparin chain. Thus, even though these residues that engage 
heparin in FGF3 are connected on the surface, they actually form two individual HBSs. 
The prediction of an HBS-3 in FGF3 is borne out by the present results. Thus, N-terminal to β-
strand I are three labelled arginine residues, R44, R45 and R46. They are isolated from R155, the 
nearest residue of HBS-1, by an acidic border (Fig 5.13C), hence likely form an independent 
HBS, HBS-3. In addition, R89 on β-strand V is also isolated from HBS1 and HBS4 by acidic 
residues (Figure 13C), so is likely to contribute to HBS-3. 
FGF3 possesses one of the longest C-terminal tails of the FGFs, and it contains nine arginine 
residues and two lysine residues. However, only R186 and R192 reacted with HPG (peptide 4, 
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Table 5.13B), indicating that they bind to heparin. Since this part of the sequence is not covered 
by a structure, it is not possible to assign these residues to a particular HBS. 
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Figure 5.13: Heparin binding arginine and lysine residues in FGF3. 
The model of FGF3 structure is built on the template of FGF10 crystal structure (PBD code 
1nun [31]). The electrostatic potential of FGF3 was computed using the Poisson-Boltzmann 
algorithm in Swiss-PDBView with the positively charged areas coloured blue and the 
negatively charged areas coloured red. Labelled lysine residues [102] are presented as yellow. 
Labelled arginine residues (Tables 5.13A, B) are coloured green. A) The positions of basic 
residues R104, (peptides 2, 8 and 9, Table 5.13A) (peptide 1, Table 5.13B), R120 (peptide 10, 
Table 5.13B), R132 (peptide 3, Table 5.13A) (peptide 2, Table 5.13B), R170 and R171 (peptides 
6 and 7, Table 5.13A) (peptides 3 and 11, Table 5.13B) along with K101 and K168 defined 
previously [102] on the surface. B) The positions of basic residues R63 (peptides 4 and 5, Table 
5.13A) (peptide 6, Table 5.13B), R102, R104 (peptides 2, 8 and 9, Table 5.13A) (peptide 1, Table 
5.13B), R162, R164, R165, R170 and R171 (peptides 6 and 7, Table 5.13A) (peptides 3 and 11, Table 
5.13B) along with K160 defined previously [102] on the surface. C) The positions of basic 
residues R44, R45, R46 (peptide 1, Table 5.13A) (peptide 9, Table 5.13B) and R89 (peptide 12, 
Table 5.13B). On surface between these arginine residues and other residues is negatively 
charged. D) Sequence, secondary structure, location of labelled arginine and lysine 
residues in heparin-binding sites. Uniprot ID of FGF3 sequence is: P11487-1. E) The “T” 
shape formed by the labelled residues of FGF3. 
5.2.4.4 FGF22 
FGF22 possesses a single lysine residue in the sequence, which was found to contribute to 
heparin binding, since it was biotinylated (Table 5.14C), thus there was little information other 
than sequence alignment to determine its HBSs. The labelled arginine residues were: R41, 43R 
on β-strand I (peptides 6 and 7, Table 5.14B); R54 on β-strand II (peptide 2, Table 5.14A) 
(peptide 3, Table 5.14B); R60 on the loop between β-strands II–III (peptide 2, Table 5.14A) 
199 
 
 
(peptide 3, Table 5.14B); R77 on β-strand V (peptide 8, Table 5.14B); 99RR100 and R102 on the 
loop between β-strands VI–VII (peptide 3, Table 5.14A), (peptide 2, Table 5.14B); R114 
(peptide 8, Table 5.14A), R116, R118 (peptide 6, Table 5.14A) on β-strand VIII; R131, 133RRR135 
(peptide 6, Table 5.14A) (peptide 5, Table 5.14B) on the loop between β-strands XI–X; R145, 
R146, R150, R154, R156 and R157 (peptide 4 and 5, Table 5.14A) (peptide 4, Table 5.14B) in the 
core of HBS-1.  
Organisation of HBS 
The core of the canonical HBS-1 comprises six arginine residues R145, R146, R150, R154, R156 
and R157 that reacted with HPG and so were engaged to heparin. However, despite of their 
closeness in the sequence, R145, R146 are distant from R150, R154, R156 and R157 on the surface 
(Figure 14B), but there are no acidic amino acids between these two groups, indicting they are 
part of HBS-1. Alignment predicted that the residues on the loop between β-strands IX–X to 
be part of HBS-1 [36][37]. In FGF22, this region contains four arginines R131, 133RRR135 and 
all of them reacted with HPG. R114, R116, R118 on β-strand VIII are adjacent to R131, 133RRR135, 
indicating that they are an extension of HBS-1, though there are no aligned basic residues in 
this area in other members of FGF7 subfamily that engage heparin [36][37].  
Like the other three members of the sub-family, FGF22 likely possesses a HBS-1 and a HBS-
4. However, the HBS4 in FGF22 is more extensive and four of its residues are parallel to HBS-
1 (Fig. 5.14). The HBS-1 in this model of binding is composed of R150, R154, R156 and R157 as 
well as R145 and R146 on the loop between β-strands X–XI (Fig 5.14E). HBS-4 in FGF22 is not 
linear, but forms a dogleg with the corner at R131. This arrangement may lend itself to a number 
of different binding modes. In one, HBS-1 would run from R157/R145 on the central of HBS-1 
to R134 on the loop between β-strands IX and X, and HBS-4 from R118 on β-strand VIII, through 
R100, R102 to finish at R54 on the loop between β-strands II and III. An alternative would be for 
200 
 
 
HBS-1 to include R102, R99 on the loop between β-strands VI and VII, R60 and R54 and for HBS-
4 to terminate at R133/R100. It seems unlikely that a single polysaccharide chain could engage 
these residues because the distance from R116 to R146 is 3.2 nm, whereas the distance between 
charged groups on opposite sides of the sugar chain is ~0.8 nm.  
The difference observed here between FGF22 and the other three members of the FGF7 
subfamily is largely due to six arginine residues in FGF22, R114, R116, R118 on β-strand VIII 
and R130, R132, R133 on the loop between β-strands IX and X, that bind heparin. In which, R118 
is conserved among members and corresponding to R130 in FGF22 is K140 in FGF7, leaving 
four unique arginines in FGF22. On the surface, these six residues are adjacent, and together 
form the part of HBS-4 that is parallel to HBS1 (Fig 5.14E). The other members of the 
subfamily only have one residue in each of these areas that engages heparin. Hence, the four 
arginine residues unique to FGF22 make its HBS4 different from that of the other members of 
the FGF7 sub-family. Consequently, in terms of heparin binding, FGF22 is the most distinct 
member of the subfamily.  
In addition to HBS-4, FGF22 possesses a HBS-3 on β-strand I. In this area, even though R41, 
R43 and R44 are close in the sequence, modifications on the peptides (peptides 6 and 7, Table 
5.14B) indicates that only two of them reacted with HPG and the other reacted with PGO. 
Inspection of the surface shows that R41 and R43 are adjacent, but R44 is distant from any 
labelled residues. This observation suggested that the former two are heparin-binding residues. 
R41 and R43 are separated from HBS-1 by an acidic barrier (Figure 14C), so likely forming an 
independent HBS-3. K87 (data) and R77 (peptide 8, Table 5.14B) were found to engage heparin. 
On the surface they are close to R41 and R43, so are part of HBS-3. 
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Figure 5.14: Heparin binding arginine and lysine residues in FGF22. 
The model of FGF22 structure is built on the template of FGF10 crystal structure (PBD code 
1nun [31]). The electrostatic potential of FGF22 was computed using the Poisson-Boltzmann 
algorithm in Swiss-PDBView with the positively charged areas coloured blue and the 
negatively charged areas coloured red. Labelled lysine residues (Table 5.14C) are presented as 
yellow. Labelled arginine residues (Tables 5.14A, B) are coloured green. A) The positions of 
basic residues R100, R102 (peptide 3, Table 5.14A), (peptide 2, Table 5.14B), R114 (peptide 8, 
Table 5.14A), R116, R118 (peptide 6, Table 5.14A), R132, R133, R134 (peptide 6, Table 5.14A) 
(peptide 5, Table 5.14B), R156 and R157 (peptide 4 and 5, Table 5.14A) (peptide 4, Table 5.14B) 
on the surface. B) The positions of R54 (peptide 2, Table 5.14A) (peptide 3, Table 5.14B), R60 
(peptide 2, Table 5.14A) (peptide 3, Table 5.14B), R99 (peptide 3, Table 5.14A), (peptide 2, 
Table 5.14B), R145 and R146 (peptide 4 and 5, Table 5.14A) (peptide 4, Table 5.14B) on the 
surface. C) The positions of basic residues K87 (Table 5.14C), R77 (peptide 8, Table 5.14B), 
R41, R43 (peptides 6 and 7, Table 5.14B) on the surface of FGF22. On surface, between these 
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arginine residues and other residues is negatively charged. D) Sequence, secondary structure, 
location of labelled arginine and lysine residues in heparin-binding sites. Uniprot ID of 
FGF22 sequence is: Q9HCT0. E) Schematic of the relative positions of the labelled residues 
of FGF22. 
5.3 DISCUSSION 
5.3.1 Architecture of HBSs in the paracrine FGFs  
The alignment of the amino acid sequences of the 15 paracrine FGFs with ClustalX was done 
to gain an insight into the diversification of their HBSs. The core beta trefoil structure is fairly 
constant across the 15 members of the 5 sub-families, but, as expected, the amino acid 
sequences of these FGFs vary to a greater extent. GAG binding regulates important aspects of 
FGF function: stability, diffusion and formation of signalling complexes (Sections 1.4.6). Thus, 
it is now possible to examine how changes in amino acid sequence that alter GAG binding 
relate to the evolution of the FGFs. 
HBSs are more conserved within a subfamily than between subfamilies in terms of length, size, 
and shape. These factors will affect the selectivity and potentially the binding kinetics of the 
FGF for structures in HS. The type of basic residue (arginine or lysine) likely contributes 
mainly to the binding kinetics. For example, the HBS1 of FGF10 has more arginine residue 
than that of FGF7 and this results in a reduced dissociation rate of FGF10 from heparin [215].  
The HBS-1 of members of the FGF8 sub-family is the most distinct. FGF8, FGF17 and FGF18 
have heparin binding residues located in the area from β-strand VI till the loop between β-
strands VII-VIII (Fig 5.15), in addition to the residues in the core of HBS-1, which aligns across 
the FGF family. Those two parts make the HBS-1 in members of FGF8 subfamily relatively 
wide and result in a dogleg shape. The HBS1 of the FGF7 sub-family also has a unique 
architecture, since it abuts the secondary HBS-4. On the surface, the labelled basic residues 
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form a “T” shaped basic patch of binding and there are potentially different binding modes for 
two polysaccharide chains to this structure. 
5.3.2 Differences among members of a subfamily due to amino acid substitutions 
The core of HBS-1 varies in sequence, but is present in all the paracrine FGFs and in this way 
is relatively invariant. This may reflect in part the need for this core to engage the 
polysaccharide in the ternary signalling complex with the FGFR [144] [216], which may 
constrain the amount of change possible. Thus, the greatest changes to heparin binding occur 
elsewhere on the surface and here, small differences in one or a few amino acids can have a 
major effect on the structure of HBS-1 and the presence or absence of secondary binding sites. 
In the FGF1 subfamily, there is a major difference in terms of binding sites, since FGF1 
possesses a single HBS-1, whereas there are three HBSs assigned in FGF2 isolated by acidic 
borders. The border between HBS-1 and HBS-2 in FGF2 is absent in FGF1, due to the 
substitution of E86 in FGF2 by T83, whereas the substitution of E68 in FGF2 by S65 in FGF1 
abolishes the barrier between HBS-1 and HBS-3 (Section 4.2).  
For the FGF4 subfamily, FGF4 and FGF6 both engage heparin through a single HBS-1. 
However, a closer examination reveals some district features of these two FGFs. In detail, the 
aligned residue of labelled K173 on FGF4 is L176 in FGF6. This change disconnects the aligned 
K158 of FGF6 (R170) to the core of HBS-1, whereas the core of HBS-1 and K158 of FGF4 are 
linked. In fact, R170 reacted with PGO (Section 5.2.1.2). This alters the direction of sugar 
engagement on FGF6, compared to FGF4, so that FGF6 engages to heparin in the direction 
connecting K185 and R205 (Section 5.2.1.2). 
For the FGF9 subfamily, only FGF20 possesses a secondary HBS, HBS-3, consisting of R65, 
R66 and R67 (Section 5.2.2.2). This difference stems from the substitution of R91 on the loop 
between the β-strands III-IV in FGF9 by L97 in FGF20, resulting in the polysaccharide likely 
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adopting a different orientation on the surface of FGF20 and so a separation of the HBS-3 
region from that of HBS-1 in FGF20. Only FGF20 in this subfamily had a labelled K124, 
whereas the corresponding K121 of FGF9 and R120 of FGF16 were protected (Section 5.2.2.2). 
Although it was suggested previously that this lysine in FGF20 may act as an individual HBSs 
[37], the addition of the arginine residues that bind heparin into HBS-1 indicates that this lysine 
is actually an extension of HBS-1. 
In the FGF8 subfamily, FGF8 and FGF17 likely engage to heparin through a dogleg shaped 
basic patch. However, FGF18 is different from other members due to the substitution of D121 
in FGF18 for S121 in FGF17 and N139 in FGF8, which creates a negatively charged barrier on 
the protein surface in FGF18, resulting in the independence of HBS-2 from the primary HBS-
1 (Section 5.2.3.3). On β-strand I, R52 of FGF8 was labelled, whereas the corresponding 
arginines in FGF17 and FGF18 were not. This arginine on FGF8 contributes to the extension 
of HBS-1 (Fig 5.8). 
In the FGF7 subfamily, FGF3, FGF7 and FGF10 have a conserved arrangement of HBS-1 and 
HBS-4, which form a “T” shape on the protein surface. However, in FGF22, this is altered. 
Thus, while there are still two independent binding sites, the structure is more ‘Y’ shaped, with 
two arms of HBS-1 and HBS-4 being parallel. This is due to the engagement of heparin by the 
unique R116, R118 on β-strand VIII and R132, R133 on the loop between β-strands IX and X of 
FGF22. Finally, FGF10 differs from the rest of the subfamily in that it does not possess and 
HBS-3 (Section 5.2.4.2). 
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5.3.3. Heparin binding sites and the classification of FGFs into subfamilies 
It should be recalled that there is a debate regarding the subfamily to which FGF3 and FGF5 
belong. From the alignment of amino acid sequence, FGF3 was assigned to the FGF7 subfamily 
and FGF5 to the FGF4 subfamily, whereas consideration of synteny assigned FGF3 to the 
FGF4 subfamily and FGF5 to the FGF1 subfamily (Section 1.2.1).  
FGF5 possesses a longer loop between β-strands IX and X than that FGF4 and FGF6 (3 
residues), hence, the labelling of arginine residues in this area of FGF5 results in a difference 
in binding to heparin. FGF2 possesses a secondary HBS-2, which locates on β-strand IX and 
the loop between β-strands IX –X, however, this loop is also short in FGF2. In contrast, this 
loop is relatively longer in FGF1 with 6 residues, but none of them engage heparin. Thus, the 
data on HBSs in FGF5 do not add evidence to its assignment to a particular subfamily. It should 
be noted that this loop is only long in FGF5 and FGF3 and the classification of both of them is 
still not conclusive.  
FGF3 possesses a HBS-3 and a HBS-4, which are similar in architecture to the members of the 
FGF7 subfamily. In contrast, FGF4 and FGF6 possess a single, long HBS-1, with no evidence 
for a ‘T’ shaped HBS-1/HBS-4 structure or a HBS3 on their surface. Therefore, the present 
data support the assignment of FGF3 by sequence alignment to the FGF7 subfamily and 
consequently the observed synteny would have arisen by chance. 
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Figure 5.15: Positions of labelled arginine and lysine residues in the picture of the 
subfamily sequence alignment. The sequence alignment was performed with ClustalX and 
the input sequences were taken from Uniprot. Labelled lysine residues are presented as blue. 
Labelled arginine residues are coloured red. The secondary structures of the FGF1 subfamily 
is assigned from a FGF1 structure (PBD code 2erm [33]), FGF4 subfamily from a FGF4 
structure [207] (PBD code 1ijt), FGF9 subfamily from a FGF9 structure [212] PBD code 
5w59), FGF8 subfamily from a FGF8b structure [213] (PBD code 2fdb) and FGF7 from  a 
FGF7 crystal structure (PBD code 1qqk) [31]. The assigned HBSs are highlighted in red boxes. 
5.3.4 Assignment of HBSs in the FGFs is supported by measurement of cross-linking of HS 
chains 
The present data together with those acquired previously on lysine residues [120] [36][37] 
provide insight into the basic residues in the fifteen paracrine FGFs that bind heparin. The 
existence of secondary HBSs in FGFs emerged from the analysis of the interactions of nested 
synthetic peptides covering the amino acid sequence of FGF2 and was supported by later work, 
including lysine protect and label experiments [36]. Analysis of further FGFs identified that 
there were likely three different secondary HBSs in the paracrine FGFs, HBS-2 located at the 
area of β-strands IX and X, HBS-3 at the N terminus of β-strand I and sometimes including 
residues from the C-terminus and, unique to the FGF7 subfamily, HBS4, which with HBS1 
formed a T-shape patch, which could only be bound by two heparin chains [36]. The 
identification of the secondary binding sites led to the idea of the engagement of a single FGF 
to multiple polysaccharide chains at the same time and this was vindicated by a biophysical 
analysis, which showed that FGF2 (HBS-1, -2 and -3), but not FGF9 (only HBS-1) was able 
to cross-link HS chains in vitro [126]. More recent work suggested that this interpretation was 
either too simplistic or that what had been considered to be independent secondary HBSs [37] 
were in fact extensions of HBS1 [203]. 
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The data acquired here provide a resolution of this issue. Thus, there would appear to be a 
single HBS-1 on FGF4 and FGF6 and no secondary HBS. This re-assignment of residues is 
due to what was considered previously to be an electronegative region between the HBSs 
arising from the peptide backbone and/or a hydrophilic side chain, rather than an acidic side 
chain. The updated assignment agrees with data that have been acquired on cross-linking HS 
chains in a bush: FGF4 and Halo-FGF6 were found not to cross-link HS chains [126] [203]. In 
some cases only partial cross-linking was observed, e.g., FGF17 [203], but there was no 
structure-based explanation for this observation. The identification of an dogleg shaped basic 
binding site (Sections 5.2.4) suggests that this FGF may have two binding modes, one to a 
single chain with a substantial bend in the polysaccharide, the other to two chains. FGF10 was 
demonstrated to partially cross-link HS chains as well [203]. Since FGF10 does not possess 
HBS-3, the partial cross-link observed in this FGF10 is entirely due to HBS-1 and HBS-4. 
Therefore, their simultaneous engagement to two polysaccharide chains would appear to be 
only one binding mode, in other(s) the heparin-binding residues of either one of HBS1 or HBS4 
in FGF10 would not engage the polysaccharide. The structure of available binding sites in HS 
would then likely determine the partitioning and equilibrium between these binding modes and 
so the degree of cross-linking observed.  
The presence of secondary HBSs in particular paracrine FGFs is likely to affect the functions 
of the growth factors. Differences in the diffusion of FGFs in pericellular matrix [217] [125] 
are likely to arise from the interplay between the kinetics of binding of HBS1, the presence of 
secondary HBSs and the availability of unoccupied binding sites in matrix HS. However, the 
relationship between the ability of an FGF to cross-link HS chains and the diffusion of that 
FGF in extracellular matrix remains to be established.  
  
209 
 
 
5.3.5 The definition of secondary HBS 
The identification of both arginine and lysine residues that bind heparin has allowed refinement 
of the assignment of residues to the primary HBS-1 and secondary HBSs in the FGFs. There 
are at least two factors that determine whether heparin binding residues are in a secondary HBS 
or part of the primary HBS-1.  One is the presence of an acidic border made by acidic side 
chains, rather than the sum of partial charges of the backbone amides and polar side chains, 
such as alcohols.  The second is the geometrical relationship of the basic residues on the surface 
of the FGF that are not separated by an acidic border. While heparin, and certainly HS has 
considerable flexibility [84] [37] [85] [91], there are limits to this. Thus, whereas a sugar chain 
may accommodate a 90° bend in a binding site, such dogleg binding sites, as found on FGF8 
subfamily members, need to be examined carefully to establish whether a NA domain of HS 
could be able to bend over the angle. In contrast, ‘T’ shaped binding structures, as found in the 
FGF7 subfamily would appear to require two polysaccharide chains.  
5.3.6 HS and FGFR may compete for HBS3 residues 
The observation that heparin binding sites on some FGFs include residues that have been found 
in co-crystals to bind to receptors has been reported in some other proteins, including 
chemokines [155], FGF2 [218] [130], FGF1 [36][143]. In FGF8 [213], R48 has been shown to 
interact with the alternative spliced region of D3 whereas, R52 engages to D3 of FGFR2c. On 
the loop of β-strand I and II, R59 bound to D2 region of FGFR2c [213]. In FGF9, while R62 and 
R64 are part of HBS-1, they are also involved in binding to FGFR1c [219]. In FGF7, R65 of 
HBS-3 is defined as a residue interacting with FGFR2IIIb [220]. Interestingly, the latter study 
also found another function of R65 besides interacting with D3, whereby it forms an 
intramolecular hydrogen bond, which is potentially required for maintaining the local 
conformation of FGF7 [220]. The fact that this arginine was labelled indicates that any such 
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intramolecular bonding is dynamic and that the side chain of this arginine is exposed to solvent 
at least part of the time. When an arginine is involved in stable intramolecular bonding it does 
not react with PGO/HPG and is not a substrate for Arg-C, as found for R42 in FGF2 (Section 
4.2). Thus, the heparin-binding residue of HBS-3 and some others may have two competing 
partners, HS and FGFR. This suggests that upon the formation of the ternary signalling 
complex, FGF:HS:FGFR, that there may be a rearrangement of HS:FGF interactions to allow 
full interaction with the FGFR. The interactions with polysaccharide may also, in some cases, 
prevent the formation of a signalling complex with the FGFR. 
5.3.7 Basic residues at the C-terminus of FGFs that bind heparin  
FGF5 possesses both a long N-terminus extending well beyond β-strand I of the β-trefoil 
structure and the longest C-terminal tail of the FGF family. The functions of these parts of 
FGF5 are unknown, but the data here suggest that they may be involved in binding HS. FGF3 
also has a long C-terminal tail, which is very basic, with nine arginine residues and two lysine 
residues, though only two arginines R186 and R192 reacted with HPG (peptide 4, Table 5.13B), 
indicating that they bind to heparin. The functions of the other lysines and arginines remain 
unresolved.  The residues of C-terminus contributing to the engagement with heparin are also 
observed in FGF17 (Section 5.2.3.2), FGF9 and FGF20 (Section 5.2.2). 
 
 
 
 
 
 
211 
 
Table 5.1: List of paracrine FGFs. FGF names along with their amino acid numbering of the 
sequences are according to the UniProt entry. FGF1 is an N-terminal truncated protein [221]. 
FGF2 does not possess a secretory signal sequence. The full length protein sequence of FGF9, 
FGF16 and FGF20 was expressed because they contain no signal peptide recognised in 
Uniprot. FGF5 was expressed as the full length sequence as well. For all other FGFs, the protein 
expressed was without the Uniprot determined secretory signal sequence. The N-terminal tag 
of each FGF was indicated. 
Name UniProt accession 
number 
Residues Molecular mass 
(kDa) 
Tag 
FGF1 P05230 16–155 19.1       No 
FGF2 P09038-2 1-155 17.3 No 
FGF3 P11487-1 18-239 26.887 6xHis 
FGF4 P08620 31–206 19.29 6x His 
FGF5 P12034-1 1-268 29.551 Halo 
FGF6 P10767 38-208 51.1  Halo 
FGF7 P21781 32–194 22.2  6x His 
FGF8b P55075-3 23-215 57.5  Halo 
FGF9 P31371 1–208 23.4 6x His 
FGF10 O15520 38-208 22.7  6x His 
FGF16 O43320 1-207 21.4 6x His 
FGF17 O60258-1 23-216 23.3 6x His 
FGF18 O76093 28–207 20.9 6x His 
FGF20 Q9NP95 1-211 58.8  Halo 
FGF22 Q9HCT0 23-170 52.3  Halo 
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Table 5.2A: FGF4 MS analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF4” present the predicted m/z and sequence of each peptide after digestion of FGF4 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF4 P&L” present the predicted and 
observed m/z for FGF4 after selective labelling. FGF4 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [102] to be in an HBS of FGF4. The final column indicates the modification occurring 
on the arginine residues of peptides. 
  Native FGF4 FGF4 P&L 
 Ref.no. Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 976.50 44ERRWESL50 1240.55 1240.62 HBS3 R45 and R46 2R+ 132 (HPG)  + 132 (HPG) 
2 1237.86 77LLGIKRLRRL86 1601.93 1601.94 HBS3 R82 2R + 132 (HPG)  + 116  + 116 
3 1700.92 130GVASRFFVAMSSKGKL145 1834.94 1834.94 R134 R + 134 
4 1806.99 119SPVERGVVSIFGVASRF135 2055.03 2055.11 HBS3 R123 2R + 132 (HPG)  + 116 
5 1902.01 39EAELERRWESLVALSL53 2166.06 2165.99 HBS3 R45 and R46 2R + 132 (HPG)  + 132 (HPG) 
6 2049.11 117ELSPVERGVVSIFGVASRF135 2413.20 2413.11 HBS3 R123 2R + 132 (HPG)  + 232 
7 2313.21 95HLQALPDGRIGGAHADTRDSLL116 2577.25 2577.38 R103 and R112 2R  + 132 (HPG)  + 132 (HPG) 
8 2412.29 54SLARLPVAAQPKEAAVQSGAGDYL77 2644.36 2644.36 R57 R + 232 
9 2309.27 116LELSPVERGVVSIFGVASRFF136 2673.35 2673.30 HBS3 R123 2R  + 132 (HPG)  + 232 
10 2658.49 179IALSKNGKTKKGNRVSPTMKVTHF202 2791.51 2791.47 HBS3 R192 2R + 132 (HPG) 
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Table 5.2B: FGF4 MS analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF4” present the predicted m/z and sequence of each peptide after digestion of FGF4 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF4 P&L” present the predicted and 
observed m/z for FGF4 after selective labelling. FGF4 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [102] to be in an HBS of FGF4. The final column indicates the modification occurring 
on the arginine residues of peptides. 
  Native FGF4 FGF4 P&L 
 Ref.no. Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z observed Match HBS Modifications 
1 1257.69 44ERRWESLVAL53 1523.74 1523.74 HBS3 R45 and R46 2 R + 132 (HPG)  + 132 (HPG)   
2 1400.92 78LGIKRLRRL86 1997.08 1997.00 HBS3 R82 3 R + 132 (HPG)  + 232 + 232 
3 1806.99 119SPVERGVVSIFGVASRF135 2055.03 2055.10 HBS3 R123 2 R + 132 (HPG)  + 116 
4 2062.06 97QALPDGRIGGAHADTRDSLL116 2312.12 2312.07 R103 and R112 2 R + 134  + 116 
5 2049.11 117ELSPVERGVVSIFGVASRF135 2413.20 2413.11 HBS3 R123 2 R + 132 (HPG)  + 232 
6 2115.21 79GIKRLRRLYCNVGIGFHL96 2513.28 2513.19 HBS3 R82 3 R + 132 (HPG)  + 134 + 134 
7 2496.33 117ELSPVERGVVSIFGVASRFF136 2762.38 2762.46 HBS3 R123 2 R + 132 (HPG)  + 134 
8 2855.56 119SPVERGVVSIFGVASRFFVA139 3219.65 3219.65 HBS3 R123 2 R + 132 (HPG)  + 232 
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Table 5.3A: FGF6 MS analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two columns 
under “Native FGF6” present the predicted m/z and sequence of each peptide after digestion of FGF6 by chymotrypsin. The bold arginines in the 
3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF6 P&L” present the predicted and observed 
m/z for FGF6 after selective labelling. FGF6 bound to a heparin affinity column (protection step) was reacted with PGO, following elution, then 
arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide as being 
considered from sequence alignment in the literature [102] to be in an HBS of FGF6. The final column indicates the modification occurring on the 
arginine residues of peptides. 
  Native FGF6 FGF6 P&L  
 Ref.no. Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z observed Match HBS Modifications 
1 859.51 58LSRSRAGL65 1224.61 1224.60 HBS3 R60 and R62 2R + 133 + 232  
2 1083.63 199TVTHFLPRI206 1215.65 1215.67 HBS3 R205 1R + 132 (HPG) 
3 1288.80 80VGIKRQRRLY89 1652.87 1652.96 HBS3 R84 3R + 132 (HPG) + 116 + 116  
4 1414.83 187GRVKRGSKVSPIM199 1678.87 1678.94 HBS1 R188 and R191 2R + 132 (HPG) + 132 (HPG) 
5 1853.02 131FGVRSALFVAMNSKGRL147 2201.12 2201.11 R134 and R146 2R + 116 + 232 
6 2028.10 55GTLLSRSRAGLAGEIAGVNW74 2292.14 2292.14 HBS3 R60 and R62 2R + 132 (HPG) + 132 (HPG) 
7 2580.422 118LEISTVERGVVSLFGVRSAL137 2944.56 2944.51 HBS3 R125 2R + 132 (HPG) + 232 
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Table 5.3B: FGF6 MS analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF6” present the predicted m/z and sequence of each peptide after digestion of FGF6 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF6 P&L” present the predicted and 
observed m/z for FGF6 after selective labelling. FGF6 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [102] to be in an HBS of FGF6. The final column indicates the modification occurring 
on the arginine residues of peptides. 
  Native FGF6 FGF6 P&L  
 Ref.
no. 
Predicted 
native peptide 
m/z 
Sequence 
Predicted 
modified peptide 
m/z 
m/z 
observed 
Match HBS Modifications 
1 859.51 58LSRSRAGL65 1224.61 1224.60 HBS3 R60 and R62 2R + 133 + 232  
2 1083.63 199TVTHFLPRI206 1215.65 1215.67 HBS3 R205 1R + 132 (HPG) 
3 1288.80 80VGIKRQRRLY89 1652.87 1652.96 HBS3 R84 3R + 132 (HPG) + 116 + 
116  
4 1414.83 187GRVKRGSKVSPIM199 1678.87 1678.94 HBS1 R188 and R191 2R + 132 (HPG) + 132 
(HPG) 
5 1853.02 131FGVRSALFVAMNSKGRL147 2201.12 2201.11 R134 and R146 2R + 116 + 232 
6 2028.10 55GTLLSRSRAGLAGEIAGVNW74 2292.14 2292.14 HBS3 R60 and R62 2R + 116 + 232 
7 2479.44 187GRVKRGSKVSPIMTVTHFL203 2744.49 2744.49 HBS1 R188 and R191 2R + 132 (HPG) + 132 
(HPG) 
8 2580.422 118LEISTVERGVVSLFGVRSAL137 2944.56 2944.51 HBS3 R125 2R + 132 (HPG) + 232 
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Table 5.4A: FGF5 MS analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two columns 
under “Native FGF5” present the predicted m/z and sequence of each peptide after digestion of FGF5 by chymotrypsin. The bold arginines in the 
3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF5 P&L” present the predicted and observed 
m/z for FGF5 after selective labelling. FGF5 bound to a heparin affinity column (protection step) was reacted with PGO, following elution, then 
arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide as being 
considered from sequence alignment in the literature [102] to be in an HBS of FGF5. The final column indicates the modification occurring on the 
arginine residues of peptides. 
  Native FGF5 FGF5 P&L 
 Ref.
no. 
Predicted 
native peptide 
m/z 
Sequence 
Predicted 
modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 866.54 262RLKFRF267 1132.59 1132.46 HBS3 R262 and R266 2R + 132 (HPG) + 132 (HPG) 
2 1017.54 82SPSGRRTGSL91 1281.59 1281.63 HBS3 R86 and R87 2R + 132 (HPG) + 132 (HPG) 
3 1228.57 163RERFQENSY171 1492.61 1492.66 HBS2 R163 and R165 2R + 132 (HPG) + 132 (HPG) 
4 1316.61 157TDDCKFRERF166 1680.69 1680.89 HBS2 R163 and R165 2R + 132 (HPG) + 232 
5 1641.85 175ASAIHRTEKTGREW188 1905.89 1905.86 HBS2 R180 and R186 2R + 132 (HPG) + 132 (HPG) 
6 1909.08 250SAPRKNTNSVKYRLKFR266 2305.14 2305.13 HBS3 R253, R262 and 
R266 
3R + 132 (HPG) x 3 
7 1912.98 82SPSGRRTGSLYCRVGIGF99 2509.24 2509.32 HBS3 R86 and R87 3R + 132 (HPG) + 232 + 232 
8 2227.12 80QWSPSGRRTGSLYCRVGIGF99 2723.25 2723.35 HBS3 R86 and R87 3R + 132 (HPG) + 132 (HPG)  + 232 
9 2632.45 193NKRGKAKRGCSPRVKPQHISTHF215 3130.57 3130.57 HBS1 R195 and R200 3R + 132 (HPG) + 132 (HPG)  + 232 
10 2915.64 190VALNKRGKAKRGCSPRVKPQHISTHF215 3546.80 3546.77 HBS1 R195 and R200 3R + 132 (HPG) + 250 +250 
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Table 5.4B: FGF5 MS analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF5” present the predicted m/z and sequence of each peptide after digestion of FGF5 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF5 P&L” present the predicted and 
observed m/z for FGF5 after selective labelling. FGF5 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [102] to be in an HBS of FGF5. The final column indicates the modification occurring 
on the arginine residues of peptides. 
  Native FGF5 FGF5 P&L 
 Ref
.no. 
Predicted native 
peptide m/z 
Sequence 
Predicted 
modified peptide 
m/z 
m/z 
observed 
Match HBS Modifications 
1 532.32 216LPRF219 764.39 764.22 HBS3 R218 1R + 232 
2 607.33 163RERF166 871.37 871.23 HBS2 R163 and R165 2R + 132 (HPG) + 132 (HPG) 
3 751.39 93CRVGIGF99 867.42 867.40 R94 1R + 116 
4 810.46 20AHGEKRL26 942.48 942.53 HBS3 R25 1R + 132 (HPG) 
5 1017.54 82SPSGRRTGSL91 1281.59 1281.63 HBS3 R86 and R87 2R + 132 (HPG) + 132 (HPG) 
6 1364.73 250SAPRKNTNSVKY261 1496.75 1496.67 HBS3 R253 1R + 132 (HPG) 
7 1641.85 175ASAIHRTEKTGREW188 1905.89 1905.87 HBS2 R180 and R186 2R + 132 (HPG) + 132 (HPG) 
8 2632.45 193NKRGKAKRGCSPRVKPQHISTHF215 3130.57 3130.57 HBS1 R195 and R200 3R + 132 (HPG) + 132 (HPG)  + 232 
 
218 
 
Table 5.4C: Selective labelling of lysine residues. FGF5 peptide analysis based on prediction by PeptideMass. The reference number of the 
peptide is followed by the predicted m/z and with the sequence of the peptide following cleavage of native FGF5 by chymotrypsin.  The two 
columns under “Native FGF5” present the predicted m/z and sequences of peptides after chymotrypsin digestion of FGF5. The first two columns 
under “FGF5 protect and label (P&L)” present the observed and predicted m/z for FGF5 after modifications of lysine residues. The third column 
is the assignment of the peptide to one of the three HBSs of FGF5 [36], [183]. The final columns indicates the modification occurring on the lysine 
residues of the peptides. 
  Native FGF5 FGF5 protect and label (P&L) 
 Ref
.no. 
Predicted native 
peptide m/z 
Sequence 
Predicted 
modified peptide 
m/z 
m/z 
theoretical 
Published HBS Modifications 
1 660.44 145SKKGKL150 1356.55 1356.47 HBS1 K146, K147 and 
K149 
3K + 232 (biotin) x 3 
2 1316.61 157TDDCKFRERF166 1358.54 1358.62 K161 1K + 42 (acetyl) 
3 810.46 20AHGEKRL26 1042.46 1042.47 HBS3 K24 1K + 232 (biotin) 
4 1471.79 216LPRFKQSEQPEL227 1703.80 1703.88 HBS3 K220 1K + 232 (biotin) 
5 1633.91 250SAPRKNTNSVKYRL263 2097.93 2098.12 HBS3 K254 and K260 2K + 232 (biotin) x 2 
6 1641.85 175ASAIHRTEKTGREW188 1874.02 1873.86 HBS1 K183 1K + 232 (biotin) 
7 2009.95 100HLQIYPDGKVNGSHEANM117 2051.96 2052.07 K108 1K + 42 (acetyl) 
8 2785.34 27APKGQPGPAATDRNPRGSSSRQSSSSAM54 3017.47 3017.35 HBS3 K29 1K + 232 (biotin) 
9 2632.45 193NKRGKAKRGCSPRVKPQHISTHF215 3370.69 3370.59 HBS1 K194, K197 and 
K199 
4K + 232 (biotin) x 3 + 42 
(acetyl) 
 
219 
 
Table 5.5A: FGF9 peptide analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF9” present the predicted m/z and sequence of each peptide after digestion of FGF9 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF9 P&L” present the predicted and 
observed m/z for FGF9 after selective labelling. FGF9 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [102] to be in an HBS of FGF9. The final column indicates the modification occurring 
on the arginine residues of peptides. 
  Native FGF9 FGF9 protect and label (P&L) 
 Ref
.no. 
Predicted 
native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z 
theoretical 
Published HBS1 Modifications 
1 996.472 67YCRTGFHL74 1132.02 1131.50 R69 1R + 134 
2 891.53 62RRRQLY67 1288.12 1287.59 HBS3 R62, R63 and R64 3R + 132 (HPG) x 3 
3 1287.58 130TQECVFREQF140 1419.79 1419.61 HBS1 R137 1R + 132 (HPG) 
4 1131.60 154KHVDTGRRY162 1495.17 1495.69 HBS1 R160 and R161 2R + 132 (HPG) + 232 
5 1504.92 55DHLKGILRRRQL66 1900.90 1900.98 HBS3 R62, R63 and R64 3R + 132 (HPG) x 3 
6 1844.79 130TQECVFREQFEENW144 1977.15 1976.81 HBS1 R137 1R + 132 (HPG) 
7 1740.92 153YKHVDTGRRYYVAL166 2005.01 2004.96 HBS1 R160 and R161 2R + 132 (HPG) + 132 (HPG) 
8 2023.06 185THFLPRPVDPDKVPELY201 2155.04 2155.09 HBS1 R190 1R + 132 (HPG)  
9 2103.07 75EIFPNGTIQGTRKDHSRF92 2367.14 2367.11 HBS1 R86 and R91 2R + 132 (HPG) + 132 (HPG) 
10 2156.143 167NKDGTPREGTRTKRHQKF184 2420.15 2420.18 HBS1 R173, R177 and R180 3R + 132 (HPG) x 2 
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Table 5.5B: FGF9 peptide analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF9” present the predicted m/z and sequence of each peptide after digestion of FGF9 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF9 P&L” present the predicted and 
observed m/z for FGF9 after selective labelling. FGF9 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [102] to be in an HBS of FGF9. The final column indicates the modification occurring 
on the arginine residues of peptides. 
  Native FGF9 FGF9 protect and label (P&L) 
 Ref
.no. 
Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z 
theoretical 
Published HBS. Modifications 
1 996.472 67YCRTGFHL74 1132.02 1131.50 R69 1R + 134 
2 891.53 62RRRQLY67 1288.12 1287.59 HBS3 R62, R63 and R64 3R + 132 (HPG) x 3 
3 1165.62 105VSIRGVDSGLY115 1297.09 1297.642 HBS1 R108 1R + 132 (HPG) 
4 1287.58 130TQECVFREQF140 1419.79 1419.61 HBS1 R137 1R + 132 (HPG) 
5 1131.60 154KHVDTGRRY162 1495.17 1495.69 HBS1 R160 and R161 2R + 132 (HPG) + 232 
6 2103.07 75EIFPNGTIQGTRKDHSRF92 2367.14 2367.11 HBS1 R86 and R91 2R + 132 (HPG) + 132 
(HPG) 
7 2156.143 167NKDGTPREGTRTKRHQKF184 2420.15 2420.18 HBS1 R173, R177 and R180 3R + 132 (HPG) x 2 
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Table 5.6A: FGF20 peptide analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF20” present the predicted m/z and sequence of each peptide after digestion of FGF20 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF20 P&L” present the 
predicted and observed m/z for FGF20 after selective labelling. FGF20 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [102] to be in an HBS of FGF20. The final column indicates the modification 
occurring on the arginine residues of peptides. 
 Native FGF20 FGF20 protect and label (P&L) 
Ref.
no. 
Predicted 
native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z 
theoretical 
Published HBS. Modifications 
1 728.46 65RRRQL69 1124.56 1124.53 HBS-3 65R, R66, R67 3R + 132 (HPG) x 3 
2 583.27 71CRTGF75 715.318 715.2868 HBS-1 R72 1R + 132 (HPG) 
3 579.29 140REQF143 711.366 711.3096 HBS-1 R140 1R + 132 (HPG) 
4 1653.80 152SSNIYKHGDTGRRY165 1917.928 1917.851 HBS-1 R163 and R164 3R + 132 (HPG) x 2 
5 1271.77 25LLPPAGERPPLL37 1405.709 1405.796 R33 1R + 134 
6 1002.56 108VSIRGVDSGL117 1134.511 1134.579 HBS-3 R111 1R + 132 (HPG) 
7 1519.81 157KHGDTGRRYFVAL169 1783.858 1783.855 HBS-1 R163 and R164 2R + 132 (HPG) x 2 
8 2381.29 166VALNKDGTPRDGARSKRHQK186 2645.293 2645.333 HBS-1 R176, R180, and R183 3R + 132 (HPG) x 2 
9 2098.10 169NKDGTPRDGARSKRHQKF187 2362.068 2362.143 HBS-1 R176, R180, and R183 3R + 132 (HPG) x 2 
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Table 5.6B: FGF20 peptide analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF20” present the predicted m/z and sequence of each peptide after digestion of FGF20 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF20 P&L” present the 
predicted and observed m/z for FGF20 after selective labelling. FGF20 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [102] to be in an HBS of FGF20. The final column indicates the modification 
occurring on the arginine residues of peptides. 
  Native FGF20 FGF20 protect and label (P&L)  
Ref. 
no. 
Predicted native 
peptide m/z 
Sequence 
Predicted 
modified peptide 
m/z 
m/z 
theoretical 
Published HBS Modifications 
1 728.46 65RRRQL69 1124.56 1124.53 HBS-3 65R, R66, R67 3R + 132 (HPG) x 3 
2 996.472 69YCRTGFHL77 1128.49 1128.49 HBS-1 R72 1R + 132 (HPG) 
3 1002.558 108VSIRGVDSGL117 1134.51 1134.58 HBS-3 R111 HR + 132 (HPG) 
4 1089.555 KHGDTGRRY166 1353.60 1353.60 HBS-1 R163 and R164 2R + 132 (HPG) x 2 
5 1271.77 25LLPPAGERPPLL37 1405.71 1405.79 R33 1R + 134 
6 1519.81 157KHGDTGRRYFVAL169 1783.86 1783.86 HBS-1 R163 and R164 2R + 132 (HPG) x 2 
7 1653.80 152SSNIYKHGDTGRRY165 1917.93 1917.85 HBS-1 R163 and R164 3R + 132 (HPG) x 2 
8 1800.878 162SSNIYKHGDTGRRYF 2064.86 2064.92 HBS-1 R163 and R164 2R + 132 (HPG) x 2 
9 2381.29 166VALNKDGTPRDGARSKRHQK186 2895.38 2895.40 HBS-1 R176, R180, and R183 3R + 132 (HPG) x 2 + 250 
10 2381.29 166VALNKDGTPRDGARSKRHQK186 2761.35 2761.36 HBS-1 R176, R180, and R183 3R + 132 (HPG) x 2  + 116 
11 2665.33 71CRTGFHLQILPDGSVQGTRQDHSL94 2929.351 2929.37 HBS-1 R72 and R89 2R + 132 (HPG) x 2 
12 1516.85 191LPRPVDPERVPEL203 1880.93 1880.92 HBS-1 R199 and R192 2R + 132 (HPG) + 232 
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Table 5.7A: FGF16 peptide analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF16” present the predicted m/z and sequence of each peptide after digestion of FGF16 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF16 P&L” present the 
predicted and observed m/z for FGF16 after selective labelling. FGF16 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [102] to be in an HBS of FGF16. The final column indicates the modification 
occurring on the arginine residues of peptides. 
  Native FGF16 FGF16 protect and label (P&L) 
 Ref.
no. 
Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z 
theoretical 
Published HBS. Modifications 
1 833.4087 67CRTGFHL73 1083.45 1083.45 R68 1R + 250 
2 1122.52 166NKDGSPREGY175 1254.52 1254.54 HBS1 R172 1R + 132 (HPG) 
3 1314.63 130TRECVFREQF139 1578.76 1578.67 HBS3 R131 and HBS1 R136 2R + 132 (HPG) x 2 
4 1430.75 124YGSKKLTRECVF135 1562.78 1562.77 HBS3 R131 1R + 132 (HPG) 
5 1475.66 152YKHSDSERQYY162 1607.73 1607.68 HBS1 R159 1R + 132 (HPG) 
6 1485.82 176RTKRHQKFTHF186 1765.97 1765.96 HBS1 R176 and R179 2R + 132 (HPG) x 2 
7 1568.77 162YVALNKDGSPREGY175 1700.80 1700.79 HBS1 R172 1R + 132 (HPG) 
8 1669.99 97ISLAVGLISIRGVDSGL113 1801.91 1802.01 HBS1 R107 1R + 132 (HPG) 
9 1833.05 97ISLAVGLISIRGVDSGLY114 1965.06 1965.07 HBS1 R107 1R + 132 (HPG) 
10 2390.21 74EIFPNGTVHGTRHDHSRFGIL94 2654.23 2654.25 HBS1 R131 and HBS3 R136 2R + 132 (HPG) x 2 
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Table 5.7B: FGF16 peptide analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF16” present the predicted m/z and sequence of each peptide after digestion of FGF16 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF16 P&L” present the 
predicted and observed m/z for FGF16 after selective labelling. FGF16 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF16. The final column indicates the 
modification occurring on the arginine residues of peptides. 
  Native FGF16 FGF16 protect and label (P&L) 
 Ref.
no. 
Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z 
theoretical 
Published HBS. Modifications 
1 891.53 61RRRQLY66 1287.76 1287.59 HBS3 R61, R62 and R63 3R + 132 (HPG) x 3 
2 937.45 200SRDLFHY206 1069.66 1069.47 HBS3 R90 1R + 132 (HPG) 
3 1122.52 166NKDGSPREGY175 1254.52 1254.54 HBS1 R172 1R + 132 (HPG) 
4 1314.63 130TRECVFREQF139 1578.76 1578.67 HBS3 R131 and HBS1 R136 2R + 132 (HPG) x 2 
5 1393.74 118NERGELYGSKKL129 1525.89 1525.76 R120 1R + 132 (HPG) 
6 1405.71 163VALNKDGSPREGY175 1537.69 1537.73 HBS1 R172 1R + 132 (HPG) 
7 1430.75 124YGSKKLTRECVF135 1562.78 1562.77 HBS3 R131 1R + 132 (HPG) 
8 1475.66 152YKHSDSERQYY162 1607.73 1607.68 HBS1 R159 1R + 132 (HPG) 
9 1485.82 176RTKRHQKFTHF186 1765.97 1765.96 HBS1 R176 and R179 2R + 132 (HPG) x 2 
10 1568.77 162YVALNKDGSPREGY175 1700.80 1700.79 HBS1 R172 1R + 132 (HPG) 
11 1669.99 97ISLAVGLISIRGVDSGL113 1801.91 1802.01 HBS1 R107 1R + 132 (HPG) 
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12 1821.97 184THFLPRPVDPSKLPSM199 1954.11 1953.99 R189 1R + 132 (HPG) 
13 1833.05 97ISLAVGLISIRGVDSGLY114 1965.06 1965.07 HBS1 R107 1R + 132 (HPG) 
14 2204.14 165NKDGSPREGYRTKRHQKF182 2600.10 2600.20 HBS1 R172, R176 and R179 3R + 132 (HPG) x 3 
 
Table 5.7C: Selective labelling of lysine residues. FGF16 peptide analysis based on prediction by PeptideMass. The reference number of the 
peptide is followed by the predicted m/z and with the sequence of the peptide following cleavage of native FGF16 by chymotrypsin.  The two 
columns under “Native FGF16” present the predicted m/z and sequences of peptides after chymotrypsin digestion of FGF16. The first two columns 
under “FGF16 protect and label (P&L)” present the observed and predicted m/z for FGF16 after modifications of lysine residues. The third column 
is the assignment of the peptide to one of the three HBSs of FGF16 [36], [183]. The final columns indicates the modification occurring on the 
lysine residues of the peptides. 
  Native FGF16 FGF16 protect and label (P&L) 
  Predicted native 
peptide m/z 
Sequence m/z observed m/z theoretical Published HBS Modifications 
1 1138.517 NKDGSPREGY 1371.627 1371.75 K167 1K + 232 (biotin)  
2 1595.781 KHSDSERQYYVAL 1827.791 1827.93 K153 1K + 232 (biotin)  
3 1430.746 YGSKKLTRECVF 1895.00 1894.766 K127 and K128 2K + 232 (biotin) x 2 
4 2903.594 RTKRHQKFTHFLPRPVDPSKLPSM 3603.77 3603.624 K178, K182 and K195 3K + 232 (biotin) x 3 
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Table 5.8A: FGF8 peptide analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF8” present the predicted m/z and sequence of each peptide after digestion of FGF8 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF8 P&L” present the predicted and 
observed m/z for FGF8 after selective labelling. FGF8 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [102] to be in an HBS of FGF8. The final column indicates the modification occurring 
on the arginine residues of peptides. 
  Native FGF8 FGF8 protect and label (P&L) 
 Ref.
no. 
Predicted native 
peptide m/z 
Sequence 
Predicted 
modified m/z 
m/z 
theoretical 
Published HBS. Modifications 
1 1087.6218 42VTDQLSRRL50 1351.73 1351.664 HBS2 R48 and R49 2R + 132 (HPG) x 2 
2 1097.5698 33TQHVREQSL41 1229.78 1229.591 HBS2 R37 1R + 132 (HPG) 
3 1357.7659 94GSRVRVRGAETGL106 1753.67 1753.829 HBS2 R96, R98 and R100 3R + 132 (HPG) x 3 
4 1520.8292 94GSRVRVRGAETGLY107 1916.9 1916.893 HBS2 R96, R98 and R100 3R + 132 (HPG) x 3 
5 1648.7748 69ANKRINAMAEDGDPF83 1780.63 1780.796 HBS1 R72 1R + 132 (HPG) 
6 1786.9275 190RFEFLNYPPFTRSL203 2283.11 2283.038 R190 and R201 3R + 232 + 232  
7 1966.0042 195NYPPFTRSLRGSQRTW210 2464.19 2464.13 R201, R204 and R208 3R + 232 + 134+ 134 
8 2149.1876 51IRTYQLYSRTSGKHVQVL68 2497.28 2497.282 HBS-2 R52 ; HBS1 R59 2R + 232 + 116 
9 2166.1738 33TQHVREQSLVTDQLSRRL50 2562.22 2562.245 HBS2 R37, R48 and R49 3R + 132 (HPG) x 3 
10 2589.446 154TRKGRPRKGSKTRQHQREVHF174 3232.94 3233.03 HBS1 R155, R158, R160, R170 5R + 132 (HPG) x 4 + 116 
11 2766.3767 69ANKRINAMAEDGDPFAKLIVETDTF93 2898.3 2898.398 HBS1 R72 1R + 132 (HPG) 
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Table 5.8B: FGF8 peptide analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF8” present the predicted m/z and sequence of each peptide after digestion of FGF8 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF8 P&L” present the predicted and 
observed m/z for FGF8 after selective labelling. FGF8 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [102] to be in an HBS of FGF8. The final column indicates the modification occurring 
on the arginine residues of peptides. 
 Native FGF8 FGF8 protect and label (P&L) 
Ref.
no 
Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z theoretical Published HBS. Modifications 
1 1357.7659 94GSRVRVRGAETGL106 1753.67 1753.83 HBS2 R96, R98 and R100 3R + 132 (HPG) x 3 
2 1520.8292 94GSRVRVRGAETGLY107 1916.9 1916.89 HBS2 R96, R98 and R100 3R + 132 (HPG) x 3 
3 1963.073 176KRLPRGHHTTEQSLRF191 2677.48 2677.24 R177, R180 and R190 3R + 232 + 232 + 250 
4 2078.088 194LNYPPFTRSLRGSQRTW210 2710.71 2711.24 R201, R204 and R208 2R + 250 + 250 + 134 
5 2166.1738 33TQHVREQSLVTDQLSRRL50 2562.22 2562.24 HBS2 R37, R48 and R49 3R + 132 (HPG) x 3 
6 2514.372 55QLYSRTSGKHVQVLANKRINAM76 2896.83 2896.46 HBS1 R59 and R72 2R + 132 (HPG) + 250 
7 2536.396 954GSRVRVRGAETGLYICMNKKGKL116 2932.84 2932.46 HBS2 R96, R98 and R100 3R + 132 (HPG) x 3 
8 2766.3767 69ANKRINAMAEDGDPFAKLIVETDTF93 2898.3 2898.39 HBS1 R72 1R + 132 (HPG) 
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Table 5.8C: Selective labelling of lysine residues. FGF8 peptide analysis based on prediction by PeptideMass. The reference number of the 
peptide is followed by the predicted m/z and with the sequence of the peptide following cleavage of native FGF8 by chymotrypsin.  The two 
columns under “Native FGF8” present the predicted m/z and sequences of peptides after chymotrypsin digestion of FGF8. The first two columns 
under “FGF8 protect and label (P&L)” present the observed and predicted m/z for FGF8 after modifications of lysine residues. The third column 
is the assignment of the peptide to one of the three HBSs of FGF8 [36], [183]. The final columns indicates the modification occurring on the lysine 
residues of the peptides. 
 Native FGF8 FGF8 protect and label (P&L) 
Ref
.no. 
Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z 
observed 
Published HBS. Modifications 
1 1034.585 108ICMNKKGKL116 1556.11 1556.61 HBS1 K111, K112 and 
K114 
3K + 232 (biotin) x 2 + 42 
(acetyl) and oxidation 
2 1366.715 117IAKSNGKGKDCVF129 1872.62 1872.7 HBS1 K119, K123 and 
K125 
3K + 232 (biotin) x 2 + 42 
(acetyl) 
3 1443.69 139TALQNAKYEGWY150 1485.70 1485.00 K145 1K + 42 (acetyl) 
4 1976.986 69ANKRINAMAEDGDPFAKL86 2253.50 2252.01 HBS1 K71 2K + 232 (biotin) + 42 
(acetyl) 
5 2499.304 175MKRLPRGHHTTEQSLRFEFL194 2737.57 2737.314 HBS2 K176 1K + 232 (biotin) and 
oxidation 
6 3117.65 150YMAFTRKGRPRKGSKTRQHQREVHF174 3813.96 3813.68 HBS1 K155, K161 and 
K164 
3K + 232 (biotin) x 3 
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Table 5.9A: FGF17 MS analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF17” present the predicted m/z and sequence of each peptide after digestion of FGF17 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF17 P&L” present the 
predicted and observed m/z for FGF17 after selective labelling. FGF17 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF17. The final column indicates the 
modification occurring on the arginine residues of peptides. 
 Native FGF17 FGF17 on column 
Ref.no. 
Predicted 
native peptide 
m/z 
Sequence 
Predicted 
modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 1078.586 106ICMNKRGKL116 1210.607 1210.531 HBS1  R113 1R + 132 (HPG) 
2 997.4599 142QNARHEGW149 1129.481 1129.43 HBS1  R145 1R + 132 (HPG) 
3 1654.749 34NQYVRDQGAMTDQL47 1786.77 1786.746 R38 1R + 132 (HPG) 
4 1316.613 139TAFQNARHEGW149 1448.634 1448.643 HBS1  R145 1R + 132 (HPG) 
5 1107.602 48SRRQIREY58 1487.67 1487.735 HBS1 R49 and R50 3R + 132 (HPG) x 2 + 116 
6 2915.478 151MAFTRQGRPRQASRSRQNQREAHF174 3691.598 3691.01 HBS1 R155, R158, R160, 
R164 and R166  
6R + 132 (HPG) x 5 + 116 
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Table 5.9B: FGF17 MS analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF17” present the predicted m/z and sequence of each peptide after digestion of FGF17 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF17 P&L” present the 
predicted and observed m/z for FGF17 after selective labelling. FGF17 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF17. The final column indicates the 
modification occurring on the arginine residues of peptides. 
  Native FGF17 FGF17 on column 
 Ref.
no. 
Predicted 
native peptide 
m/z 
Sequence 
Predicted 
modified peptide 
m/z 
m/z 
observed 
Match HBS Modifications 
1 1564.82 44TDQLSRRQIREY58 1962.89 1960.91 HBS1 R49 and R50 3R + 132 (HPG) x 3 
2 1316.61 139TAFQNARHEGW149 1448.63 1448.64 HBS1  R145 1R + 132 (HPG) 
3 1181.54 34NQYVRDQGAM43 1313.56 1313.58 R38 1R + 132 (HPG) and oxidation 
4 
2077.22 198VGSAPTRRTKRTRRPQPL215 2957.43 2942.40 
R204, R205, R208,  
R210 and R211 
5R + 116 + 250 + 250 +  
132 (HPG) x 2 
5 1579.86 94GSRVRIKGAESEKY107 1843.90 1843.89 HBS1 R96 and R98 2R + 132 (HPG) x 2 
6 
2702.41 59SRTSGKHVQVTGRRISATAEDGNKF83 3182.52 3182.48 
HBS1 R60; R71  
and R72 
3R + 132 (HPG) + 116 + 116 
7 693.4453 175IKRLY178 825.46 825.16 HBS1 R177 1R + 132 (HPG) 
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Table 5.10A: FGF18 MS analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF18” present the predicted m/z and sequence of each peptide after digestion of FGF18 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF18 P&L” present the 
predicted and observed m/z for FGF18 after selective labelling. FGF18 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF18. The final column indicates the 
modification occurring on the arginine residues of peptides. 
 Native FGF18 FGF18 on column 
Ref
.no. 
Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 949.51 108CMNRKGKL116 1082.54 1082.59 HBS1 R112 1R + 132 (HPG) 
2 1062.59 107LCMNRKGKL116 1294.66 1294.76 HBS1 R112 1R + 232 
3 1388.76 58YSRTSGKHIQVL69 1520.79 1520.86 HBS1 R60 1R + 132 (HPG) 
4 1579.79 70GRRISARGEDGDKY83 1828.85 1828.94 R71, R72 and R76 3R + 116 + 134 
5 1754.94 94GSQVRIKGKETEFYL108 1886.96 1886.95 HBS1 R98 1R + 132 (HPG) 
6 2007.12 176KRYPKGQPELQKPFKY191 2139.14 2139.09 HBS1 R177 1R + 132 (HPG) 
7 3303.725 143SGWYVGFTKKGRPRKGPKTR166 3594.01 3593.87 HBS1 R158, R160 and R166 3R + 132 (HPG) x 2 
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Table 5.10B: FGF18 MS analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF18” present the predicted m/z and sequence of each peptide after digestion of FGF18 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF18 P&L” present the 
predicted and observed m/z for FGF18 after selective labelling. FGF18 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF18. The final column indicates the 
modification occurring on the arginine residues of peptides. 
 Native FGF18 FGF18 on column 
Ref
.no. 
Predicted native 
peptide m/z 
Sequence 
Predicted modified 
peptide m/z 
m/z observed Match HBS Modifications 
1 949.51 108CMNRKGKL116 1097.53 1097.44 HBS1 R112 1R + 132 (HPG) and 
oxidation 
2 1062.59 107LCMNRKGKL116 1194.61 1194.60 HBS1 R112 1R + 132 (HPG) 
3 1346.72 175MKRYPKGQPEL185 1478.75 1478.82 HBS1 R177 1R + 132 (HPG) 
4 1388.76 58YSRTSGKHIQVL69 1520.79 1520.86 HBS1 R60 1R + 132 (HPG) 
5 1715.96 176KRYPKGQPELQKPF189 1847.98 1847.98 HBS1 R177 1R + 132 (HPG) 
6 1754.94 94GSQVRIKGKETEFYL108 1886.96 1886.95 HBS1 R98 1R + 132 (HPG) 
7 1877.09 191TTVTKRSRRIRPTHPA207  2573.30 2573.41 R197, R199, R200 and 
R202 
4R + 232 x 4  
8 1891.79 70GRRISARGEDGDKYAQL86 2388.07 2387.09 R71, R72 and R76 3R + 250 + 134 + 116 
9 2810.528 151VGFTKKGRPRKGPKTRENQQ170 3212.64 3207.60 HBS1 R158, R160 
and R166 
3R + 132 (HPG) x 2 + 134 
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Table 5.11A: FGF7 peptide analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF7” present the predicted m/z and sequence of each peptide after digestion of FGF7 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF7 P&L” present the predicted and 
observed m/z for FGF7 after selective labelling. FGF7 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF7. The final column indicates the modification 
occurring on the arginine residues of peptides. 
 Native FGF7 FGF7 protect and label (P&L) 
Ref.n
o. 
Predicted 
native peptide 
m/z 
Sequence m/z observed 
Predicted 
modified 
peptide m/z 
Published HBS. Modifications 
1 872.3719 71CRTQWY76 1004.456 1004.393 HBS1 R72 1R + 132 (HPG) 
2 1003.445 70FCRTQWY76 1135.444 1135.467 HBS1 R72 1R + 132 (HPG) 
3 1132.524 70FCRTQWYL77 1264.599 1264.546 HBS1 R72 1R + 132 (HPG) 
4 2278.245 95LRIDKRGKVKGTQEMKNNY78 2542.38 2542.33 HBS1 R78 and R82 1R + 132 (HPG) x 2 
5 2399.222 65MEGGDIRVRRLFCRTQWYL77 2795.241 2795.286 HBS3 R65, R67 and R68 3R + 132 (HPG) x 3 
6 2554.359 96NIMEIRTVAVGIVAIKGVESEFY119 2686.375 2686.38 HBS1 R101 1R + 132 (HPG) 
7 2564.229 63DYMEGGDIRVRRLFCRTQWY76 2960.25 2960.292 HBS3 R65, R67 and R68 3R + 132 (HPG) x 3 
8 2706.589 165ALNQKGIPVRGKKTKKEQKTAHF188 2838.577 2838.61 HBS1 R175 1R + 132 (HPG) 
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Table 5.11B: FGF7 peptide analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF7” present the predicted m/z and sequence of each peptide after digestion of FGF7 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF7 P&L” present the predicted and 
observed m/z for FGF7 after selective labelling. FGF7 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF7. The final column indicates the modification 
occurring on the arginine residues of peptides. 
 Native FGF7 FGF7 protect and label (P&L) 
Ref. 
no 
Predicted 
native peptide 
m/z 
Sequence 
m/z 
observed 
Predicted modified 
peptide m/z 
Published HBS. Modifications 
1 969.46 71CRTQWYL77 1001.46 1101.48 HBS1 R72 1R + 132 (HPG) 
2 1003.45 70FCRTQWY76 1135.45 1135.47 HBS1 R72 1R + 132 (HPG) 
3 1170.67 60EGGDIRVRRL69 1869.99 1869.92 HBS3 R65, R67 and R68  3R + 232 x 3 
4 1992.03 60EGGDIRVRRLFCRTQW75 2522.27 2522.12 
HBS1 R72 
HBS3 R65, R67 and R68 
4R + 132 (HPG) x 3 + 
116 
5 2099.92 41ATNVNCSSPERHTRSYDY58 2368.27 2368.01 R51 and R54 1R + 134 x 2 
6 2706.59 165ALNQKGIPVRGKKTKKEQKTAHF188 2838.58 2838.61 HBS1 R175 1R + 132 (HPG) 
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Table 5.12A: FGF10 peptide analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF10” present the predicted m/z and sequence of each peptide after digestion of FGF10 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF10 P&L” present the 
predicted and observed m/z for FGF10 after selective labelling. FGF10 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF10. The final column indicates the 
modification occurring on the arginine residues of peptides. 
 Native FGF10 FGF10 protect and label (P&L) 
Ref.
no. 
Predicted native 
peptide m/z 
Sequence m/z observed 
Predicted modified 
peptide m/z 
Published HBS. Modifications 
1 1157.654 74QGDVRWRKL82 1523.83 1523.73 R78 and R80 2R + 134 +250 
2 1333.586 168NWQHNGRQMY177 1465.548 1465.607 HBS1 R174 1R + 132 (HPG) 
3 1349.58 68NWQHNGRQMY177 1481.616 1481.602 HBS1 R174 
1R + 132 (HPG) and 
oxidation 
4 1449.825 80RKLFSFTKYFL90 1581.917 1581.846 HBS3 R80 1R + 132 (HPG) 
5 1537.823 74QGDVRWRKLFSF85 1805.781 1805.865 R78 and R80 2R + 134 * 2 
6 1638.723 166ASFNWQHNGRQMY177 1770.841 1770.744 HBS1 R174 1R + 132 (HPG) 
7 2367.298 180NGKGAPRRGQKTRRKNTSAHF201 2763.41 2763.39 
HBS1 R187, R188, 
R193 and R194 
4R + 132 (HPG) x 3 
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Table 5.12B: FGF10 peptide analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The 
two columns under “Native FGF10” present the predicted m/z and sequence of each peptide after digestion of FGF10 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF10 P&L” present the 
predicted and observed m/z for FGF10 after selective labelling. FGF10 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF10. The final column indicates the 
modification occurring on the arginine residues of peptides. 
 Native FGF10 FGF10 protect and label (P&L) 
Ref.no. 
Predicted 
native 
peptide m/z 
Sequence m/z observed 
Predicted 
modified 
peptide m/z 
Published HBS. Modifications 
1 797.47 80RKLFSF85 1031.00 1031.53 R80 1R + 232 
2 1157.65 74QGDVRWRKL82 1523.83 1523.73 R78 and R80 2R + 134 +250 
3 1332.65 170QHNGRQMYVAL180 1464.84 1464.67 HBS1 R174 1R + 132 (HPG) 
4 1390.68 58SSPSSAGRHVRSY70 1640.72 1640.73 R65 and R68 2R + 116 + 134 
5 1491.65 166ASFNWQHNGRQM176 1623.70 1623.68 HBS1 R174 1R + 132 (HPG) 
6 2367.30 180NGKGAPRRGQKTRRKNTSAHF201 2763.41 2763.39 HBS1 R187, R188, R193 and R194 4R + 132 (HPG) x 3 
7 2809.27 147NNDCKLKERIEENGYNTYASFNW169 2941.26 2941.29 HBS1 R155 1R + 132 (HPG) 
8 2373.11 142GSKEFNNDCKLKERIEENGY161 2504.84 2505.13 HBS1 R155 1R + 132 (HPG) 
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Table 5.13A: FGF3 peptide analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF3” present the predicted m/z and sequence of each peptide after digestion of FGF3 by chymotrypsin. The bold arginines 
in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF3 P&L” present the predicted and 
observed m/z for FGF3 after selective labelling. FGF3 bound to a heparin affinity column (protection step) was reacted with PGO, following 
elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide 
as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF3. The final column indicates the modification 
occurring on the arginine residues of peptides. 
 Native FGF3 FGF3 protect and label (P&L) 
Ref
.no. 
Predicted native 
peptide m/z 
Sequence 
m/z 
observed 
Predicted modified 
peptide m/z 
Published HBS. Modifications 
1 1010.633 40GGAPRRRKL48 1274.742 1274.675 HBS3 R44, R45 and R46 2R + 132 (HPG) x 2 
2 1108.604 98AMNKRGRLY106 1356.616 1356.652 HBS1 R102 and R104 2R + 132 (HPG) + 116 
3 1207.574 125GYNTYASRLY134 1339.681 1339.595 HBS1 R132 1R + 132 (HPG) 
4 1264.676 57QLHPSGRVNGSL68 1396.752 1396.697 HBS1 R63 1R + 132 (HPG) 
5 1264.676 56QLHPSGRVNGSL68 1396.752 1396.697 HBS1 R63 1R + 132 (HPG) 
6 1351.781 168KTRRTQKSSLF178 1715.914 1715.87 HBS1 R170 and R171 2R + 132 (HPG) + 232 
7 1429.814 155VSVNGKGRPRRGF177 1827.45 1827.88 HBS1 R162, R164 and R165 3R + 132 (HPG) x 2 + 134 
8 1521.843 93SGRYLAMNKRGRL105 1920.01 1919.91 HBS1 R102 and R104 3R + 132 (HPG) x 2 + 134 
9 1668.912 92FSGRYLAMNKRGRL105 1801.001 1800.933 HBS1 R102 and R104 1R + 132 (HPG) 
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Table 5.13B: FGF3 peptide analysis based on prediction by PeptideMass. The two columns under “Native FGF3” present the predicted m/z 
and sequence of each peptide after digestion of FGF3 by chymotrypsin. The bold arginines in the 3rd column (“Sequence”) are those identified as 
labelled with HPG. The first two columns under “FGF3 P&L” present the predicted and observed m/z for FGF3 after selective labelling. FGF3 
bound to a heparin affinity column (protection step) was reacted with PGO, following elution, then arginine residues of binding sites exposed to 
solvent were reacted with HPG (labelling step). The 3rd column identifies the peptide as being considered from sequence alignment in the literature 
[36], [183] to be in an HBS of FGF3. The final column indicates the modification occurring on the arginine residues of peptides. 
 Native FGF3 FGF3 protect and label (P&L) 
Ref
.no. 
Predicted native 
peptide m/z 
Sequence m/z observed 
Predicted 
modified peptide 
m/z 
Published HBS. Modifications 
1 961.536 98AMNKRGRL106 1225.35 1225.578 HBS1 R102 and R104 2R + 132 (HPG) x 2 
2 1044.511 125GYNTYASRL133 1176.21 1176.532 HBS1 R132 1R + 132 (HPG) 
3 1429.813 155VSVNGKGRPRRGF177 1827.49 1827.87 HBS1 R162, R164 and R165 3R + 132 (HPG) x 2 + 134 
4 1451.681 184DHRDHEMVRQL195 1715.15 1715.723 R186 and R192 2R + 132 (HPG) x 2 
5 1508.782 221EPSHVQASRLGSQL264 1641.61 1641.803 R229 1R + 134 
6 1513.819 55HLQLHPSGRVNGSL68 1645.96 1645.84 HBS1 R63 1R + 132 (HPG) 
7 1533.76 179LPRVLDHRDHEM190 1801.79 1801.81 R181 and R186 2R + 134 x 2 
8 1542.788 26RRDAGGRGGVYEHL39 1926.57 1926.86 R26, R27 and R32 3R + 134 + 134 + 116 
9 1552.882 37EHLGGAPRRRKLY48 1950.34 1951.96 HBS3 R44, R45 and R46 2R + 132 (HPG) x 2 + 134 
10 1561.732 112SAECEFVERIHEL124 1693.15 1693.753 HBS1 R120 1R + 132 (HPG) 
11 1592.877 154YVSVNGKGRPRRGF177 1989.04 1988.94 HBS1 R162, R164 and R165 3R + 132 (HPG) x 3 
12 1686.98 77EITAVEVGIVAIRGLF92 1819.00 1819.00 HBS1 R89 1R + 132 (HPG) 
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Table 5.14A: FGF22 peptide analysis based on prediction by Prospector. The reference number (Ref.no.) of the peptide is column 1. The two 
columns under “Native FGF22” present the predicted m/z and sequence of each peptide after digestion of FGF22 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF22 P&L” present the 
predicted and observed m/z for FGF22 after selective labelling. FGF22 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF22. The final column indicates the 
modification occurring on the arginine residues of peptides. 
  Native FGF22 FGF22 protect and label (P&L) 
 Ref.
no. 
Predicted native 
peptide m/z 
Sequence 
m/z 
observed 
Predicted modified 
peptide m/z 
Published HBS. Modifications 
1 925.485 57RHGQDSIL74 1040.96 1041.50 R67 1R + 116 
2 1483.788 54RVDPGGRVQGTRW66 1747.74 1747.83 HBS1 R54 and R60 2R + 132 (HPG) x 2 
3 1398.742 94YVAMNRRGRLY104 1794.77 1794.806 HBS1 R99, R100 and R102 3R + 132 (HPG) x 3 
4 2054.159 140LALDRRGGPRPGGRTRRY158 2714.31 2714.21 
HBS1 R145, R146, R150, R153, 
R155 and R156 
6R + 132 (HPG) x 5 
5 2054.159 140LALDRRGGPRPGGRTRRY158 2848.13 2846.23 
HBS1 R145, R146, R150, R153, 
R155 and R156 
6R + 132 (HPG) x 5 + 134 
6 2146.017 116RERIEENGHNTYASQRW132 2674.2 2674.102 HBS1 R116, R118 and R131 3R + 132 (HPG) x 3 
7 2533.303 95VAMNRRGRLYGSRLYTVDCRF115 3077.72 3077.66 
R107 
HBS1 R99, R100, R102 and R114 
5R + 132 (HPG) x 4 and 
oxidation 
8 2533.303 95VAMNRRGRLYGSRLYTVDCRF115 3077.72 3077.66 
R107 
HBS1 R99, R100, R102 and R114 
5R + 132 (HPG) x 4  + 250 
and oxidation 
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Table 5.14B: FGF22 peptide analysis based on prediction by PeptideMass. The reference number (Ref.no.) of the peptide is column 1. The 
two columns under “Native FGF22” present the predicted m/z and sequence of each peptide after digestion of FGF22 by chymotrypsin. The bold 
arginines in the 3rd column (“Sequence”) are those identified as labelled with HPG. The first two columns under “FGF22 P&L” present the 
predicted and observed m/z for FGF22 after selective labelling. FGF22 bound to a heparin affinity column (protection step) was reacted with PGO, 
following elution, then arginine residues of binding sites exposed to solvent were reacted with HPG (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [36], [183] to be in an HBS of FGF22. The final column indicates the 
modification occurring on the arginine residues of peptides. 
  Native FGF22 FGF22 protect and label (P&L) 
 Ref
.no. 
Predicted 
native peptide 
m/z 
Sequence 
m/z 
observe
d 
Predicted modified 
peptide m/z 
Published HBS. Modifications 
1 925.485 57RHGQDSIL74 1040.96 1041.50 R67 1R + 116 
2 1398.742 94YVAMNRRGRLY104 1794.77 1794.80 HBS1 R99, R100 and R102 3R + 132 (HPG) x 3 
3 1596.87 53LRVDPGGRVQGTRW76 1994.99 1994.94 R76 ; HBS1 R54 and R60 3R + 132 (HPG) x 2  + 134 
4 2871.58 144DRRGGPRPGGRTRRYHLSAH163 3522.49 3522.54 
HBS1 R145, R146, R150, R153, 
R155 and R156 
5R + 132 (HPG) x 5 
5 1160.65 132RRRGQPMFL141 1540.73 1540.71 HBS1 R132, R133 and R134 3R + 132 (HPG) x 2 + 116 
6 1333.712 37EGDVRWRRLF46 1732.81 1732.78 HBS3 R41, R43 and R44 3R + 132 (HPG) x 2 + 134 
7 1186.644 37EGDVRWRRL45 1585.75 1585.71 HBS3 R41, R43 and R44 3R + 132 (HPG) x 2 + 134 
8 2447.348 75EIRSVHVGVVVIKAVSSGFY94 2579.34 2579.37 HBS3 R77 1R + 132 (HPG)  
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Table 5.14C: Selective labelling of lysine residues. FGF22 peptide analysis based on prediction by PeptideMass. The reference number of 
the peptide is followed by the predicted m/z and with the sequence of the peptide following cleavage of native FGF22 by chymotrypsin.  The two 
columns under “Native FGF22” present the predicted m/z and sequences of peptides after chymotrypsin digestion of FGF22. The first two columns 
under “FGF22 protect and label (P&L)” present the observed and predicted m/z for FGF22 after modifications of lysine residues. The third column 
is the assignment of the peptide to one of the three HBSs of FGF22 [36], [183]. The final column indicates the modification occurring on the lysine 
residues of the peptides. 
 Native FGF22 FGF22 protect and label (P&L) 
Ref.no. 
Predicted 
native 
peptide m/z 
Sequence 
m/z 
observed 
Predicted modified 
peptide m/z 
Published HBS. Modifications 
1 3199.8 75EIRSVHVGVVVIKAVSSGFYVAMNRRGRL103 3431.57 3431.81 HBS1 K87 1K + 232 (biotin)  
2 2146.202 75EIRSVHVGVVVIKAVSSGFY94 2377.15 2378.212 HBS1 K87 1K + 232 (biotin) 
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CHAPTER 6 ELECTROSTATIC INTERACTIONS BETWEEN 
FIBROBLAST GROWTH FACTORS OF FGF7 SUBFAMILY AND 
CHONROITIN SULFATE, DEMATAN SULFATE IN SOLUTION 
6.1 INTRODUCTION 
For a variety of reasons, the protein interactions of heparin and HS attract more interest than 
those of other GAGs. The commercial availability of heparin means that there is a readily 
available experimental proxy for HS, including in the form of affinity chromatography 
supports. However, the relative homogeneity of heparin’s sulfation and IdoA content compared 
to HS does not reflect the diversity of sulfation of HS, which is in at least some instances key 
for the selectivity of interaction with a protein partner (Section 1.3.3.1). CS and DS are 
abundant in the extracellular matrix (Section 1.3.2.2). Compared to HS and heparin, the number 
of known protein partners established for CS or DS is far more limited, which may reflect in 
part the absence of off the shelf affinity chromatography supports for these GAGs. Examination 
of GAG preferences for the paracrine FGFs [37] [36] indicates that at least some FGFs do 
engage CS and/or DS, though apparently less strongly than heparin. This is the case for 
members of the FGF7 subfamily [37] [36] [127], which bind CS species, including DS. To gain 
an understanding of whether these CS species may engage proteins through the same binding 
site(s) as heparin, an “in solution” selective labelling protocol was developed using commercial 
CS and DS. Importantly, such a protocol would bypass the requirement for an affinity column, 
which has hindered the wider application of the protect and label strategy to any protein 
interaction involving basic residues. For example, the analysis of the FGF2-pleiotrophin 
interaction required the immobilisation of the FGF2, and achieving this in a way that did not 
affect its interactions with its protein partner  presented a major challenge [189]. 
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The FGF7 subfamily comprises FGF3, FGF7, FGF10 and FGF22 (Section 1.2.1). Their 
binding properties to HS, CS, DS and various modifications of heparin have been studied using 
differential scanning fluorimetry (DSF) [37][36]. Briefly, DSF provides information on the 
melting temperature of protein and how this changes upon binding to a GAG. In these studies, 
whereas FGF-3 interacted with DS but not CS, FGF7 and FGF10 bound both CS and DS, 
though the former more weakly [37][36]. The in solution selective protect and labelling method 
was initially developed for lysine residues, due to the simpler analysis of the mass spectrometry 
data.  
6.2 RESULTS 
6.2.1 FGF7 
The lysine residues on FGF7 contributing to the engagement to heparin identified in a previous 
study [36] were assigned to HBS1 (K170, K177, K178, K180 and K181 in the core of the canonical 
HBS-1, K155 of β-strand IX, K123 and K126 on the loop of β-strands VI-VII) and HBS4 (K81 and 
K84 ) on the loop of β-strands II-III. There are no lysines in the HBS-3 of FGF7, since it is 
composed entirely of arginine residues (Section 5.2). Here, the interactions between FGF7 and 
other sulfated GAGs, CS/DS, were determined using in-solution selective labelling, which 
bypasses the need for an affinity matrix. First, heparin in solution was used, to enable method 
development to be benchmarked to the previous work done using a heparin affinity column.  
This method was then applied to CS and DS (Section 2.7).  
6.2.1.1. The interaction of FGF7 with heparin performed in PB buffer containing 50 mM 
NaCl 
The selective labelling of lysine residues in solution starts with a protection step, in which the 
solvent exposed lysine side chains of protein bound to heparin are reacted with NHS-acetate, 
which yields a single acid, stable product. Following the removal of NHS-acetate and 
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dissociation of protein and heparin using 3 M NaCl (Section 2.9), any residues engaged with 
heparin will now be exposed to solvent and is able to react with the added NHS-biotin. 
Biotinylated peptides are readily purified prior to mass spectrometry [120]. The resulting 
peptides with information about modification, sequence, and final m/z are presented in Tables 
1A and the spectra are in Supplementary Figs 6.1A. 
Using the list of peptides generated by Prospector, seven peptides containing the biotinylated 
lysine residues were identified (Table 1A). A number of biotinylated lysine residues 
corresponded to ones identified previously [36], but there were differences. 
A first difference was on β-strand V, since K111 was found to be labelled by NHS-biotin 
(peptide 6, Table 1A) and so engaged to heparin, whereas when the interaction was performed 
on the heparin affinity mini column, this lysine was exposed to solvent, hence not involved in 
heparin binding [36]. The second difference is the status of K130, K131 and K140. Peptides 5 and 
7 (Table 1A) are sisters, containing two adjacent lysine residues K130 and K131 on β-strand VII 
and K140 on β-strand VIII. However, whereas peptide 5 possessed the mass shift of three NHS-
biotin products meaning that all three lysines were biotinylated and bound to heparin, in peptide 
7 showed only two out of three lysine residues reacted with NHS-biotin and one reacted with 
NHS-acetate, hence was not bound to heparin. Moreover, in peptide 2 (Table 1A) K140 was 
biotinylated so this lysine was engaged to heparin. Importantly, K130, K131 and K140 were not 
labelled when the interaction was performed on an affinity mini-column [36], indicating a 
significant difference in the dynamic of interactions depending on whether the polysaccharide 
was free in solution or linked to a chromatography support. It could be interpreted that an 
individual bond between protein and heparin was transient over the time of the protection 
reaction and its reaction with NHS-acetate prevented re-binding. 
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Other lysine residues, all assigned to HBS1 [36], were labelled, and so engaged to heparin: 
K123 and K126 on the loop of β-strand VI-VII  (peptide 3, Table 1A; K155 on β-strand IX ( peptide 
1, Table 1A); the core five lysines of HBS-1, K170, K177, K178, K180 and K181 (peptide 4, table 
1A). 
The binding state of K81 and K84 on the loop of β-strand II-III was not addressed here, since no 
peptide with those lysine residues in the sequence was identified. This is due to the use of 
chymotrypsin as protease on modified FGF7 resulting in peptides that are either too short or 
too long for identification by MALDI-TOF MS. 
6.2.1.2. The interaction of FGF7 with CS performed in PB buffer, 10 mM NaCl  
In DSF assays, the thermal stability of FGF7 was increased by CS than by DS and HS, which 
in turn were less effective than heparin [36]. This suggests that the binding of FGF7 to CS is 
weaker than to the other GAGs. Consistent with this interpretation, when the interaction 
between FGF7 and CS was conducted in PB buffer containing 50 mM NaCl, as was done for 
heparin (Section 6.2.1.1), all lysines were protected and none were labelled with biotin (Data 
not shown). This may have been due to the weaker interaction of FGF7 with CS, resulting in 
the individual bonds being transient over the time of the protection reaction. This has been seen 
previously, for example, with neuropilin-1 [157]. In the latter case, although the protein has a 
very high affinity for heparin (~ nM), and it bound to the heparin column, upon application of 
NHS-acetate it eluted. The interpretation was that individual bonds between protein and 
heparin were dynamic, and reaction with NHS-acetate prevented re-binding, resulting in the 
protein ‘peeling off’ the heparin.  The solution in this instance was to reduce the concentration 
of electrolytes in the mobile phase. The same strategy was used here. FGF7 was, therefore, 
bound to CS in phosphate buffer containing 10 mM NaCl. Under these conditions not all lysine 
residues were protected. Following the addition of NaCl to 3 M to dissociate the sugar-protein 
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complex, the lysine residues previously bound to GAG were now exposed to solvent and 
reacted with NHS-biotin. The protein was then incubated with chymotrypsin to generate 
peptides, which were analysed by MALDI-TOF MS. Six peptides were identified when FGF7 
was bound to CS in PB buffer containing 10 mM NaCl (Table 1B). 
K111 on β-strand V reacted with NHS-biotin (peptide 4, Table 1B) and so was bound to CS, 
which was alike to its status in the heparin “in solution” work (Section 6.2.1.1). This is in 
contrast to the protection (acetylation of this residues when the reaction was performed on a 
heparin affinity mini column [36]. Peptide 6 (Table 1B) contains two adjacent lysine residues, 
K130 and K131 on β-strand VII, and K140 on β-strand VIII. This peptide had a mass shift 
corresponding to two biotins and one acetate, hence only two out of three lysine residues were 
bound to CS. Again, though these lysine residues were bound to heparin in solution, they were 
not when the analysis was performed on a mini-affinity column [36]. 
The HBS-1 lysine residues [36], K123 and K126   (peptides 1 and 3, Table 1B), K155 (peptide 2, 
table 1B) and those in the core of HBS-1, K170, K177, K178, K180 and K181 were all labelled 
(peptide 6, Table 1B), as found for heparin in solution (6.2.1.1). As for heparin, (Section 
6.2.1.1), K81 and K84 were missing from the analysis.  
6.2.1.3. The interaction of FGF7 with DS performed in PB buffer, 10 mM NaCl  
The list of the five peptides containing biotinylated lysines when FGF7 bound to DS in 10 mM 
NaCl, PB buffer is in Table 1C. There were differences from what had been observed when 
FGF7 was bound to a heparin affinity mini-column or in solution and when FGF7 bond CS in 
solution. Thus, three lysines K130, K131 on β-strand VII and K140 on β-strand VIII were all 
biotinylated, since the mass shift of peptide 4 corresponded to that of three biotin products 
(Table 1C). In contrast only two of K130, K131 and K140 were found to be biotinylated when 
FGF7 bound to heparin in solution (Section 6.2.1.1) or to CS (6.2.1.2), whereas when FGF7 
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bound to a heparin affinity column, these residues were not labelled. This observation indicated 
that FGF7 binds DS differently to heparin and CS. 
The remaining labelled lysines, K123 and K126 (peptide 3, Table 1C), K155 (peptide 1, Table 1C), 
K170, K177, K178, K180 and K181 (peptide 5, Table 1C),  all in HBS1 [36] were consistent with 
those identified with CS and heparin in solution and heparin in an affinity column and, as for 
heparin and CS, K81 and K84 were not observed.  
6.2.1.4. Location of labelled lysine residues on the surface 
Surprisingly, the pattern of labeled lysines identified by the protect and label experiments with 
heparin, CS and DS in solution were more similar to each other (Section 6.2.1.1, 6.2.1.2 and 
6.2.1.3) than to the experiments using a heparin affinity column [36]. Thus, K130, K131 and K140 
were only labelled when FGF7 bound heparin was in solution, and two of these three lyines 
were labelled when FGF7 bound CS or DS. It may be that these interactions were only detected 
because the concentration of electrolytes (50 mM NaCl for heparin and 10 mM NaCl for CS, 
DS) was below the physiologically relevant concentration (~140 mM) used in the experiments 
with a heparin affinity column. However, several lines of evidence suggest that the identified 
interactions are relevant. First, not all lysine amino acids were protected/labelled, indicating 
that binding remains selective at the lower concentrations of electrolytes. Second, there are 
lysine residues which were labelled when protein bound to heparin on a chromatography 
support, but were protected when the interactions were in solution, for example, K160 of FGF3 
(Section 6.2.2) or three lysine residues, K183, K191 and K195 in the core area of HBS-1 of FGF10 
(Section 6.2.3). Third, whereas heparin and CS bound two of, K130, K131 and K140, DS bound 
all three. Fourth, the location of these lysine residues on the surface of FGF7 is consistent with 
the proposed sites of interaction, determined by previous work [36] and the arginine protect 
and label experiments (Section 4.2). 
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On the surface, K140 is adjacent to the core of HBS-1 (Figure 6.1). Thus, though distant in the 
sequence, K140 is on the surface a neighbour of K177 and K123 (Figure 6.1).  The fact that heparin 
on the affinity column did not engage this residue may due to steric effects caused by the 
immobilisation of the polysaccharide. In addition, K111, which was also only labelled when 
FGF7 bound polysaccharides in solution, is adjacent to R101 and R67 (Figure 6.1), which have 
been assigned to HBS-3 (Section 5.2). Next to K111 are K130 and K131, which were similarly 
only labelled when FGF7 bound to GAG in solution (Sections 6.2.1.1, 6.2.1.2 and 6.2.1.3) 
(Figure 6.1). Importantly, the addition of these residues into the binding site connects HBS-3, 
which was isolated previously, to HBS-1 and HBS-4 (Section 5.2). This implies that HBS-3, 
defined when FGF7 was bound to heparin beads is in fact an extension of HBS-4 or HBS-1; 
because they are orthogonal on the surface, HBS-1 and HBS-1 remain as independent binding 
sites, that is they cannot bind a single polysaccharide chain.  
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Figure 6.1: Labelled lysine residues in GAG-binding sites of FGF7. The FGF7 structure 
(PBD code 1qqk) is shown as a surface. Locations of lysine residues engaging heparin/CS/DS 
on the sequence. FGF7 sequence, Uniprot code: P21781-1. A) K81, K84, K123, K126, R175, K177, 
K178, K180, K181 and K184 are indicated. Lysine residues which engage heparin beads on the 
affinity column are coloured as blue. B and C) Lysine residues bound to heparin/CS/DS in 
solution, but not heparin beads are coloured as pink. Positions of K111, K130, K131 and K140 
relative to the core of HBS-1 on the surface. D) Positions of lysine residues involved in 
engagement of heparin/CS/DS in solution are indicated on the sequence. 
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6.2.2 FGF3 
The lysine residues involving in the engagement of FGF3 to heparin have been identified by 
selective labelling on a heparin affinity mini-column, followed by mass spectrometry analysis 
[37]. They are K53 on the loop of β-strand II-III, K101 on the loop of β-strand VI-VII, K160 and 
K168 in the core of the canonical HBS-1. Here, the interactions between FGF3 and DS were 
determined using in-solution selective labelling, but not those with CS, because DSF showed 
that any interaction between FGF3 and CS is too weak to detect or has no effect on the thermal 
stability of the protein [37]. 
6.2.2.1 The interaction of FGF3 with heparin 
Using the approach used with FGF7 (Section 6.2.1), FGF3 was bound heparin in phosphate 
buffer containing 50 mM NaCl and NHS-acetate was used for the protection of exposed lysine 
residues. Following the addition of NaCl to 3 M to dissociate the sugar-protein complex, NHS-
biotin was added to react with the lysine residues previously bound to GAG that were now 
exposed to solvent. The list of the six peptides containing biotinylated lysine residues was 
provided in Table 2A.  
Differences were observed between lysine residues bound to heparin in solution here and the 
ones identified previously using a heparin affinity column [37]. First, on β-strand I, K47 was 
found to be labelled by NHS-biotin (peptide 3, Table 2A) and so engaged to heparin. In 
contrast, this lysine reacted with sulfo-NHS-acetate when the interaction between FGF3 and 
heparin was conducted on a heparin mini-affinity-column [37]. The second difference was the 
status of K160 and K174. Peptide 6 (Table 2A) contains three lysine residues of the canonical 
HBS-1 [37], K160, K168 and K174, showing the mass shift corresponding to two biotin reactions 
and one acetyl modification. Meanwhile, in peptide 2 (Table 2A) that has two lysine residues, 
K168 and K174, and both were labelled. Consequently, it could be deduced that K160 reacted with 
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NHS-acetate and was not involved in the interaction with heparin. In contrast, when FGF3 
bound to heparin on a chromatography support, K160 bound to heparin and K174 did not [37]. 
This change of binding status of K160 provides evidence that in 10 mM NaCl, phosphate buffer, 
heparin does not bind indiscriminately to basic residues and so indicates that the observed 
pattern of interaction is likely to reflect a true binding mode of FGF3 to heparin (Section 
6.2.1.4).  
The other biotinylated residues are identical to those identified previously using a heparin 
affinity column [37] is K53 on the loop between β-strands I and II (peptide 1, Table 1A), K101 
on the loop between β-strands VI VII (peptides 4 and 5, Table 1A).  
6.2.2.2 The interaction of FGF3 with DS performed in PB buffer 10 mM NaCl 
When FGF3 bound to DS, seven peptides were found to contain biotinylated lysine residues 
(Table 2B). Similar to when FGF3 bound heparin in solution (Section 6.2.2.1), K47 on β-strand 
I was found to engage to DS (peptide 6, Table 2B). In contrast, K160 (Section 6.2.2.1 and [37]) 
was labelled by NHS-biotin (peptide 4, Table 2B), hence was engaged to DS in solution, 
whereas this residue was biotinylated when FGF3 bound heparin on an affinity column [37], 
but not heparin in solution (Section 6.2.2.1). Peptide 7 contains three lysine residues K160, K168 
and K174, but only two were modified by biotin and the other by NHS-acetate (Table 2B). 
Because K160 was already identified as being labelled (peptide 4, Table 2B), along with the 
evidence from initial work on FGF3 on the affinity column [37], it is likely that K168  not K174 
bound DS in solution. This conclusion is in accord with the labelling pattern of lysines when 
the interaction between FGF3 and heparin was on an affinity-column [37], but not in solution 
(Section 6.2.2.1).  
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K53 (peptide 1, Table 2B) and K101 (peptides 2, 3 and 5, Table 2B) behaved similarly to when 
FGF3 bound to heparin in both contexts, on the chromatographic support [37] and in solution 
(Section 6.2.2.1). 
6.2.2.3 Location of labelled lysine residues in FGF3 on the surface 
Although not involved in binding to heparin on beads, K47 engages to both heparin and DS in 
solution. On the surface this lysine is adjacent to K53 (Fig 6.2) which has been assigned to HBS-
1 [37], indicating the potential for the sugar chain to crossover. 
Distinct from its state when FGF3 bound to heparin on beads, K160 did not engage heparin in 
solution. This lysine was originally assigned to HBS-1. On the surface, this lysine is located at 
the end of HBS-1 (Fig 6.2). Hence, the lack of engagement of this lysine to heparin in solution 
may indicate a shorter heparin chain involved in binding FGF3. 
On the other hand, K174 is labelled when FGF3 bound to heparin and DS in solution, but not on 
a heparin mini-column. On the surface, this lysine is nearby the arginine residues of HBS-1 
and K168 (Fig 6.2). This observation implies the different binding preference of GAG on FGF3 
in solution compared to that found on an affinity chromatography column. 
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Figure 6.2: Labelled lysine residues in GAG-binding sites of FGF3. The model of FGF3 
structure is constructed from the crystal structure of FGF7 (PBD code 1qqk). Locations of 
lysine residues engaging heparin/CS/DS on the sequence. FGF3 sequence, Uniprot code: 
P11487-1. A) Lysine residues which engage heparin beads on the affinity column are coloured 
blue. K53, K101, K160 and K168 were indicated. B) Lysine residues bound to heparin/ DS in 
solution, but not heparin beads are coloured as pink. Positions of K47 and K174 relative to the 
core of HBS-1 on the surface. C) Positions of lysine residues involved in engagement of 
heparin/DS in solution are indicated on the sequence. 
6.2.3 FGF10 
The lysine residues involving in the engagement of FGF10 to heparin identified previously  
[37] are K81 on the loop between β-strands I-II; K86, K94 and K97 on the loop between β-strands 
II-III; K136, K137 and K139 on the loop between β-strands VI-VII; K183, K191, and K195 in the core 
of the canonical binding site. It has been showed that FGF10 interacts with both CS or DS [37]. 
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The peptides identified as containing biotinylated lysine residues when FGF10 bound to 
heparin, CS and DS are in Tables 3A, 3B, 3C. 
6.2.3.1 Lysine residues involving in the engagement of FGF10 to heparin 
Using the same approach as for FGF7 (Section 6.2.1) and FGF3 (Section 6.2.2), FGF10 was 
bound heparin in phosphate buffer containing 50 mM NaCl. NHS-acetate and NHS-biotin were 
then used for the protection of exposed lysine residues and then labelling of lysines involved 
in binding, respectively. Five peptides containing lysine residues were identified when FGF10 
engaged heparin in solution (Table 3A). The differences were observed between lysine residues 
bound to heparin in solution here and the ones identified previously [37]. 
A first difference is the status of K81. Peptide 4 (Table 3A) contains two lysine residues K81 
and K86, but showed a mass shift corresponding to one modification of biotin and one of acetyl, 
indicating that one lysine was biotinylated and the other was acetylated. Since peptide 1 (Table 
3A) had the mass shift of the NHS-biotin reaction product, K86 was bound to heparin in solution 
and K81 was acetylated. In contrast, this lysine was defined as part of HBS-3 when FGF10 
bound to the heparin affinity column [37]. A second difference is shown by peptide 5 (Table 
3A), which has a mass shift corresponding to two products of acetylation, indicating that two 
lysine residues K94 and K97 in its sequence were both acetylated. Hence similar to K81, K94 and 
K97 were not involved in binding heparin in solution in contrast to when FGF10 bound to 
heparin in the context of a chromatography support [37]. 
The other lysine residues shown previously to  be engaged to heparin [37] were also observed 
to be biotinylated when FGF10 bound heparin in solution: K136, K137 and K139 on the loop 
between β-strands VI-VII (peptide 3, Table 3A); K183, K191 and K195 in the core of the canonical 
HBS1 (peptide 2, Table 3A). 
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6.2.3.2 Lysine residues involving in the engagement of FGF10 to CS 
When FGF10 bound CS in solution in phosphate buffer containing 10 mM NaCl six peptides 
containing lysine residues were identified as modified by biotin (Table 3B). There were 
differences observed between lysine residues bound to CS in solution and the ones bound to 
heparin in solution (Section 6.2.3.1) and on an affinity column [37]. 
In contrast to what was found when FGF10 bound to heparin in solution (Section 6.2.3.1), but 
similar to FGF10 bound to a heparin affinity column [37], K81 on the loop between β-strands 
I-II was engaged to CS, because it was biotinylated (peptide 2 and 4, Table 3B). Moreover, 
FGF10 bound to CS compared to FGF10 bound to heparin in solution and on beads had 
different labelling in the loop between β-strands VI-VII (K136, K137 and K139).  Peptide 3 (Table 
3B) contains these lysine residues and showed a mass shift corresponding to one biotin and 
two acetyl groups, so only one of these lysines bound to CS, whereas all three bound to heparin 
([37] and Section 6.2.3.1). K153 which was not found to bind to heparin (Section 6.2.3.1 and 
[37]) was biotinylated (peptide 5, Table 3B), indicating that it was engaged to CS in solution. 
Finally, of three lysine residues, K183, K191 and K195 in the core area of HBS-1, only one reacted 
with NHS-biotin and two were acetylated (peptide 6, Table 3B). This indicates a fundamental 
difference in how FGF10 engages CS compared to heparin. The only residue which retained 
its binding state compared to heparin (Section 6.2.3.1 and [37]) was K86,since peptide 1 showed 
a modification corresponding to biotinylation (peptide 1, Table 3B).  
6.2.3.3 Lysine residues involved in the engagement of FGF10 to DS 
FGF10 was then bound to DS in solution and following acetylation, lysine residues involved 
in binding DS were biotinylated. Six peptides containing biotinylated lysine residues were 
identified (Table 3C). Again there were differences to the data acquired with a heparin affinity 
column, and heparin and CS in solution. Interestingly, peptide 6 (Table 3C) showed a mass 
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shift of two NHS-biotin reaction products, indicating that both lysine residues bound to DS in 
solution. Peptide 6 encompasses the loop between β-strands III-IV and contains K102 and K103, 
so this identifies a new area of binding sites on the FGF10 surface. As with CS, but different 
from heparin, K81 and K86 were found to interact with DS (peptides 1 and 4, Table 3C). Peptide 
3 and 4 (table 3C) contains three lysine residues K136, K137 and K139, but two were acetylated 
and only one was biotinylated. Thus, only one out of these three lysines bound to DS, which 
was similar what was observed with CS (Section 6.2.3.2). Again, for the core of HBS-1, 
covered by peptide 5 (Table 3C), of K183, K191 and K195, one was biotinylated and the other two 
acetylated as seen with CS (Section 6.2.3.2)  
6.2.3.4 Location of labelled lysine residues on the surface 
When FGF10 bound to heparin in solution, K91, K94 and K97, which were previously assigned 
to HBS-4 (Section 5.2) were not labelled, indicating that heparin did not engage HBS-4 in 
solution and only bound to HBS-1 (Fig 6.3). The HBS-3 of FGF10 contains only arginine 
residues, hence, engagement of HBS-3 could not be addressed. 
In the case of CS and DS in solution, one of three K136, K137 and K139 was labelled, however, 
since MADLI-TOF only provides the information of the overall mass shift, it could not be 
concluded which lysine was involved in binding. The positions of these three lysines were 
shown on the surface (Fig 6.3).  K139 is adjacent to K97, which was acetylated, so it is less likely 
to be involved in binding. K137 is closer to R188 of HBS-1 than K136 (Fig 6.3). These 
observations implied that K137 was involved in GAG binding. 
K153 only bound to CS and this lysine neighbours to R155 of HBS-1 (Fig 6.3). K102 and K103 
only bound to DS, but not heparin or CS in solution. These lysine residues are adjacent to K86 
which was also biotinylated. K86 was assigned by the previous work on heparin on beads to 
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HBS-4 [37]. The addition of K102 and K103 in fact extended the area of HBS-4, making the T-
shape formed by HBS-4 and HBS-1 become larger when protein bound to DS. 
Of the three lysine residues of the core of HBS-1, K183, K191 and K195, only one was engaged 
to CS/DS. On the surface, K183 is closer to the group of labelled residues including K86, K102 
and K103 so maybe this residue is the one which was biotinylated. The acetylation of two lysine 
residues in the core of HBS-1 when FGF10 bound to CS/DS in solution indicates a significant 
difference in how the protein engages these GAGs compared to heparin.  
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Figure 6.3: Labelled lysine residues in GAG-binding sites of FGF10. The FGF10 structure 
(PBD code 1nun) is shown as a surface. Locations of lysine residues engaging heparin/CS/DS 
on the sequence. FGF10 sequence, Uniprot code: O15520-1. A) The information on arginine 
residues which bound to heparin on the chromatography support (Section 5.2) is also presented. 
Lysine residues which engage heparin beads on the affinity column are coloured blue. B) 
Positions of lysine residues involved in engagement of heparin/CS/DS in solution are indicated 
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on the sequence. C and D) Lysine residues bound to heparin/CS/DS in solution, but not heparin 
beads are coloured pink. Lysine residues engaging heparin, but not bound to heparin/CS/DS in 
solution are coloured green.  
6.3 DISCUSSION 
The selective labelling in solution opens a new perspective of studying protein - GAG 
interactions. FGF3, FGF7 and FGF10 all belong to the FGF7 sub-family, and, as demonstrated 
by previous work on selective labelling of arginine and lysine [37] [36] (Section 5.2) using an 
affinity column, they share a similar architecture of heparin binding sites, consisting of three 
independent binding sites, HBS-1, HBS-3 and HBS-4,. However, their interactions with 
different GAGs in solution are distinct. For FGF7, K130, K131 on β-strand VII and K140 on β-
strand VIII  bind to DS in solution, but not to heparin on a chromatography support [36]. This 
area of binding was not detected when FGF3 or FGF10 bound to GAG in solution. In addition, 
for FGF3 and FGF7, the lysine residues in the core of HBS-1 also bound GAGs in solution 
(Section 6.2.1 and Section 6.2.2), however, this was not the case for FGF10, in which only one 
of these three lysine residues in the core of HBS-1 was biotinylated (Section 6.2.3). In FGF10 
K102 and K103 bound to DS, though not to CS or heparin. These residues are located on the loop 
between β-strands III-IV, an area that has not been implicated in GAG binding in other 
members of FGF7 subfamily. 
The addition of lysine residues when a FGF of FGF7 subfamily bound to GAG in solution 
sometimes extended the region of HBS-4, making the T-shaped basic patch formed by HBS-1 
and HBS-4 become large, for example, K102 and K103 of FGF10 when this protein bound to DS 
in solution (Section 6.2.3). In contrast, the absence of some lysines in binding may alter the 
binding pattern of GAG to the protein, for instance, K160 of FGF3 when it interacts with DS in 
solution (Section 6.2.2) which seems to shorten the length of binding pattern on HBS-1.  
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The addition of K111, K130 and K131 when FGF7 bound to GAGs irrespectively in solution raised 
an interesting point that the HBS3 and the rest of positively charged surface containing HBS-
1 and HBS-4 are connected. Hence, there is no acidic border between them. As raised before a 
sugar chain cannot bend over to reach HBS-1 and HBS-4 which are orthogonal to each other. 
Hence, K111, K130 and K131 should contribute to either HBS-1 or HBS-4. This conclusion may 
require further analysis, especially the electrostatic potential of FGF7 surface. 
The selective labelling of lysines in solution with different GAGs makes it possible to study 
the interactions of proteins with any GAG, or indeed acidic partner. However, the apparent 
requirement of a reduced concentration of electrolytes, is a concern, since it may result in 
artefactual interactions being identified. However, as argued (Section 6.2.1), the fact that the 
main observation is a shift in labelled lysine residues, rather than simply an increase in these, 
strongly suggests that any such artefacts are limited. There is, nevertheless, scope for a more 
detailed examination of the effects of electrolytes and of GAG chain immobilisation on binding 
of proteins.  
One such question to tackle is the effect of reducing electrolytes which may be more complex 
than simply increasing electrostatic bonds. Regarding that, one major conclusion is that these 
FGFs have an “adaptable” surface which is able to accommodate different GAGs that present 
charged groups on different spatial dispositions. This would reflect a functional requirement 
for such adaptability. These observations may indicate that the evolutionary selectivity impacts 
differently on the interactions of FGF family and GAGs. Interactions between members of 
FGF7 family to heparin may be highly conserved but not in relation to other GAGs. This 
demonstrated the difference in selectivity of FGF10 toward DS compared to CS and heparin 
which may be underlined by the structural features of DS. 
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Table 6.1A: FGF7 interaction with heparin, MS analysis. The reference number (Ref.no.) of the peptide is column 1. The two columns under 
“Native FGF7” present the predicted m/z and sequence of each peptide after digestion of FGF7 by chymotrypsin. The bold lysines in the 3rd column 
(“Sequence”) are those identified as labelled with NHS-biotin. The first two columns under “FGF7 heparin” present the predicted and observed 
m/z for FGF7 after in-solution selective labelling. FGF7 bound to heparin (protection step) was reacted with NHS-acetate, following dissociation, 
then lysine residues of binding sites exposed to solvent were reacted with NHS-biotin (labelling step). The 3rd column identifies the peptide as 
being considered from sequence alignment in the literature [102] to be in an HBS of FGF7. The final column indicates the modification occurring 
on the lysine residues of peptides. 
  Native FGF7 FGF7 heparin 
 Ref.
no. 
Predicted 
native peptide 
m/z 
Sequence Predicted 
modified peptide 
m/z 
m/z 
observed 
Match HBS Modifications 
1 578.29 152ASAKW156 810.3033 810.1159 HBS-1 K155 1K + 232 (biotin) 
2 615.4076 140KELIL144 847.4176 847.3779 K140 1K + 232 (biotin) 
3 1329.69 118YLAMNKEGKLY128 1793.71 1793.97 HBS-1 K123 and K126 2K + 232 (biotin) x 2 
4 2423.40 168NQKGIPVRGKKTKKEQKTAHF188 3623.90 3623.81 HBS-1 K170, R175, K177, K178, 
K180, K181 and K184 
6K + 232 (biotin) x 5 + 
42 (acetyl) 
5 2603.1905 128YAKKECNEDCNFKELILENHY145 3299.9260 3299.2205 K130 and K131; K140 3K + 232 (biotin) x 3 
6 2667.44 96NIMEIRTVAVGIVAIKGVESEFYL119 2900.45 2900.38 K111 1K + 232 (biotin) 
7 2981.34 128YAKKECNEDCNFKELILENHYNTY148 3487.37 3486.99 K130 and K131; K140 3K + 232 (biotin) x 2 + 
42 (acetyl) 
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Table 6.1B: FGF7 interaction with CS, MS analysis. The reference number (Ref.no.) of the peptide is column 1. The two columns under “Native 
FGF7” present the predicted m/z and sequence of each peptide after digestion of FGF7 by chymotrypsin. The bold lysines in the 3rd column 
(“Sequence”) are those identified as labelled with NHS-biotin. The first two columns under “FGF7 CS” present the predicted and observed m/z 
for FGF7 after in-solution selective labelling. FGF7 bound to CS (protection step) was reacted with NHS-acetate, following dissociation, then 
lysine residues of binding sites exposed to solvent were reacted with NHS-biotin (labelling step). The 3rd column identifies the peptide as being 
considered from sequence alignment in the literature [102] to be in an HBS of FGF7. The final column indicates the modification occurring on the 
lysine residues of peptides. 
  Native FGF7 FGF7 CS 
 Ref.
no. 
Predicted native 
peptide m/z 
Sequence Predicted modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 1069.53 120AMNKEGKLY128 1533.75 1533.751 HBS-1 K123 and K126 2K + 232 (biotin) x 2 
2 1499.66 145ENHYNTYASAKW156 1733.67 1733.98 HBS-1 K155 1K + 232 (biotin) 
3 1329.69 118YLAMNKEGKLY128 1793.71 1793.97 HBS-1 K123 and K126 2K + 232 (biotin) x 2 
4 2667.44 96NIMEIRTVAVGIVAIKGVESEFYL119 2900.45 2900.38 K111 1K + 232 (biotin) 
5 2980.34 128YAKKECNEDCNFKELILENHY145 3485.37 3485.86 K130 and K131; K140 3K + 232 (biotin) x 2+ 
42 (acetyl) 
6 2423.40 168NQKGIPVRGKKTKKEQKTAHF188 3623.90 3623.81 HBS-1 K170, R175, K177, 
K178, K180, K181 and K184 
6K + 232 (biotin) x 5 + 
42 (acetyl) 
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Table 6.1C: FGF7 interaction with DS, MS analysis. The reference number (Ref.no.) of the peptide is column 1. The two columns under “Native 
FGF7” present the predicted m/z and sequence of each peptide after digestion of FGF7 by chymotrypsin. The bold lysines in the 3rd column 
(“Sequence”) are those identified as labelled with NHS-biotin. The first two columns under “FGF7 DS” present the predicted and observed m/z 
for FGF7 after in-solution selective labelling. FGF7 bound to DS (protection step) was reacted with NHS-acetate, following dissociation, then 
lysine residues of binding sites exposed to solvent were reacted with NHS-biotin (labelling step). The 3rd column identifies the peptide as being 
considered from sequence alignment in the literature [102] to be in an HBS of FGF7. The final column indicates the modification occurring on the 
lysine residues of peptides. 
  Native FGF7 FGF7 DS 
 Ref.no. Predicted native 
peptide m/z 
Sequence Predicted modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 578.29 152ASAKW156 810.3033 810.1159 HBS-1 K155 1K + 232 (biotin) 
2 615.4076 140KELIL144 847.4176 847.3779 K140 1K + 232 (biotin) 
3 1019.56 119LAMNKEGKL127 1499.58 1499.60 HBS-1 K123 and K126 2K + 232 (biotin) x 2 and 
oxidation 
4 2059.98 128YAKKECNEDCNFKELIL142 2756.01 2755.87 K130 and K131; K140 3K + 232 (biotin) x 3 
5 2423.40 168NQKGIPVRGKKTKKEQKTAHF188 3623.90 3623.81 HBS-1 K170, R175, 
K177, K178, K180, K181 
and K184 
6K + 232 (biotin) x 5 + 
42 (acetyl) 
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Table 6.2A: FGF3 interaction with heparin, MS analysis. The reference number (Ref.no.) of the peptide is column 1. The two columns under 
“Native FGF3” present the predicted m/z and sequence of each peptide after digestion of FGF3 by chymotrypsin. The bold lysines in the 3rd column 
(“Sequence”) are those identified as labelled with NHS-biotin. The first two columns under “FGF3 heparin” present the predicted and observed 
m/z for FGF3 after in-solution selective labelling. FGF3 bound to heparin (protection step) was reacted with NHS-acetate, following dissociation, 
then lysine residues of binding sites exposed to solvent were reacted with NHS-biotin (labelling step). The 3rd column identifies the peptide as 
being considered from sequence alignment in the literature [102] to be in an HBS of FGF3. The final column indicates the modification occurring 
on the lysine residues of peptides. 
  Native FGF3 FGF3 heparin 
 Ref
.no. 
Predicted 
native peptide 
m/z 
Sequence Predicted modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 835.41 50CATKYHL56 1067.42 1067.58 HBS1 K53 1K + 232 (biotin) 
2 1204.71 168KTRRTQKSSL177 1668.73 1668.92 HBS1 K168 and K174 2K + 232 (biotin) x 2 
3 1173.70 40GGAPRRRKL48 1405.71 1405.78 HBS3 K47 1K + 232 (biotin) 
4 1668.91 91FSGRYLAMNKRGRL105 1900.92 1900.88 HBS1 K101 1K + 232 (biotin) 
5 1700.90 93SGRYLAMNKRGRLY106 1932.91 1933.03 HBS1 K101 1K + 232 (biotin) 
6 2762.58 155VSVNGKGRPRRGFKTRRTQKSSLF172 3268.61 3268.51 HBS1 K160, K168 and K174 3K + 232 (biotin) x 2 + 
42 (acetyl) 
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Table 6.2B: FGF3 interaction with DS, MS analysis. The reference number (Ref.no.) of the peptide is column 1. The two columns under “Native 
FGF3” present the predicted m/z and sequence of each peptide after digestion of FGF3 by chymotrypsin. The bold lysines in the 3rd column 
(“Sequence”) are those identified as labelled with NHS-biotin. The first two columns under “FGF3 DS” present the predicted and observed m/z 
for FGF3 after in-solution selective labelling. FGF3 bound to DS (protection step) was reacted with NHS-acetate, following dissociation, then 
lysine residues of binding sites exposed to solvent were reacted with NHS-biotin (labelling step). The 3rd column identifies the peptide as being 
considered from sequence alignment in the literature [102] to be in an HBS of FGF3. The final column indicates the modification occurring on the 
lysine residues of peptides. 
  Native FGF3 FGF3 DS 
 Ref.
no. 
Predicted 
native 
peptide m/z 
Sequence Predicted modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 998.48 49YCATKYHL56 1230.49 1230.40 HBS1 K53 1K + 232 (biotin) 
2 1108.60 98AMNKRGRLY106 1340.61 1340.74 HBS1 K101 1K + 232 (biotin) 
3 1521.84 93SGRYLAMNKRGRL105 1753.85 1753.77 HBS1 K101 1K + 232 (biotin) 
4 1592.88 154YVSVNGKGRPRRGF167 1866.90 1866.96 HBS1 K160 2K + 232 (biotin) 
5 1700.90 93SGRYLAMNKRGRLY106 1932.91 1933.03 HBS1 K101 1K + 232 (biotin) 
6 2534.40 26RRDAGGRGGVYEHLGGAPRRRKL48 2766.41 2766.35 HBS3 K47 1K + 232 (biotin) 
7 2762.58 155VSVNGKGRPRRGFKTRRTQKSSLF172 3268.61 3268.51 HBS1 K160, K168 and K174 3K + 232 (biotin) x 2 + 42 
(acetyl) 
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Table 6.3A: FGF10 interaction with heparin, MS analysis. The reference number (Ref.no.) of the peptide is column 1. The two columns under 
“Native FGF10” present the predicted m/z and sequence of each peptide after digestion of FGF10 by chymotrypsin. The bold lysines in the 3rd 
column (“Sequence”) are those identified as labelled with NHS-biotin. The first two columns under “FGF10 heparin” present the predicted and 
observed m/z for FGF10 after in-solution selective labelling. FGF10 bound to heparin (protection step) was reacted with NHS-acetate, following 
dissociation, then lysine residues of binding sites exposed to solvent were reacted with NHS-biotin (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [102] to be in an HBS of FGF10. The final column indicates the modification 
occurring on the lysine residues of peptides. 
  Native FGF10 FGF10 heparin 
 Ref. 
no. 
Predicted native 
peptide m/z 
Sequence Predicted 
modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 939.46 83FSFTKYF89 1171.471 1171.612 K86 1K + 232 (biotin) 
2 2650.487 178VALNGKGAPRRGQKTRRKNTSAHF201 3349.52 3349.63 HBS-1 K183, K191 
and K195 
3K + 232 (biotin) x 3  
3 1181.67 131YLAMNKKGKL140 1889.83 1889.99 HBS-1 K136, K137 
and K139 
3K + 232 (biotin) x 3 and 
oxidation 
4 1336.741 80RKLFSFTKYF89 1798.761 1798.89 K81 and K86 2K + 232 (biotin)  x 2 
5 2596.42 89FLKIEKNGKVSGTKKENCPYSIL101 2806.42 2806.40 K91, K94, K97, K102 
and K103 
5K + 42 (acetyl) x 5 
6 2373.11 142GSKEFNNDCKLKERIEENGY161 2647.34 2647.35 K144, K151 and K153 3K + 232 (biotin) + 42 
(acetyl) 
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Table 6.3B: FGF10 interaction with CS, MS analysis. The reference number (Ref.no.) of the peptide is column 1. The two columns under 
“Native FGF10” present the predicted m/z and sequence of each peptide after digestion of FGF10 by chymotrypsin. The bold lysines in the 3rd 
column (“Sequence”) are those identified as labelled with NHS-biotin. The first two columns under “FGF10 CS” present the predicted and observed 
m/z for FGF10 after in-solution selective labelling. FGF10 bound to CS (protection step) was reacted with NHS-acetate, following dissociation, 
then lysine residues of binding sites exposed to solvent were reacted with NHS-biotin (labelling step). The 3rd column identifies the peptide as 
being considered from sequence alignment in the literature [102] to be in an HBS of FGF10. The final column indicates the modification occurring 
on the lysine residues of peptides. 
  Native FGF10 FGF10 CS 
 Ref.no. Predicted 
native 
peptide 
m/z 
Sequence Predicted modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 905.48 84SFTKYFL90 1137.49 1137.41 K86 1K + 232 (biotin) 
2 1903.0086 71NHLQGDVRWRKLFSF85 2135.0186 2134.927 K81 1K + 232 (biotin) 
3 1068.59 133AMNKKGKLY141 1384.62 1384.77 
K136, K137 and 
K139 
3K + 232 (biotin) + 42 (acetyl) x 2 
4 1189.67 80RKLFSFTKY88 1653.69 1653.86 K81 and K86  2K + 232 (biotin) x 2 
5 1820.85 153KERIEENGYNTYASF167 2052.86 2052.95 K153 1K + 232 (biotin) 
6 2650.487 178VALNGKGAPRRGQKTRRKNTSAHF201 2966.51 2966.63 K183, K191 and 
K195 
3K + 232 (biotin) + 42 (acetyl) x 2 
7 2596.42 89FLKIEKNGKVSGTKKENCPYSIL101 2806.42 2806.40 
K91, K94, K97, 
K102 and K103 
5K + 42 (acetyl) x 5 
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Table 6.3C: FGF10 interaction with DS, MS analysis. The reference number (Ref.no.) of the peptide is column 1. The two columns under 
“Native FGF10” present the predicted m/z and sequence of each peptide after digestion of FGF10 by chymotrypsin. The bold lysines in the 3rd 
column (“Sequence”) are those identified as labelled with NHS-biotin. The first two columns under “FGF10 DS” present the predicted and 
observed m/z for FGF10 after in-solution selective labelling. FGF10 bound to DS (protection step) was reacted with NHS-acetate, following 
dissociation, then lysine residues of binding sites exposed to solvent were reacted with NHS-biotin (labelling step). The 3rd column identifies the 
peptide as being considered from sequence alignment in the literature [102] to be in an HBS of FGF10. The final column indicates the modification 
occurring on the lysine residues of peptides. 
  Native FGF10 FGF10 DS 
 Ref.
no. 
Predicted native 
peptide m/z 
Sequence Predicted modified 
peptide m/z 
m/z 
observed 
Match HBS Modifications 
1 905.48 84SFTKYFL90 1137.49 1137.41 K86 1K + 232 (biotin) 
2 1018.61 132LAMNKKGKL140 1524.64 1524.80 K136, K137 and K139 3K + 232 (biotin) x 2 + 42 
(acetyl)  
3 1181.67 131YLAMNKKGKL140 1497.70 1497.73 K136, K137 and K139 3K + 232 (biotin) + 42 
(acetyl) x 2 
4 1189.67 80RKLFSFTKY88 1653.69 1653.74 K81 and K86 2K + 232 (biotin) x 2 
5 2650.487 178VALNGKGAPRRGQKTRRKNTSAHF201 2966.51 2966.63 K183, K191 and K195 3K + 232 (biotin) + 42 
(acetyl) x 2 
6 2203.01 98NNDCKLKERIEENGYNTY114 2667.03 2666.26 K102 and K103 2K + 232 (biotin) x 2 
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CHAPTER 7 SELETIVE LABELLING OF LYSINE AND ARGININE 
RESIDUES FOR NON- FIBROBLAST GROWTH FACTORS PROTEIN- 
HS4C3 ANTIBODY 
7.1 INTRODUCTION 
There are over 800 HBPs identified [139] in the context of pancreas, and this number will keep 
increasing. So far, selective labelling has been applied for a limited number of HBPs in which 
FGFs were the centre of the interest [120][218] [102]. However, ideally, selective labelling 
could be able to apply to any electrostatic interactions with an appropriate model. Moreover, it 
will be useful when there is difficulty in crystalizing the protein. Hence, a question raised then 
is the capability of the selective labelling of lysine and arginine residues on HBPs rather than 
FGFs. Moving a step forward from the well-known area of FGFs and HS, among many of 
proteins having affinity with HS, we got HS4C3 antibody, as gift from Prof Toin H. van 
Kuppevelt (Netherland) to examine the applicability of the selective labelling. 
Single chain variable fragment (scFv) antibodies are synthetic antibodies which adopt the 
structures of human ones with a heavy and light chain variable regions but being randomly 
assembled in vitro for certain purpose [188]. HS4C3 is one of them which displays antibodies 
selected against bovine kidney HS. It binds to HS through a sequence, GRRLKD, which so-
called CDR3 region. This sequence of HS4C3 fits into the proposed consensus sequence of 
glycosaminoglycan binding site XBBXBX (B, basic amino acid residue; X, any amino acid 
residue) [110] (Section 1.4.3).  Moreover, it has been shown that this sequence of HS4C3 is 
selective to 3-O-sulfation in HS [222]. A study measured the binding affinity between the 
antibody and hexa- to octasaccharide fragment and found that HS4C3 showed weak binding 
with the sugar fragments with any N-sulfated, 2-O-and 6-O-sulfated but in contrast, it interacted 
strongly to the oligosaccharide having 3-O-sulfated glucosamine residue in the sequence [189].  
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The previous bodies of work on HS4C3 over-focused on the CDR3 region with little 
knowledge of the rest of the engagement. Bear in mind that CDR3 is composed of only two 
arginine residues and one lysine, hence, the length of polysaccharide chain bound to this area 
is just a trisaccharide or a tetrasaccharide, whereas the length of HS is much longer. From this 
point of view, the selective labelling of lysine and arginine were applied on HS4C3 to 
investigate further the binding pattern of this antibody and HS. 
7.2 RESULTS 
7.2.1 Optimization of the conditions for protect and label on heparin mini-column 
The selective labelling of lysine residues on HS4C3 was first conducted following the standard 
protocol using 150 mM NaCl, PB buffer and Sulfo-NHS acetate as reagent (Figure 7.1A). 
When antibody (Figure 7.1A - Loading) was loaded onto the heparin mini-column, there were 
several bands observed in the flow through (FT) and wash fractions (Wash) (Figure 7.1A - 
LF/T and Wash), however, none of them was HS4C3 indicating that HS4C3 bound as expected 
(FT and W lanes). After the on-column reaction with 50 mM sulfo-NHS-acetate, the excess 
reagent was removed (Figure 7.1A NHS F/T) and the column was washed by Na-1 buffer 
(Figure 7.1A NHS W) before elution with Na-2 buffer (Figure 7.1A Elute). In all fractions, the 
bands with equivalent molecular weight to HS4C3 were observed indicating the partial elution 
of the antibody during the reaction. The use of sulfo-NHS-acetate with sulfo groups may cause 
competition in the ionic binding to heparin, resulting in the dissociation of engaged residues 
from heparin, their reaction with NHS acetate and consequently the partial elution of HS4C3. 
In the next test, we changed the reagent to NHS acetate and repeated the experiment. A large 
band was observed in the flow through (FT, Figure 7.1B- F/T), however, it was of lower 
molecular size lower than HS4C3, showing that antibody bound to the heparin column. In the 
following factions before Elute, there was no band observed. After the antibody was eluted by 
2 M NaCl, in elute fraction (Figure 7.1B- Elute), a band with the same molecular weight as 
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HS4C3 appeared, indicating that under these conditions lysines on the antibody do not 
dissociate during the reaction and so the antibody remains bound to the column. Note that by 
changing reactions times and electrolyte concentrations it would be possible potentially to 
access the local kinetics of interactions of individual residues. This may be of interest in terms 
of engineering the kd of the antibody, since reducing the dissociation rate constant will increase 
the efficacy of washes and so the stringency of immunofluorescence on cells and tissues. 
 
Figure 7.1: Testing conditions for the selective labelling of lysine residues on HS4C3. A) 
Sulfo-NHS-acetate was used for the protection of exposed lysine residues. Lane loading, 
the raw material before selective labelling, lane F/T: Flow through fraction after HS4C3 was 
loaded onto the heparin mini-column, lane wash: wash fraction after Na-1 buffer was loaded, 
lane NHS/FT: the fraction after PB buffer containing 50 mM sulfo-NHS-acetate was loaded 
onto the mini-column for the protection, lane NHS wash: wash fraction after Na-1 buffer was 
loaded, lane Elute: Elute fraction after PB buffer containing 2 M NaCl was loaded onto the 
mini-column, lane Bead wash: the heparin bead was mixed with SDS and boiled at 96 oC. B) 
NHS-acetate (no sulfo) was used for the protection of exposed lysine residues. Lane 
loading, the raw material before selective labelling, lane F/T: Flow through fraction after 
HS4C3 was loaded onto the heparin mini-column, lane wash: wash fraction after Na-1 buffer 
was loaded, lane NHS/FT: the fraction after PB buffer containing 50 mM NHS-acetate was 
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loaded onto the mini-column for the protection, lane NHS wash: wash fraction after Na-1 buffer 
was loaded, lane Elute: Elute fraction after PB buffer containing 2 M NaCl was loaded onto 
the mini-column. 
7.2.2 Protect and Label strategy for the identification of arginine/lysine in proteins that 
engage heparin (Section Method 2.7, 2.8 and 2.9) 
The peptides generated from native HS4C3 by cleavage with chymotrypsin were predicted by 
Prospector in the mass range from 500 Da to 4000 Da, with a maximum missed cleavages of 
5. The predicted lists were then filtered with the script PGO-HPG mass predictor to remove 
peptides without arginine residues. PGO-HPG mass predictor then predicted the mass shifts 
arising from the reaction of arginine side chains (Table 7.2) and added these to the mass of 
each peptide. This additional processing step is necessary, because there are three possible 
reactions products with PGO. All combinations of mass changes were covered. The predicted 
lists were then matched to lists of observed masses using the Matchmaker script with the 
difference between two peptides set at 0.1-0.5 Da (Section 2.9). The resulting peptides with 
information about modification, sequence and final m/z are presented in Tables 7.2. 
All the matching peaks are present in Supplementary Figure 7.1. 
The same process was conducted to lysine with corresponding mass shift for NHS-acetate and 
NHS-biotin. The resulting peptides with information about modification, sequence and final 
m/z are presented in Tables 7.1. 
7.2.3 Locations of modified arginine residues in the sequence and structure. 
The CDR3 region of HS4C3 is indicated by the red box, including three arginine residues and 
one lysine. All of them are detected by the selective labelling method. 
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In addition, there are five other arginine, as well as 6 other lysine residues labelled, indicating 
they too are bonded to heparin. The location of each residue is shown in the sequence (Figure 
7.2) as well as on the surface (Figure 7.3A). 
 
Figure 7.2: The locations of labelled lysine and arginine residues on the sequence of the 
antibody. The red box locates the CDR3 region of HS4C3 which is shown to bind to 
heparin/heparan sulfate. Arginine residues that bind to heparin are in green and the heparin-
engaging lysine residues are in blue.  
From the point of view of the surface, CDR3 locates in the central basic area of the antibody 
(Figure 7.3B). This basic area extends from the light chain through the linker to the heavy chain 
without any acidic boundaries, indicating that they cooperate to bind a single sugar chain. This 
claim is support by both algorithms used by Pymol and SwissPDB. Whereas Pymol relies on a 
single residue charge, SwissPDB viewer considers atomic partial charge to build the surface 
electrostatic potential. Both models indicate the binding orientation of heparin through the 
CDR3 (Figure 7.4). 
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Figure 7.3: The locations of lysine, arginine residues engaging heparin. A) The locations 
of labelled R, K residues on the surface of HS4C3. B) Electrostatic density was built using 
Pymol, which shows the only charged residues. The highly basic area (blue colour) which 
covers the CDR3 and extends through to some K and R residues of the Light and Heavy chains 
suggests a potential direction of heparin when bound to the antibody.  
 
Figure 7.4: Electrostatic density of Antibody surface. Electrostatic density was built using 
Swiss-PDB View.  Superimposed on the electrostatic surface potential map is the location of 
labelled arginine/lysine residues on the surface, shown as: HPG-modified arginine residues in 
pink; biotin labelled lysine residues in green; in yellow are the residues of CDR3 
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Table 7.1: MS analysis based on prediction by Prospector for the modifications on lysine 
residues of the antibody. The reference number of the peptide is followed by the predicted 
m/z and with the sequence of the peptides following cleavage of native antibody by 
chymotrypsin. The two columns under “Lysine modifications” present the m/z for peptides 
cleaved from antibody reacted in solution with NHS-acetate when bound to a heparin affinity 
column (protection step) and then, following elution, reaction of any protected lysine residues 
with NHS-biotin (labelling step). The final column indicates the modification occurring on the 
lysine residues of peptides. 
 m/z 
theoretical 
Native 
Sequence 
Lysine modifications 
 m/z 
observed 
Modifications 
1 904.4523 KDWGQGTL 1136.4623 1K + 232 (Biotin) 
2 925.5578 VRQAPGKGL 1157.5678 1K + 232 (Biotin) 
3 1148.591 TISRDDSKNL 1380.6006 1K + 232 (Biotin) 
4 1228.668 YQQKPGQAPVL 1460.6784 1K + 232 (Biotin) 
5 1457.761 GKNNRPSGIPDRF 1689.7708 1K + 232 (Biotin) 
6 1597.818 VGRIKSKTDGGTTDY 1871.838 2K + 232 (Biotin) + 42 (acetyl) 
7 1660.826 M(Oxidation)SWVRQAPGKGLEW 1892.8364 1K + 232 (Biotin) 
8 1803.896 SNAWM(Oxidation)SWVRQAPGKGL 2035.9059 1K + 232 (Biotin) 
9 1879.971 YCARGRRLKDWGQGTL 2111.9808 1K + 232 (Biotin) 
10 1948.033 ASWYQQKPGQAPVLVIY 2180.0427 1K + 232 (Biotin) 
11 2052.012 TFSNAWM(Oxidation)SWVRQAPGKGL 2284.022 1K + 232 (Biotin) 
12 2111.096 YASWYQQKPGQAPVLVIY 2343.106 1K + 232 (Biotin) 
13 2239.183 AAPVKGRFTISRDDSKNLTY 2513.203 2K + 232 (Biotin) + 42 (acetyl) 
14 2424.299 VGRIKSKTDGGTTDYAAPVKGRF 2930.3294 3K + 232 (Biotin) x 2 + 42 
(acetyl) 
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Table 7.2: MS analysis based on prediction by Prospector for the modifications on 
arginine residues of the antibody. The reference number of the peptide is followed by the 
predicted m/z and with the sequence of the peptides following cleavage of native antibody by 
chymotrypsin. The two columns under “Arginine modifications” present the m/z for peptides 
cleaved from antibody reacted in solution with PGO when bound to a heparin affinity column 
(protection step) and then, following elution, reaction of any protected arginine residues with 
HPG (labelling step). The final column indicates the modification occurring on the arginine 
residues of peptides. 
 m/z 
theoretical 
Native 
Sequence 
Arginine modifications 
 m/z observed Modifications 
1 932.4261 RSYYASW 1064.4472 1R + HPG 
2 1525.785 CARGRRLKDW 1657.8068 3R + HPG + PGO (134) x 2 
3 1597.818 TISRDDSKNLTYL 1729.839 1R + HPG 
4 1260.674 CARGRRLKDW 1856.8315 3R + HPG + PGO (232) x 2 
5 1946.939 GQTVRITCQGDSLRSYY 2194.9862 2R + HPG + PGO (116) 
6 2097.977 YCNSRDSSGNHVVFGGGTKL 2229.9982 1R + HPG 
7 2331.166 KTEDTAVYYCARGRRLKDW 2727.2297 3R + HPG x 3 
8 2660.371 EVQLVESGGGLVKPGGSLRLSCAASGF 2792.3923 1R + HPG 
9 2781.3914 VIYGKNNRPSGIPDRFSGSSSGNTASL 2913.4125 1R + HPG 
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7.3 DISCUSSION 
The finding from the selective labelling of basic amino acids, lysine, and arginine, reinforced 
the previous definition of CDR3 on the HS4C3. The labelled lysine and arginine residues 
located on the electropositive charged surface of the antibody without any acidic border, 
indicating that a sugar chain may engage them. The previous definition of CDR3 contained R5, 
R6 and K5. However, this piece of work highly recommended the addition of R4 into the centre 
of binding, CDR3 (Figure 7.3 and 7.4). Previous work [189] used hexa- to octasaccharide 
fragment to study the binding properties, indicating that HS4C3 employed more than three 
basic residues of CDR3, which engage only a trisaccharide, to the binding.  Moreover, it opens 
a chance to see the whole picture of sugar engagement on the antibody rather than focus on the 
core region of binding. 
The engagement between HS4C3 and heparin was performed here at 150 mM NaCl. However, 
the study on the selectivity of HS4C3 toward 3-O-sulfate was in 500 mM NaCl [188]. As 
discussed in Section 6.2, the concentration of NaCl may affect electrostatic interactions. In the 
same meaning, it could be seen that the use of sulfo-NHS-acetate interfered the engagement of 
the antibody and heparin bead (Section 7.2.1). It was because sulfo carries hydorxyl group 
which result in the competition in the ionic binding.  
It has been known that HS4C3 is selective for the 3-O-sulfation on the antibody, hence a 
question risen is which residue of CDR3 engages to 3-O-sulfation? Indeed, with the knowledge 
of the relative positions of lysine and arginine residues on the surface, is that possible to assign 
the binding of each amino acid to the charged groups on the heparin?   
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CHAPTER 8 PREDICTIVE MODEL FOR HBS(S) ON HB4C3 USING 
POSITIVELY CHARGED RESIDUES AND CRYSTAL STRUCTURE OF HEPARIN 
8.1 INTRODUCTION 
Longstanding questions are how specific and selective protein-glycosaminoglycan interactions 
are, to what extent can HBSs be predicted, and, if the residues in an HBS are known, what 
might be the sugar specificity of that protein. It is generally accepted that the spatial disposition 
of sulfate, the carboxyl and hydroxyl groups on the polysaccharide is important for engaging 
groups on the protein. However, the extent to which this is selective in the sense that there are 
differences in the binding structures in the polysaccharide recognised by different proteins that 
have functional significance is a matter of debate. Moreover, there is, as yet no informatics 
approach that allows any sort of prediction. For example, the Cardin-Weintraub ‘consensus 
sequence’ in a peptide will form an alpha helix, though it is based on the 310 helix of collagen 
and it is linear, yet many GAG-binding sites in proteins are formed by amino acids distant in 
sequence, but adjacent in structure [110] . 
This thesis and previous work have generated a dataset based on the selective labelling of lysine 
and arginine residues that interact with heparin in the 15 paracrine fibroblast growth factors 
[36] [37] (Section 4.2, Section 5.2) and a ‘phage display antibody (Section 7.2)). These data 
can now be exploited to determine whether it may be possible to now develop a predictive 
model of heparin binding sites in proteins. The data are structure based, in that the geometric 
positions of the labelled lysines and arginines in the antibody and the FGFs are defined by 
structural models of the proteins (or ones based on a template model). There are also structural 
models of heparin oligosaccharides based on NMR experiments [92] and co-crystals of these 
with proteins [223] [143]. In this first attempt at exploring modelling of protein-GAG 
interactions, processive manual docking of the charged groups on a heparin trisaccharide to the 
relative spatial positions in 2-D of the lysine and arginine residues that bind sugar has been 
279 
 
used. A trisaccharide was chosen to try to bypass some of the uncertainty relating to the 
interpretation of the NMR structure of a heparin decasaccharide [92] (Section 1.4). A 2-D 
approach was chosen on the grounds that sugar flexibility is sufficient for a 2-D model to apply 
in 3-D. In future, torsion angles might be used to refine the models.  
The first step was to match the potential geometric relations of charged groups on a 
trisaccharide (GlcNS,6S(0)-IdoA2S(+1)- GlcNS (+2)) derived from 1HPN to the heparin 
binding lysine and arginine residues in the central part of HBS1 (Fig 8.1A, B). The 
trisaccharide was then moved stepwise a disaccharide unit towards each end of the binding site, 
each time keeping the previously determined binding geometry of the overlapping IdoA2S, and 
then determining consistent interactions of the terminal disaccharide. The distance between 
sulfate (SO3) groups of adjacent monosaccharides was measured between S atoms, whereas the 
distance between sulfate (SO3) and the carboxyl groups was value of the distance between the 
respective S and C atoms. This seemed reasonable, since ionic bonds can vary in length and 
the position of the charge on the sulfate is not fixed to a particular oxygen. On the protein, the 
distance between basic residues was measured from the nitrogen (N) of the lysine side chain 
and from the carbon in the guanidino side chain of arginine. There are many possible ‘registers’ 
for the starting trisaccharide. Two different pieces of information were used to discriminate 
between registers and so models: the known selectivity of the protein for particular patterns of 
sulfation, determined previously by DSF [36] [37]  and the requirement for all labelled lysines 
and arginines to have an interaction with a charged group on the sugar. 
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8.2 RESULTS 
8.2.1. Model for the engagement of heparin dodesaccharide to the antibody HS4C3 
8.2.1.1 CDR3 loop 
The CDR3 loop is the variable region in the ‘phage display library used to identify single chain 
variable fragment (scFv) antibodies that bind selectively to different structures in GAGs [224]. 
It is the CDR3 that is considered to impart such selectivity, since the remainder of the scFv is 
the same in all members of the library. The HS3C4 antibody is selective for glucosamine 
residues that are both N- and 3-O sulfated. Since this selectivity is imparted by its CDR3 
sequence, then this was used as a starting point. K5, R4, R5 and R6 in HS3C4’s CDR3 were 
identified as binding to heparin (Section 7.1), so these were matched to GlcNS-3S-IdoA2S-
GlcNS6S unit (Figure 8.1). The only way to ensure these residues in the CDR3 were forming 
bonds with charged groups on the trisaccharide was for the face of the sugar, with the N-sulfate 
and 3-O-sulfate of GlcN together with 2-O-sulfate of IdoA +1 and the 6-O-sulfate of GlcNS 
+2 to engage the CDR3 of the antibody (Figure 8.1C, D). The comparison of the triangles 
formed by the anionic groups on GlcNS, 0 and IdoA, +1 to the triangles formed by R5, R6 and 
K5 supports this interpretation. In detail, the distance between the N-sulfate of GlcNS and the 
2-O-sulfate of IdoA, +1, measured between the two S atoms of the two sulfate groups is 0.61 
nm (Figure 8.1D), which approximates the distance between R6 and the adjacent side chain of 
K5, 0.8 nm (Figure 8.1C). The distance between the 3-O-sulfate and the N-sulfate of GlcNS 
(0) is 0.46 nm, whereas the R5 to R6 distance is 0.97 nm. However, because the 3-O-sulfate is 
missing from this structure and the size of sulfate group itself is quite massive, implying that 
the distance between the 3-O-sulfate and the N-sulfate of GlcNS (0) could vary considerably. 
The angle of the triangle formed by the 3-O-sulfate of GlcNS, the N-sulfate of GlcNS  the 
2-O-sulfate of IdoA +1 is 124.4º (Figure 8.1D), which matches to the angle of the triangle R5-
R6-K5 on the antibody, which is 123.5º (Figure 8.1C). Hence, R5 may engage the 3-O-sulfate 
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of central GlcNS and R6 interacts with N-sulfate of GlcNS (0), whereas K5 has ionic interaction 
with the 2-O-sulfate of IdoA+1. 
The second comparison was performed between the triangle formed by the N-sulfate of GlcNS 
(0), the 2-O-sulfate of IdoA+1, the 6-O-sulfate of IdoA +2 and  the triangle of R6, K5, R4 on 
the antibody. There was the already defined edge of 0.61 nm between the N-sulfate of GlcNS 
(0) and the 2-O-sulfate of IdoA+1, which was approximate to the edge of 0.8 nm between K5 
and R6 on the antibody.  The distance between the 2-O-sulfate of IdoA+1, the 6-O-sulfate of 
IdoA +2 was 0.61 nm, which was close value to the edge of 0.69 nm between K5 and R4 on 
the antibody (Figure 8.1D). The angle formed by the N-sulfate of GlcNS (0)  the 2-O-sulfate 
of IdoA+1  the 6-O-sulfate of IdoA +2 was 78.9º (Figure 8.1D), which matched the angle of 
71.4º between R6  K5  R4 on the antibody (Figure 8.1C). Hence, in addition to defined 
interactions of residues of CDR3 above, R4 may engage the 6-O-sulfate of IdoA, +1. The 
summary of the binding between CDR3 and central trisaccharide derived from the 1HPN 
dodesaccharide is shown Figure 8.1B. 
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Figure 8.1: The binding of CDR3 to the core of heparin dodesaccharide. A, B) This uses 
the rigid model of 1HPN. Monosaccharide nomenclature is that used in the 1HPN structure: 
SGN = GlcNS, 6S; IDS = IdoA, 2S. The core trisaccharide centred on GlcNS, 3S, 6S will be 
fairly rigid; obviously the geometry of the NS-3S unit is fixed; 6S on the glucosamine exerts a 
‘push’ on the neighbouring IdoA, so ensuring its COO- is in the right orientation for binding. 
This will increase the association rate constant and likely decrease the dissociation rate 
constant, so though unlikely to bind, 6S may play an indirect role. C, D) Distance and angle 
measurements for the residues in CDR3 identified as binding heparin, followed by the 
comparison to those parameters of the heparin trisaccharide. 
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8.2.1.2 Territory of the antibody binding to the reducing end sugars -1 to -5 
The trisaccharide was moved a series of disaccharide in the reducing direction, using the 
constraints imposed by reducing end iduronate, whose interactions were fixed in the previous 
step. Then, triangles of groups on the sugar were matched to labelled residues on the antibody, 
with successive triangles incorporating previously assigned interactions. In this way, the 
modelling would be consistent with the geometry of a full-length binding oligosaccharide. 
 
Figure 8.2: Territory of the antibody binding reducing end sugars -1 to -5. A) The distance 
and angle of the corresponding triangles on the antibody composing of R9, R7, K7, R8  B) The 
dimensions angle of the triangles composing the carboxyl of IdoA (-1), the 6-O-sulfate of 
GlcNS6S (-2), the N-sulfate of GlcNS (-4) and the carboxyl of IdoA (-5). 
The reducing end starts from IdoA (-1), with the carboxyl is close to the 3-O-sulfate of GlcNS 
(0). Since the 3-O-sulfate of GlcNS (0) has been shown above to interact with R5 of CDR3, 
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the potential binding partner of the carboxyl of IdoA (-1) is R9 (Fig 8.2A). For the flexibility 
of the 3-O-sulfate and the lack of the information, the comparison of triangle is not applied in 
this case. However, for the neighbourhood of R9 to R6 on the antibody and the carboxyl of 
IdoA (-1) to the N-sulfate of GlcNS (0), this is most likely hypothsis in the perspective of this 
register on CDR3. 
Moving a further to the reducing end there are IdoA (-1), GlcNS6S (-2), IdoA (-3) and GlcNS 
(-4) (Figure 8.2B). There are two triangles being compared. First, the triangle of the carboxyl 
(IdoA, -1), the 6-O-sulfate (GlcNS, -2), the N-sulfate (GlcNS, -4) was compared with the 
triangle of R9, R7 and K7 on the antibody. The edge of the carboxyl (IdoA, -1) and the 6-O-
sulfate (GlcNS, -2) is 0.73 nm (Figure 8.2B), which is close in value to the edge of 0.81 between 
R9 and R7 on HS4C3 (Figure 8.2A). The distance between the 6-O-sulfate (GlcNS, -2) and the 
N-sulfate (GlcNS, -4) is 0.78 nm (Figure 8.3A), which with the length of an ionic bond 
approximates to the distance of 1.2 nm between R7 and K7 (Figure 8.3B).  The angle of the 
carboxyl (IdoA, -1)  the 6-O-sulfate (GlcNS, -2)  the N-sulfate (GlcNS, -4) on the sugar 
are 107.8º (Figure 8.2B), which is close to the value of the angle made by R9, R7 and K7, 
108.4º (Figure 8.3B). Hence, R9 interacts with the carboxyl (IdoA, -1), R7 engages the 6-O-
sulfate (GlcNS, -2) and the binding partner of K7 is the N-sulfate (GlcNS, -4). 
Second, the triangles formed by the 6-O-sulfate (GlcNS, -2), the N-sulfate (GlcNS, -4) and the 
carboxyl of IdoA (-5) match that of R7, K7 and R8 (Figure 8.2A, B). The edge of the N-sulfate 
(GlcNS, -4) and the carboxyl (IdoA, -5) is 0.71 nm, which when adding in the length of ionic 
bonds is equivalent to the distance between K7 and R8 on HS4C3, 1.57 nm (Figure 8.2A). The 
angle formed by the 6-O-sulfate (GlcNS, -2)  the N-sulfate (GlcNS, -4)  the carboxyl of 
IdoA (-5) is 97.2º (Figure 8.2B). The angle formed between R7-K7 to K7-R8, 126.9º (Figure 
8.2A). Since the side chain of K8 is relatively more flexible than the side chain of arginine 
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amino acid and the 6-O-sulfate (GlcNS, -2) could rotate considerably, R8 likely interact with 
the carboxyl group of IdoA, -5. 
The engagement of the 2-O-sulfate of IdoA (-3) is missing, but for the fact the not all C2 of 
IdoA would be sulfated. The case proposed above is sensible. 
8.2.1.3 Territory of the antibody binding non-reducing end sugars +3 to +6 
 
Figure 8.3: Territory of the antibody binding non-reducing end sugars +3 and +6. A, B) 
The distance and angle of the corresponding triangle on the antibody. C) The dimensions and 
angle of the interested triangles on dodesaccharide.  
For K2 is neighbour to R4, hence the carboxyl group of IdoA (+3) likely engages this residue. 
The next comparison is between the triangle of the carboxyl of IdoA (+3), the N-sulfate of 
GlcNS (+4) and the 2-O-sulfate of IdoA (+5) and that of K2, R3, K4 on antibody. The distance 
between the carboxyl of IdoA (+3) and the N-sulfate of GlcNS (+4) is 0.71 nm. This value 
adding up with the length of ionic bonds which is ~ 0.5 nm is approximate to the distance of 
1.21 nm between K2 and R3 on the antibody (Fig 8.3B). The edge formed by the N-sulfate of 
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GlcNS (+4) and the 2-O-sulfate of IdoA (+5) is 0.61 nm which in addition with the length of 
ionic bonds is close to the distance of 1.31 nm between R3 and K4 (Fig 8.3A). The angle 
formed by the carboxyl of IdoA (+3)  the N-sulfate of GlcNS (+4)  the 2-O-sulfate of IdoA 
(+5) is 143.5º (Figure 8.3C) which is close to the value of the angle between K2  R3  R1, 
which is 145.8º (Figure 8.3B). Hence, K2 may engage to the carboxyl of IdoA (+3), the 
interactor of R3 is the N-sulfate of GlcNS (+4) and K4 likely interacts with the 2-O-sulfate of 
IdoA (+5). 
The triangle formed by the N-sulfate of GlcNS (+4) and the 2-O-sulfate of IdoA (+5) and the 
6-O-sulfate of GlcNS (+6) was compared with the triangle of K2, K4 and R1 on HS4C3. The 
edge of the N-sulfate of GlcNS (+4) and the 2-O-sulfate of IdoA (+5) has been assigned above. 
The, the distace between the 2-O-sulfate of IdoA (+5) and the 6-O-sulfate of GlcNS (+6) was 
0.61 nm which is equivalent to the distace of 0.73 nm between K4 and R1 on the antibody. The 
angle formed by by the N-sulfate of GlcNS (+4)   the 2-O-sulfate of IdoA (+5)  the 6-O-
sulfate of GlcNS (+6) was 78.8 º (Fig 8.3C) which is appoximate to the angle on the antibody 
formed by K2  K4  R1 which is 74.5 º (Fig 8.3A). Those comparisons lead to the 
conclusion that R1 likely engages to the 6-O-sulfate of GlcNS (+6). 
The summary of the engagement model is presented in Fig 8.4. 
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Figure 8.4: Model for binding of labelled lysine and arginine residues on antibody to 
sugar based on distance.  
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8.2.1.4 Conclusion 
The above model identifies three regions of the antibody that bind the sugar. The CDR3 loop, 
a reducing end territory and a non-reducing end territory. Whereas antibodies are selected on 
the basis of CDR3 loop sequence, it is established [225] that efficient binding requires 
oligosaccharides that are much longer than the CDR3. This earlier work agrees with the results 
of the protect and label analysis of the antibody, which identified lysine and arginine residues 
in the CDR3 and ones outside this as binding heparin. Given the importance of the CDR3 in 
defining antibody selectivity, this was chosen as the starting point for modelling. The 
selectivity of the antibody for the 3-O sulfated glucosamine fixed the orientation of this residue 
in the trisaccharide and hence that of the flanking IdoA residues. Overall, the approach seems 
to have been successful, in that it was possible to identify partners on the sugar for all labelled 
residues in the antibody and to remain within the likely tolerance of ionic and H-bonds. 
The model suggests that there is limited scope for increasing selectivity of the antibody by 
altering the CDR3 loop. However, changes to the reducing and non-reducing end territories 
could alter binding. On the kinetic front, it should be possible to reduce the dissociation rate 
constant, which would allow more stringent washing. This might be achieved by swapping 
lysine for arginine (bearing in mind that the ‘reach’ of arginine is less). In addition, placing 
residues in more favourable positions would be expected to increase the delta G of the 
interaction.  Finally, in contrast to most mammalian heparin-binding proteins (Sections 4.2, 
FGF2, Section 5.2.1.3, FGF5, Section 5.2.3.3, FGF18), there is no insulation by acidic residues 
on the antibody. The absence of acidic borders might allow variations in sequence selectivity 
for binding and might in some instances even compensate for a lack of 3-O sulfate. Therefore, 
an unforeseen conclusion is that altering some of the non-binding residues flanking the labelled 
K and R residues to D or E might be a very effective way to constrain and so tailor the 
antibody’s selectivity. However, to make changes that would increase binding to the product 
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of a specific HS3ST would require knowledge of the structures that the enzyme sulfates. One 
target would be the so-called gD recognition structure, where the Glc3S is flanked by IdoA2S 
[51]–[53]. In contrast, the present antibody, which binds ATIII recognition structures, where 
interaction comprise the 2-S of one of the flanking IdoA residues and the other flanking uronic 
acid (IdoA and GlcA being equivalent) is bound via its carboxylic acid. 
8.3 DISCUSSION 
By fulfilling the map of electrostatic map on each FGF, one may draw the binding path of 
sulfate or the carboxyl groups of HS on proteins. Some FGFs prefer a long chain HS, some 
choose short chain HS. The specificity is possible to predict as well, because the space distance 
and angle of the 6-O-sulfate, 3-O-sulfate, 2-O-sulfate. This is an addition piece of information 
to allow us to design and alter the binding affinity and binding specificity of protein to GAG 
on purpose.  
The model offers a view on the potential engagement of polysaccharide on protein but not the 
direct evidence of the binding, hence, it may require an approach to validate. These could 
include mutagenesis or chemical modifications to specifically address each point of binding.  
Indeed, there is a weakness of using crystal structure for modelling. First, it is well known that 
crystal structure is fairy rigid but the interactions in the cell is fairly flexible with the induced 
conformation changed on both protein and sugar, making it difficult to study using an 
experimental model. NMR shows the conformation of protein but in free form which varies 
even more than the crystal structures in this case. 
This approach has been applied to the ‘phage’ display antibody HS4C3 (Chapter 7). There are 
many FGFs for which selectivity toward the sulfation of GAG were established and they will 
be the future object to the method of modelling initiated here. The eventual automation of this 
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approach, allied to machine learning, may enable a reasonable tool for the prediction of heparin 
binding sites to be developed. 
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CHAPTER 9 GENERAL DISCUSSION AND PERSPECTIVE 
9.1 DISCUSSION 
The first aim of this thesis was to develop an approach for the identification of the arginine 
residues in proteins that interact with heparin/HS. The identification of such arginine residues 
would complement the established method for identifying lysine side chains that form bonds 
with the polysaccharide [120][36][37]. In this way a complete description of the electrostatic 
interactions between a protein surface and a sulfated GAG could be obtained. Once a robust 
method was developed, it was then used to identify heparin-binding arginines in all fifteen 
paracrine FGFs. This not only provided a further test of the methodology, but also produced a 
rich and unique dataset on heparin binding surfaces in an evolutionary related set of proteins.  
Chapter 4 (Section 4.2) describes the work relating to the first aim, the development and 
validation of the “selective labelling of arginine residues” method for the identification of 
arginine residues involved in GAG binding. This approach was inspired by the strategy used 
to selectively labelling lysine residues with the replacement of the NHS-based reagents 
(Section 2.7), which are specific primary amines by the dialdehydes PGO and HPG, selective 
for the guanidine group of arginine. Although the chemical modification of arginine by 
dialdehydes is not new, it was challenging for several reasons. First, the reaction between the 
guanidino group of arginine and PGO produces multiple products (Section 4.1). Second, other 
dialdehydes require the presence of borate buffer to stabilize the final product, but this buffer 
may react with the vicinal diols of heparin, so interfering with the desired reaction (Section 
4.1). Two well-studied FGFs were tested to optimize the conditions of the reaction between 
PGO/HPG and arginines on proteins. LC MS/MS was the first candidate for the method of 
analysing the peptide after cleavage by enzymes. The LC MS/MS confirmed the protein was 
FGF2 (data not shown), however, there was no modification of PGO found. This may be due 
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to the sensitivity of the PGO reaction product to the acidic conditions of LC-MS/MS sample 
preparation and the hard ionization of the process [167]. Subsequently, the analysis was 
changed to MALDI-TOF MS, which employs less acidic conditions and the ionization is 
relatively softer than in MS/MS. Since the protein introduced to the MALDI-TOF is relatively 
pure (as confirmed by the prior silver stain SDS-PAGE), the resolution of MALDI-TOF was 
deemed sufficient for the analysis.  
The second aim of this thesis was to identify arginine residues in the HBSs of all fifteen 
paracrine FGFs (Section 5.2). One of the early challenges was the purification of FGF5, FGF8 
and FGF22 (Section 3.2). Previous efforts had largely failed, due to the aggregation of the 
recombinant protein in inclusion bodies. Hence, N-terminal fusions with Halo-tag were used, 
as Halo-tag was previously found to be a good solubilisation tag for other FGFs [226]. A range 
of conditions of expression were tested to identify ones suitable for protein production. For 
Halo-FGF5, it was found to be best expressed at low temperature for a short time (Section 3.2). 
This may be due to the reaction of the bacteria to the FGF5 protein. Although not toxic like 
FGF7 [227], the observation of rapid degradation is consistent with the interpretation that the 
bacteria will remove this protein if possible. Moreover, even though later being expressed well, 
Halo-FGF5 produced in bacteria seemed to be prone to aggregation (Section 3.2) as it was 
eluted at a broad range of NaCl concentrations. This was similar to what was observed with 
Halo-FGF22, but the underlying reason is not known (Sections 3.2). In contrast, with Halo-
FGF8, overnight expression produced the most protein and its chromatography on heparin was 
simpler (Section 3.2). 
In Chapter 5, the successful purification of FGF5, FGF8 and FGF22 as Halo-tag fusions made 
it possible to complete the analysis of the heparin binding arginines in the fifteen paracrine 
FGFs, in addition to the identification of lysines in HBS of the FGFs missing from previous 
work [36][37][120]. The identification of labelled arginine residues in the FGFs was in some 
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cases supported by other data. For example, X-ray crystallography of FGF9 identified R137 
which locates on the loop of β-strand VIII and R161 on β-strand X as engaged to sulfate anions 
from the crystallisation buffer [211]. The engagement of R161 to heparin is unique for FGF9, 
because the corresponding residues across other FGFs are not positively charged. There is also 
indirect evidence for the involvement of R134 of FGF1 in heparin binding  since in an NMR 
structure that used inositol hexasulfate as a substitute for heparin it was found to be bound to 
this sulfated saccharide [200]. Later work using a synthetic heparin hexasaccharide provided 
direct evidence for the engagement of R137 of FGF1 to heparin [33], [201]. In the case of FGF2, 
a docking model demonstrated that the involvement of R90 in heparin binding in which it 
engages the N-sulfate group of glucosamine 5 (GlcNS, -5) at the reducing end of the sugar 
ligand [185][186]. 
In Chapters 4 and 5, the results produced a number of surprises. First, even though they belong 
to the same sub-family, FGF1 and FGF2 are fundamentally different in terms of engagement 
to heparin. Whereas the basic FGF2 possesses three independent HBSs, the acidic FGF1 is 
capable of binding to heparin through a long, continuous HBS (Section 4.2). This interpretation 
is supported by an analysis of the ability of different FGFs to cross-link HS chain brushes. 
Whereas FGF2 is able to cross-link HS chains in a brush [126] [203], FGF1 cannot [203]. 
Underlying the differences between FGF1 and FGF2 was the absence of key residues in FGF1 
(Sections 4.2 and 5.3.2), which allows a single polysaccharide chain to engage all the heparin 
binding residues in FGF1. 
Second, rather than possessing a secondary HBS-3, as previously thought [102], FGF4 and 
FGF6 now should be considered to have a single, long HBS (Section 5.2). This again accords 
with the observation that FGF4 and Halo-tag FGF6 do not cross-link HS chains [203]. An 
important issue with respect to determining whether a group of basic residues form an 
independent HBS or not, is the consideration of the atomic details underlying the surface 
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electrostatic potential. The latter arises from both the side chains of amino acid residues and 
the peptide backbone itself and it seems reasonable to suggest that only acidic side chains (D 
and E) can form a barrier to the path of the polysaccharide. For example, although the surface 
between K158 of β-strand VIII of FGF4 and K173, assigned to HBS1 is electronegative, the actual 
side chain separating them is Y172 (Section 5.2), which is not an acidic amino acid, and it should 
not present a barrier to the polysaccharide chain. The assignment of HBSs in members of the 
FGF9 subfamily (FGF9, 16 and 20) was consolidated (Section 5.2). Again the issue of the 
electronegative surface needed to be considered for the assignment of K124 in FGF20 to HBS-
1, whereas the protection of an arginine in FGF20. There are no data regarding the ability of 
FGF16 and FGF20 with respect to cross-linking HS chains, but it would appear that this 
biophysical measurement may be an important piece of evidence to determine whether there 
are truly independent secondary heparin binding sites in a protein.  
As a third surprise, in contrast to other two members of FGF4 subfamily, was the presence of 
what appeared to be a truly independent secondary HBS in FGF5, which included the residues 
in the loop of β-strands IX-X (Section 5.2). This area of binding corresponded to HBS-2 of 
FGF2 (Section 4.2), though by itself, this was deemed insufficient to support the assignment 
of FGF5 to the FGF4 or the FGF1 subfamily (Section 1.2). Another FGF for which the sub-
family classification is still under debate, is FGF3 (Section 1.2). However, in terms of heparin 
binding properties, this FGF resembles the FGF7 sub-family (Section 5.2.4, and the present 
data do not support its re-assignment to the FGF4 subfamily. 
The data in Chapter 5 enable an examination of heparin binding sites from the viewpoint of 
each subfamily and so insights into their evolutionary relationships. Within subfamilies, there 
were differences in the lysine and arginine side chains contributing to each HBS, and in some 
cases, the presence or absence of what could reasonably be called an independent secondary 
HBSs (Sections 5.2.1, 5.2.2, 5.2.3). These changes to the configuration of HBSs across 
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members of an FGF subfamily could be ascribed to relatively small changes in the sequence. 
The alterations to GAG binding would at the least impact on the diffusion of an FGF between 
its source and target cells and in the selectivity of an FGF for particular GAG structures. This 
suggests that this divergence may contribute to the differentiation of the functions of the FGFs, 
allowing new functions to be acquired following a genome duplication event. The details of 
the FGFR isoform preferences [228] also show some differences within members of the same 
subfamily. This would suggest that the functional differentiation of FGFs within subfamilies 
occurred through relatively modest changes leading to differences in HS and FGFR binding.  
There are several examples of changes to the HBS configuration within a subfamily: FGF1 and 
FGF2; FGF5; FGF18; FGF22. Though the differences between FGF1 and FGF2 are the 
greatest (one HBS versus three, FGF1 is perhaps the most unusual of the FGFs, since it binds 
to all FGFR isoforms [228]. FGF22 is a unique FGF with only arginine residues in the binding 
site and the position of a group of arginines on the surface of the protein contributed to the 
distinct shape of its HBS-1/HBS-4. 
Table 9.1: FGF subfamilies with differences in HBS configuration  
Subfamily ‘Standard’ HBSs 
configuration 
HBS 
configuration 
Member with 
altered HBS 
configuration 
HBS 
configuration 
FGF1 
subfamily 
FGF2 HBS1, HBS-2, 
HBS-3 
FGF1 HBS-1 
FGF4 
subfamily 
FGF4, FGF6 HBS-1 FGF5 HBS-1, HBS-2 
FGF9 
subfamily 
FGF9, FGF16 HBS-1 FGF20 HBS-1, HBS-3 
FGF8 
subfamily 
FGF8, FGF17 Dogleg HBS-1 FGF18 HBS-1, HBS-2 
No Dogleg 
FGF7 
subfamily 
FGF7, FGF3, 
FGF10 
“T” shape, HBS-
1, HBS-4 
FGF22 “Y” shape, 
HBS-1, HBS_4 
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The third purpose of this work was to see if the protect and label strategy could be applied to a 
GAG in solution, which would overcome the reliance on heparin as the binding partner and 
allow physiologically relevant GAG chains (Section 1.3.3), to be used. Moreover, this would 
pave the way for eventually applying the methodology to an extracellular matrix. As discussed 
(Section 1.3.3.3) heparin and HS are different and other GAGs can interact with at least a subset 
of so-called HBPs. For example, the interaction between FGF7 and DS has been shown to play 
a role in wound healing [229]. Hence, a modified technique called “in-solution selective 
labelling” was developed and demonstrated using commercially available GAGs and a 
selection of FGFs. Method development was performed with FGF7 and heparin and the results 
indicated that a more extensive panel of GAGs and proteins should be tested to determine the 
potential of the approach. Published results analysing FGF-GAG interactions by DSF were 
used to guide which combinations of FGF and GAG to use [37]. Since the FGF7 subfamily has 
one of the wider repertoires of GAG partners, this became the focus of the work. While this 
method has been used in the context of lysine, in the future, the similar definition of arginine 
residues involved in binding GAGs in solution should be easy to develop using the methods 
described in Chapter 4. One interesting aspect of this work is the impact of electrolyte 
concentration on the interaction between GAGs and proteins. DSF measures protein 
stabilisation, which necessitates an interaction, but it does not provide much insight into 
binding kinetics, except in the extreme case where the kd is so low that over the time of the 
DSF measurement, binding is essentially irreversible. This has been seen with FGF10, since 
two populations of FGF10 , bound FGF10 and unbound FGF10, are apparent as the heparin 
concentration is varied in DSF [230]. The dissociation of complexes of the selected FGFs from 
CS and DS in PBS occurred on a time scale shorter than the reaction time, so all lysines were 
protected. Consequently the concentration of NaCl was reduced. Compounding the problem 
might be the choice of protection agent: NHS acetate will place a carboxylic acid on lysine 
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residues. Thus, should a lysine be involved in binding GAG dissociate, its reaction would not 
only prevent re-binding, but may accelerate the dissociation of neighbouring lysine residues 
for the GAG. Thus, replacing NHS acetate with an NHS containing compound that did not 
repel GAGs might allow higher NaCl concentrations to be used during the protection step.   
The selective labelling of lysine and arginine residues involved in binding sulfated GAGs has 
applications well beyond the FGFs. For example, the selective labelling of lysine successfully 
identified lysine residues of PF-4 (platelet factor-4) and PTN (pleiotrophin) engaged to heparin 
[2]. In the context of this thesis, the antibody HS4C3 (as a gift from Professor Toin van 
Kuppeveldt), which selectively recognizes heparin and HS structures with a 3-O sulfated 
glucosamine through its CDR3, was successfully analysed (Section 7.2). As a result, a complete 
set of electrostatic interactions between HS4C3 with heparin was identified, which provides 
scope for a structure-guided engineering of the selectivity of this antibody for particular 3-O 
sulfated structures, such as those recognised by AT-III and the herpes simplex gD protein. 
Given that the number of extracellular heparin-binding proteins is now of the order of 830 
[139], there is considerable scope for applying selective labelling in this context. Moreover, 
with the development of the in solution approach, any protein interaction involving lysine or 
arginine residues can now be probed in this way. 
Chapter 8 introduced the idea of modelling the sugar binding to the protein, using constraints 
from protect and label identification of lysines and arginines involved in binding. However, 
the model approximates the binding surfaces to 2-D and has several weaknesses. First, the lack 
of 3-O-sulfation on the crystal structure of a heparin oligosaccharide, 1 HPN, makes it difficult 
to address the case of some proteins which are (or may be) selective for 3-O-sulfated 
glucosamine, such as HS4C3 and FGF7 [222][32]. Second, the structure of 1HPN is rigid, 
meaning that it does not include the information of the torsion of the pyranose rings along the 
sugar chain. Third, 1HPN is an approximation of the S-domain of HS rather than NA-NS-S 
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domains which could be critical for the interaction of a protein with its solution structure. 
Nonetheless, the approach developed in this thesis would appear to have some merit (Section 
8.2). Future developments would be to incorporate the information from selective labelling and 
DSF analysis of preferred sulfation pattern as constraints into a docking program.
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Further work 
The success of the selective labelling approach of arginine and lysine on FGFs naturally leads 
to applying this approach to molecular assemblies involving interactions between proteins and 
sulfated GAGs, such as the ternary complex of FGF ligand, HS and cognate FGFR. This would 
complement the several available crystal structures of FGFR, FGF with heparin-derived 
oligosaccharides, for example [223] [143], and give an insight into the solution complex. The 
parallel analysis of binary complexes of FGF and FGFR would also enable the confirmation of 
an overlap or otherwise between the HBS-3 of many FGFs, e.g. FGF2 and FGF7 (Sections 4.2 
and 5.2) with FGFR binding sites.  More complex would be the interactions of heparin-binding 
proteins such as FGFs, with extracellular matrix. In the past this could only be analysed through 
binding assays using radioactive ligand [231]. More recently, advanced microscopy techniques 
have allowed different insights into these interactions [125][127]. An analysis of the degree to 
which the lysine and arginine residues found in vitro to interact with sulfated GAGs are 
similarly engaged to these in a matrix would shed light on, for example, the role of secondary 
HBSs. Thus, binding assays only measure binding and secondary HBSs are not apparent. In 
microscopy and biophysical measurements, such as the cross-linking of HS chains in a brush 
[203] [217], there are some correlations between FGF movement and secondary binding sites. 
For example, FGF1 appears to move shorter distances, but to diffuse faster than FGF2 in the 
pericellular matrix of rat mammary fibroblasts [127]. However, while a protect and label 
experiment on extracellular matrix would entail analysis of peptides from endogenous heparin-
binding proteins, as well as ones from any exogenously-added protein, it may be difficult to 
reliably identify labelled peptides directly at a suitable sensitivity in such a complex mixture. 
For lysine, the biotinylation step allows purification of the peptides, which would simplify the 
analysis. For arginine, the multiple product of the PGO reaction may preclude such an analysis. 
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Therefore, one useful development would be a biotin-PGO (or biotin-HPG) in the labelling 
step, to allow the labelled peptides to be purified before analysis. A potential problem with this 
is the high concentration of TFA (20% v/v) required for quantitative elution of peptides from 
Streptactin Sepharose (other forms of biotin binding proteins, such a mono avidin, fail to yield 
quantitative recovery [120]). The very low pH will cause the product of reaction of PGO/HPG 
with arginine to degrade. One solution would be to insert a disulphide between the PGO and 
the biotin (Figure 9.1) so that DTT could be used to cleave S-S and peptides with PGO could 
be eluted from the column without affecting the PGO-arginine reaction products. 
 
Figure 9.1: The chemical structure of Biotin-S-S-linker-PGO. 
As mentioned above, the in solution selective labelling of arginine residues is required to 
establish the molecular basis of the interaction between protein and GAG (heparin/CS/DS) 
without the limitation of an affinity chromatography column. The in solution selective labelling 
of lysine residues revealed a difference in protein bound even when comparing the same GAG, 
heparin, with beads and in solution. For example, the lysine residues of FGF10 which engage 
to heparin in solution were not identical to those identified when FGF10 bound to heparin on 
the affinity mini column. However, due to the lack of data on the arginine residues involved in 
binding in solution, the definition of binding sites is limited and only partial.  
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The “T” shaped basic patch of binding formed by HBS-1 and HBS-4 observed in members of 
FGF7 sub-family may require additional evidence to show that there are more than one GAG 
chain engaging to protein. The primary test could be done by cross-link which was performed 
before for FGF10 and found partial cross-link to HS brush. Later, the mutation of the basic 
amino acids in the joins would enable to separate HBS-1 and HBS-4, hence providing more 
evidence for this model.  
The weakness of identifying peptides by MADLI-TOF is that this technique only able to 
identify the overall modifications on a peptide. Thus, for peptides containing multiple arginine 
residues and multiple products, it cannot determine which residues have been modified in a 
particular way, e.g.,  reacted with PGO or HPG. The list of peptides where there is uncertainty 
regarding the labelled arginine is provided in Table 9.1.  
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  Native FGF6 FGF6 P&L  
 R
ef.
no
. 
Predicted 
native 
peptide 
m/z 
Sequence Predicted 
modified 
peptide 
m/z  
m/z 
observed 
Match HBS Modifications 
1 1288.80 80VGIKRQRRLY89 1652.87 1652.96 HBS3 R84 3R + 132 (HPG) + 
116 + 116  
 Native FGF5 FGF5 P&L 
2 1316.61 157TDDCKFRERF166 1680.69 1680.89 HBS2 R163 and 
R165 
2R + 132 (HPG) + 
232 
3 2227.12 80QWSPSGRRTGSLYCR
VGIGF99 
2723.25 2723.35 HBS3 R86 and 
R87 
3R + 132 (HPG) + 
132 (HPG)  + 232 
 Native FGF9 FGF9 protect and label (P&L)  
4 1131.60 154KHVDTGRRY162 1495.17 1495.69 HBS1 R160 and 
R161 
2R + 132 (HPG) + 
232 
 Native FGF20 FGF20 protect and label (P&L)  
5 2381.29 166VALNKDGTPRDGAR
SKRHQK186 
2895.38 2895.40 HBS-1 R176, 
R180, and R183 
3R + 132 (HPG) x 
2 + 250 
6 1516.85 191LPRPVDPERVPEL203 1880.93 1880.92 HBS-1 R199 
and R192 
2R + 132 (HPG) + 
232 
 Native FGF8 FGF8 protect and label (P&L)  
7 2589.446 154TRKGRPRKGSKTRQ
HQREVHF174 
3232.94 3233.03 HBS1 R155, 
R158, R160, R170 
5R + 132 (HPG) x 
4 + 116 
8 2514.372 55QLYSRTSGKHVQVLA
NKRINAM76 
2896.83 2896.46 HBS1 R59 and 
R72 
2R + 132 (HPG) + 
250 
 Native FGF17 FGF17 protect and label (P&L)  
9 1107.602 48SRRQIREY58 1487.67 1487.735 HBS1 R49 and 
R50 
3R + 132 (HPG) x 
2 + 116 
10 2915.478 151MAFTRQGRPRQASR
SRQNQREAHF174 
3691.598 3691.01 HBS1 R155, 
R158, R160, R164 
and R166  
6R + 132 (HPG) x 
5 + 116 
 Native FGF7 FGF7 protect and label (P&L)  
11 1992.03 60EGGDIRVRRLFCRTQ
W75 
2522.27 2522.12 HBS1 R72 
HBS3 R65, R67 
and R68 
4R + 132 (HPG) x 
3 + 116 
 Native FGF3 FGF3 protect and label (P&L)  
12 1108.604 98AMNKRGRLY106 1356.616 1356.652 HBS1 R102 and 
R104 
2R + 132 (HPG) + 
116 
13 1429.814 155VSVNGKGRPRRGF177 1827.45 1827.88 HBS1 R162, 
R164 and R165 
3R + 132 (HPG) x 
2 + 134 
 Native FGF22 FGF22 protect and label (P&L)  
14 2054.159 140LALDRRGGPRPGGR
TRRY158 
2848.13 2846.23 HBS1 R145, 
R146, R150, 
R153, R155 and 
R156 
6R + 132 (HPG) x 
5 + 134 
15 2533.303 95VAMNRRGRLYGSRL
YTVDCRF115 
3077.72 3077.66 R107 
HBS1 R99, 
R100, R102 and 
R114 
5R + 132 (HPG) x 
4  + 250 and 
oxidation 
 
Table 9.1: The list of peptides for further analysis. 
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The work on modelling samples proteins provides an opportunity for the engineering of 
antibodies or natural HBPs to alter their selectivity toward GAGs. This would also provide 
evidence that the modelling was a good approximation and should perhaps be done in tandem 
with the development of an automated predictive docking system. There are a number of 
considerations that would be involved in such engineering of a HBS. For example,, arginine 
binds stronger to sulfate groups than lysine, but it has a shorter side chain. Hence, using 
arginine rather than lysine would likely decrease the dissociation of the protein from the 
polysaccharide and, in the context of neighbouring basic residues, potentially enable selection 
of a 3S-NS unit, as seen in the HS4C3 antibody. In addition, a two dimensional binding surface 
would likely be more selective than a linear one, as has been proposed from a limited analysis 
of HBSs [232]. Allied to this point is the shape of the HBS may also impart selectivity, with 
likely differences arising due to the HBS being linear, possessing a dogleg, or something in 
between these two extremes.  
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